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Objective: To assess the evidence that three marketed gene expression-based assays improve 
prognostic accuracy, treatment choice, and health outcomes in women diagnosed with early stage 
breast cancer. 
 
Data Sources: MEDLINE®, EMBASE, the Cochrane databases, test manufacturer Web sites, 
and information provided by manufacturers. 
 
Review Methods: We evaluated the evidence for three gene expression assays on the market; 
Oncotype DX™, MammaPrint® and the Breast Cancer Profiling (BCP or H/I ratio) test, and for 
gene expression signatures underlying the assays. We sought evidence on: (a) analytic 
performance of tests; (b) clinical validity (i.e., prognostic accuracy and discrimination); (c) 
clinical utility (i.e., prediction of treatment benefit); (d) harms; and (e) impact on clinical 
decision making and health care costs. 
 
Results: Few papers were found on the analytic validity of the Oncotype DX and MammaPrint 
tests, but these showed reasonable within-laboratory replicability. Pre-analytic issues related to 
sample storage and preparation may play a larger role than within-laboratory variation. For 
clinical validity, studies differed according to whether they examined the actual test that is 
currently being offered to patients or the underlying gene signature. Almost all of the Oncotype 
DX evidence was for the marketed test, the strongest validation study being from one arm of a 
randomized controlled trial (NSABP-14) with a clinically homogeneous population. This study 
showed that the test, added in a clinically meaningful manner to standard prognostic indices. The 
MammaPrint signature and test itself was examined in studies with clinically heterogeneous 
populations (e.g., mix of ER positivity and tamoxifen treatment) and showed a clinically relevant 
separation of patients into risk categories, but it was not clear exactly how many predictions 
would be shifted across decision thresholds if this were used in combination with traditional 
indices. The BCP test itself was examined in one study, and the signature was tested in a variety 
of formulations in several studies. One randomized controlled trial provided high quality 
retrospective evidence of the clinical utility of Oncotype DX to predict chemotherapy treatment 
benefit, but evidence for clinical utility was not found for MammaPrint or the H/I ratio. Three 
decision analyses examined the cost-effectiveness of breast cancer gene expression assays, and 
overall were inconclusive. 
 
Conclusions: Oncotype DX is furthest along the validation pathway, with strong retrospective 
evidence that it predicts distant spread and chemotherapy benefit to a clinically relevant extent 
over standard predictors, in a well-defined clinical subgroup with clear treatment implications. 
The evidence for clinical implications of using MammaPrint was not as clear as with Oncotype 
DX, and the ability to predict chemotherapy benefit does not yet exist. The H/I ratio test requires 
further validation. For all tests, the relationship of predicted to observed risk in different 
populations still needs further study, as does their incremental contribution, optimal 
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Breast cancer is the most commonly diagnosed cancer in women. This tumor is the second 
leading cause of cancer-related deaths in women in the United States, with approximately 
178,000 new cases and 40,000 deaths expected among U.S. women in 2007.  Treatment for 
breast cancer usually involves surgery to remove the tumor and involved lymph nodes. 
Frequently, surgery is followed by radiation therapy (in case of breast conservation or in women 
with large tumors or many involved lymph nodes), endocrine therapy (for essentially all women 
with tumors that express the estrogen receptor (ER-positive)), and/or chemotherapy (for women 
having a high risk for a poor outcome such as those with large tumors, involved lymph nodes, 
advanced disease, or inflammatory breast cancer). More than three-quarters of patients are 
expected to survive with this multi-modality approach.  
 Gene expression profiling has been proposed as an approach to address this issue in clinical 
settings, and three breast cancer gene expression assays are now available in the U.S. The 
Oncotype DX™ Breast Cancer Assay, the MammaPrint® Test, and the Breast Cancer Profiling 
test (BCP or H/I ratio). MammaPrint is based on the use of microarray technology, while the 
other two assays are based on the reverse transcriptase polymerase chain reaction (RT-PCR). All 
of these tests combine the measurements of gene expression levels within the tumor to produce a 
number associated with the risk of distant disease recurrence. These tests aim to improve on risk 
stratification schemes based on clinical and pathologic factors currently used in clinical practice. 
As therapeutic decisions are based on risk estimates, tests that improve such estimates have the 
potential to affect clinical outcome in breast cancer patients by either avoiding unnecessary 
chemotherapy and its attendant morbidity or by employing it where it might not otherwise have 
been used, thereby reducing recurrence risk. 
The literature was searched for evidence about the use of gene expression profiling in breast 
cancer. Our analytical framework for reporting the results distinguishes between the assays, as 
they are offered to patients, and the underlying signatures, which comprise the genes whose 
expression is measured. This measurement of expression can be done in a number of ways that 
may not be identical to the procedures used for the marketed test, producing an unknown number 




 Working with the Agency for Healthcare Research and Quality (AHRQ), the Centers for 
Disease Prevention and Control (CDC), the Evaluation of Genomic Applications in Practice and 
Prevention (EGAPP) working group, and members of a technical expert panel, we formulated 
four key questions, and addressed them on the basis of the evidence available about the specific 
assays and the underlying gene expression signatures. The original set of key questions was 
refined to focus primarily on two gene expression profiling tests: Oncotype DX (Genomic 
Health, Inc.) and MammaPrint (Agendia). During the course of the evaluation, a third gene 
expression profiling test came to our attention, the H/I ratio test based on the two-gene signature 
(AviaraDX/Quest Diagnostics, Inc.), and was thus investigated. We searched and retrieved 
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studies in MEDLINE®, EMBASE, and the Cochrane databases (1990-2006). We supplemented 
this search with recent publications that appeared after the time period initially considered in the 
systematic search, and about the two-gene test (H/I ratio). We also searched for relevant 
documents on the Food and Drug Administration’s web site, and solicited additional 
documentation from the companies offering the tests. The systematic searches yielded a total of 
12983 citations. Specific inclusion and exclusion criteria were developed and pairs of readers 
reviewed each title; the same procedure was used to review selected abstracts. We identified 63 
studies for full text review. We developed tables to summarize each article. Initial data were 
abstracted by investigators and entered directly into evidence tables. Quality and consistency of 
the abstracted data was then evaluated by a second reviewer, and a senior investigator examined 
all reviews to identify potential problems with data abstraction. These were discussed at 





Literature on Key Questions 
 
 Key Question 1. What is the direct evidence that gene expression profiling tests in women 
diagnosed with breast cancer (or any specific subset of this population) lead to improvement in 
outcomes? 
 Direct evidence was defined as a study where the primary intervention is the use of a 
prognostic test (with therapeutic decisionmaking directed by the result) and the outcomes are 
patient morbidity, mortality and/or quality of life.  No direct evidence was found in the published 
data on improvement of patients’ outcomes due to such testing in women diagnosed with breast 
cancer, nor were there any randomized studies using the tests’ predictions to manage patients. 
However, as described under Key Questions 3 and 4, some of the tests’ supporting evidence was 
derived from past randomized controlled trials (RCTs) with prospectively gathered patient 
samples, giving them strong evidential value. Two ongoing RCTs, TAILORx and MINDACT 
(using Oncotype DX, and MammaPrint respectively), will provide further evidence allowing 
almost direct inference about the impact on patient outcomes. 
 
 Key Question 2. What are the sources of and contributions to analytic validity in these two 
gene expression-based prognostic estimators for women diagnosed with breast cancer? 
 In the field of gene expression there are no “gold standards” outside the technologies used in 
the tests under study, i.e., microarrays and RT-PCR. Consequently, a definitive evaluation of the 
analytic validity of expression-based tests is difficult. Evidence about operational characteristics 
was partial and limited to a few publications. A 2007 paper by Cronin and colleagues, on the 
analytic validity of Oncotype DX was the most detailed study for any of these tests so far, 
showing good performance for a number of analytic components of the assay. Data about the 
sources and contributions to variability of the tests and about their reproducibility was generally 
limited to analyses of few samples, and thus a complete evaluation of the impact of such 
variability on risk assessment was not available. Partial evidence about analytic validity was 
provided in the percentage of subjects whose samples were successfully analyzed with these 
tests, and those numbers were fairly good. Continuous monitoring of laboratory procedures and 
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careful evaluation of the quality of the submitted specimens are major factors affecting test 
reliability.  
 
 Key Question 3. What is the clinical validity of these tests in women diagnosed with breast 
cancer? 
a. How well does this testing predict recurrence rates for breast cancer compared to 
standard prognostic approaches? Specifically, how much do these tests add to currently 
known factors or combination indices that predict the probability of breast cancer 
recurrence, (e.g., tumor type or stage, age, ER, and human epidermal growth factor 
receptor 2 (HER-2) status)?  
b. Are there any other factors, which may not be components of standard predictors of 
recurrence (e.g., race/ethnicity or adjuvant therapy), that affect the clinical validity of 
these tests, and thereby generalizability of results to different populations? 
Clinical validity is defined as the degree to which a test accurately predicts the risk of an 
outcome (i.e., calibration), as well as its ability to separate patients with different outcomes into 
separate risk classes (discrimination). Clinical validity was documented to some degree for all 
three gene expression signatures. Oncotype DX was validated on a homogenous population of 
lymph node negative, ER positive patients all treated with tamoxifen, derived from an arm of an 
RCT, the National Surgical Adjuvant Breast and Bowel Project (NSABP-14). MammaPrint, on 
the other hand, was validated on samples from a clinical series with a wide range of clinical and 
treatment characteristics, and sometimes it was the signature and not the MammaPrint test itself 
that was validated. Data that made clear the incremental value of the test over standardized risk 
predictors using classical clinical factors, in the form of risk reclassification tables, was limited 
to Oncotype DX in one population, and for one of those predictors (Adjuvant! Online for 
MammaPrint). The evidence behind the two-gene test is quite heterogeneous, in that the specific 
manner in which the index was calculated differed in each, and only one examines the index that 
is to be used as part of the BCP (or H/I ratio) test in a study that was still using statistical 
methods to find optimal cut points, i.e., a training study. So the Oncotype DX test, which has 
been validated in exactly the form given to patients on clinically homogeneous samples with 
clear treatment implications, is regarded as the index with the strongest claim to clinical validity. 
It is not yet as clear to which populations MammaPrint best applies, and how much incremental 
value it would have within those clinically homogeneous populations above various standard 
predictors. Since the number of validation studies for any of the tests is still relatively small, 
more remains to be learned about stability between different populations of the relationship 
between expression-based score and the absolute observed risk. Essentially nothing is known 
about how specific characteristics of these populations might affect test performance. 
 While the H/I ratio test shows some promise, it must be regarded as still being in a 
developmental phase; it cannot yet be considered fully validated. It was not clear whether 
samples were processed by Quest Diagnostics, which hold the current license. There are a 
number of intriguing biological insights and plausible mechanisms to support the rationale for 
the test, but its consistent value in well-defined clinical settings has not yet been firmly 
established. 
 
 Key Question 4. What is the clinical utility of these tests? 
a. To what degree do the results of these tests predict the response to chemotherapy, and 
what factors affect the generalizability of that prediction? 
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b. What are the effects of using these two tests and the subsequent management options on 
the following outcomes: testing or treatment related psychological harms, testing or 
treatment related physical harms, disease recurrence, mortality, utilization of adjuvant 
therapy, and medical costs. 
c. What is known about the utilization of gene expression profiling in women diagnosed 
with breast cancer in the United States? 
d. What projections have been made in published analyses about the cost-effectiveness of 
using gene expression profiling in women diagnosed with breast cancer? 
Few studies addressed the clinical utility of Oncotype DX recurrence score (RS) in predicting 
the benefits of adjuvant chemotherapy, although the probability of recurrence represents an 
upper bound on the degree of absolute benefit. One fairly strong retrospective study produced 
preliminary evidence that the RS has predictive power in assessing the benefit of chemotherapy 
usage in ER-positive, lymph node negative breast cancer patients. This study was embedded 
within a large, well conducted RCT (National Surgical Adjuvant Breast and Bowel Project 
(NSABP B-20)). Some patients from the tamoxifen-only arm of the trial were in the training data 
sets for the Oncotype DX assay development, and this could potentially translate into a 
somewhat enhanced estimate of the discriminatory effect of Oncotype DX, although it is unlikely 
to eliminate entirely the effect seen here. Other studies produced preliminary evidence that the 
RS from the Oncotype DX assay has predictive power in assessing the likelihood of pathologic 
complete response after pre-operative chemotherapy with various drugs and regimens, although 
very limited sets of patients have been used. One study produced preliminary evidence that the 
RS cannot predict pathologic complete response after primary chemotherapy in advanced breast 
cancer patients. 
One study produced preliminary evidence that the knowledge of the RS from the Oncotype 
DX assay can have an impact on the clinical management of patients diagnosed with ER 
positive, lymph node negative, and early breast cancer. However, it did not report specifically 
what the patients (or doctors) were told or understood about their absolute risk of recurrence, and 
therefore was minimally informative as to the actual risk thresholds used by women and their 
treating physicians, or whether absolute risks even entered into the decision. 
There were no studies that addressed the clinical utility of the MammaPrint or H/I ratio tests. 
 Three published studies have addressed economic outcomes associated with use of the breast 
cancer gene expression tests. One study reported that using the 21-gene RT-PCR assay to 
reclassify patients who were defined by 2005 National Comprehensive Cancer Network (NCCN) 
criteria as low risk (to intermediate or high risk) would lead to an average gain in survival per 
reclassified patient of 1.86 years. The associated cost-utility of using recurrence score testing for 
this cohort was $31,452 per quality-adjusted life-year (QALY) gained. The analysis also reported 
that using the 21-gene RT-PCA assay to reclassify patients who were defined by 2005 NCCN 
criteria as high risk (to low risk) was cost saving. In a hypothetical population of 100 patients 
with characteristics similar to those of the NSABP B-14 participants, more than 90 percent of 
whom were NCCN-defined as high risk, using the 21-gene RT-PCR assay was expected to 
improve quality-adjusted survival by a mean of 8.6 years and reduce overall costs by about 
$203,000. However, the EPC team had only moderate confidence in the results of this analysis 
because the study was sponsored in part by the manufacturer of the 21-gene RT-PCR assay and 
the authors did not provide sufficient information about methodological and structural 
uncertainties as well as other potential sources of bias such as the derivation of the utility 
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estimates. Furthermore, the 2007 NCCN guideline indicates that the use of chemotherapy in 
these patients is now considered optional, further diminishing the usefulness of these projections. 
 The second study reported that use of the 21-gene RT-PCR assay was associated with a gain 
of 0.97 QALYs and a cost-utility ratio of $4432 per QALY compared with use of tamoxifen 
alone, and a gain of 1.71 QALYs with net cost savings when compared with the chemotherapy 
and tamoxifen combination. However, the EPC team had little confidence in the results of this 
analysis, which was supported in part by the manufacturer, because the study did not meet many 
of the standards that the team used for appraising the quality of the analysis.  
 The third study compared the cost-effectiveness of the Netherlands Cancer Institute gene 
expression profiling (GEP) assay (MammaPrint) to the U.S. National Institutes of Health (NIH) 
guidelines for identification of early breast cancer patients who would benefit from adjuvant 
chemotherapy. The GEP assay was projected to yield a poorer quality-adjusted survival than the 
NIH guidelines (9.68 vs. 10.08 QALYs) and lower total costs ($29,754 vs. $32,636). To improve 
quality-adjusted survival, the GEP assay would need to have a sensitivity of at least 95 percent 
for detecting high risk patients while also having a specificity of at least 51 percent. The EPC 
team had confidence in the results of this analysis because it met most of the standards for 
appraising the quality of an economic analysis. 
 Based on the appraisal of these three studies, the overall body of evidence on economic 
outcomes was inconclusive.  
 
Limitations of the Report 
 
     The report included only English publications and was restricted to three gene expression 
tests. 
 
Limitations of the Literature and Implications for  
Future Research 
 
 There are several issues that concern all of these tests.  
 
1. While all of the tests exhibit a fair bit of risk discrimination (i.e., separating patients into 
different risk groups), the calibration of the estimates (i.e., how close the predicted risk is 
to the observed risk) in varying settings is still not as well established. Of greatest interest 
is the observed risk in the lowest risk groups, since the absolute level of this risk is 
critical for informed decisionmaking, and patients may forego chemotherapy on the basis 
of this information. 
 
2. The manner in which the tests are best used–in combination with other prediction scores, 
as continuous scores, or as categorical predictors–has not been established. In addition, 
the current cut-points for designation of Low and High risks (with or without an 
intermediate category) are not clearly derived from decision-analytic criteria. 
 
3. The incremental value of these tests is best assessed from cross-classification tables that 
show how many subjects are placed in different risk categories (corresponding to 
different clinical decisions) by the addition of the information from the test in comparison 
6 
or in addition to standard predictors. Such tables have been developed for Oncotype DX, 
but for only one set of risk thresholds, and some of the conventional guidelines used for 
those comparisons have since been updated. 
 
4. In practice, pre-analytic issues related to sample preparation, transport and processing 
could cause the tests to perform differently in practice than in investigational contexts; 
continued monitoring of test procedures and performance will be important as they are 
used more widely. 
 
5. The relevance of validation studies in past tamoxifen-treated populations for current 
populations treated with aromatase inhibitors needs further research. 
 
6. Studies examining the use of the tests should provide women and physicians with 
quantitative risk information and report how this alters clinical decisionmaking. The 




1. The role of the RS in guiding treatment of HER-2 positive patients is unclear, as most of 
these patients were classified in the high RS group in the initial trials. 
2. While awaiting the TAILORx results, the findings of the Paik 2006 study predicting 




1. The prognostic value of the 70-gene signature has been assessed in different populations 
facing different therapeutic choices. In the analysis by van de Vijver and colleagues, 130 
of the 295 patients received adjuvant therapy in a non-randomized fashion. Patients in the 
original development cohort were not treated, and Buyse validated the marketed assay in 
untreated patients. It is not yet clear which are the optimal patient populations for the use 
of this test, exactly what its performance is in those populations, and how many of its 
predictions would result in different therapeutic decisions. Larger independent validation 
studies in therapeutically homogeneous groups would be very valuable. 
2. There is no evidence for the degree to which this test predicts the benefit of adjuvant 
chemotherapy. 
 
Breast Cancer Profile (H/I ratio) Test 
 
1. The BCP test is not yet as well validated as either of the other tests, with most of the 
supporting studies examining slightly different ways of either performing (e.g., different 
reference standards) or calculating the index. More work needs to be done documenting 
the risk discrimination and risk calibration of the marketed test in clinically homogeneous 
populations, as well as its incremental value. 




In addition to the conclusions above, a series of other observations were made on the basis of 




 In general, it is clear that validation studies need to deal with populations for whom the 
decision-making implications of various risk groupings are clear. For all tests except Oncotype 
DX, both validation and development studies have been on mixed populations, without sufficient 
sample sizes to stratify into large enough homogeneous groups to guide clinical decisionmaking. 
In addition, validation samples are often re-used by other investigators; the pool of such samples 
in the public domain needs to be greatly expanded. 
 
Potential for Scale Problems 
 
 One problem that may be faced in the future is that of the consequences of an increase in 
demand for these tests. Whether the degree of accuracy seen in investigational settings can be 
maintained with increasing demands should be monitored by scientific or regulatory bodies. 
 
Genetic Variability and Gene Expression 
 
 It is unknown whether gene expression profiles are more or less likely than more traditional 
biomarkers to be generalizable beyond the populations in which they were initially developed. 
Gene expression may reflect fundamental biological tumor features, and thus be relatively stable 
across ethnic groups. This speaks to the importance of validating these tests in populations with 
varying genetic background. Of particular interest will be the variation of the observed absolute 
risk in those populations, and its correlates. 
 
The Need for Databases, Reproducibility, and Standards 
 
 Consideration should be given to the development of databases with complete data on each 
patient tested with these and future tests (absent identifiers). The data should include all the 
analyses performed, laboratory logs, the raw and processed data, and all the information about 
procedures and analyses that have been performed to produce a risk estimate from a tumor 
sample.  
 
Where is the Field Going? 
 
 We can expect many new tests, as well as new uses for the assays that already exist. More 
genes might be added to the signatures, and in the particular case of MammaPrint this will be 
possible without changing the experimental procedures, since the array contains more genes than 
the ones that are incorporated in the 70-gene signature. In this regard, we might also expect other 
modifications: subsets of the current signatures might be proposed as alternatives to current 
clinical risk factors, or be proposed in different populations or for different purposes. For 
Oncotype DX, a natural evolution could be related to its use as an alternative to 
immunohistochemistry and/or pathology to evaluate tumor Grade, S-phase index, ER, 
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progesterone receptor, and HER2 expression, since such genes are part of the set included in the 
assay.  Reporting of individual gene expression results may also prove useful.  
 
“Comparative Effectiveness” Studies 
 
 As these tests mature and proliferate, an important question will be how they compare to 
each other, and whether there is value in their combination. In the therapeutic domain, this has 
been called “comparative effectiveness” research. Such research has traditionally been difficult 
to fund by government or by industry, because it may not hold out as much therapeutic promise 
as new discoveries, and because industry understandably is not anxious to fund head-to-head 
comparisons with competitive products. This same dynamic could easily take hold in the risk 
prediction arena, with a proliferation of licensed prediction indices without any clear notion of 
what new ones are contributing over previous tests. In this perspective, development of future 




 The introduction of these gene-expression tests has ushered in a new era in which many 
conventional clinical markers and predictors may be seen merely as surrogates for more 
fundamental genetic and physiologic processes. The multidimensional nature of these predictors 
demands both large numbers of clinically homogeneous patients to be used in the validation 
process, and exceptional rigor and discipline in the validation process, all with an eye toward 
how the test will be used in a clinical decisionmaking context. Every study provides an 
opportunity to tweak a genetic signature, but we must find the right balance between speed of 
innovation and development of scientifically and clinically reliable tools. Going forward, it will 
be important to harness, if possible, as much genetic and clinical information on patients who 






















 Breast cancer is the most commonly diagnosed cancer in women.1 This tumor is currently the 
second leading cause of cancer-related deaths in women in the U.S., with approximately 178,000 
new cases and 40,000 deaths expected among U.S. women in 2007.1  Treatment for breast cancer 
usually involves surgery to remove the tumor and involved lymph nodes. Frequently, surgery is 
followed by radiation therapy (in case of breast conservation or in women with large tumors or 
many involved lymph nodes), endocrine therapy (for essentially all women with tumors that are 
estrogen receptor (ER)-positive (see Appendix Aa for a list of acronyms), and/or chemotherapy 
(for women having a high risk for a poor outcome, such as those with large tumors, involved 
lymph nodes, advanced disease, or inflammatory breast cancer). Chemotherapy administered in 
addition to surgery is called “adjuvant” chemotherapy. More than three-quarters of all patients 
are expected to survive with this multi-modality approach.  
One major challenge in breast cancer treatment relates to the decision about whether or not to 
use adjuvant chemotherapy. Although adjuvant chemotherapy can reduce the annual odds of 
recurrence and death for many women with breast cancer, especially those with ER-negative 
tumors,2 it has considerable adverse effects. Even though most women with early-stage breast 
cancer are advised to undergo chemotherapy, not all will benefit from it and some may remain 
free of disease recurrence at 10 years without it, especially those with small tumors and ER-
positive disease. Decisionmaking protocols have been proposed with the intent of guiding 
clinicians involved in breast cancer treatment. Examples include the National Institutes of Health 
(NIH) Consensus Development criteria,3,4 the St. Gallen expert opinion criteria,5 the National 
Comprehensive Cancer Network (NCCN) guideline,6 and the computer-based algorithm 
Adjuvant! Online,7,8 which produces risk assessment and recommendations based on patient 
information, clinical data, tumor staging, and tumor characteristics (including age, menopausal 
status, comorbidity, tumor size, number of positive axillary nodes, and ER status). In addition, 
measurement of the human epidermal growth factor receptor 2 (HER-2) is now established as 
another predictive marker and has been incorporated into some of these indices,9 as it serves to 
identify candidates for adjuvant therapy with the monoclonal antibody trastuzumab (Herceptin®; 
Genentec, Inc., San Francisco, CA).  Such patients may also be candidates for adjuvant treatment 
with other new agents such as the tyrosine kinase anti-HER-2 inhibitor lapatinib (Tykerb®, GSK, 
PA) and the anti-vascular epithelial growth factor (VEGF) receptor antibody bevacizumab 
(Avastin®; Genentech), which are being studied in trials now in progress. With the proliferation 
of treatment advances in breast cancer, treatment decisions have become more complex, thereby 
increasing the demand for tests and predictive models that could help identify those patients most 
likely to benefit from specific therapies.  
 Breast cancer is increasingly understood as a broad umbrella label, with various tumor 
subtypes exhibiting different prognoses and different responses to the various treatment options 
available for use in the adjuvant setting.  Evidence from large randomized trials, and systematic 
reviews, forms the basis of the various treatment algorithms and nomograms described above.  
These tools help caregivers determine the risk of recurrence and death and the chances of 
                                                 
a   Appendixes cited in this report are provided electronically at: http://www.ahrq.gov/clinic/tp/brcgenetp.htm 
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benefiting from a specific therapy within a tumor subtype (e.g., anti-estrogens alone for ER-
positive disease, trastuzumab for HER-2-positive disease). Unfortunately, the predictive utility of 
these tools for an individual patient within a specific tumor subset is quite limited, and a large 
number of patients with ER-positive disease or HER-2-positive disease still experience tumor 
recurrence and die from their disease despite having received adjuvant anti-estrogen therapy or 
trastuzumab, respectively. Therefore, there is great interest in developing, testing, and validating 
strong predictive markers that can be used in daily clinical practice to accurately identify those 
patients most likely to benefit from specific therapy options such as chemotherapy, endocrine 
therapy, and anti-HER-2 therapy, alone or in combination.  
 
Gene Expression Profiling 
 
 Gene expression profiling (see Glossary, Appendix B) is an emerging technology for 
identifying genes whose activity may be helpful in assessing disease prognosis and guiding 
therapy. Gene expression profiling examines the composition of cellular messenger ribonucleic 
acid (RNA) populations. The identity of the RNA transcripts (see Glossary, Appendix B) that 
make up these populations and the number of these transcripts in the cell provide information 
about the global activity of genes that give rise to them. The number of mRNA transcripts 
derived from a given gene is a measure of the “expression” of that gene. Given that messenger 
RNA (mRNA) molecules are translated into proteins, changes in mRNA levels are ultimately 
related to changes in the protein composition of the cells, and consequently to changes in the 
properties and functions of tissues and cells in the body. However, only 2 percent of the genome 
(see Glossary, Appendix B) is translated into proteins, and little is known about how the 
expression of this 2 percent is controlled. The key intermediate is the transcriptome (see 
Glossary, Appendix B), which is made up of all the individual transcripts produced by the cell 
(see Figure 1). 
 
 
Figure 1: Increasing complexity of information from genome to transcriptome and proteome: gene 
expression profiling focuses on the analysis of the transcriptome. 
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 Investigators have developed approaches to gene expression analysis that have led to 
substantial advances in our understanding of basic biology. Gene expression profiling has been 
applied to numerous mammalian tissues, as well as plants, yeast, and bacteria.10-14 These studies 
have examined the effects of treating cells with chemicals and the consequences of 
overexpression of regulatory factors in transected cells. Studies also have compared mutant 
strains with parental strains to delineate functional pathways. In cancer research, such 
investigation has been used to find gene expression changes in transformed cells and metastases, 
to identify diagnostic markers, and to classify tumors based on their gene expression profiles (see 
Glossary, Appendix B).15-18 The use of this approach for specific clinical problems, however, is 
relatively recent and poses several challenges related to the validity, reproducibility, and 
reliability required for use in diagnostic or predictive testing. 
 In recent years, gene expression profiling has been successfully used in breast cancer 
research. For instance, distinct subtypes of breast tumors (such as tumors expressing HER-2) 
have been identified as having distinctive gene expression profiles, representing diverse biologic 
entities associated with differences in clinical outcome.19-23 Other investigators 24 have found 
gene expression signatures (see Glossary, Appendix B) associated with the ER and lymph node 
status of patients, thus identifying subgroups of patients with different clinical outcomes after 
therapy. From such studies, investigators have proposed a number of gene expression profiles 
that could be used to classify prognosis. In a case-control study from the Netherlands Cancer 
Institute (Amsterdam, the Netherlands), one such gene profile, consisting of 70 genes, was 
developed using archived frozen tissue from 78 young, node-negative women with breast 
cancer.21 In this study, tumors from patients who suffered rapid relapses after primary therapy 
had gene expression profiles that were quite distinct from those who remained disease-free. 
These gene expression profiles were then applied to a second validation set of 295 frozen tissue 
specimens collected from young women (including 61 patients from the previous cohort), 
yielding very similar results.25 Indeed, it appeared that this 70-gene profile more accurately 
predicted outcomes than did the traditional clinical criteria. Results from these preliminary 
studies further suggested that gene expression profiling may provide a powerful tool for 
estimating prognosis and the likelihood of benefit from selected therapeutic agents. 
 
Breast Cancer Assays on the Market 
 
 Three breast cancer gene expression profiling-based assays are now available in the U.S. 
These assays investigate the expression of specific panels of genes by measuring their RNA 
levels in breast cancer specimens using different techniques, real-time reverse transcription-
polymerase chain reaction (RT-PCR) 26 (Glossary) and DNA microarrays27 (see Glossary, 
Appendix B): 
 
1. The Oncotype DX™ Breast Cancer Assay (Genomic Health, Redwood City, CA) 
quantifies gene expression for 21 genes in breast cancer tissue by RT-PCR.28 This test is 
intended to predict the likelihood of recurrence in women of all ages with newly 
diagnosed Stage I or II breast cancer, lymph node-negative and ER-positive, who will be 
treated with tamoxifen, an anti-estrogen agent.  
2. The MammaPrint® Test is based on microarray technology, uses the 70-gene expression 
profile developed by van’t Veer and colleagues,21,25 and is marketed by Agendia 
(Amsterdam, the Netherlands). This is a prognostic test for women 61 years of age or 
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younger with primary invasive breast cancer who are lymph node-negative and ER-
positive or negative. The company voluntarily submitted this test to the U.S. Food and 
Drug Administration for approval under proposed new guidelines for such tests, and 
received such approval in February 2007. These guidelines were finalized in July 2007. 
3. The Breast Cancer Profiling Test is based on the expression ratio of the two genes 
HOXB13 and IL17RB, and for this reason is also known as the H/I ratio test. The assay 
was developed by AviaraDX and licensed to Quest Diagnostics, Inc. (Lyndhurst, NJ). 
This assay is based on RT-PCR and is offered to treatment-naïve women with ER-
positive, lymph node-negative breast cancer. 
 
All three tests have defined protocols for evaluating the tumor content of the specimens to be 
analyzed, preparing the RNA samples, normalizing the raw expression measurements, and 
computing summary indices which are related to patient prognosis. The characteristics of the 
assays, the gene panels used, and the procedures involved in the analysis are summarized in 
Table 1. Detailed descriptions of the genes can be found in Appendix C. These differences 
between tests must be taken into account in the evaluation of the available evidence about such 
tests. In the following section, we provide a brief description of the technologies that are used. A 




 RT-PCR is a molecular biology technique that combines reverse transcription with real-time 
PCR (see Glossary, Appendix B). This methodology allows the quantification of a defined RNA 
molecule. It is accomplished by reverse transcription of the specific RNA into its complementary 
DNA, followed by amplification of the resulting DNA using PCR. The quantification of the 
DNA produced after each round of amplification is accomplished by the use of fluorescent dyes 
that intercalate with double-stranded DNA, or by modified DNA oligonucleotide probes (see 
Glossary, Appendix B) that fluoresce when hybridized with complementary DNA. 
 In a PCR template, relative ratios of the product and reagent vary. At the beginning of the 
reaction, reagents are in excess, and template and product are present in low concentrations and 
do not compete with primer binding, so that the amplification proceeds at a constant, exponential 
rate. After this initial phase, the process enters a linear phase of amplification, and then in the 
late reaction cycles, the amplification reaches a plateau phase and no more product accumulates 
To achieve accuracy and precision, it is necessary to collect quantitative data during the 
exponential phase of amplification, since in this phase the reaction is extremely reproducible. In 
RT-PCR, this process is automated, and measurements are made at each cycle. Finally, several 
implementations of this technique allow multiple DNA species to be measured in the same 
sample (multiplex PCR), since fluorescent dyes with different emission spectra may be attached 
to the different probes. Multiplex PCR allows internal controls to be co-amplified with the target 
transcripts (see Glossary, Appendix B) and permits allele discrimination in single-tube, 





Figure 2: Quantitative RT-PCR. Panel A: PCR reaction using sets of quenched primers and probes. Panel B: 
binding of fluorescent probe molecules to double-stranded DNA. Panel C: fluorescence intensity curves for 
different dyes and samples: on the x-axis, the number of PCR cycle is shown, and on the y-axis, the 
corresponding fluorescence detected is indicated; the dashed line is used to calculate the cycle threshold 
for each sample. Panel D: computation of the relative levels of expression. 
  
 This technique is extremely sensitive. The development of novel chemistries and 
instrumentation platforms has led to widespread adoption of real-time RT-PCR as the method of 
choice for quantifying absolute changes in gene expression. Moreover, this technique has 
become the preferred method for validating results obtained from microarray analyses and other 




 The analysis of gene expression by microarray technology is based on the Watson-Crick 
pairing of complementary nucleic acid molecules. In this technique, a collection of DNA 
sequences, called probes (see Glossary, Appendix B), are “arrayed” on a miniaturized solid 
support (microarray) and used to detect the concentration of the corresponding complementary 
RNA sequences, called targets (see Glossary, Appendix B), present in a sample of interest. The 
advancements made in attaching or synthesizing nucleic acid sequences to solid supports and 
robotics have allowed investigators to miniaturize the scale of the reactions, and it is now 
possible to assess the expression of thousands of different genes in a single reaction.29-31 
 In the basic microarray experiment, RNA harvested from the sample of interest is labeled 
with a fluorescent dye and hybridized to the microarray, then incubated in the presence of RNA 
from a different sample labeled with a different fluorescent dye. In this two-color experimental 
design, samples can be directly compared to one another or to a common reference RNA, and 
their relative expression levels can be quantified. After hybridization, gray-scale images 
corresponding to fluorescent signals are obtained by scanning the microarray with dedicated 
instruments, and the fluorescence intensity corresponding to each gene investigated is quantified 
by specific software. After normalization, the intensity of the hybridization signals can be 
compared to detect differential expression by using sophisticated computational and statistical 





Figure 3: Schematic model for microarray hybridizations. Panel A: two-color scheme design. Panel B: single-
color design. 
 
Sources of Variability in Gene Expression Analysis 
 
 Gene expression analysis poses several general challenges that can affect the reproducibility 
and reliability of the measurements obtained. The control of such sources of variability is clearly 
a concern when such technologies are used to make decisions about the clinical management of 
patients. Given the complexity of the procedures used in this type of investigation, the sources of 
uncertainty are multiple, from the preparation of tissue specimens to the computational analysis 
used to quantify expression levels. 
 The first source of variability relates to the various types of specimens that can be used to 
prepare the RNA to be used in gene expression analysis, including tissue specimens obtained in 
vivo. In this case, the resulting RNA template will be a mixture of the RNA content of all the 
cells contained in the specimen, and the relative content of the different cell populations 
(malignant vs. normal) present in the specimen processed is a major source of variability in gene 
expression. For this reason, special care must be taken when tumors are sampled for gene 
expression analysis. In general, macro- or micro-dissection of the samples is performed to ensure 
that the specimens contain a sufficient percentage of cancer cells. 
 A second major source of variability is related to the protocols used to prepare the specimens, 
since several alternatives have been used in the field, including the use of formalin-fixed, 
paraffin-embedded (FFPE) tumor specimens or laser-captured, micro-dissected (see Glossary, 
Appendix B) specimens and fresh or snap-frozen samples. Other factors likely to affect RNA 
quality include storage time and the reagents, and particular batches used. Unlike DNA, RNA is 
very unstable. The degradation of RNA can be triggered by pH changes as well as by specific 
enzymes called ribonucleases (see Glossary, Appendix B) that are present in cells and that can 
remain active in the RNA preparation if the RNA isolation is not properly carried out. 
 Watson-Crick hybridization of complementary nucleic acid moieties is the fundamental 
principle that forms the basis of any gene expression analysis. For this reason, sequence selection 
and gene annotation (see Glossary, Appendix B) are among the most relevant factors that can 
contribute to variability in the analysis of gene expression. 
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 As in any other laboratory investigation, the use of different platforms (see Glossary, 
Appendix B), protocols, and reagents can also affect the variability of the obtained 
measurements, and thus the reproducibility within and across laboratories. Indeed, numerous 
platforms exist to perform both RT-PCR and microarray-based gene expression analyses. 
Moreover, within each technique, the same procedure can be performed using different 
instruments, each with its own different operational characteristics and performance. 
 Finally, since gene expression measures are virtually never used as raw output but rather 
undergo sequential steps of mathematical transformation, another source of variability is data 
pre-processing and analysis. Moreover, the levels of gene expression can be further processed 
and combined according to complex algorithms to obtain composite summary measurements that 
are associated with the phenotypes investigated. 
 International standards have been developed to address the quality of microarray-based gene 
expression analysis, focusing on documentation of experimental design, details, and results (see 
MIAME in Glossary, Appendix B).32 Several publications also have addressed the levels of 
reproducibility across platforms and laboratories.33,34 Such efforts emphasize the importance of 
trying to control the many described sources of variability in gene expression analysis and of 
ensuring that the information derived from such analyses is specific and does not represent 
accidental associations. 
 
Objectives of the Evidence Report 
 
 The overall purpose of this evidence report is to review and synthesize the available evidence 
concerning the analytic and clinical validity of breast cancer gene expression profiling in 
predicting disease recurrence, as well as its efficacy and effectiveness in improving 
chemotherapy choices and subsequent outcomes (clinical utility) in women newly diagnosed 
with early-stage breast cancer. The report was prepared by the Evidence-based Practice Center 
(EPC) at the Johns Hopkins University (JHU) Bloomberg School of Public Health in response to 
a task order issued by the Agency for Healthcare Research and Quality (AHRQ) on behalf of the 
Centers for Disease Control and Prevention (CDC) Evaluation of Genomic Applications in 
Practice and Prevention (EGAPP) Project. The key questions we were charged with addressing 
in this evidence report were: 
 
1.  What is the direct evidence that gene expression profiling tests in women diagnosed with 
breast cancer (or any specific subset of this population) lead to improvement in 
outcomes? 
2.  What are the sources of and contributions to analytic validity in these gene expression-
based prognostic estimators for women diagnosed with breast cancer? 
3.  What is the clinical validity of these tests in women diagnosed with breast cancer? 
a. How well does this testing predict recurrence rates for breast cancer when compared 
to standard prognostic approaches? Specifically, how much do these tests add to 
currently known factors or combination indices that predict the probability of breast 
cancer recurrence (e.g., tumor type or stage, ER and HER-2 status)?  
b. Are there any other factors, which may not be components of standard predictors of 
recurrence (e.g., race/ethnicity or adjuvant therapy), that affect the clinical validity of 
these tests and thereby the generalizability of the results to different populations? 
4.  What is the clinical utility of these tests? 
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a. To what degree do the results of these tests predict the response to chemotherapy, and 
what factors affect the generalizability of that prediction? 
b. What are the effects of using these two tests and the subsequent management options 
on the following outcomes: testing- or treatment-related psychological harms, testing- 
or treatment-related physical harms, disease recurrence, mortality, utilization of 
adjuvant therapy, and medical costs? 
c. What is known about the utilization of gene expression profiling in women diagnosed 
with breast cancer in the United States? 
d. What projections have been made in published analyses about the cost-effectiveness 
of using gene expression profiling in women diagnosed with breast cancer? 
 
 This task is of particular relevance, since the National Cancer Institute (NCI) recently 
announced its sponsorship of a clinical trial to be conducted by The North American Breast 
Cancer Intergroup (TBCI) assessing individualized options for breast cancer treatment: the Trial 
Assigning Individualized Options for Treatment (TAILORx). In this trial, tumors of patients with 
ER-positive and lymph node-negative breast cancer (and who will be treated with tamoxifen) 
will be tested using the Oncotype DX assay, and patients will be divided into groups according to 
the recurrence scores derived from the use of the assay. Patients showing low recurrence scores 
will receive endocrine therapy alone, while patients with high recurrence scores will receive 
endocrine therapy and adjuvant chemotherapy. Patients with mid-range scores will receive 
endocrine therapy and be randomly assigned to chemotherapy or no chemotherapy. This trial is 
designed to evaluate the treatment implications of Oncotype DX results in a large representative 
patient population, focusing primarily on patients with intermediate recurrence scores. The trial 
will also allow for generation of new data on patients with recurrence scores near the ends of the 
spectrum. Patients at the low end of the recurrence score spectrum will be compared to a pre-
specified target of 95 percent recurrence-free survival. It should be noted that the cutoff values 
used in the TAILORx trial are different than those delineated in other studies of Oncotype DX. 
The results of the TAILORx trial will not be available for some time (around 2013) and with 
growing interest in and use of these tests (particularly Oncotype DX) in the oncology 
community, this evidence review could have an impact on clinical practice in the interim.35  
 A separate trial (MINDACT, or Microarray in Node-negative Disease may Avoid 
ChemoTherapy) has recently been activated by TRANSBIG (Translating molecular knowledge 
into early breast cancer management: building on the Breast International Group (BIG)), a 
research network of 39 institutions in 21 countries. The trial will compare two different ways of 
assessing the risk of cancer recurrence and making therapeutic decisions: a “traditional method” 
using Adjuvant! Online versus the MammaPrint assay. The rationale for this study is that many 
women who actually have “low risk” tumors are currently classified as “average” or “high risk” 
and therefore ultimately are recommended to receive adjuvant chemotherapy that ultimately may 
be of no benefit. The investigators estimate that 12-20 percent of women with early-stage breast 
cancer fall into this category.36  
 
Structured Approach to Assessment of the Questions 
 
 The EPC team used a structured approach to assess the evidence regarding the key questions 
listed above. The structured approach was based on the following questions: 
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1. What was tested? One fundamental concept is the distinction between the investigated 
gene expression signatures (see Glossary, Appendix B) and the actual gene expression-
based tests. The gene “signature” is the collection of genes whose expression levels are 
measured in a given test, together with the algorithm that combines those levels into a 
prognostic index; akin to a test’s “recipe.” But just like a recipe can be implemented in 
subtly different ways with different results, this signature can be measured using a variety 
of technologies and procedures which may not be identical to those used in the actual 
marketed test being offered to patients. This distinction is important because clinicians’ 
decisions, patients’ choices, and the resulting benefits and harms will ultimately depend 
on the performance of marketed tests rather than on the more general gene expression 
signatures, although they typically track closely. Information about the signatures is 
highly relevant to the assessment of the marketed test, but is not identical. 
2. What population was tested? This question required consideration of whether the study 
involved a representative sample of patients, from a clinical series or from a clinical trial 
subject to detailed eligibility criteria. This also required consideration of whether the 
population was clinically homogeneous enough for the implications of risk prediction to 
be clear and similar for every member of the study population (or for each subgroup). For 
example, predicting the relapse of patients on tamoxifen therapy may be different than 
predicting outcomes for untreated patients. The latter tests “intrinsic tumor 
aggressiveness,” which may not be the same as the factors that determine resistance to 
tamoxifen.   
3. Was the study a developmental or validation study? Developmental studies were defined 
as the original reports in which new gene expression signatures were first described or in 
which previously developed gene expression signatures were first proposed to have a use 
different from the original use (e.g., the use on different subsets of patients with different 
purposes). Validation studies were defined as those that confirmed results in independent 
populations (with approximately the same characteristics as the population of the 
corresponding development study). If a developmental study, were appropriate statistical 
methods used to adjust for multiplicities, and was internal validation done? If a validation 
study, were all the test procedures, cutoffs, definitions, and measurements predefined?  
4. Is it clear, from a clinical decisionmaking perspective, what is the incremental value of 
the test over and above standardized clinical predictors? It was not sufficient to simply 
insert clinical predictors into regression equations since this does not properly quantify 
the numerical consequences of decisions made with and without the new test. 
5. Were the ways in which the tests had been evaluated optimal for clinical 
decisionmaking? This question required consideration of the choice of cutoffs, definition 
of categories, and combinations (or lack thereof) with other predictors. 
6. What was the strength of the study design used to estimate clinical utility? Randomized 
controlled trials, with all samples taken concurrently, which could have taken place in the 
past, provide the strongest evidence of utility.  
7. For studies of clinical utilization, what specific information was provided to patients and 
their physicians? Such studies are informative only if they are specific about the 
information that was given and how it informed decisionmaking.  
  
 Using this structured approach, the EPC team evaluated the evidence regarding the key 
questions of analytic validity, clinical validity, and clinical utility of each test, evaluated 
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separately. The EPC team then used the review of the evidence to formulate both test-specific 
and general conclusions. 
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Chapter 2. Methods 
 
 
 The CDC submitted a request for an evidence report on the “Impact of Gene Expression 
Profiling Tests on Breast Cancer Outcomes” to the AHRQ on behalf of the EGAPP. This 
evidence report will be used to inform the CDC’s Working Group as part of their work in 
formulating evidence-based recommendations. Our project consisted of recruiting technical 
experts, formulating and refining the specific questions, performing a comprehensive literature 
search, summarizing the state of the literature, constructing evidence tables, and submitting the 
evidence report for peer review. 
 
Recruitment of Technical Experts and Peer Reviewers 
 
 At the beginning of the project, we assembled a core team of experts from JHU who had 
strong expertise in medical oncology, clinical trials, and biostatistics as well as a special interest 
in gene expression profiling tests. We also recruited external technical experts from diverse 
professional backgrounds, including academic, clinical, and corporate settings. The core team 
asked the technical experts and members of the EGAPP working group to give input regarding 
key steps of the process, including the selection and refinement of the questions to be examined. 
Peer reviewers were recruited from professional societies with an interest in breast cancer and 
gene expression profiling tests. Representatives from Agendia (MammaPrint®), Genomic Health, 
Inc. (Oncotype DX™), and  Quest Diagnostics, Inc.® (BCP or H/I ratio) were also asked to 




 The core team worked with the technical experts and representatives of the EGAPP and 
AHRQ to develop the Key Questions that are presented in the Specific Aims section of Chapter 1 
(Introduction).  The Key Questions apply to any gene expression profiling test, but they have 
been focused primarily on two gene expression profiling tests; Oncotype DX, and MammaPrint, 
because these are the tests that were expected to be commercially available in 2007. During the 
course of this review, the third gene expression profiling test, the Breast Cancer Profiling (BCP, 
or H/I ratio) Test (AviaraDX through Quest Diagnostics, Inc.) came to our attention. Although 
the BCP test was not included in our initial consideration of the Key Questions, we added studies 
regarding this test as an example of the types of gene expression profiling tests that are likely to 
be available in the coming years. 
 
Literature Search Methods 
 
 Searching the literature involved identifying reference sources, formulating a search strategy 
for each source, and executing and documenting each search. For the searching of electronic 
databases we used medical subject heading (MeSH) terms that were relevant to breast cancer and 
                                                 
a Appendixes cited in this report are provided electronically at: http://www.ahrq.gov/clinic/tp/brcgenetp.htm 
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gene expression profiling. We used a systematic approach for searching the literature to 
minimize the risk of bias in selecting articles for inclusion in the review. In this systematic 
approach, we were very specific about defining the eligibility criteria for inclusion in the review. 
The systematic approach was intended to help identify gaps in the published literature.  
 This strategy was used to identify all the relevant literature that applied to our Key Questions. 
The team specifically looked for articles that would provide information about the gene 
expression profiling tests identified in the Key Questions. We also looked for eligible studies by 
reviewing the references in eligible studies and pertinent reviews, by querying our experts, by 





Our comprehensive search plan included electronic and hand searching. On January 9, 2007, 
we ran searches of the MEDLINE® and EMBASE® databases, and on February 7, 2007, we 
searched the Cochrane database, including Cochrane Reviews and The Cochrane Central 
Register of Controlled Trials (CENTRAL), and CINAHL®. All searches were limited to articles 
published in 1990 or later. This cut-off year was established based on the introduction date of the 
MeSH heading “gene expression profiling,” 2000, and the introduction date of the MeSH 
heading “gene expression,” 1990. Also, test searches of earlier dates returned limited and 
irrelevant results. 
 “Gray” literature was searched following a protocol that was reviewed and approved by 
EGAPP and the technical expert panel:  
1.   Conference abstracts were reviewed using the same criteria as for journal articles but 
were only included if we felt we had a sufficient understanding of the underlying study 
and the data reported were critical enough to merit inclusion.  
 2.  Web sites for the gene profiling tests included in this review, Agendia (MammaPrint®) 
and Genomic Health (Oncotype DX™), were searched for additional information not 
available in the peer-reviewed literature.  
 3.  Agendia and Genomic Health, Inc. were contacted directly with requests for the 
following information:  
  a.  A listing of articles that applied to the analytic validity or clinical utility of the gene   
profiling test,  
  b.  Marketing materials on the gene profiling test, and  
  c.  Any pertinent unpublished data.  
 4.  We searched the Web site of the Food and Drug Administration (FDA) Center for 
Devices and Radiological Health for additional publicly available, unpublished 
information. 37-39  
 5. A request was sent to the Center for Medical Technology Policy (CMTP) Gene 
Expression Profiling for Early Stage Breast Cancer Work Group to provide all 
background materials available on our study topic.  
 
Search Terms and Strategies 
 
 Search strategies specific to each database were designed to enable the team to focus 
available resources on articles most likely to be relevant to the Key Questions. We developed a 
23 
core strategy for MEDLINE, accessed via PubMed, based on an analysis of the MeSH terms and 
text words of key articles identified a priori. The PubMed strategy formed the basis for the 
strategies developed for the other electronic databases (see Appendix F). 
 
Organization and Tracking of the Literature Search 
 
 The results of the searches were downloaded into ProCite® version 5.0.3 (ISI ResearchSoft, 
Carlsbad, CA). Duplicate articles retrieved from the multiple databases were removed prior to 
initiating the review. We then reviewed the citations by scanning the titles, abstracts, and the full 




 To efficiently identify citations that were obviously not relevant, paired reviewers first 
independently scanned the article titles.  For a title to be eliminated at this level, both reviewers 




Inclusion and Exclusion Criteria 
 
 The abstract review phase was designed to identify articles that reported on the analytic 
validity, clinical validity, and/or clinical utility of the gene expression profile tests of interest. 
Abstracts were reviewed independently by two investigators and were excluded only if both 
investigators agreed that the article met one of the following exclusion criteria:  
 1. The study applied only to breast cancer biology;  
 2. The study did not involve Oncotype DX or MammaPrint,  
 3.  The study did not involve original data or original data analysis;  
 4.  The study did not involve women;  
 5.  The study did not involve breast cancer patients;  
 6. The study was not in the English language; or  
 7.  The study did not apply to the key questions.  
 We excluded letters to the editor and editorials when they did not present original data 
(usually in the form of electronic supplements in the case of letters). If a letter or editorial cited  
Some original data, it generally was not sufficiently original for consideration in this report. As 
mentioned earlier, the initial scope of this project did not include the H/I ratio test, and thus this 
test was not identified on the abstract review form (Appendix G, Abstract Review Form). 
 Abstracts were promoted to the article review level if both reviewers agreed that the abstract 
could apply to one or more of the key questions. Differences of opinion regarding abstract 







 Full articles selected for review during the abstract review phase underwent another 
independent review by paired investigators to determine whether they should be included in the 
full data abstraction. At this phase of review, investigators determined which of the Key 
Questions each article addressed (see Appendix G, Article Inclusion/Exclusion Form). If articles 
were deemed to have applicable information, they were included in the final data abstraction. 
Differences of opinion regarding article eligibility were resolved through consensus adjudication. 






































* See Methods section for details 
 † Total is greater than 1144, reviewers were allowed to choose more than one reason for exclusion at this level. 
 ‡ Gene expression profile tests of interest: Oncotype DX (Genomic Health, Inc.), MammaPrint (Agendia), and The Two-gene 
Ratio (Quest Diagnostics, Inc.) 
║Total number of articles retrieved, 25. The Two-gene Ratio articles are not included in the body of the report but were pulled as 
articles of interest for comparison. One article applied to both the MammaPrint test and the Two-gene ratio test. 
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Reasons for Exclusion  
at the Abstract Review Level†  
 
Article applied only to cancer biology: 37 
Article applied to single or multiple gene predictors not involved 
in one of the gene expression profile tests of interest:‡ 150 
Article does not involve one of the three gene expression tests 
of interest: 659 
No original data or original analyses: 75 
Study does not involve women: 2 
Does not involve breast cancer patients: 10 
Does not apply to the key questions: 472 
Letter to the editor/editorial: 199 
Reasons for Exclusion  
at the Article Inclusion/Exclusion Level 
 





 The purpose of the article review was to confirm the relevance of each article to the research 
questions and to collect evidence that addressed the questions. Articles eligible for full review 
had to address one or more of the Key Questions. Because of the heterogeneous nature of the 
applicable literature, we used a loosely structured approach for extracting data from the studies. 
Reviewers were given a standard matrix in which to enter data from each article (Appendix G, 
Data abstraction tables). 
 For all the data abstracted from the studies, we used a sequential review process. In this 
process, the primary reviewer completed all data abstraction forms. The second reviewer 
checked the first reviewer’s data abstraction forms for completeness and accuracy. Reviewer 
pairs were formed to include personnel with both clinical and methodological expertise. 
Reviewers were not masked to the articles’ authors, institutions, or journal.40 In most instances, 
data were directly abstracted from the article. If possible, relevant data were also abstracted from 
the figures. A number of articles provided links to supplemental data, and these resources were 
used during the data abstraction process. Differences of opinion were resolved through 
consensus adjudication.  
 For all articles, reviewers extracted information on general study characteristics, such as 
study design, study participants, and sample size (see Appendix G, Data abstraction tables). Data 
abstracted regarding participants’ characteristics were: information on intervention arms, age, 
menopausal status, race, diagnoses, methods of diagnosis, exclusion criteria, treatments, and 
treatment outcomes.  
 An analytic validity (Key Question 2) data abstraction matrix was developed by the team (see 
Appendix G, Data abstraction tables). Our data abstraction was designed to capture data in the 
following general areas: tumor specimens’ processing validity, annotation validity; within- and 
across-laboratory validity; and validity associated with gene expression data preprocessing and 
analysis. 
 Studies addressing clinical validity (Key Question 3a, 3b) and utility (Key Question 4a, 4b, 
4c) were approached in a similar manner (see Appendix G, Data abstraction tables). The free-
form tables developed for these questions were designed to capture details regarding a study’s 
context, the methods used to analyze the data collected, results of the study, and conclusions 
made by the study authors. 
 Only three articles addressed the cost-effectiveness of the gene expression profiling tests. 
Therefore, the reviewers did not use standardized data abstraction forms to abstract results from 
these studies. Instead, the reviewers extracted information directly into the table that is presented 
as Evidence Table 5. Please refer to the Philips, 2004 41 article for a detailed explanation of why 




 We used a synthesis of the general principles of the REporting recommendations for tumour 
MARKer prognostic studies (REMARK)42 and Standards for Reporting of Diagnostic Accuracy 
(STARD)43 guidelines. The REMARK guidelines were developed to encourage transparent and 
relevant reporting of study design, preplanned hypotheses, patient and specimen characteristics, 
assay methods, and statistical analysis methods, in order to help others judge the usefulness of 
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the data presented.42 STARD was developed to improve the accuracy and completeness of 
studies reporting diagnostic accuracy, in order to allow readers to assess the potential for bias in 
a study and to evaluate the generalizability of the results43 (Appendix G, Quality Assessment 
Matrix). 
 Because of the extreme variability of the articles included in this report, we did not 
systematically apply the general principles to them. The strengths and weaknesses of each study 
were also dependent on the question(s) to which it applied. These strengths and weaknesses are 
highlighted in the Results section and the Discussion. 
 The EPC team appraised economic analyses using published guidelines for good practice in 
decision-analytic modeling in health technology assessment (Phillips 2004). The appraisal took 





 We created a set of detailed evidence tables containing all the information extracted from 
eligible studies and stratified the tables according to the gene expression profile test. The 
investigators reviewed the tables and eliminated items that were rarely reported. They then used 
the resulting versions of the evidence tables to prepare the text of the report and selected 
summary tables.  
 
Data Entry and Quality Control 
 
 Initial data were abstracted by the investigators and entered directly into the data abstraction 
tables. Second reviewers were generally more experienced members of the research team, and 
one of their main priorities was to check the quality and consistency of the first reviewers’ 
answers. In addition to the second reviewers checking the consistency and accuracy of the first 
reviewers, a senior investigator examined all reviews to identify problems with the data 
abstraction. If problems were recognized in a reviewer’s data abstraction, the problems were 
discussed at a meeting with the reviewers. In addition, research assistants used a system of 
random data checks to assure data abstraction accuracy. 
 
Grading of the Evidence 
 
 After reviewing the available evidence on the Key Questions, the core team concluded that it 
would be inappropriate to grade the overall body of evidence using any of the published schemes 
for grading evidence. None of the grading schemes fit the nature of the data in these studies 
about gene expression profiling tests. The team therefore decided that it was more appropriate to 




 Throughout the project, the core team sought feedback from the external technical 
experts and the EGAPP Working Group through ad hoc and formal requests for guidance. A 
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draft of the report was sent to the technical experts and peer reviewers, as well as to 
representatives of AHRQ, the CDC, the NIH, and the FDA. In response to the comments from 
the technical experts and peer reviewers, we revised the evidence report and prepared a summary 
of the comments and their disposition that was submitted to the AHRQ. 
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Chapter 3. Results 
 
Key question 1. What is the direct evidence that gene 
expression profiling tests in women diagnosed with breast 
cancer, or any specific subset of this population, lead to 
improvement in outcomes? 
 
 In a study defined as providing direct evidence of improvement in outcomes, the use of the 
test in decisionmaking is compared to not using the test, with health outcomes as an endpoint, 
generally in the form of an RCT. There is currently no direct evidence that the investigated gene 
expression profiling tests lead to improvement in outcomes in any subset of women diagnosed 
with breast cancer. Two ongoing RCTs aim to provide almost direct evidence for Oncotype 
DX™, and for MammaPrint®. These studies are described at the end of this chapter. 
 
 
Key question 2. What are the sources of and contributions to 
analytic validity in these gene expression-based prognostic 
estimators for women diagnosed with breast cancer? 
 
 Analytical validity is usually assessed by determining how much observed measurements 
differ from expected values derived from a standard reference method.  In the measurement of 
gene expression, however, universal standard reference RNAs and universally accepted, 
definitive methods of analysis are not available. Consequently, a definitive evaluation of the 
analytic validity of such type of test is difficult. It is more appropriate to focus instead on test 
variability. In clinical use, gene expression-based prognostic tests involve multiple steps with 
individual components that are difficult to separate. Ultimately, reproducibility of patient 
classification into clinically relevant risk groupings is what matters.  From this perspective, the 
most important sources of variability are tumor sampling and handling, specimen preparation, 
and biologic variation within and between different samples of the same tumor.  The analytic 
validity of expression-based tests can therefore be assessed by asking the following questions: 
  1. How reproducible is the test when applied repeatedly to the same patient, either by 
examining the same specimen, or a different specimen? 
2. How reproducible is the test over time? 
3. What are the factors that most affect the overall performance of the test? 
 Few existing studies directly address analytical issues involved with the assays, and 
additional information could only be collected from clinical studies. Overall, this evidence was 
heterogeneous, spanning technical aspects, reproducibility, the number of successfully performed 
assays, or the comparison of RNA and protein levels of individual genes. Table 1 describes the 







 Evidence about the analytic validity of Oncotype DX is available from two technical studies, 
Cronin et al, 2004,44 and Cronin et al. 2007,45) and from several clinical reports. Information 
about the overall success rate of the assay was documented in 9 studies (Chang, 2007,55 
Cobliegh, 2005,47 Esteva, 2005,48 Gianni, 2005,49 Habel, 2006,50 Mina, 2006,51 Oratz, in press,52 
Paik, 2004,28and Paik, 200653). This success rate ranged from 78.9 percent to 98.9 percent, and 
only some of the studies provided detailed descriptions of the reasons for assay failure. Reported 
failures were mainly ascribed to an insufficient number of cancer cells in the specimens, to poor 
RNA quality, and in a few cases, to failure of the RT-PCR technique. A synopsis of this evidence 
is provided in Table 2. 
 Data on assay variability and reproducibility were available from 3 studies (Cronin, 2007,45 
Habel, 2006,50 and Paik, 200428). These studies assessed the variability of repeated gene 
expression measurements using RNA from either the same or different FFPE blocks at repeated 
time points, and across different instruments and operators. Data reported in the study concerned 
the variability of individual genes in the assay as well as the RS reproducibility. Variability 
evidence was reported for 66 FFPE blocks from 22 distinct patients, and from repeated 
measurements of two aliquots of a pooled reference RNA. Overall, the standard deviation (SD) 
for the recurrence score was below 3 RS units, although the authors did not discuss the impact on 
risk stratification. This evidence is reported in Table 3. 
 Two studies addressed technical and operational aspects of analytic validity (Cronin, 2004,44 
and Cronin, 200745). The first study presented data about the development the assay procedures, 
comparing gene expression measurements between frozen tumor specimens and FFPE blocks.  
The optimization of the RT-PCR primers (see Glossary, Appendix B1), and the normalization 
strategy were discussed. The second study addressed relevant analytic components of the assay, 
such as detection and quantification limits (limit of detection (LOD) and limit of quality (LOQ) 
respectively), amplification efficiency, linearity, dynamic range, accuracy, precision, and assay 
reproducibility. The available evidence is reported in Table 4. 
 Finally, eight studies (Chang, 2007,55 Cobliegh, 2005,47 Esteva, 2005,48 Gianni, 2005,49 
Cronin, 2004,44 Habel, 2006,50 Mina, 2006,51 and Paik, 200428) compared gene expression 
measurements of specific individual genes (ER, progesterone receptor (PR), HER-2) to 
measurements of the corresponding proteins produced by those genes as obtained by other 
techniques, in particular immunohistochemistry (IHC). Such studies used various cycle 
thresholds (CTs) to define positivity for the genes (see Table 5). Overall agreement between RT-
PCR and IHC proved generally good for ER (k statistics ranging from 0.80 to 1). In one study 
(Habel, 200650), agreement was low (0.49), although RT-PCR measurements were comparable to 
data available in the clinical records.  In general, agreement for PR and HER-2 was moderate or 
poor. Such evidence is reported here for completeness (see Table 5), although it does not contain 
any relevant information about the assay as a whole. 
 Individual studies are briefly described below.  
 
                                                 
1 Appendixes cited in this report are provided electronically at: http://www.ahrq.gov/clinic/tp/brcgenetp.htm 
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 Cronin et al., 2004.44 In this study, the authors discussed the primer (see Glossary, Appendix 
B) design optimization and expression level normalization necessary to obtain reliable RT-PCR 
measurements from archival FFPE samples, with the goal of establishing the reliability of their 
results with partially degraded RNA samples. The authors compared gene expression levels in 62 
matched FFPE and frozen tissue specimens prepared from the same breast tumor.  They showed 
that the relative expression profiles obtained from the two analyses were similar (correlation = 
0.91, P value < 0.0001), although the magnitude of the measurements differed. They successfully 
corrected the differences using normalization based on the expression of five reference genes. 
Convincing evidence supporting the use of the implemented protocols in assessing gene 
expression levels from archival (i.e., formalin-fixed, paraffin-embedded) tumor specimens was 
shown. 
 The authors also analyzed several genes that were reported to show similar patterns in the 
literature20 for co-expression,54 and confirmed these correlations. Specifically, the expression of 
cytokeratin 5 and cytokeratin 17 (r = 0.85), LPL and RBP4 (r = 0.84), HER-2 and GRB7 (r = 
0.71), ER1 and GATA3 (r = 0.6) were highly correlated. 
 Additionally, the authors compared RT-PCR measurements of ER, PR, and HER-2 (all 
components of Oncotype DX) expression to IHC analysis of corresponding protein levels, and to 
fluorescent in situ hybridization (FISH) analysis for HER-2 for a subset of 17 samples. The 
concordance among the different assays detecting the protein products of the genes and the 
relative RNA levels as measured by RT-PCR was high (94 percent, 84 percent, and 100 percent, 
respectively, see Table 5). 
 In summary, this study provided a foundation for the use of the Oncotype DX assay in 
archival tissue, although it did not contain data about the development of the RS (Appendix I, 
Evidence Tables 1, 2 and 3). 
 Paik et al., 2004.28 In this clinical study, the authors reported data on the variability of the 
RS, and the overall success rate of the assay. The authors evaluated the reproducibility of the 
Oncotype DX assay within and between FFPE blocks from the same patient. The Oncotype DX 
assay was carried out on 5 serial sections from 6 different blocks from 2 distinct patients.  
Seventy nine blocks out of 754 were not analyzed due to insufficient tumor content, but RT-PCR 
was successful in 668 of the remaining 675 (98.9 percent) tissue blocks.  
 For the 16 genes considered in the RS, the SD of expression ranged from 0.07 to 0.21 
expression units across serial sections from the same block. The within-block SD of the 
combined RS proved to be 0.72 RS units (with 95 percent CI: 0.55–1.04), while the within-
patient SD, which included both among-block and within-block variation, proved to be 2.2 RS 
units. The impact of this variation on the risk stratification provided by the RS was not discussed 
in the paper. The difference between the low- and high-risk groups is 14 RS units, far larger than 
the standard deviations reported. Although ER, PR and HER-2 were also assessed by other 
techniques, the agreement of the measurement obtained by the different technologies was not 
reported. 
 In summary, this paper reported evidence about the fraction of tissue blocks that can be 
successfully typed by the Oncotype DX  assay, as well as limited data about the reproducibility 
of the RS between different sections and FFPE blocks from the same patient. The impact of such 




 Esteva et al., 2005.48 In this study, the authors evaluated the correlation of RS, both as a 
whole and broken into its components, with known standard prognostic markers in FFPE tumor 
specimens. Specifically, the relationship between RT-PCR and IHC for ER, PR, and HER-2 was 
examined. The concordance for PR status was poor (k of 0.48), high for ER (k = 0.81), and 
proved moderate for HER-2 (k = 0.60).  
 A logistic model using IHC HER-2 measurement as a quantal response indicated a 
significant (P < 0.0001) degree of correlation between IHC and RT-PCR. Sensitivity and 
specificity for HER-2 were also measured, using different RT-PCR cutoff points and positivity, 
and are reported in Table 5. 
 In summary, this paper reported evidence about the percentage of successfully-analyzed 
samples (67.7 percent, 149/220) in a large population from a single institution (M.D. Anderson 
Cancer Center) (Table 5, Appendix I, Evidence Tables 1, 2 and 3). 
 Cobleigh et al., 2005.47 This study reports on the development of the 21-gene Recurrence 
Score assay (Oncotype DX), Duplicated gene expression measures were obtained by RT-PCR in 
archival FFPE tumor tissue blocks. An initial set of 192 genes (187 cancer-related and 5 
controls) were analyzed and 16 additional candidate genes were added at a later time. Ninety-one 
point six percent (78/85) of samples were successfully analyzed 
 IHC-measured protein levels and RT-PCR mRNA levels for ER, PR, HER-2, and Ki-
67/MIB-1 (a proliferation marker of cancer cells) were compared. The concordance was high for 
both ER (k = 0.83) and HER-2 (k = 0.67), somewhat lower for PR (k = 0.40), and poor for Ki-67 
(k = 0.22). (Table 5, Appendix I, Evidence Tables 1, 2 and 3). 
 Gianni et al., 2005.49 The authors of this paper evaluated the correlation of IHC-measured 
protein levels with RT-PCR mRNA measurements of ER and PR expression in tumors. The 
concordance was high for ER (k = 0.84; 95 percent CI, 0.71 to 0.96) and moderate for PR (k = 
0.71; 95 percent CI, 0.56 to 0.86). This paper also reports preliminary evidence about the use of 
the Oncotype DX assay in fixed core biopsies from breast cancer patients. The percentage of 
successfully analyzed samples was 93.6 percent (89/95) (Table 5, Appendix I, Evidence Tables 
1, 2 and 3). 
 Mina et al., 200651 In this study, the authors evaluated the usefulness of FFPE core biopsies 
from a completed phase II trial in identifying genes that correlated with a response to primary 
chemotherapy. Out of the 70 patients enrolled in the study, 67 gave their consent, and specimens 
from 57 patients were available to perform gene expression analysis by RT-PCR. Out of these 57 
patients, gene expression levels could be accurately measured in 45 patients.  Failures were due 
either to low RNA yield (9 patients) or low tumor content in the biopsies (3 patients). 
 In this study the authors compared the expression levels of ER mRNA obtained by RT-PCR 
to ER protein expression as measured by IHC. Using a pre-defined cutoff of 6.5 CT, 64 percent 
of the 45 tumors were ER positive, while 36 percent were considered ER negative. ER 
expression by IHC correlated well with ER mRNA expression by RT-PCR (see Table 5), and 
only four of the 45 samples did not show agreement. The authors concluded that gene expression 
analysis on core biopsy samples was feasible. Data for PR, HER-2 and Ki-67 were not reported. 
 In summary, this paper reported preliminary evidence about the expression of some of the 
Oncotype DX assay genes in fixed core biopsies from breast cancer patients. The percentage of 
successfully analyzed samples was about 79 percent (45/57), raising concerns about the real 
feasibility in clinical settings (Table 5, Appendix I, Evidence Tables 1, 2 and 3). 
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 Habel et al., 2006.50 This study contains several results that are relevant for the overall 
analytic validity of the Oncotype DX assay. The authors cited two unpublished studies with data 
concerning the reproducibility of the RS. These studies analyzed, respectively, 60 blocks from a 
total of 20 distinct patients, and 49 core biopsies or resections from advanced breast cancer 
patients. In the first study the RS SD between different blocks from the same patient was 3.0 RS 
units, and less than 2.5 for 16 out of 20 patients. Similar results were claimed for the second 
study, although the actual data were not shown. 
 Finally, the authors compared the agreement of ER status, as obtained by RT-PCR, to the ER 
status reported in the medical records. A positive or negative classification was based on a CT 
cutoff point of 6.5.  The RT-PCR failure rate was about 1 percent for specimens available after 
pathological review, and 7.9 percent of the samples were not assessable due to low tumor 
contents. In this study population, the concordance between RT-PCR and the medical chart 
information was only moderate (k = 0.49, 95 percent CI 0.41–0.56). In the multivariate models 
used in the following statistical analyses, the RT-PCR based ER status was used. 
 In summary, this paper reported a high percentage of successfully analyzed samples in a 
large population from a single institution and the reproducibility of the RS between different 
blocks from the same patient. The impact of such variability on the risk stratification was not 
addressed (Table 5, Appendix I, Evidence Tables 1, 2 and 3). 
 Paik et al., 2006.53 In this clinical study the authors reported several results that can be used 
as indirect evidence for the overall analytic validity of the Oncotype DX assay. Particularly 
relevant, FFPE blocks with sufficient tumor content were available from 670 of the 2,299 
eligible patients in the NSABP N-20 trial, and the RT-PCR assay was successful on 651 of the 
670 patients (97.2 percent).  (Appendix I, Evidence Tables 1, 2 and 3). 
 Cronin et al., 2007.45 This study is the most extensive analysis to date of the analytic 
components of the Oncotype DX assay. Detection and quantification limits of the RT-PCR 
reactions, amplification efficiency, linearity, dynamic range, accuracy, precision, and assay 
reproducibility were investigated in serial dilution experiments, using a common RNA obtained 
by pooling 15 distinct RNA samples. 
 Detection and quantification limits proved to be well within the instrument’s pre-specified 
CT unit limits for all the genes. Amplification efficiencies (100 percent efficiency means that the 
RT-PCR reaction products achieved perfect doubling) for the 16 cancer-related genes ranged 
from 75 percent to 112 percent, with an average of 96 percent, while the mean efficiency proved 
to be 88 percent for the reference genes, with a range from 75 percent to 101 percent. 
 Accuracy and precision studies were conducted at the target RNA concentration of 2 ng per 
assay well, which is what is used in the Oncotype DX assay. The mean percent bias from each 
gene target was -0.3 percent (ranging from –10 percent to 6 percent) for cancer-related genes, 
and 0.7 percent for reference genes (-1.5 percent to 3.3 percent), indicating 99 percent mean 
quantitative correctness at this assay condition. The CV averaged 5.7 percent for the cancer-
related genes and 3.2 percent for reference genes. The implications of such variability for RS 
were not discussed. 
 Finally, individual gene and RS reproducibility were measured by performing repeated 
analyses across multiple days, operators, RT-PCR plates, RT-PCR instruments, and liquid-
handling robots. Two operators obtained replicate CT measurements on two aliquots of a single 
RNA sample over the course of five days with three real time PCR instruments (7900HT 
instruments) and two liquid-handling robots. The study design allowed the estimation of all main 
effects, including operator, RT-PCR instrument, and liquid-handling robot. Total SD in CT 
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measurements varied from 0.06 to 0.15 CT units across the 21 genes, and the upper bounds on 2-
sided 95 percent confidence intervals for the CV were all within 10 percent. The authors reported 
that a maximum SD of 0.15 at a CT of 30 translates into a CV of 0.5 percent, allowing a 15 
percent change in gene expression to be distinguished. The day-to-day SD for all 21 genes 
ranged from 0 to 0.055, the between-plate SD ranged from 0 to 0.09, while the within-plate SD 
ranged from 0.057 to 0.147. The standard deviation for the overall RS (total and within-plate) 
was 0.8 RS unit. The largest differences between operators, as well as between liquid handling 
robots and 7900HT instruments, were 0.5 CT units for each of the 21 Oncotype DX genes, while 
SD and CV for the RS were not reported. 
 In summary, this study presented extensively detailed results about several relevant analytic 
components of the assay (Table 4, Appendix I, Evidence Tables 1, 2 and 3). 
 Chang et al., 2007.55 This clinical study reported several results that can be used as indirect 
evidence for the overall analytic validity of the Oncotype DX assay. Ninety-seven FFPE blocks 
from core biopsies were analyzed by the standard assay protocols, and the percentage of 
successfully analyzed samples was 82.4 percent.  
 In summary, this paper provides preliminary evidence about the use of the Oncotype DX 
assay in fixed core biopsies from breast cancer patients (Table 2, Appendix I, Evidence Tables 1, 
2 and 3). 
 Oratz et al., in press.56 This clinical study evaluated the impact of the Oncotype DX assay 
on clinical management, and also provided indirect evidence for the assay’s overall analytic 
validity. Seventy-four FFPE blocks were analyzed by the standard assay protocols, and the 
percentage of successfully analyzed samples was 97.3 percent. No explicit eligibility criteria 
were used. The samples were included based on the request for analysis from the patient’s 
clinician.  
 In summary this paper contains evidence about the use of the Oncotype DX assay on FFPE 




 Analytic validity and variability evidence for MammaPrint was available from two technical 
studies ( Ach, 2007,57and Glas, 200658) and information on the overall success rate of the assay 
was documented in just one study, Buyse, 200659(80.9 percent).  
 Data about variability and reproducibility were obtained in these studies using repeated gene 
expression measurements over time, within and across individual microarrays, across different 
laboratories, protocols instruments, and operators (see Tables 6, 7, 8). No comparisons were 
made between expression measurements of individual genes and their corresponding protein 
level by IHC. 
 The following is a brief description of each study. 
 Glas et al., 2006.58 In this study the authors reported a summary of the results obtained 
during the development of the commercially marketed version of the 70-gene prognostic 
signature,21,25 the expression array-based test known as MammaPrint. The authors evaluated and 
compared both technical aspects and the clinical validity of the assay using the originally 
published data (see Key Question 3). 
 MammaPrint uses a microarray accounting for 1,900 features (individual microarray 
locations where the probes are positioned), containing each of the 70 genes in the signature 
spotted in triplicates. In this paper the authors re-analyzed the data from the original series21,25 
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using the new array, a dye-swap hybridization design, a different reference RNA and a different 
approach to computing gene expression levels. Triplicate measurements were obtained for each 
gene of the 70-gene signature and summarized by an error-weighted average, rather than the  
approach proposed by Hughes et al., 2000,60 which was used in the original studies. 
 The results obtained with the new signature were comparable to the original results. Briefly, 
MammaPrint proved reproducible on the original development series21 (Pearson's correlation 
coefficient = 0.92 P value < 0.0001), and in a subset of the van de Vijver cohort25 (Pearson's 
correlation coefficient of 145/151 lymph node-negative patients  = 0.88, P value < 0.0001). The 
replication of the experiment within patients and along time suggested high reproducibility as 
well. In particular, the Pearson's correlation coefficient on 49 patients analyzed twice was 0.995, 
and no significant variability within individuals was found by an analysis of variance (ANOVA) 
for the 70-gene signature P value = 0.96). 
 Risk classification by MammaPrint is obtained by measuring the cosine correlation of 
individual patients’ gene expression profiles to the mean gene expression profile obtained in the 
van’t Veer21 series. The variability of such correlation was measured by repeated analysis of 3 
patients over time and showed very small SDs (0,028, 0,028 and 0.027 respectively).  
 In summary, this study reported detailed data about the development of the MammaPrint 
assays as it is offered in clinical settings, as well as data about the reproducibility of the assay 
within a single laboratory (Tables 7 and 8, Appendix I, Evidence Tables 6, 7 and 8). 
 Buyse et al., 2006.59 In this clinical study the authors reported several results that can be 
used as indirect preliminary evidence for the overall analytic validity of the MammaPrint® 
assay. Fresh frozen blocks from primary breast cancer patients collected in 5 distinct institutions 
were shipped for analysis to Agendia, and the percentage of successfully analyzed samples was 
80.9 percent (326/403 patients) (Appendix I, Evidence Tables 6, 7 and 8). 
 Ach et al., 2007.57 The inter-laboratory reproducibility of the MammaPrint assay was 
assessed in this paper.  Results for the same set of four patients were obtained at three different 
sites and compared in order to assess the variation resulting from several important phases of 
analysis, including RNA amplification and labeling, hybridization and wash, and slide scanning. 
The same input RNA was used for all experiments. 
 In the first phase of the analysis, two laboratories, one in Amsterdam and one in California, 
amplified and labeled the RNA samples, then exchanged aliquots of the templates. Hybridization 
and slide scanning were performed at both locations and the scanned slides were then exchanged 
for re-analysis by the other laboratory. The same lot of labeling kits and microarrays were used 
at both sites. Technical replication variability was assessed by analyzing two separate slides in 
two different days. This experimental design allowed examination of both intra- and inter-
laboratory variation. 
 The Pearson correlation coefficient across all technical replicates for all tumors analyzed 
proved to be above 0.983, indicating that the signals from replicate hybridizations correlated 
extremely well for genes expressed at all the measured intensity levels. 
 The reproducibility of laboratory scanning procedures was evaluated by scanning each of the 
16 microarray slides at both sites. Signals for green fluorescent dye proved extremely 
reproducible, irrespective to the site of first hybridization and scan (Pearson correlation 
coefficient > 0.995, slope = 0.97), while signals for the red dye correlated less well and were 
always lower on the rescanned slide.  The correlation of the 70-gene expression profile to the 
previously developed59 mean signature58 was computed for each dye-swapped pair of arrays and 
ANOVA was used to evaluate the variability by hybridization site, labeling site, and 
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hybridization day. No significant differences were found between hybridization sites, or 
hybridization days (regardless of site), but two tumors showed a statistically significant 
difference (P value <0.05) between labeling sites. Variability due to the RNA labeling site was 
further confirmed for expression measurements of individual genes of the 70-gene expression 
profile, as well as on the 182 most highly expressed genes. 
 In the second phase of the study, the assay performance was evaluated by a third laboratory 
in Paris, France, using a different batch of arrays, reagents, and labeling kits, on the same four 
tumor RNAs, several months after the initial comparison. The 70-gene signature correlation 
values for each of the four tumors were compared by ANOVA analysis, and significant 
differences were found for two of the tumors, when stratified by labeling site (P values of 0.0004 
and 0.01 respectively), whereas one tumor proved to be significantly different (P value, 0.016) 
by hybridization site. The authors predicted, but did not provide supporting data, that if 
variations in the washing protocols were introduced between laboratories, significant 
discrepancies in the 70-gene signature results would emerge. They concluded that while some 
sources of variation have measurable influence on individual microarray measurements, the 
overall impact on the 70-gene signature is low. 
 In summary, this study thoroughly investigated factors that could affect the reproducibility of 
the 70-gene signature within and across different laboratories. RNA labeling proved to be the 
largest contributor to inter-laboratory variation, but the authors did not address the impact of 
such factors on the classification of individual patients into different risk groups.  The data 
(although from only four distinct patients) implies that results from MammaPrint testing cannot 
be compared across laboratories and that the test must be centralized (Tables 7 and 8, Appendix 




 None of the studies reviewed here explicitly referred to the marketed H/I ratio (BCP assay). 
However, one publication described the analytic procedures involved with such test, Ma, 2006.61 
The rest of the available analytic validity and variability evidence was specific to the way in 
which the two-gene ratio profile was computed in each clinical study, and did not contain direct 
information about the marketed test. 
 Three studies (Goetz 2006,62 Jerevall 2007,63 Ma 200661) reported the overall success rate of 
the analyses, one report, Jerevall 2007,63 assessed the reproducibility between two different 
institutions, one assessed the correlation between RT-PCR and microarray based gene expression 
measurements for the two genes (HOXB13 and IL17RB), and one, Ma 2004,64 study compared 
ER status by RT-PCR and IHC (see Tables 9, 10, and 11). No comparisons were made between 
expression measurements of HOXB13 and IL17RB transcripts and the corresponding proteins by 
IHC. For completeness, a brief description of individual studies follows. 
 Ma et al., 2004.64 In this study the authors developed the HOXB13/IL17BR two-gene ratio 
signature.  They identified differentially expressed genes associated with breast cancer 
recurrence in patients who were treated with tamoxifen, using gene expression arrays on whole 
mount as well as on laser micro-dissected (LMC) specimens. From a total of 5,475 genes 
selected because of their high variability across tumors, three differentially expressed genes 
proved to be common between the two analyses (macro-dissected specimens vs. LCM).  These 
genes were HOXB13 (identified twice as AI700363 and BC007092), the 17B receptor IL17BR 
(AF208111), and EST AI240933. 
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 HOXB13 was found to be over-expressed in tamoxifen recurrence cases, whereas IL17BR 
and AI240933 were over-expressed in tamoxifen non-recurrence cases. The authors confirmed 
relative gene expression by RT-PCR microarray analysis on 59 out of the 60 original patients. 
The Pearson correlation coefficient between array and RT-PCR results was 0.83 for HOXB13, 
and r = 0.93 for IL17BR. The RT-PCR-derived HOXB13/IL17BR ratios also highly correlated 
with its microarray-derived counterpart (0.83). The authors also evaluated by RT-PCR 20 
additional ER-positive early-stage primary breast tumors from women treated with adjuvant 
tamoxifen monotherapy between 1991 and 2000. These were used as a validation set (see Key 
Question 3).  
 In summary, this study provides a foundation for the use of the H/I ratio signature in LMC 
FFPE specimens (Table 10, Appendix I, Evidence Tables 10, 11 and 12). 
 Ma et al., 2006.61 The authors developed the two-gene index concept in this study, based on 
the two-gene ratio they originally published in Ma et al, 2004.64 New RT-PCR primers/probes 
for HOXB13 and IL17BR were used, and four reference genes were introduced for 
normalization. Total RNA was isolated from two 7-micrometer thick tissue sections for each 
sample, reverse transcribed into cDNA using a pool of gene-specific primers, and quantitated by 
TaqMan RT-PCR in duplicate in a 384-well plate. For each sample, CT values for the four 
reference genes were averaged and the relative expression level of each target gene was 
expressed as the difference from mean reference CT after Z-transformation. This resulting value 
is no longer a simple ratio, and is thus referred to as the two-gene index. 
 RNA for this study was prepared from cancer cells isolated by LCM from FFPE tissue 
microarray sections (see Glossary, Appendix B) of originally frozen tumor specimens. From 870 
patients, 98.0 percent of samples were successfully processed (Table 9).    
 In this study the authors evaluated the concordance between ER and PR protein levels 
assessed by IHC and the corresponding gene expression measured by RT-PCR. Since the 
distributions were found to be bimodal for both genes, the midpoints between the two 
populations were used as cutoff points (2.5 CT for ER and 5.9 for PR). Both the ER (91 percent 
concordance; kappa = 0.83; P value = .0001), and PR (85 percent concordance; kappa = 0.70; P 
value = .0001) status proved to be highly concordant. According to the authors, this confirms the 
significant correlations between mRNA and protein levels for ER and PR and provided 
validation of their gene expression analysis.  
 In summary, this clinical study, in which the HOXB13-to-IL17BR index was developed, 
represents the foundation for using the two-gene ratio signature in tissue microarray FFPE 
specimens analysis (Table 11, Appendix I, Evidence Tables 10, 11 and 12). 
 Goetz et al., 2006.62  In this clinical study, FFPE tumors samples from 206 of 211 primary 
breast cancer patients were successfully processed by laser micro-dissection (LMC) prior to total 
RNA preparation.  This study provides generic evidence about the analytic validity of the two-
gene signature in primary breast cancer patients, as computed from LMC processed FFPE blocks 
(Table 9, Appendix I, Evidence Tables 10, 11 and 12). 
 Jerevall et al., 2007.63 This paper quantified expression of HOXB13 and IL17BR 
(normalized to beta-actin) by RT-PCR in fresh frozen specimens from two distinct institutions in 
Sweden. RT-PCR reactions at the two institutions were performed using the same sets of primers 
and fluorescent probes, and two distinct instruments. Ninety-six percent of the 373 samples were 
successfully analyzed.  
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 In summary, good reproducibility of the measurement between institutions was documented 
for each individual gene and the ratio (Pearson’s correlation coefficient = 0.99, P value < 0.001) 
(Table 10, Appendix I, Evidence Tables 10, 11 and 12). 
 
Key Question 3. What is the clinical validity of gene 
expression profiling tests in women diagnosed with 
breast cancer? 
 





 Paik et al., 2004.28 This study was the first to validate the prognostic validity of Oncotype 
DX in a population independent from that used to develop the test. The population consisted of a 
sample of 668 (out of 2617) lymph node-negative, ER positive breast cancer patients from the 
tamoxifen-treated arm of the National Surgical Adjuvant Breast and Bowel Project (NSABP) 
Trial B-14.  This 668-patient subset had enough analyzable tissue in paraffin blocks to be 
evaluated using the Oncotype DX assay, and was reported to be similar in baseline 
characteristics to the overall sample.  A more complete sample was impossible because of 
sample unavailability or processing problems. In this study, the overall 10-year distant 
recurrence rate was 15 percent and the RS was significantly correlated with disease-free survival 
and overall survival (P<0.001 for both). The authors reported that RS alone was a better 
predictor of the distant recurrence risk than traditionally used predictors. In a multivariate model 
including age, tumor size grade, ER, PR, and HER, the RS Hazard Ratio was 2.81 (95 percent 
CI, 1.70–4.64, P<0.001, per 50 unit increase). Forty-four patients out of the 109 with small 
tumors (diameter less than 1 cm), were classified using Oncotype DX  into the intermediate or 
high risk groups (Table 12, Appendix I, Evidence Tables 1, 2 and 4). 
 Esteva et al., 2005.48 In this study the Oncotype DX assay was evaluated in a population of 
149 patients treated at the MD Anderson Cancer Center between 1978 and 1995.  These patients 
had been diagnosed with node-negative breast cancer and did not receive tamoxifen or 
chemotherapy, and had a median 18 year followup. The number of recurrences was not reported, 
and this study failed to find correlation between RS and distant breast cancer recurrence. ER, PR, 
and HER-2 showed no prognostic value, and well-differentiated tumors were correlated with 
worse survival than higher grade tumors, the reverse of expected. The population was unusual in 
that it received no treatment, and was different from the one used by Paik et al.28 (Table 12, 
Appendix I, Evidence Tables 1, 2, and 4). 
 Cobleigh et al., 2005.47 This report is the only study among the three used to develop the 21-
gene Recurrence Score assay (Oncotype DX) to be published in a peer-reviewed journal. 
Seventy-eight breast cancer patients with more than 10 positive nodes from Rush University 
Cancer Center were studied, and 55 had recurred. Two hundred and fifty-five candidate genes 
were amplified with RT-PCR from FFPE tumor tissue obtained as long as 24 years ago. Twenty-
two genes were significantly correlated with distant recurrence-free survival (DRFS) (unadjusted 
P value < 0.05). An RS was developed using these genes which very strongly predicted disease-
free survival, but as this was training and not validation data, it has minimal evidential value in 
39 
assessing Oncotype DX predictive properties (Table 12, Appendix I, Evidence Tables 1, 2 and 
4). 
 Habel et al., 2006.50 The Oncotype DX  assay was used to assess the risk of breast cancer-
specific mortality among women in a large case-control study population derived from fourteen 
Northern California Kaiser community hospitals with ER positive, node-negative breast cancer.    
 There were a total of 4,964 eligible patients, 220 had died and 570 were living controls. All 
were younger than 75 years old, diagnosed between 1985 and 1994, and had not been treated 
with adjuvant chemotherapy. For ER positive tamoxifen-treated patients, RS risk groups (as 
defined by pre-specified thresholds chosen by the test developers) showed similar 10-year risks 
of death from breast cancer (3 percent, 12 percent, and 27 percent respectively for low, 
intermediate, and high risk, groups) as Paik28 reported for the NSABP B-14 patients.  
Multivariate analysis showed that RS and tumor size were significant and independent risk 
predictors of breast cancer death in both ER positive, tamoxifen-treated (hazard ratio per 50 units 
= 7.6, P<0.001) and untreated patients (RS hazard ratio per 50 units = 4.1, P<0.001). Tamoxifen-
treated patients were shown to have a higher risk of death, and tumor grade proved to be a 
significant, independent predictor as well.  The RS score showed some prognostic value in ER 
negative patients, although this group was too small to perform a reliable analysis. 
 ER status was missing from the medical record for a substantial proportion of patients in this 
study, and therefore ER status based on gene expression was used in the analysis. Cases and 
controls were matched with respect to tamoxifen treatment, so it was not possible to assess 
whether the RS was able to identify patients who are likely to respond to tamoxifen therapy. The 
performance of the Oncotype DX assay RS was not compared to standard risk stratification 
methods (e.g., St. Gallen, NIH criteria, or Adjuvant! Online) (Table 12, Appendix I, Evidence 
Tables 1, 2, and 4). 
 Paik et al., 2004,65 Bryant 2005,66 and Hornberger et al., 2005.67 These posters showed 
the cross-classified risk predictions of the Oncotype DX assays compared to the risk 
stratifications using the 2004 NCCN and 2003 St. Gallen criteria, with the observed 10 year risks 
of relapse in the cross-classified strata.  NCCN guidelines have since been modified, and the St. 
Gallen criteria did not accounted for HER-2. Patients came from the Paik65 NSABP-14 
validation cohort, N=668. Using the 2004 NCCN guidelines, the study indicated that of the 92 
percent who were in the high-risk NCCN category, about half were reclassified as low-risk by 
RS, with a 10-year relapse risk of 7 percent (95 percent CI, 4-11 percent), which is similar to the 
risk observed in the low risk RS group, without the NCCN information65. Finally, against the 
Adjuvant Online criteria, roughly 40 percent of those assessed to be at high risk (22 percent 
relapsed) were reclassified as having an 8 percent risk if they had a low RS score. These data, 
demonstrate that optimal predictions may come from a combination of expression predictors and 
standardized indices, although the latter contribute less than the RS to the risk estimate (Tables 




A synopsis of the clinical validity evidence presented in the following section is reported in 
Table 16. In the following section we will be distinguishing between MammaPrint, the marketed 
assay, and the gene expression profile which is the 70-gene signature originally published by 
van’t Veer et al., in 2002.21 
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 van’t Veer et al., 2002.21 This study reported the development data for the 70-gene panel 
that is the basis for the MammaPrint test. A gene expression array containing 25,000 features 
was used to select genes associated with metastases-free survival at 5 years from surgery in 78 
node negative patients, including 34 patients who recurred at 5 years and 44 who had not. Using 
the development of metastasis within 5 years as the first relapse event, 65 out of the 78 patients 
were correctly classified into good and poor prognosis groups by the 70-gene signature. Among 
the 13 misclassified patients, 5 patients with poor prognosis were in the good prognosis group, 
while 8 patients with good prognosis were classified in the poor prognosis group. Seventeen of 
19 were correctly classified in the validation set.  
 The odds ratio (OR) to develop metastases within 5 years was 28, (95 percent CI, 7-107), 
while after leave-one-out cross-validation it was 15 (95 percent CI, 4-56).  Using univariate 
analysis, the 70-gene signature performed better than tumor grade, size, patient age (less than 
40years), ER status, and angioinvasion. Using multivariate analysis, the 70-gene signature was 
an independent predictor of metastases within 5 years, OR = 18 (95 percent CI, 3.3-94) (Tables 
16 and 17, Appendix I Evidence Tables 6, 7 and 9). 
 van de Vijver et al., 2002.25 This was the first major validation of the 70-gene signature as 
reported in van’t Veer 2002 using the same protocol and approach. Banked tumor specimens 
from the Netherlands Cancer Institute were used from a consecutive series of 295 women with 
breast cancer, with a mix of lymph node positivity, ER status, chemotherapy, and tamoxifen 
treatment. Time to metastases, as well as overall survival (OS) were used as primary end points 
in survival models, and 61 patients in this cohort had been in van’t Veer’s21 original 78 patient 
training set. 
 Patients were young (less than 52 years) with small tumors (less than 5 cm). The 70-gene 
signature was shown to be associated with grade, size and ER positivity, with almost all of ER 
positive patients falling into the good prognosis category. Those with “good prognosis” 70-gene 
expression signatures had dramatically better 5-year (95 percent vs. 61 percent) and 10-year (85 
percent vs. 51 percent) DRFS and OS (95 percent vs. 55 percent at 10 years) than the “poor 
prognosis” group.  Multivariate analysis showed that the prognosis group, tumor size, and 
adjuvant chemotherapy were the strongest predictors of distant metastases.  The “poor 
prognosis” signature had the largest hazard ratio = 4.6 (95 percent CI, 2.3-9.2). Analyses 
excluding the 61 previously-included patients produced similar results.  Fourteen of the 115 
“good signature” patients experienced a recurrence by 10 years, demonstrating that the “good 
prognosis” group may not be at low enough long-term risk to justify forgoing chemotherapy 
when the 70-gene signature is used alone.  
 The authors did not compare a regression-based predictor using only conventional variables 
with one including the 70 gene panel. However the authors demonstrated the prognostic value of 
the 70 gene index using survival curves stratified by the NIH and St. Gallen criteria, which 
showed substantial separation between 70-gene prognostic groups that were either low or high 
risk by those conventional indices.  These stratified survival curves also showed that optimal 
prediction was achieved when the gene index and conventional predictors were combined (Table 
16, Appendix I, Evidence Tables 6, 7, and 9). 
 Buyse et al., 2006.59 This study compared the MammaPrint assay with the conventional 
combination risk predictors Adjuvant Online, Nottingham Prognostic Index, and St. Gallen. 
Patients were drawn from five distinct European institutions, in the context of an independent, 
multicenter validation study performed by the TRANS-BIG consortium. Gene expression in 
frozen tumor specimens from node negative patients younger than 60 years old who did not 
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receive systemic adjuvant chemotherapy, and were diagnosed between 1980 and 1998 was 
characterized using the MammaPrint® assay. Final results were obtained for 302 out of 402 
eligible patients. The median followup was 13.6 years, and the overall rate of distant metastasis 
was 25 percent. 
 The three primary end points of the study were time to distant metastases (TTM), DFS, and 
OS. The hazard ratios of the MammaPrint assay for TTM and OS were statistically significant 
after adjustment for St. Gallen, NPI and Adjuvant! On-line, but were generally far below (in the 
1.5-2.5 range) that seen in the original validation cohort.25,58  The partial explanation offered by 
the authors was that this study had a longer median followup time than the one used by the van 
de Vijver25 cohort. Additionally, the authors introduced an interesting analysis showing the 
marked (3-6 fold) lowering of the hazard ratio for various endpoints when patients were 
artificially censored at increasing times, up to 10 years. Also, none of the ER positive patients 
reported in this study received hormonal therapy as did some of  the original van de Vijver25 
cohort. 
 Specificity and sensitivity of the MammaPrint assay and the Adjuvant! algorithm were 
compared for distant metastases within 5 years and for death within 10 years. Similar 
sensitivities were found, but a higher specificity was demonstrated for MammaPrint. The areas 
under the Receiver operating characteristic (ROC) curves were comparable between 
MammaPrint and Adjuvant! (0.68 vs. 0.66 for distant metastases at 5 years). The use of 
alternative thresholds for the Adjuvant! Online results did not change the overall results, and 
Adjuvant! hazard ratios were greater than unity but not statistically significant when adjusted for 
the gene signature. Finally, there was no statistical heterogeneity in any outcomes between 
centers, suggesting that this prediction model has transportability across populations with 
possibly different genotypic patterns. 
 This study is particularly important in that it provided the first evidence for the degree of 
clinical validity of the MammaPrint assay distinct from the 70-gene signature. It provided insight 
into the impact of differing lengths of followup in validation cohorts, and concluded that the 
prognostic contribution was sizable.  However, this study’s predictions were made in the context 
of no adjuvant hormonal or chemotherapy treatment, thus its applicability to women over 60 
years old and treated with tamoxifen is unknown68 (Table 16, Appendix I Evidence Tables 6, 7, 
and 9). 
 Glas et al., 2006.58 This study used the same patients as in the van’t Veer,21 and van de 
Vijver25 studies and compared the currently offered MammaPrint assay results to the results of 
the previous studies. RNA was available for all the 78 patients in the van’t Veer series, but only 
145 lymph node negative patients were available for reanalysis from the van de Vijver series. A 
different reference RNA was used, as well as a different quantification method, however odds 
ratios and hazard ratios were very similar. A total of 15 patients were incorrectly classified into 
discrepant risk categories. The results of the 70-gene signature used in the original cohorts 
therefore apply equally to the MammaPrint assay based on that signature (Table 16, Appendix I 








 Ma et al., 2004.64 This study reported the development of the two-gene ratio predictor. The 
authors generated gene expression profiles with gene chips from whole and laser-capture 
microdissected (LCM) frozen tumor specimens from 60 ER positive, node positive or negative 
breast cancer patients all treated with adjuvant tamoxifen monotherapy. Twenty-eight of the 
cohort (46 percent) experienced a distant recurrence within 4 years and 54 percent had no 
recurrence by 10 years. Twenty-two thousand genes were screened in the whole tissue sections 
and in LMC samples for their ability to predict DFS. Only three genes were highly predictive of 
DFS in both tissue sets, with over-expression of HOXB13 predicting recurrence and over-
expression of IL17BR predicting non-recurrence. These expression values were combined in the 
form of a ratio, which outperformed both existing biomarkers and either gene alone. The 
univariate OR (interquartile) was 10.2 (95 percent CI, 2.9-36), multivariate OR was 7.3 (95 
percent CI, 2.1-26.3) with adjustment for tumor size, PR and ERBB2 (none statistically 
significant) in a logistic regression. Area under the receiver-operating-characteristic curve 
(AUCs) for the ratio were reported in the 0.8 range. 
 Next, the above analysis was repeated using just the two-gene ratio calculated by RT-PCR on 
59 fresh-frozen samples from the training set along with 20 additional FFPE specimens to 
independently validate the ratio. Sixteen of these 20 were accurately predicted. The RT-PCR-
measured expression was reported to have similar predictive power to that measured via gene 
arrays. No comparison with the full array of clinical predictors (e.g. tumor grade) or with 
standard combination predictors (e.g., Adjuvant!) was performed (Table 18, Appendix I, 
Evidence Tables 10, 11, and 13). 
 Reid et al., 2005.69 In this paper the authors attempted to validate the two-gene ratio on an 
independent cohort of 58 patients with ER positive breast cancer.  These patients had been 
treated with tamoxifen monotherapy, had larger tumors, a higher frequency of lymph node 
metastases (78 percent vs. 47 percent), and a higher HER-2 positivity (21 percent vs. 5 percent) 
than those in the Ma et al., 2004 study. Eighteen patients had distant recurrences within a median 
time of 31 months, and 40 had no recurrence after a median of 93 months (range 70-125). The 
expression of the genes HOXB13 and IL17BR was measured by RT-PCR and the association 
between their expression and outcome was assessed by use of univariate logistic regression, 
AUC, a two-sample t test, and a Mann–Whitney test. None of these analyses revealed any 
statistical relationship with outcome. 
 The authors then took the original data of Ma et al.64 and applied standard supervised 
methods to this and to another independent data set with 99 similar patients.70 They tried to 
estimate the classification accuracy obtainable by using two or more genes in a microarray-based 
predictive model, using linear discriminant analysis and extensive cross-validation. The authors 
failed to validate the two-gene ratio and found high error rates with two-gene predictors. 
 Overall, findings from this paper argued against the prognostic utility of the two-gene ratio in 
ER positive breast cancer patients treated with tamoxifen. However, it must be noted that a 
different part of the transcripts were assayed in the two studies and that differences could be due 
to the documented differences in the populations used, which were neither clinically nor 
therapeutically homogeneous, with small validation sets71 (Table 18, Appendix I, Evidence 
Tables 10, 11 and 13). 
 Goetz et al., 2006.62 To investigate the prognostic performance of the two-gene ratio, this 
study analyzed FFPE samples from 206 ER-positive patients treated in the tamoxifen-only arm 
of a Phase III randomized trial of tamoxifen alone versus tamoxifen plus fluoximesterone 
conducted through the NCCTG (North Central Cancer Treatment Group).64  RT-PCR expression 
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values for each gene were normalized using a standard curve (Appendix D) obtained by 
analyzing the human universal total RNA (Stratagen, La Jolla, CA), rather than the standard 
reference gene method, although the authors stated that control genes were not necessary to 
assess the expression ratio. The following end points were considered: RFS (time from 
randomization to any event of recurrence, contralateral breast cancer or death), DFS (time from 
randomization to any event of recurrence, or contralateral breast cancer, or other cancer, or 
death), and OS (time from randomization to death). 
 Cutoffs points that best predicted RFS, DFS and OS were identified: the optimal cut-off for 
the entire cohort was -1.85, corresponding to the 58th percentile, whereas the 59th percentile (-
1.34) was used for the node-negative group (n = 130), and the 90th percentile (4.4) best 
discriminated in the node positive group (n = 86). 
 The ratio showed modest outcome prediction value in the entire cohort, with cross-validated 
hazard ratios near 1.5 and P values around 0.05, with the predictive value being restricted to the 
node-negative subset of patients (hazard ratios 1.7 to 2, P values = 0.04-0.06). In the node-
positive group the ratio had no relationship to relapse or survival. The authors concluded that a 
high 2-gene expression ratio is associated with increased relapse and death in patients with node-
negative, ER positive breast cancer treated with tamoxifen. 
 Overall this study provided some support of the two-gene ratio signature’s prognostic value 
in ER positive, lymph node negative patients, but both the magnitude of that effect and the 
statistical support were modest, and the relevant cutoffs used for discrimination between high 
and low risk were optimized for each endpoint and patient subgroup. Hence, this is closer to a 
training than validation exercise (Table 18, Appendix I, Evidence Tables 10, 11 and 13). 
 Ma et al., 2006.61 This study examined a consecutive series of patients from Baylor 
University diagnosed between 1973 and 1993 with stage I or II breast cancer.  The patients did 
not have distant spread, and non-relapsed cases had a median followup of 6.8 years. The authors 
reported data on the clinical validity of the two-gene expression index (HOXB13:IL17BR), 
which is the base of the H/I assay. A different normalization strategy (Table 1) from Ma et al., 
200464 was applied to obtain this index. FFPE samples only yielded 852 analyzable cases out of 
1,002 patients.  
 This population had 72 percent node negative, 73 percent ER positive, and 16 percent HER-2 
positive patients, with an overall recurrence rate of 31 percent. A higher HOXB13:IL17BR index 
was associated with a higher risk of relapse (hazard ratio=1.5, P<0.001). In a stratified analysis, 
univariate Cox regression indicated that the HOXB13:IL17BR index was only significant in 
node-negative patients (hazard ratio = 1.6, P<0.001 vs. hazard ratio=1.2, P=0.1,) and further 
subsetting indicated that the interaction with node status was statistically significant for the 
HOXB13:IL17BR index (P= 0.02) only in ER positive patients. The HOXB13:IL17BR index 
correlated significantly with predictors of poor prognosis (i.e., HER-2 amplification, S-phase 
fraction, and number of positive lymph nodes) and correlated inversely with ER and PR 
expression. 
 The authors identified the optimal cut-off point for the index by analyzing a training set of 
ER-positive untreated patients (n=205), in order to obtain the smallest P value from a log-rank 
test in Kaplan-Meier survival analysis. The selected threshold (of about 1.0) was validated in a 
separate test set of untreated patients (n=103), and was also applied in the analysis of the 
tamoxifen-treated group of patients (n=122). Kaplan-Meier curves and univariate Cox regression 
analysis indicated that this cut point stratified patients into significantly different risk groups. 
Results from the Kaplan-Meier plots suggested that the prognostic power of the two-gene index 
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was independent of tamoxifen therapy. The hazard ratio obtained in multivariate Cox 
proportional hazards regression, incorporating age, tumor size, S-phase fraction, PR status, and 
tamoxifen therapy, confirmed the prognostic role of the HOXB13:IL17BR index (hazard 
ratio=3.9, 95 percent CI = 1.5 to 10.3, P value = 0.007), in ER positive, node negative, patients 
irrespective of tamoxifen treatment. The index was also demonstrated to be a continuous 
predictor of DFS in untreated patients. The authors concluded that the two-gene index was a 
significant predictor of clinical outcome in ER positive, node-negative, patients regardless of 
tamoxifen therapy. 
 This study validated the two-gene ratio gene expression profile, developed the two-gene 
index, and provided preliminary evidence for its prognostic value. Classification probabilities 
were not presented, and its incremental value over conventional predictors was not reported, 
although some components of such predictors were included in the multivariate analyses (Table 
18, Appendix I, Evidence Tables 10, 11 and 13). 
 Jansen et al., 2007.72 This clinical study evaluated the ability of the HOXB13-to-IL17BR 
expression ratio to predict DFS in breast cancer patients treated with tamoxifen. The HOXB13 
and IL17BR expression levels were measured by RT-PCR in 1,252 primary breast tumor patients 
and normalized with respect to 3 housekeeping genes73. The study population was a mix of ER-
positive (73 percent), lymph node-positive (52 percent), tamoxifen-treated (14 percent), and 
chemotherapy-treated (17 percent) patients, with additional patients treated with tamoxifen or 
chemotherapy after relapse (55 percent). Patients with ER-positive tumors with node negative 
primary breast cancer (N = 468) were followed for DFS.  Patients with recurrent breast cancer 
treated with first-line tamoxifen monotherapy (N = 193) were followed for progression free 
survival (PFS). This study used different populations, protocols, normalization strategy, and ratio 
thresholds than Ma et al. 2006.61 
 The study evaluated the relation between the HOXB13-to-IL17BR ratio and tumor 
aggressiveness in lymph node negative, ER positive patients who did not receive adjuvant 
systemic chemotherapy (N=468). Of these patients, 46 percent had a relapse during the followup 
period. The HOXB13-to-IL17BR ratio, as a univariate continuous variable, was significantly 
associated with a poor DFS (hazard ratio=1.6, P=0.02) and a poor OS (P<0.001, data not 
reported). When traditional factors were added to the model, the HOXB13-to-IL17BR ratio 
continued to contribute significantly to DFS and OS prediction, either as a continuous variable or 
after dichotomization according to published pre-specified thresholds61 (Table 18). 
 The same analysis was performed on ER-positive, lymph node-positive tumors from 
untreated patients, who were mainly enrolled in the early 1980’s (n=151). Univariate analysis of 
the continuous HOXB13-to-IL17BR ratio was associated with a poor DFS and a poor OS.  In the 
multivariate model for this population, the index was significantly associated with OS (P value = 
0.001), but less strongly with DFS (P value = 0.065). The dichotomized index was not related to 
DFS (data not shown). 
 Finally, the authors evaluated the prognostic performance of the HOXB13-to-IL17BR ratio 
in 193 ER-positive primary breast tumors in relapsed patients treated with first-line tamoxifen 
monotherapy. Both univariate and multivariate analyses revealed that the ratio, continuous and 
dichotomized, was strongly associated with PFS (Table 18). 
 This study is by far the largest done so far concerning the potential value of the 2-gene ratio.  
It provided evidence of the clinical validity of the HOXB13-to-IL17BR ratio in ER positive, 
node negative patients who did not receive systemic adjuvant therapy, and also in ER positive 
relapsing patients whose relapse was treated with tamoxifen.  However, the study was calculated 
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and dichotomized in a somewhat different manner than in Ma et al., 2006.61  Additionally, 
comparisons were not provided with conventional combination risk indices, nor were 
classification probabilities provided for the models with and without the ratio.  Therefore, 
incremental predictive values could not be accurately assessed. Although qualitative conclusions 
are not affected, there are some differences between the quantitative results reported in the text 
and tables (Table 18, Appendix I, Evidence Tables 10, 11 and 13). 
 Jerevall et al., 2007.63 In this paper the authors investigated whether the two-gene ratio can 
predict the benefit of 2 versus 5 years of tamoxifen treatment in postmenopausal breast cancer 
patients, and also predict the ratio’s prognostic value in systematically untreated pre-menopausal 
patients. Expression of HOXB13 and IL17BR were quantified by RT-PCR in tumors from 264 
randomized postmenopausal patients and 93 systemically untreated premenopausal patients. The 
two study populations were collected as part of a collaborative study between two centers in 
Sweden, and 72 percent of the randomized patients were lymph node positive and 74 percent ER 
positive. To stratify the patients into risk groups the authors dichotomized the ratio using the 
median, a procedure and dichotomization differing from the approach used by Ma 2006.61 The 
results from the prediction of prolonged treatment benefit are reported under Key Question 4, 
Clinical Utility.  
 The ratio proved to be significantly correlated to tumor size, ER, PR, HER-2, Nottingham 
histologic grade (NHG), ploidy, and S-phase. ER, HER-2, S-phase and NHG correlations were 
mostly due to IL17BR, while PR and ploidy correlations showed contribution from both genes. 
The authors concluded that a lower expression of IL17BR, but not HOXB13, was correlated to 
several factors related to poor prognosis, and thus IL17BR might be an independent prognostic 
factor in breast cancer, and that HOXB13 may be correlated with tamoxifen resistance. However, 
the ratio had no prognostic value in ER negative postmenopausal patients and they were 
excluded from subsequent analyses. 
 In summary, this study produced additional developmental evidence of the prognostic value 
of the HOXB13-to-IL17BR ratio, and of the two individual genes, in ER positive breast cancer 
patients who received systemic adjuvant therapy. However, neither the patient profile nor the 
mode of calculation of the ratio were identical to previous studies, and the results differed from 
previous reports, as the ratio predicted for worse outcome in lymph node positive patients (Table 
18, Appendix I, Evidence Tables 10, 11 and 13). 
 
Key Question 4. What is the clinical utility of these tests? 
 
 The clinical utility of a test tells us whether the test helps discriminate between those who 
will have more or less benefit from a therapeutic intervention. This can only be assessed in the 
context of randomized clinical trials, where benefit can be measured in terms of an improvement 
of clinical outcomes such as overall survival, disease-free survival, chemotherapy toxicity, or 
quality of life. 
 The prognostic estimates provided in the previous section, however―have a relationship to 
clinical utility—providing an upper limit on the degree of clinical benefit that can be provided by 
chemotherapy for a given endpoint. For example, if the 10-year cancer recurrence rate without 
adjuvant chemotherapy is estimated to be 5 percent, the maximum absolute benefit to be derived 
from chemotherapy cannot exceed 5 percent. Furthermore, knowledge that chemotherapy 
generally only prevents a minority of recurrences tells us that the absolute benefit in terms of 
recurrence in that situation will be likely less than 2 percent. So while prognostic estimates are 
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not direct estimates of benefit per se, they provide enough information that could be used to 




 Currently a prospective randomized clinical trial, TAILORx, is underway with the goal of 
assessing the value of adjuvant chemotherapy among patients with mid-range RS results. 
However, one other published study does address the potential value of the RS in predicting 
chemotherapy benefit. 
 A synopsis of the clinical utility evidence presented in the following section is reported in 
Table 19. 
 Paik et al., 2006.53 The authors used the Oncotype DX assay to investigate whether the RS 
was a predictor of the benefit from chemotherapy in ER-positive, lymph node negative, breast 
cancer patients. This study used 651 patients from the NSABP B-20 randomized trial and 
compared a group treated with both tamoxifen and chemotherapy with a group of patients who 
were randomized to tamoxifen only. Gene expression analysis was found to be correlated with 
chemotherapy benefit, defined in terms of 10-year distant recurrence-free survival (DRFS). 
 Kaplan-Meier analysis on all patients showed a significant benefit from the use of  
chemotherapy (P value = 0.02), however when the data was stratified by RS risk groups, only the 
high RS risk group of patients benefited from using chemotherapy (P value = 0.001).   
 When the authors used multivariate Cox proportional hazard analysis, findings about the 
benefit from chemotherapy use were unclear due to large confidence intervals in the low and 
intermediate RS risk groups (low RS risk group, RR=1.31; 95 percent CI: 0.46–3.78; 
intermediate RS risk group, RR = 0.61; 95 percent CI, 0.24 to 1.59).  Patients classified in the 
high RS risk group, however, showed a significant benefit from the use of chemotherapy 
(RR=0.26; 95 percent CI: 0.13–0.53). 
 The authors also looked for interaction between each variable and chemotherapy treatment 
using separate likelihood ratio tests.  The RS was the only significant interaction (P=0.038), with 
only slight statistical weakening when age, tumor size, tumor grade and site were added to the 
model individually (P values from 0.035 to 0.068). When RS was fit as a continuous score, there 
was not a clear threshold that predicted no benefit for chemotherapy.53  
 Overall, this study produced preliminary, high-quality evidence that the RS from the 
Oncotype DX assay has clinical utility, i.e. predictive power in assessing the benefit of 
chemotherapy usage in ER-positive, lymph node negative breast cancer patients. The embedding 
of this study within a large, well conducted RCT was a strength. However, some patients from 
the tamoxifen-only arm of the NSABP B-20 trial were in the training data sets for the Oncotype 
DX assay.  While the algorithm was trained for the outcome of recurrence and not chemotherapy 
benefit, optimization of recurrence prediction in one arm of this study could translate into a 
somewhat enhanced estimate of chemotherapy benefit, although it is unlikely to account for the 
large effect seen here. Finally, while the models could not sustain the inclusion of all possible 
clinical variables, they could have included a composite score, either standard risk predictors, or 
one tailored for the data set (Table 19, Appendix I, Evidence Tables 1, 2 and 4). 
 Correlation between RS and chemotherapy response.  
 Gianni et al., 2005.49 This study focused on the complete pathological response (pCR) to 
preoperative chemotherapy in node negative and positive patients, looking at the correlation 
between pCR and RS. Two independent cohorts of patients were used, the cohort from the Italian 
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National Cancer Institute of Milan, Italy,  and the M.D. Anderson Cancer Center cohort from the 
M.D. Anderson Cancer Center of Houston, U.S. (Appendix I, Evidence Table 2), and were 
evaluated by two different technologies (RT-PCR and the Affymetrix hgu133a array). The study 
also identified additional genes that are associated with pCR and allowed the development of a 
new gene panel associated with pCR, as well as the evaluation of the association of Oncotype 
DX RS with pCR. 
 Results of the Oncotype DX assay in the Milan cohort.  Three hundred and eighty-four genes 
were analyzed by RT-PCR in the Milan cohort of patients, including the 21 genes assessed by 
the Oncotype DX assay.  Data showed good discrimination of pCR by RS. Probit regression-
based models with and without the incorporation of the RS resulted in a P value of 0.005 in a 
global likelihood ratio test. 
 Preliminary evidence that the RS from the Oncotype DX assay has predictive power in 
assessing the likelihood of pCR after pre-operative chemotherapy was obtained in this study.   
(Table 19, Appendix I, Evidence Tables 1, 2 and 4). 
 Mina et al., 2006.51 In this study paraffin-embedded pre-treatment core biopsies from a 
completed phase II trial of 70 patients with newly diagnosed stage II or III breast cancer who 
were treated with sequential doxorubicin and docetaxel were used to identify genes that correlate 
with response to pCR. Gene expression was investigated by RT-PCR in 45 patients, using the 
same procedures of the Oncotype DX assay. A total of 192 genes (187 candidate genes and 5 
reference genes) were tested, including those used to compute the Oncotype DX Recurrence 
Score. 
 Individual genes, as well as groups of biologically related genes, were found to be associated 
with pCR, however no correlation between Oncotype DX RS and pCR was found (P = 0.67).  A 
total of 22 individual genes had an uncorrected P value of less than 0.05 in a likelihood ratio test 
derived from logistic regression models; however 13 genes would be expected to correlate with 
pCR at the P value level of 0.05 level by chance alone. 
  This study provides preliminary evidence that the RS from the Oncotype DX  assay cannot 
predict pCR after primary chemotherapy in advanced breast cancer patients (with variable ER 
and HER-2 status, lymph node involvement, tumor size, and tumor grade) (Table 19, Appendix I, 
Evidence Tables 1, 2 and 4). 
 Chang et al., 2007.55  This study is currently in press for Breast Cancer Research Treatment. 
The authors investigated if expression of the 21 genes of the Oncotype DX assay and other 
candidate genes in locally advanced breast cancer tumors could be used to predict response to 
docetaxel treatment. The 97 women in this study were diagnosed and were enrolled into three 
phase II studies with the neoadjuvant docetaxel at Baylor College of Medicine, Houston, U.S. 
Clinical response was assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 
criteria: clinical complete response (CR) was defined as complete disappearance of the tumor, 
while partial response (PR) was defined as at least 30 percent decrease in unidimensional size. 
An increase of more than 25 percent was defined as clinical progressive disease (PD). Any 
response that did not meet the definition of CR, PR, or PD was defined as stable disease (SD). 
All patients received primary surgery and standard adjuvant therapy. Core biopsies from 97 
patients were obtained before treatment and RNA levels of expression for the selected genes 
were studied by RT-PCR, following the specified protocols for the Oncotype DX assay. 
 Of the selected 97 patients, 81 (84 percent) had sufficient invasive cancer, 80 (82 percent) 
had sufficient RNA to perform the RT-PCR based assay, and 72 (74 percent) had known clinical 
response data. The mean age was 48.5 years, while the median tumor size was 6 cm. A clinical 
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CR was observed in 12 patients (16.7 percent) a partial response in 41 (56.9 percent), a stable 
disease in 17 (23.6 percent), while progressive disease was present in 2 patients (2.8 percent). 
Pathologically, pCR was observed in 2 patients (3.2 percent), ‘incomplete’ responses were 
observed in 61 patients (96.8 percent), and pathologic response was unknown for 9 patients. 
 The authors found that a CR was more likely associated with a high RS (P = 0.008). When 
the RS was used as continuous variable, a 50 unit increase in the RS was associated with a five-
fold increase in the odds of achieving clinical CR (95 percent CI 1.3, 6.0). Moreover, the logistic 
model for the RS indicated that a 14-unit increase in the RS (the difference between low and 
high risk groups, as defined by the standard thresholds) was associated with a complete clinical 
response odds of 1.7 (95 percent CI 1.15, 2.60). The authors concluded that a high risk patient is 
at least 1.7 times more likely to achieve a clinical CR with neoadjuvant chemotherapy compared 
to a low risk patient. Finally, the accuracy of the Oncotype DX RS in predicting the response to 
adjuvant chemotherapy with docetaxel throughout the range of RS values was judged to be at 
least moderate, with AUC of 0.73. 
 Overall, this study provided preliminary evidence that the RS from the Oncotype DX assay 
has predictive value in assessing the likelihood of a clinical CR to primary chemotherapy with 
docetaxel. However the small cohort patients points to the need for further confirmation (Table 
19, Appendix I, Evidence Tables 1, 2 and 4). 
 Oncotype influence on decisionmaking.   
 Oratz et al., 2007 (in press).56 This study investigated whether the Oncotype DX  RS had 
influenced both clinicians’ treatment recommendations and the actual treatment administered in 
patients with ER positive, lymph node negative, early (stage I or II) breast cancer. A 
retrospective analysis was performed on 74 patients from a community-based oncology practice 
for whom RS was determined. Treatment recommendations prior to RS knowledge were 
compared with treatment recommendations after RS knowledge, and to the treatment eventually 
administered. 
 Knowledge of RS changed the clinicians’ treatment recommendations in 21 percent of 
patients, and the actual administered treatment in 25 percent of the patients. In particular, the 
decision to add chemotherapy to the hormonal therapy was generally associated with the high-
risk group, whereas the decision to change from chemotherapy to hormonal therapy was 
associated, in general, with low RS.  
 While this study produced preliminary evidence that knowledge of the RS from the Oncotype 
DX  assay can have an impact on the clinical management of patients diagnosed with ER 
positive, lymph node negative, early breast cancer, it did not report specifically what the patients 
(or doctors) were told or understood about their risk of recurrence.  Because it is unknown 
whether absolute risks were a factor in decision-making, the study is minimally informative as to 
the actual risk thresholds used by women and their treating physicians (Appendix I, Evidence 
Tables 1, 2 and 4). 
 Economic studies.   
 Hornberger et al., 2005.67 The objectives of this study were twofold.  First, the authors 
sought to estimate the incremental benefits, costs, and cost-effectiveness of using Oncotype DX 
to better assign risk of distant recurrence-free survival associated with early stage breast cancer.  
Secondly, the authors wanted to assess the factors that most influence potential benefits and 
efficient use of the 21-gene RT-PCR recurrence score. The outcomes of interest to the study 
included overall survival, relevant costs of breast cancer care, and distant recurrence-free 
survival.   
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 Cost-utility analyses used a Markov model to forecast overall survival, quality of life, costs, 
and cost-effectiveness. Two scenarios were considered , based on NCCN classification of 
patients with lymph node negative, ER positive, early stage breast cancer who were expected to 
receive 5 years of hormonal therapy into a low risk (T1a N0-1mi) group that did not receive 
chemotherapy versus a high risk (T1b with unfavorable features or T1c) group that did receive 
chemotherapy.  Patients were then reclassified using the RS. Annual risks of recurrence and 
survival were obtained from published meta-analyses of clinical trials, and the study model 
included costs of the assay and drugs, including chemotherapy (Table 20, Appendix I, Evidence 
Tables 1, 2, and 5). 
 Summary of study findings. The analysis reported that using the 21-gene RT-PCR assay to 
reclassify patients who were defined by NCCN criteria as low risk (to intermediate or high risk) 
would lead to an average gain in overall survival per reclassified patient of 1.86 years. Total cost 
estimates increased by about $25,000. This amount included $12,190 to identify intermediate- or 
high-risk patients and at least $15,000 for chemotherapy, and was offset by savings of $2,344 
because of the lower risk of recurrence. The cost-utility of RS testing for this cohort was $31,452 
per quality-adjusted life-year (QALY) gained.  
 The authors also reported that reclassifying patients defined as high risk (by 2005 NCCN 
criteria) to low risk (using the 21-gene RT-PCR assay) was cost saving. The added cost of testing 
($7,073) to identify 1 reclassified patient was offset by an estimated $15,000 in savings for 
eliminating the need for chemotherapy.  
 Using the 21-gene RT-PCR assay was expected to improve quality-adjusted survival by a 
mean of 8.6 QALYs and reduce overall costs by about $203,000 in a hypothetical population of 
100 patients with characteristics similar to those of the NSABP B-14) participants, more than 90 
percent of whom were NCCN-defined as high risk. The estimated cost-effectiveness was most 
influenced by the propensity to administer chemotherapy based on the RS, and by the very small 
proportion of patients at low risk as defined by 2005 NCCN guidelines.  The 2007 NCCN 
guideline indicates that the use of chemotherapy in these patients is now considered optional, 
thereby diminishing the utility of this model. 
 Critical appraisal of the analysis. The EPC team appraised the analysis using published 
guidelines for good practice in decision-analytic modeling in health technology assessment, 
Philips 2004.41 The appraisal took into consideration the domains of structure, data, and 
consistency (Table 20, Appendix I, Evidence Table 5). 
 Structure and Data.  The authors provided a clear description of many aspects of the structure 
of the analysis, including the decision problem, objectives of the evaluation, perspective of the 
analysis, rationale for the model structure, and structural assumptions. However, the model 
inputs were not entirely consistent with the stated perspective of the analysis.  For instance, the 
model did not include all costs that are relevant from a societal perspective such as decreased 
productivity and days lost from work. Also the authors did not address the limitations in how 
utility estimates were derived. This is an important limitation because utility estimates can vary a 
lot depending on the methods that are used to derive the estimates. The authors also did not 
justify extrapolating beyond the 10-year followup period for which recurrence data is available.  
Finally, the authors did not report much information about their assessment of methodological 
and structural uncertainties. Without such information it is difficult to determine how their 
projections might differ if different assumptions were made in the decision model. 
 The authors correctly pointed out that the 2005 version of the NCCN breast cancer guideline 
recommends chemotherapy for all node-negative tumors greater than 1 cm (T1a).74  Since 84 
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percent of the patients included in the Paik study28 had tumors larger than 1 cm (T1c), it is 
unsurprising that a very large proportion of patients overall would be spared chemotherapy (gene 
expression profiling data expected to identify approximately half of these patients to have a low 
RS).  However, by 2007 the NCCN panel had refined its criteria for recommending 
chemotherapy6, now considered optional (adjuvant hormonal therapy ± chemotherapy) for those 
with ER-positive HER-2-negative disease and tumors greater than 1cm (T1c).  Therefore, it is 
reasonable to speculate that approximately half of these patients might opt for no chemotherapy. 
This is a similar proportion of patients that would be found to have a low RS, although these two 
groups of patients may not necessarily be the same. 
 Consistency. Appendix I, Evidence Table 5 notes that the authors did not report information 
about the internal and external consistency of their analysis. The analysis would be more 
convincing if it gave more information on whether the mathematical logic of the model had been 
tested (internal consistency) or if results from other models were available for comparison 
(external consistency).Nevertheless, the results of the model make intuitive sense and seem to be 
consistent with published data on the performance characteristics of the 21-gene RT-PCR 
recurrence score.  
 Summary of critical appraisal. Overall, the EPC team concluded that this economic analysis 
met most of the standards set by the rigorous guidelines of Phillips et al., 200441. It is not clear 
whether the limitations noted above biased the results for or against the 21-gene RT-PCR assay, 
but extension of the timeframe beyond 10 years could overstate the benefits of using the assay. 
Given that this study was sponsored in part by the manufacturer of the 21-gene RT-PCR assay 
(Genomic Health, Inc., Redwood City, California), the EPC team would have had more 
confidence in the results if the authors had provided more information about methodological and 
structural uncertainties as well as other potential sources of bias such as the derivation of the 
utility estimates. The generalizability of these results to patients in 2007 is also limited, as the 
2005 NCCN guidelines have since been updated.  Thus, the team has only moderate confidence 
that the results of the economic analysis provide reasonable estimates of the potential cost-
effectiveness of using the 21-gene RT-PCR assay to guide treatment of early stage breast cancer 
 Lyman et al., 2007.75 The main objective of the second study7 was to estimate the cost-
effectiveness of 21-gene RT-PCR assay-guided treatment of patients with ER positive, lymph 
node-negative, early-stage breast cancer with either tamoxifen alone or the combination of 
chemotherapy and tamoxifen.  
 This analysis incorporated data that validated the prognostic accuracy for distant RFS using a 
21-gene RT-PCR assay in 668 lymph node-negative, ER positive women with early-stage breast 
cancer receiving tamoxifen on NSABP B-14. The analysis also incorporated data that validated 
the predictive accuracy for treatment efficacy in 651 patients randomized in NSABP B-20, and 
645 patients in NSABP B-14. 
 The study design involved cost-utility analyses using a “clinical decision model” designed to 
compare clinical, economic, and quality of life outcomes for three adjuvant treatment strategies: 
1) tamoxifen alone, 2) chemotherapy followed by tamoxifen, or 3) therapy based on the results 
of the 21-gene RT-PCR assay. Using the RS from the 21-gene RT-PCR assay, patients were 
classified as high risk (RS ≥ 31), intermediate risk (RS 18–30), or low risk (RS < 18) for distant 
recurrence at 10 years. The third strategy assumed that low-risk patients would receive 
tamoxifen, and intermediate or high-risk patients would receive chemotherapy and tamoxifen. 
Clinical outcomes were estimated in terms of life expectancy or life-years saved as derived from 
NSABP B-20 and B-14 data. Economic outcomes included selected costs of cancer care, 
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including the costs of chemotherapy, surveillance without recurrence, use of the 21-gene RT-
PCR assay, and treatment of recurrence. Quality of life outcomes were estimated based on the 
utility associated with use of chemotherapy. The treatment strategies were compared in terms of 
the additional cost of one strategy over another (marginal cost), the additional clinical benefit 
(marginal efficacy), and the additional quality-adjusted clinical benefit (marginal utility) (Table 
20, Appendix I, Evidence Tables 1, 2 and 5). 
  Summary of study findings. The lowest expected mean cost per life-year saved was 
associated with treatment with tamoxifen alone ($11,890), whereas the greatest expected mean 
cost was associated with treatment with both chemotherapy and tamoxifen ($18,418). The 
expected cost of each strategy increased as the assumed cost of treating distant recurrence 
increased. Above a cost of $100,759 for treating recurrence, therapy guided by the RS provided a 
net cost savings compared with other strategies and was always cost-saving compared with the 
chemotherapy and tamoxifen strategy. The tamoxifen strategy was associated with the lowest 
costs for all reasonable followup cost assumptions among those without recurrence. Therapy 
guided by the RS was favored over chemotherapy and tamoxifen for total chemotherapy costs 
exceeding $5,822. The use of therapy guided by the RS was more costly for low-cost 
chemotherapy regimens not requiring additional supportive care, whereas a net cost savings 
between $500 and $10,000 was estimated with RS guided therapy for other commonly used and 
higher-cost adjuvant chemotherapy regimens.  
 Compared to tamoxifen alone, the expected incremental cost associated with RS-guided 
therapy was $4,272.  The expected incremental cost associated with chemotherapy and 
tamoxifen was $6,527. The incremental cost-effectiveness ratio compared with tamoxifen alone 
favored the use of RS-guided therapy ($1,944 per life-year saved) over the use of chemotherapy 
and tamoxifen ($3,385 per life-year saved). When the analysis considered increases in healthy 
life expectancy, the incremental life-years saved increased for the RS-guided therapy compared 
with tamoxifen alone, and the corresponding marginal cost-effectiveness decreased. 
 Expected QALYs favored RS-guided therapy over chemotherapy and tamoxifen for all 
health utility values, with increasing incremental QALYs as the impact of chemotherapy on 
measured utility increased. Recurrence-score-guided therapy had greater expected QALYs 
compared with tamoxifen alone, until the utility associated with chemotherapy fell below 0.80. 
At a utility of 0.90 for adjuvant chemotherapy, RS-guided therapy was associated with a gain of 
0.97 QALYs, a cost-utility ratio of $4,432 per QALY compared with tamoxifen alone, and a gain 
of 1.71 QALYs with net cost savings when compared with the chemotherapy and tamoxifen 
combination.  
 Critical appraisal of the analysis. The EPC team appraised the analysis using published 
guidelines for good practice in decision-analytic modeling in health technology assessment 
Phillips 200441, taking into consideration the domains of structure, data, and consistency (Table 
20, Appendix I, Evidence Table 5). 
 Structure. Although the authors provided a clear description of the decision problem, they did 
not state the perspective of the model. Moreover, the authors did not provide enough information 
about the structure of the model to allow an evaluation of the appropriateness of the model type 
or of the causal relationships described by the model. The authors also did not justify 
extrapolating beyond the 10-year period for which recurrence data is available. 
 Data. The authors provided some explanation and justification of the data used in the 
analysis, citing previous work for some of the details. However, the authors did not include all 
relevant costs. They included the costs of adjuvant chemotherapy, surveillance, use of the 
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Oncotype DX assay, and treatment of recurrence, but they did not include other treatment-related 
direct costs (e.g., costs of administration, associated testing, and transportation) or indirect costs 
(e.g., decreased productivity). Although indirect costs may be implicitly included in utility values 
assigned to relevant health states, the authors did not provide enough information to determine 
whether that was done. The analysis would have been stronger if it had estimated cost-
effectiveness with and without inclusion of indirect costs and other treatment-related costs. The 
authors did not mention any health-state utilities other than the utility with chemotherapy, and 
did not give sufficient detail about how they estimated the utility with chemotherapy. In addition, 
the authors did not report on the quality of the data. A single study was used as the source of 
estimates for the relative effects of the treatment strategies. The authors also did not report 
sufficient information about the sensitivity analysis and alternative assumptions. Finally, the 
authors did not report much information about their assessment of methodological and structural 
uncertainties. 
 Consistency. The authors did not report information about the internal and external 
consistency of their analysis, but the results of the model make intuitive sense. Generally, the 
results seem to be consistent with the cited data on the performance characteristics of the 21-
gene RT-PCR RS. 
 Summary of critical appraisal. Overall, the EPC team concluded that this economic analysis 
did not meet many of the standards set by the rigorous guidelines of Phillips et al., 200441. These 
limitations are particularly serious because the authors received research support from the 
manufacturer of the 21-gene RT-PCR assay. Consequently, the EPC team has little confidence in 
the results of this analysis.  
     Summary of available studies. Based on the evidence from the stronger of the two available 
studies, the EPC team concluded that the 21-gene assay, when used to guide treatment for 
patients previously classified as low risk by NCCN-defined criteria, may be cost-effective 
compared to standard treatment approaches in women with lymph node-negative, ER positive 
early-stage breast cancer. Similarly, the EPC team concluded that the 21-gene assay, when used 
to guide treatment for patients previously classified as high risk by NCCN criteria, may be cost-
saving compared to standard treatment. The overall body of evidence on economic outcomes is 




No published studies evaluated the ability of the 70-gene signature for the main MammaPrint 
assay to predict chemotherapy benefit. 
 Economic studies.   
 Oestericher et al., 2005.76 The main objective of this study was to compare the cost-
effectiveness of the Netherlands Cancer Institute gene expression profiling (GEP) assay to the 
NIH guidelines for the identification of early stage breast cancer patients who would benefit 
from adjuvant chemotherapy based on risk of distal recurrence. Although the references cited for 
the performance characteristics of the GEP assay indicate that the investigators were using data 
on MammaPrint, the article does not clearly state that they were analyzing MammaPrint. 
The study design involved a cost-utility analysis. Using a Markov model, the investigators 
estimated the incremental cost and QALYs associated with use of the GEP assay as compared to 
use of the NIH guidelines in a hypothetical cohort of premenopausal women averaging 44 years 
of age newly diagnosed with stage I/II breast cancer. The performance characteristics of the tests 
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were based on data from the Netherlands Cancer Institute cohort.25 In the Markov model, the 
investigators assumed that the results of the GEP assay would be used to classify patients as 
having a “good prognosis” or a “poor prognosis” based on a test cutoff derived from the first 
validation study of the GEP assay.21 They also assumed that the NIH guidelines would be used to 
classify patients as having a “good prognosis” or a “poor prognosis,” that women with a “poor 
prognosis” would receive adjuvant chemotherapy, and that women with a “good prognosis” 
would not receive chemotherapy. The model considered the following clinical events: distant 
recurrence of breast cancer, mortality due to distant recurrence, and mortality from other causes. 
The economic outcomes included the cost of the GEP assay, the cost of adjuvant chemotherapy, 
and the cost of managing distant recurrence of breast cancer. Quality of life outcomes were 
estimated in terms of QALYs, with utility estimates for specific health states derived from 
previous publications. The two strategies were compared in terms of the number of cases of 
distant recurrence prevented, costs, and QALYs.  (Table 20, Appendix I, Evidence Table 5). 
Summary of study findings. The NIH guidelines identified 96 percent of the cohort as high 
risk whereas the GEP identifies 61 percent of patients as high risk with sensitivities of 98 percent 
for the NIH guidelines and 84 percent for GEP. Specificities were 51 percent for GEP and 5 
percent for the NIH guidelines. Since there is a 35 percent risk reduction in distant recurrence 
from use of chemotherapy, using NIH guidelines to identify high-risk women and treat with 
chemotherapy prevented 34 percent of distant recurrences compared to 29 percent for GEP. After 
including the negative impact on life expectancy and quality of life from chemotherapy and 
distant recurrence, the NIH guidelines and GEP yielded 10.08 and 9.86 QALYs respectively. 
Total costs were $32,636 for the NIH guidelines and $29,754 for GEP.  
Although the GEP assay was projected to identify 35 percent fewer women for chemotherapy 
than NIH guidelines, quality of life benefits in the women who did not need chemotherapy were 
outweighed by the decrease in life expectancy in the women who needed chemotherapy but did 
not receive it because of GEP’s lower sensitivity.  
The authors concluded that, in order to improve quality of life by allowing women to safely 
avoid chemotherapy while not missing women whose survival is compromised by avoiding 
therapy, GEP’s sensitivity would have to increase to at least 95 percent while maintaining a 
specificity of 51 percent. The GEP assay did not attain a sensitivity of 95 percent regardless of 
the test cutoff used in the analysis. 
Critical appraisal of the analysis. The EPC team appraised the analysis using published 
guidelines for good practice in decision-analytic modeling in health technology assessment,41 
taking into consideration the domains of structure, data, and consistency (Table 20, Appendix I, 
Evidence Table 5). 
Structure. As indicated in Table 20, the authors provided a clear description of most aspects 
of the structure of the analysis, including the decision problem, objectives of the evaluation, 
perspective of the analysis, rationale for the model structure, and structural assumptions. The 
model inputs were consistent with the stated perspective of the analysis. The authors did not 
justify using a timeframe beyond the 6.7-year period for which recurrence data is available. 
Data. The article was very strong in providing explanation and justification of the data used 
in the analysis. Limitations were that the authors did not justify extrapolation of data beyond 6.7 
years of followup and that they only compared their model to the NIH guideline.  In addition, 
although the authors listed a number of references for their use of utilities, they did not provide 
any explanation of how they derived specific utility estimates from these references. They also 
did not provide any explanation of the methods or scaling techniques that were used to derive the 
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utility estimates. Thus, we can not determine whether the utilities were based on the standard 
gamble techniques, which is the gold standard, or on other scaling techniques. This is important 
because the standard gamble techniques generally yields utility values that are higher than the 
values derived using other techniques. The estimates used in this study seem low compared to 
the values assigned to most serious health conditions.77,78 Also, these references for the utility 
estimates are significantly more dated than some of the references used to obtain cost data.  
Consistency. The authors discussed the internal and external consistency of their analysis, 
and the results of the model make intuitive sense.  
Summary of critical appraisal. Overall, the EPC team concluded that this economic analysis 
met most of the rigorous standards set by Phillips et al., 2004.41 The EPC team therefore has 
confidence in the results of this analysis. Although we had some uncertainty about the utilities 
used in the analysis, the EPC team believes that this limitation is unlikely to have changed the 




Jerevall et al., 2007.63 This paper investigated whether the two-gene ratio can predict the benefit 
of 2 years versus 5 years of tamoxifen treatment in postmenopausal breast cancer patients, and 
also predict the prognostic value in systematically untreated premenopausal patients. Expression 
of HOXB13 and IL17BR were quantified by RT-PCR in tumors from 264 randomized 
postmenopausal patients and 93 systemically untreated premenopausal patients. The two study 
populations were collected as part of a collaborative study between two centers in Sweden, and 
72 percent of the randomized patients were lymph node positive and 74 percent ER positive.  To 
stratify the patients into risk groups the authors dichotomized the ratio using the median. Thus 
the normalization procedure and dichotomization differed from the approach used by Ma.61 The 
prognostic results from this study are reported under Key Question 3 (clinical validity). 
 Kaplan-Meier analysis of data from postmenopausal ER-positive patients demonstrated that a 
low HOXB13-to-IL17BR ratio was associated with a benefit to receiving 5 vs. 2 years of 
tamoxifen treatment (univariate P= 0.021; in KM analysis).  There was no benefit (P=0.9) in 
patients who had a high ratio, which mainly appeared due to the low expression of HOXB13 
genes (P= 0.010, in Kaplan-Meier analysis). The predictive significance of both the two-gene 
ratio and the HOXB13 gene alone was maintained using a Cox proportional hazard modeling, 
adjusting for tumor size, PR status, and lymph node status. 
 The authors concluded that the ratio, or even HOXB13 alone, could predict the benefit of 
prolonged endocrine therapy, and that a lower expression of IL17BR, given its correlation to 
poor prognosis, could be an independent prognostic factor. 
 Neither the patient profile nor the mode of calculation of the ratio were identical to previous 
studies (Table 21, Appendix I, Evidence Tables 10, 11 and 13). However this study produced 
additional developmental evidence about the prognostic utility of the HOXB13-to-IL17BR ratio, 
and of the two individual genes, in ER positive breast cancer patients who received systemic 




TAILORx (Trial Assigning IndividuaLized Options for Treatment (Rx)).  
 
 The primary objective of TAILORx is to compare the DFS of women with previously-
resected axillary-node-negative breast cancer who have an Oncotype DX RS of between 11 and 
25 when treated with both adjuvant chemotherapy and hormonal therapy versus hormonal 
therapy alone. It should be noted that this range is lower on both ends than the standard 
“Intermediate” RS range, viz. 18-30. This represents a more conservative approach to the use of 
the RS than is suggested by current categories, in that subjects who agree to forego 
chemotherapy in this trial will be at lower risk than those in the current “low risk” RS group.  
The secondary objective is to determine if adjuvant hormonal therapy alone is sufficient 
treatment (i.e., 10-year distant DFS of at least 95 percent) for patients with an RS of less than or 
equal to 10. 
 This study will not provide direct evidence for the value of Oncotype DX, as all patients in 
the trial will receive the test. The trial results will indicate whether adjuvant chemotherapy is of 
value within the trial’s intermediate RS range, and will serve as further validation of the absolute 
risk of recurrence in subjects with scores above and below the range. This will provide better 
estimates of the degree of benefit from utilization of the test, but will not directly examine what 
therapeutic choices would have been made and clinical outcomes incurred if only standard risk 
prediction tools were used. However, since standard risk prediction indices will be calculable, 
that information may be inferred. First results from this trial are expected in approximately 2013. 
 
MINDACT (Microarray for Node-Negative Disease may Avoid 
Chemotherapy).  
 
 MINDACT is a multi-center, prospective, phase III randomized study comparing use of the 
MammaPrint assay with a common clinical-pathological prognostic tool, Adjuvant! Online, to 
select patients for adjuvant chemotherapy in node-negative breast cancer. Patients at low risk by 
both MammaPrint and standard clinical-pathological criteria will not receive chemotherapy, 
patients at high risk by both criteria receive chemotherapy, and patients with discordant criteria 
will be randomized to use either MammaPrint only or standard criteria to decide treatment (i.e., 
randomized to receive adjuvant chemotherapy or not). This will directly test whether the choice 
of chemotherapy guided by MammaPrint provides benefit over that guided by the Adjuvant! 
criteria. 
 
Other Relevant Studies 
 
 Fan et al., 2006.79 No key questions relevant to the evaluation of gene expression-based 
prognostic estimators was directly addressed in this study, but the agreement between gene-
expression tests and other predictors was evaluated, as well as their individual performance on a 
common dataset. In particular, the 70-gene signature, the gene panel used in Oncotype DX, the 
2-gene ratio, and other gene expression signatures were considered. This investigation was 
carried out on the 295 samples from stage I-II breast cancer patients, which had been used to 
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develop the 70-gene test21. The Oncotype DX RS and the 2-gene ratio were estimated from 
microarray gene expression data (i.e., not RT-PCR), and thus were not obtained according to the 
protocols and methods used in the corresponding marketed assays. These are therefore described 
as “derived” scores below. 
 All tests except the 2-gene ratio (hazard ratio of about 1) were highly significant predictors of 
OS and DFS. The agreement between MammaPrint and derived RS was 81 percent (239/295).   
However the intermediate and high risk groups, as defined by the RS gene panel, were 
considered as one group in this paper and compared to the poor prognosis group of patients, as 
defined by the MammaPrint signature. ER status, tumor grade, tumor size, and lymph node 
involvement also proved to be significant univariate predictors. The coefficients of clinical 
predictors were allowed to vary between models in this analysis. All the analyses were repeated 
for the ER positive (N=225) subset with qualitatively similar results. Good, but not perfect 
correlation between predictions was found. This was surprising since classification was obtained 
using different gene sets. The degree of prediction over and above “standard” clinical stratifiers 
was not clear in the paper and the reclassification of samples was not done. 
 This study is of interest since it compared 5 different classifiers. However, it should not be 
regarded as a validation of either the Oncotype DX  or the H/I ratio assays, since actual tests 
were not used on these patients and the RS and the two-gene index estimates were obtained from 
microarray data.  In addition, since this was the same dataset used in the development of the 70-
gene signature, it would be expected to perform better than the RS, for which this was a true test 
set.   
 Espinosa et al., 2005.80 In this paper the authors developed an RT-PCR based version of the 
70-gene expression signature21,25 RT-PCR was used to measure, in breast cancer biopsy 
specimens, the expression of the 70-gene signature, as well as four additional genes (HER-2, 
EGFR, PLAT, and MUC-1) related to prognosis.  The study population was 96 patients 
diagnosed between 1991 and 1997 for whom samples and followup were available and who were 
seen in a single Madrid hospital. Half of the patients were lymph node positive, 75 percent ER 
positive, and 25 relapses were observed after a median of 70 months of followup. Eighty percent 
of ER positive patients received tamoxifen, and 74 percent of patients overall received adjuvant 
chemotherapy. 
 The objective of the authors was to reproduce the results obtained with the 70-gene profile 
through an alternative technology. However, for technical reasons only 60 of the 70 genes could 
be investigated. For this reason, the study cannot be considered a validation of the 70-gene 
signature. According to the results obtained by RT-PCR, Kaplan-Meier estimates for RFS and 
OS in the good and poor profiles patients’ groups were as follows: 
• RFS for Good vs. Poor prognosis profile 70 months after surgery: 85 percent vs. 62 
percent. 





Univariate and multivariate Cox proportional regression analyses were performed to compute 
a hazard ratio for the risk groups for both endpoints. Only the lymph node status (hazard ratio, 
1.2; 95 percent CI, 1.09 to 1.36) and the gene profile (hazard ratio, 6.3; 95 percent CI, 1.28 to 
31.07) proved to be independent prognostic variables for OS.  Only the number of positive 
lymph nodes (≤ 3 versus >3) (hazard ratio, 1.13; 95 percent CI, 1.05 to 1.25) and again the gene 
profile (hazard ratio, 2.74, 95 percent CI, 1.13 to 6.61) were independent prognostic variables for 
RFS.  
 In subgroup analyses, the signature did not predict significantly in lymph node negative 
patients (many of whom received adjuvant chemotherapy), or in women >52 years of age.  
 The profile predicted both local and distant relapses in the general population of women with 
breast cancer. In the poor-prognosis group, most patients survived less than 2 years after relapse, 
regardless of the site of first relapse. In contrast, patients in the good prognosis group usually had 
low-risk relapses and survived longer than 2 years after relapse. 
 This study cannot be considered an independent validation of the MammaPrint assay, since 
only 60 out of 70 genes were considered, the genes were assessed by a different technology (RT-
PCR rather than microarray), and the population was far more heavily treated with adjuvant 
chemotherapy than previously-tested populations. It therefore did not test a population in whom 
these results would have a clear implication for therapeutic decisions. 
 
Studies Excluded Upon Complete Review 
 
 Eden et al., 2004.81 This paper was excluded because it did not provide new information on 
the assays investigated. The gene expression markers identified by van’t Veer and colleagues21 
were compared to both conventional markers and newly constructed indices to predict distant 
metastases. However, analysis was conducted in the same van’t Veer cohort patients, and 
therefore was not a new validation of the 70-gene signature.  
 Weigelt et al., 2005.82 This paper was excluded because it does not include prognostic 
information for the investigated assays, although it does provide some useful biologic insights. 
These authors showed that distant metastases display both the same molecular breast cancer 
subtype and 70-gene prognosis signature as their primary tumors. These results suggest that the 
capacity to metastasize is an inherent feature of most breast cancers, implying that poor-
prognosis breast carcinomas, as classified by the intrinsic gene set or the 70-gene profile, 
represent distinct disease entities. These findings support the hypothesis that molecular subtypes 
might originate from different cell types within the breast, therefore reflecting different 
biological entities and maintained throughout the multistep metastatic process. Indeed the 
metastatic nature of poor-prognosis breast carcinomas, which are depicted by the 70-gene profile 
or the luminal B, HER-2 positive, or basal-like molecular subtype, is an inherent feature of breast 
cancers that remain stable with time and across distinct tumor outgrowth locations within the 
same individual.  
 Nuyten et al., 2006.83 This paper was excluded because the authors used a subset of the van 
de Vijver25 data set and looked at local recurrence.  
 This group searched for gene expression signatures that predict the risk of local recurrence 
after breast-conserving therapy (BCT) in a series of 161 early-stage breast cancer patients who 
were a subset of the original van de Vijver25 cohort. The 70-gene signature, originally designed 
to predict metastasis, failed to predict local recurrence after BCT.  
 In this paper other gene signatures were evaluated. The supervised wound-response 
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signature22,84 is the only gene expression profile that could predict a local recurrence after BCT, 
while both the 70-gene and the primary hypoxia signatures85 failed to predict metastases.  
 Naderi et al., 2007.86  This study was excluded because it was not related to the assays 
investigated for this review. The authors developed a Cox-ranked 70-gene signature, which is a 
‘new’ signature, and it is not related to the MammaPrint test. 
 Sun et al., 2007.87  This paper was also excluded because it is not related to the assays 
investigated for this review. The author developed a new predictor (with only 3 genes from the 
70-gene profile) for recurrence based on the van’t Veer data set and used the 70-gene signature 
for comparison: the new signature performed better than 70-gene signature.  
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Table 1. Description of the three gene expression profile assays 
 
Assay General Information Measurements Assay procedures 
Assay: Oncotype DX™, Genomic 
Health 
 
Analytic studies: Cronin 2004,44 
Cronin 200745 
 
Clinical validity and utility studies: 
Chang 2007,55 Cobleigh 2005,47 , 
Esteva 2005,48 Gianni 2005,49 Habel 
2006,50 Mina 2006,51 Oratz in press,56 
Paik 200428, Paik 200653 
 
Economics studies: Lyman 2007,75 
Hornberger 200567 
 
What is measured: 16 cancer genes, 
5 normalizing genes by real time RT-
PCR 
 
To whom it is offered: 
1) Stage I, ER positive, who will be 
treated with tamoxifen; 
2) Stage II, ER positive, LN 






Genes for normalization: ACTB, GAPDH, RPLPO, GUS, TFRC: 
 
Cancer related genes (the following functional groups are used to assess 
patients’ Recurrence Score): 
Proliferation: Ki67, STK15, Survivin, CCNB1, MYBL2 
HER2: GRB7, HER2 
Estrogen: ER, PGR, BCL2, SCUBE2 
Invasion: MMP11, CTSL2 
Single genes: GSTM1, CD68, BAG1 
 
Algorithm: The recurrence score (RS) is obtained in four steps as follows: 
1. The expression for each gene is normalized relative to the expression of the 
5 reference genes. Reference-normalized measurements range from 0 to 15, 
with a 1-unit increase reflecting approximately a doubling of RNA; 
2. Scores for the groups of genes are calculated from individual expression 
measurements, as follows: 
HER2 group = 0.9*GRB7 + 0.1*HER2, (set to 8, if less); 
ER group = (0.8*ER + 1.2*PGR + BCL2 + SCUBE2) ÷ 4; 
Proliferation group = (Survivin + KI67 + MYBL2 + CCNB1 + STK15 ) ÷ 5 (set 
to 6.5, if less); 
Invasion group = (CTSL2 + MMP11) ÷ 2 
3. The unscaled recurrence score (uRS) is calculated, using predefined 
coefficients defined in the three training sets: 
uRS = +0.47*HER2 group - 0.34*ER group + 1.04*proliferation group + 
0.10*invasion group + 0.05*CD68 - 0.08*GSTM1 - 0.07*BAG1 
4. The RS is rescaled from the uRS, as follows: 
RS = 0 if uRS < 0 
RS = 20* (uRS - 6.7) if 0 ≤ uRS ≤ 100 
RS = 100 if uRS >100 
5. Risk groups: 
Low risk: RS ≤ 17 
Intermediate risk: 18 ≤ RS ≤ 30 
High risk: RS ≥ 31 
1. FFPE specimen shipment. 
2. Central pathological review 
for tumor content. 
3. RNA preparation and quality 
evaluation. 
4. Triplicate real time RT-PCR. 
5. Gene expression measures 
normalization. 
6. RS score computation and 
re-scaling; Risk group 
assignment. 
 
Results: Report with RS and 
Risk Group. 
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Table 1. Description of the three gene expression profile assays (continued) 
 
Assay General Information Measurements Assay procedures 
Assay: MammaPrint®, Agendia 
 
Analytic studies: Ach 2007,57 Glas 
2006,58  
 
Clinical validity and utility studies: 
Buyse 2006,59 van de Vijver 2002,25, 
van't Veer 2002,21  
 
Other studies: Fan 2006,79 and 
Espinosa 200580  
 
What is measured: gene expression 
of 1900 genes, including the 70 genes 
in triplicate, by two-color microarray 
(Agilent Technologies); 
 
To whom it is offered: 
1) Stage I, ER positive or negative, 
< 61 years; 
2) Stage II, ER positive or negative, 








Genes for normalization: ~1800; 
 
70-gene signatures (the following functional groups are NOT used to assess 
patients’ risk): 
 
Cell signaling, growth factors, transcription: MS4A7, GPR180, RTN4RL1, 
ZNF533, GPR126, ECT2, ESM1, FGF18, FLT1, GNAZ, STK32B, IGFBP5, 
IGFBP5, MELK, EBF4, NMU, CDC42BPA, TGFB3, WISP1, SCUBE2; 
Cell cycle, chromatin, nuclear proteins: TSPYL5, CCNE2, CENPA, CDCA7, 
LGP2, EXT1, NDC80, MTDH, DTL, NUSAP1, MCM6, ORC6L, PRC1, RFC4; 
Cell adhesion, cell motility, cytoskeleton organization: AYTL2, DIAPH3, 
COL4A2, DIAPH3, DIAPH3, MMP9; 
Metabolism, Intracellular transport, Golgi: ALDH4A1, AP2B1, QSOX2, 
GMPS, GSTM3, PITRM1, OXCT1, PECI, PECI, RAB6A, SLC2A3, EGLN1; 
Ubiquitination: FBXO31, UCHL5; 
Apoptosis: BBC3; 
Drug resistance: DCK; 
Unknown function: LOC286052, PALM2-AKAP2, AA834945, LOC643008, 
AA404325, AI283268, AI224578, RUNDC1, C9orf30, AW014921, C16orf61, 
C20orf46, HRASLS, SERF1A 
 
Algorithm: classification of patients into risk groups is obtained as follows: 
1. Scanned image analysis, background correction for non-specific 
hybridization, and gene expression measurements normalization. Expression 
values are expressed as log10 ratios. Probes are excluded from further 
calculations if their background corrected intensities are below zero and/or if 
spots are flagged as outliers, as determined by the image analysis software. 
The overall expression value for each signature gene is computed using an 
error weighted mean over the triplicate probes. 
2. The gene signature risk classification is given as a dichotomized value only: 
high or low risk. A tumor is defined as having a low-risk gene signature if the 
cosine correlation coefficient for the expression of the 70-gene profile in that 
tumor with the previously established classifier is above 0.4, the cut point 
used in the original study by van't Veer, 2002.21 
1. Fresh specimen shipment; 
2. Central pathological review 
for tumor content; 
3. RNA preparation and quality 
evaluation; 
4. Dye swap microarray 
hybridization on 
MammaPrint®; 
5. Image analysis; 
6. Gene expression measures 
normalization; 
7. 70-gene signature 
computation and correlation 
to 70-gene profile; Risk 
group assignment; 
 




Table 1. Description of the three gene expression profile assays (continued) 
 
Assay General Information Measurements Assay procedures 
Assay: Breast cancer Profiling (BCP), 
also known as H/I assay, AviaraDX/ 
Quest Diagnostics 
 
Clinical validity and utility studies: 
Goetz 2006,62 Jansen 2007,72 Jerevall 
2007,63 Ma 2004,64 Ma 2006,61 Reid 
2005,69 and Fan 200679  
 
What is measured: 6 genes by real 
time RT-PCR; 
 
To whom it is offered: 
1) Treatment-naïve individuals with 







Genes for normalization: ACTB, HMBS, SDHA, and UBC; 
 
Two gene ratio: HOXB17, IL17BR; 
 
Algorithm: The H/I index is obtained in four steps as follows: 
1. For each sample, cycle threshold for the 4 reference genes are averaged to 
obtain the reference CT (refCT); 
2. Relative expression levels for HOXB13 and IL17BR are computed as 
individual CT differences from the refCT; 
3. Normalized CT differences are z-transformed and the H/I index is obtained by 
subtracting these two values; 
4. An optimized cut-off point is used to dichotomize patients into two risk 
groups, low and high 
1. FFPE Specimen shipment; 
2. Central pathological review 
for tumor content; 
3. Specimen macro-dissection, 
if needed, LCM; 
4. RNA preparation and quality 
evaluation; 
5. Duplicate real time RT-PCR; 
6. Gene expression measures 
normalization and Z-
transformation; 
7. Two-gene index 
computation; Risk group 
assignment; 
 
Results: Report with risk group 
 
FFPE = formalin-fixed paraffin-embedded; RT-PCR = reverse transcriptase polymerase chain reaction; ER = estrogen receptor; LN = lymph node; HER = human epidermal 
growth factor receptor; RS = recurrence score; CT = cycle threshold; LCM = laser-capture micro dissected 
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Table 2. Successful assays, Oncotype DX™ 
 












    
Cobleigh, 200547 Standard FFPE 78/85 (91.7%) 7 (8.2%)     1* 




 3 /220 (1.3%) 22/220 (10%)  





    
Habel, 200650 Standard FFPE 865/790 19 (7.9%)‡  59§ 1%‡   




    
Oratz, in press56 Standard FFPE 72 /74 (97.3%) 2 /74 (2.7%)      
Paik, 200428 Standard FFPE 668/675 (98.9%) 675/754 
(89.5%)¶ 
     
Paik, 200653 Standard FFPE 651/670 (97.2%)       
 
* Clinically Ineligible (Stage IV) 
† Studies performed according to Oncotype DX protocols, but not performed at Genomic Health 
‡ It is not clear what the total number was, since it was not reported 
§ 59 tumors underwent macro-dissection; it is not clear whether they were used in the subsequent analyses 
║ Out of the 70 eligible patients 57 were analyzed (No consent: 3 patients; No specimen available: 10 patients) 
¶ The total of 754 (79+675) patients was computed and not clearly reported in the study 
 
FFPE = formalin fixed paraffin embedded; RNA= ribonucleic acid; RT-PCR= reverse transcriptase polymerase chain reaction. 
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Table 3. Variability and reproducibility, Oncotype DX™ 
 
Study, year Aims and Methods: Results Conclusions 
Cronin, 
200745 
To assess individual gene and RS 
reproducibility 
 
Repeated measurements of 2 
aliquots of a single RNA across 
multiple days, operators, RT-PCR 
plates, 7900HT instruments, and 
liquid-handling robots 
 
Mixed-effect ANOVA was used to 
estimate components of variance; 
 
Reproducibility, CT measurements SD for the individual genes: 
Total SD range: 0.06 to 0.15 CT units 
Between day SD range: 0 to 0.055 CT units 
Between plated SD range: 0 to 0.090 CT units 
Within plated SD range: 0.057 to 0.147 CT units 
 
At a CT of 30 a maximum SD of 0.15 translates into a CV of 
0.5% 
 
The largest differences between operators, liquid handling 
robots, and 7900HT instruments < 0.5 CT 
 
Reproducibility, CT measurements SD for the RS: 
Total SD was 0.792 RS units 
Between day SD was 0 RS units 
Between plated was 0 RS units 
Within plated was 0.792 RS units 
Authors reported that the following 
procedures were performed to assure  
the reproducibility of the assay: 
A standard RNA control sample is 
assayed at least once per batch of 
patient (46 samples) 
PCR controls are run in every assay 
plate 
RT-PCR failures are excluded from 
analysis 
Expression values are assigned when 
at least 2 of 3 assay wells provide 
acceptable RT-PCR results 
All 21 genes must have an expression 
value assigned for an RS to be 
calculated and reported 
Habel, 200650 To assess RS reproducibility 
 
Pearson’s correlation and ANOVA 
to assess within-patients correlation 
and variability: 
60 blocks that did not undergo 
macro-dissection from 20 
patients (2 to 5 blocks per 
patient); 
49 core biopsies or tumor 
resection blocks 
RS (as a continuous value) SD and Pearson’s correlation 
observed in two unpublished studies: 
Overall between blocks SD was 3.0 RS units 
For 16 of the 20 patients, the between blocks SD was < 2.5 RS 
units 
Pearson’s correlation = 0.86 
 
Similar results from the second study 
 
 
Paik, 200428 To assess individual genes and RS 
reproducibility 
 
Reproducibility within and between 
blocks was assessed by performing 
the assay in five serial sections 




16 Cancer genes SD ranged from 0.07 to 0.21 CT units; 
Within-block RS SD = 0.72 RS unit (95% CI = 0.55 to 1.04); 
Total within-patient SD (including between and within-block 
SD) = 2.2 RS units; 
 
Similar variability in the RS was observed in reanalysis of clinical 




RS = recurrence score; RNA=ribonucleic acid; RT-PCR = reverse transcriptase polymerase chain reaction; ANOVA=analysis of variance; CT = cycle threshold; SD = standard 
deviation 
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Table 4. Analytic validity, Oncotype DX™ 
 
Study, year Context and Methods Results Comments 
Cronin, 
200444 
RT-PCR protocol optimization from FFPE 
specimens 
 
Pearson’s correlation to compare FFPE 
and frozen specimen 
 
Comparison between FFPE and frozen 
specimens, 48 genes 
Correlation = 0.91, p value < 0.0001 Gene expression profiling analysis is 
possible using FFPE blocks and comparable 
to results obtained from frozen specimens. 
Cronin, 
200745 




Dynamic range linearity 
Accuracy and precision 
Reproducibility 
 
A pooled reference RNA was used to 
perform repeated measurement and a 
serial dilutions experiment to assess 
LOD, LOQ, amplification efficiency, 
dynamic range linearity, and accuracy 
and precision 
 
In all the experiments template input was 
equivalent to 2 ng RNA; In the linearity 
study input varied between 2x10-10 and 
2000 ng per reaction 
 
Repeated measurements of 2 aliquots of 
a single RNA sample across multiple 
days, operators, RT-PCR plates, RT-
PCR instruments, and liquid-handling 
robots were performed to assess 
individual gene and RS reproducibility by 
ANOVA 
 
The LOD and the LOQ for all the genes proved to 
be within the pre-specified limits of CT units (< 40 
cycles) 
 
Amplification efficiencies for all the genes ranged 
from 75.3% (GAPDH) to 112.1% (BAG1), with 
values exceeding 100% due to the cumulative 
nature of the analysis along the sample-dilution 
series 
 
Assay linearity and dynamic range: 
6 genes were linear over the entire range; 
4 genes were linear over a range of 2e-8 to 2000 
ng; 
The estimated maximal deviation from linearity 
was below 1 CT over a linear range > 2000-
fold, as specified by CLSI 
 
Assay quantitative bias and precision at the 2-
ng/well for the 16 cancer-related genes: 
range = -10% (BAG1) to 6% (CTSL2) 
estimated mean deviation = 0.3% 
CV of 5.7% 
 
Assay quantitative bias and precision at the 2-
ng/well for the 5 reference genes: 
range = -1.5% (GUSB) to 3.3% (ACTB) 
estimated mean deviation = 0.7% 
CV of 3.2% 
Authors reported that  the following 
procedures were performed to assure  the 
reproducibility of the assay: 
A standard RNA control sample is 
assayed at least once per batch of 
patient (46 samples) 
PCR controls are run in every assay plate 
RT-PCR failures are excluded from 
analysis 
Expression values are assigned when at 
least 2 of 3 assay wells provide 
acceptable RT-PCR results 
 
All 21 genes must have an expression value 
assigned for an RS to be calculated and 
reported 
 
RT-PCR = reverse transcriptase polymerase chain reaction; FFPE = formalin-fixed paraffin-embedded; LOD = limits of detection; LOQ = limits of quantification; RNA=ribonucleic acid; 
RS = recurrence score; ANOVA = analysis of variance; CT=cycle threshold; CLSI = Clinical and Laboratory Standards Institute;  CV=coefficients of variation 
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Table 5. RT-PCR vs IHC comparison assays, Oncotype DX™ 
 
Study, year Comparison Method Details Results Comments 
Chang, 
200755 
IHC and RT-PCR 
Concordance 
 
Methods for IHC not 
described 
Cohen’s κ statistics Positivity from RT-PCR: 
ER, >6.5.0 CT 
PR, > 5.5 CT 
HER2, > 11.5 CT 
 
ER, k = 1.00, 95% CI = 1.00 to 1.00; 
PR, k= 0.57, 95% CI = 0.37 to 0.77; 
HER2, k= 0.74; 95% CI = 0.45 to 1.00 
The RT-PCR 
technology provides a 
potential platform for a 
predictive test using 






IHC and RT-PCR 
Concordance 
 
IHC by standard biotin-
streptavidin method and 
appropriate antibody 
(DAKO, CA, USA) 
Cohen’s κ statistics Positivity from RT-PCR: 
ER, >6.5.0 CT 
 
ER+ if IHC staining was 
present in more than 
10% of cells 
 
ER, k = 0.83 
PR, k= 0.40 
HER2, = 0.67 
Ki-67/MIB1, = 0.22 
The accuracy and 
specificity of this RT-
PCR assay of formalin-
fixed, paraffin 
embedded tumor tissue 
was supported by 
comparison of the 
results of RT-PCR 
assay of RNA and IHC 
assay of protein for ER, 
PR, and HER2 
Cronin, 
200444 
Methods for IHC and 
FISH not described 
Percentage of 
agreement 
ER positivity from RT-








IHC and RT-PCR 
Concordance 
 
IHC methods in Esteva 
et al., 200388 and Wang 
et al., 200289 
Cohen’s κ statistics 
 
Logistic model (IHC 
as a quantal 
response) 
Positivity from RT-PCR: 
ER, >7.0 CT 
PR, > 6.0 CT 
HER2, > 11.5 CT 
 
RT-PCR specificity and 
sensitivity, in comparison 
to IHC for HER2 were 
obtained at the different 
thresholds 
ER, k = 0.80, (=+ 0.05) 
PR, k = 0.48 
HER2, k = 0.6, (=+ 0.08) 
 
Logistic model p value: < 0.001 
 
HER2, RT-PCR > 11.50CT: 
Specificity: 77% 
Sensitivity: 84% 
HER2, RT-PCR > 11.5 CT: 
Specificity: 89% 
Sensitivity: 84% 





Table 5. RT-PCR vs IHC comparison assays, Oncotype DX (continued) 
 
Study, year Comparison Method Details Results Comments 
Gianni, 
200549 
IHC and RT-PCR 
Concordance 
 
IHC by reagents from 
Lab Vision-Neomarkers 
(Fremont, CA) 
Cohen’s κ statistics Positivity from RT-PCR: 
ER, >6.5.0 CT 
 
ER+ if IHC staining was 
present in more than 
10% of cells 
ER, k = 0.83 
PR, k= 0.40 
HER2, = 0.67 




ER status in medical and 
RT-PCR Concordance 
 
ER status methods not 
defined 
Cohen’s κ statistics Positivity from RT-PCR: 
ER, >6.5.0 CT 
ER = 0.49, 95% CI 0.41–0.56 
115/122 discordances ER+ by RT-
PCR 
 
Mina, 200651 IHC and RT-PCR 
Concordance 
 
IHC by standard biotin-
streptavidin method and 
appropriate antibody 
(DAKO, CA, USA) 
Percentage of 
agreement 
Positivity from RT-PCR: 
ER, >6.5.0 CT 
 
ER+ if IHC staining was 
present in more than 
10% of cells; 
 
41/45 concordant samples: 
2 ER+ by IHC were ER- by RT-PCR 
2 ER+ by RT-PCR were ER-by IHC 
 
Agreement data for PR, KI-67 and 
HER2/neu were not reported 
Gene expression 
analysis on core biopsy 
samples is feasible; 
 
Paik, 200428 ER and PR receptors 
proteins were measured 
by ligand-binding assays 
HER2 DNA was 
measured by a 




   
 
IHC = immunohistochemistry; RT-PCR = real time polymerase chain reaction; ER = estrogen receptor; PR = progesterone receptor; HER-2 = human epidermal growth factor 
receptor 2; FISH = Fluorescence in situ Hybridization; CT = cycle threshold; CI= confidence interval. 
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Table 6: Successful assays, MammaPrint® 
 
Study, year Protocol Measure Success 
Tumor < 















    
 
RT-PCR=reverse transcriptase polymerase chain reaction. 
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Table 7. Reproducibility, MammaPrint® 
 
Study, year Context and Methods Results Conclusions 
Ach,200757 MammaPrint assay intra- and inter-
laboratory reproducibility  
 
Variation in RNA amplification and 
labeling, hybridization and wash, 
and slide scanning was measured 
on 4 tumors, dye-swap design, 24 
slides (8 per site) 
 
Methods: To assess 
reproducibility in this study, 
ANOVA P values and Pearson’s 
correlation were used 
 Replicate hybridizations Pearson’s correlation at 
the same site: 
For 1 tumor in 1 sub-array = 0.983 
For 2 tumor in 2 sub-arrays = 0.988 
For all the other technical replicates > 0.993 
Scanning reproducibility across sites: 
Cy3: Pearson correlation >0.995, slope = 0.97 
Cy5: less reproducible (data not shown) 
70-gene signature reproducibility: 
No differences between hybridization sites 
No differences between hybridization days 
(regardless of site) 
Statistically significant difference (P value <0.05) 
between labeling sites for two tumors 
The authors showed very low influence on sample-to-
reference ratios based on averaged triplicate 
measurements in the two-color experiments 
 
RNA labeling was the largest contributor to inter-
laboratory variation 
 
Overall, despite this variation, measurement of 70-
gene signature in three different laboratories was 
found to be highly robust 
 
 
Glas, 200658 Pearson’s correlation to assess 
correlation with original data 
and reproducibility 
ANOVA analysis to model 
variability in repeated 
experiments using the 70 genes 
of the signature 
Reproducibility in time was 
assessed by repeated 
measurements of RNA aliquots: 
1 patient with cosine 
correlation to Good profile 
= 0.61, for 12 months 
1 patient with cosine 
correlation to Good profile 
= -0.44, for 12 months 
1 border-line with cosine 
correlation to Good profile 
= 0.43, for 4 months 
Comparison to original 70-gene signature data, 
Pearson's correlations and in repeated 
measurements: 
78 van't Veer21 patients, r = 0.92, p value < 
0.0001 
145 (84+61) van de Vijver25 LN-negative 
patients: r = 0.88 p value < .0001 
49 patients analyzed twice, r = 0.995 
Reproducibility results from ANOVA analysis: 
No variation within individuals (p value = 0.96) 
Significant variation between individuals and 
genes 
Reproducibility in time analysis results: 
For both patients assessed over a period of 12 
months measurements SD was 0.028 of the 
cosine correlation 
For the 1 border-line sample assessed over a 
period of 4 months measurements SD was 
0.027 of the cosine correlation 
This latter sample was misclassified 6 times 
(15%) 
Microarray technology can be used as a reliable 
diagnostic tool 
 
The MammaPrint assay performed similarly to the 




ANOVA = analysis of variance; Cy3: the green fluorescent dyes commonly used in two colors design microarray hybridization; Cy5 the red fluorescent dyes commonly used in 
two colors design microarray hybridization; LN = lymph node; SD = standard deviation 
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Table 8: Analytic validity, MammaPrint® 
 
Study, year Context and Methods: Results Comments 
Ach, 200757 Context: MammaPrint assay was used 
to evaluate the intra- and inter-laboratory 
reproducibility of the assay involving 
three laboratories. Variation in RNA 
amplification and labeling, hybridization 
and wash, and slide scanning was 
measured on 4 tumors, dye-flip design, 
24 slides (8 per site). 
 
Methods: To assess reproducibility in 
this study, ANOVA P values and 
Pearson’s correlation were used. 
Replicate hybridizations Pearson’s correlation at the 
same site: 
For 1 tumor in 1 sub-array = 0.983 
For 2 tumor in 2 sub-arrays = 0.988 
For all the other technical replicates > 0.993 
Scanning reproducibility across sites: 
Cy3: Pearson correlation >0.995, slope = 0.97 
Cy5: less reproducible (data not shown) 
70-gene signature reproducibility: 
No differences between hybridization sites 
No differences between hybridization days 
(regardless of site) 
Statistically significant difference (P value <0.05) 
between labeling sites for two tumors 
The authors showed very low influence 
on sample-to-reference ratios based on 
averaged triplicate measurements in the 
two-color experiments; 
 
RNA labeling was the largest contributor 
to inter-laboratory variation; 
 
Overall, despite this variation, 
measurement of 70-gene signature in 
three different laboratories was found to 
be highly robust; 
Glas, 200658 Context: MammaPrint assay 
development through re-analysis of 
patients from the van’t Veer21 and van 
de Vijver25 
 
A different reference RNA was used, as 
well as a different quantification method 
 
Methods: 162 total samples from fresh-
frozen specimens: 
 
84 patients from the van de Vijver25 
cohort 
 
All 78 patients form the van’t Veer 
cohort21 
 
A combination of the two population 
above: 145 (84+61) LN-negative 
patients 
 
49 patients analyzed twice 
Comparison to original 70-gene signature data, 
Pearson's correlations and in repeated 
measurements: 
78 van't Veer21 patients, r = 0.92, p value < 
0.0001 
145 (84+61) van de Vijver25  LN-negative 
patients: r = 0.88 p value < .0001 
49 patients analyzed twice, r = 0.995 
Reproducibility results from ANOVA analysis: 
No variation within individuals (p value = 0.96) 
Significant variation between individuals and 
genes 
Reproducibility in time analysis results: 
For both patients assessed over a period of 12 
months measurements SD was 0.028 of the 
cosine correlation 
For the 1 border-line sample assessed over a 
period of 4 months measurements SD was 
0.027 of the cosine correlation 
This latter sample was mis-classified 6 times (15%) 
The authors demonstrate for the first time 
that microarray technology can be used 
as a reliable diagnostic tool; 
 
The MammaPrint assay performed 





ANOVA = analysis of variance; Cy3: the green fluorescent dyes commonly used in two colors design microarray hybridization; Cy5 the red fluorescent dyes commonly used in 
two colors design microarray hybridization; LN = lymph node; SD = standard deviation 
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Table 9: Successful assays, two-gene signature and H/I ratio assays 
 












Goetz, 200662 Study 
Specific  
FFPE 206/211 (97.6%)* 211/227 
(93%) 
  5/211 (2.4%)   
Jerevall, 200763 Study 
Specific 
FFPE 357/373 (95.7%%)  16/373 
(4.3%) 
    
Ma, 200661 H/I ratio 
assay 




    
 
* Out of the 256 eligible patients 227 were analyzed (No specimen available: 29 patients) 
† Out of the 1002 eligible 
‡ Tumor content < 10%  
 
RT-PCR = reverse-transcriptase polymerase chain reaction; FFPE = formalin fixed paraffin embedded 
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Table 10: Reproducibility, two-gene signature and H/I ratio assay 
 
Study, year Methods: Results 
Jerevall, 
200763 
Reproducibility between two 
institutions, Pearson’s correlations, 
10 patients 
HOXB13:b-actin, r = 0.96, P < 0.001 
IL17BR:b-actin, r = 0.87, P = 0.002 
HOXB13:IL17BR, r = 0.99, P < 0.001 
Ma, 200464 Correlations between microarray 
and RT-PCR: 59 patients 
HOXB13, r = 0.83 
IL17BR , r = 0.93 
HOXB13/IL17BR, r = 0.83 
 
RT-PCR = real time polymerase chain reaction 
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Table 11: RT-PCR vs IHC comparison assays, two-gene signature and H/I ratio assays 
 
Study, year Comparison Method Details Results Comments 





IHC in 90 91 
Cohen’s κ 
statistics 
IHC Allred 92 scores of 3 to 8 
were considered positive for 
ER or PR93 
 
Both ER and PR mRNA 
RT-PCR measurements 
were bimodal; midpoints 
used as cutoffs: 
2.5 CT for ER 
5.9 CT for PR 
ER, 91% concordance, κ = 0.83, P value = 
.0001 
 
ER, 85% concordance, κ = 0.70, P value = 
.0001 
According to the authors these 
results confirmed the significant 
correlations between mRNA and 
protein levels for ER and PR and 
provided validation of our FFPE 
gene expression assay platform. 
 
IHC = immunohistochemistry; RT-PCR =real time polymerase chain reaction; FFPE = formalin fixed paraffin embedded; ER = estrogen receptor; PR = progesterone receptor; 
mRNA=messenger ribonucleic acid; CT =cycle threshold 
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End points and Exclusion 
criteria 
Clinical validity and utility results Conclusions/Comments 
Cobleigh, 200547 
 
78/86 analyzed patients: 
mean age 57 y, all LN+; 
TS 0-2cm: 33%; TS >5cm: 
31%; tamoxifen 54%; 
TG-1: 29%; TG-3: 36%; 
adjuvant CMF 80% 
Metastases; 
<10 LN+; 
<5% cancer cells; 
non invasive breast cancer; 
 
10 y DRFS in LN+, ER+ and 
ER- patients 
 
RS < 18:14% of patients: 
Recurrence: 29% (95%CI: 0-53%) 
RS >18 and RS < 31: 24% of patients: 
10 years recurrence: 72% (95%CI: 38-88%) 
RS > 31: 62% of patients 
10 years recurrence: 80% (95% CI: 63-89%) 
Development of RS 
 




149/220 analyzed patients: 
mean age 58 y; 
ER+: 69.1%, PR+: 66.4%; 
HER-2+: 16.8%; 
TG-1: 12.1%, TG-3: 30.2%; 
median TS 2.3 cm 
follow-up < 5y; 
adjuvant therapy; 
LN+; 
<5% of cancer cells; 
 
DFRS in LN-, untreated 
patients; 
No significant correlation between age, tumor size, or 
RS and DFRS 
 
No significant difference between RS risk groups with 
respect to distant recurrence-free survival; 
Differences between the NSABP B-14 
population used in Paik et al.: 
ER+ and ER- patients were used; 
ER+ patients not treated with 
tamoxifen; 
Association between high nuclear 
grade and improved outcome; 
Patients from a single institution 
Habel, 200650 
 
220/234 analyzed cases: 
TG-Well: 11%; TG-Poor: 
47%;TS < 2: 64%; TS >2cm: 
36%;ER+: 76% 
 
570/631 analyzed controls: 
TG-Well: 31%; TG-Poor: 
23%; TS < 2: 79%; TS >2cm: 
21%;ER+: 90% 
LN+, age >75 y; 
initially treated with 
chemotherapy; 
metastases, inflammatory or 




10 y breast cancer-specific 
mortality in ER+, LN patients; 
RS <18 / ER+, tamoxifen: 2.8%, 95%CI: 1.7-3.9 
RS <18 / ER+, no tamoxifen: 6.2%, 95%CI: 4.5-7.9 
RS 18-30 / ER+, tamoxifen: 10.7%, 95%CI: 6.3-14.9 
RS 18-30 / ER+, no tamoxifen: 17.8%, 95%CI: 11.8-
23.3 
RS ≥31 / ER+, tamoxifen: 15.5%, 95%CI: 7.6-22.8 
RS ≥31 / ER+, no tamoxifen: 19.9%, 95%CI: 14.2-25.2 
RS associated with risk of breast 
cancer death in:  
ER+ patients treated with tamoxifen; 
ER+ patients not treated with 
tamoxifen; 
ER- patients; 
Such associations remained after 
accounting for tumor size and grade. 
Moreover the RS was able to identify a 
larger subset of patients with low risk of 
breast cancer death than it was 
possible with either of these standard 
prognostic indicators 
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End points and Exclusion 
criteria 
Clinical validity and utility results Conclusions/Comments 
Paik, 200428 
 
668/754 analyzed patients 
(tamoxifen treatment arm of 
NSABP B-14) 
 
<5% cancer cells; 
insufficient RNA; 
weak RT-PCR signal 
(average cycle threshold for 
reference genes >35); 
 
distant recurrence and the 
Overall Survival in LN-, ER+ 
breast cancer; 
51% of the patients RS <18, KM estimates = 6.8, 
95%CI = 4.0–9.6 
22% of the patients RS > 18 <31, KM estimates = 
14.3-95%CI=8.3–20.3 
27% of the patients RS > 31, KM estimates =30.5-
95%CI=23.6–37.4) 
 
PR, ER, HER, age, size, grade, and RS: p-
Value=0.001, Hazard Ratio =2.81 (95%CI= 1.70–
4.64 for 50 units increase 
RS validated in tamoxifen-treated, LN-, 
ER+ breast cancer patients 
Paik, 200653 
 
651/670 analyzed patients: 
TS < 2: 66%; TG-Well: 13%; 
TG-Poor: 28%; TS >2cm: 
34%; 
ER+: 100%, LN-: 100% 
tamoxifen treatment arm of 
NSABP B-20 
<5% invasive tumor; 
insufficient RNA; 
weak RT-PCR signal 
(average cycle threshold for 
reference genes >35); 
 
distant recurrence in ER+, 
LN- breast cancer from 
NSABP B20 
20.6% of the patients RS<18, tamoxifen, 96.8 93.7% 
to 99.9% 
33.5% of the patients RS<18, chemotherapy, 95.6 
92.7% to 98.6% 
7% of the patients RS >18 <31, tamoxifen: 90.9 
82.5% to 99.4% 
13.7% of the patients RS >18 <31, chemotherapy: 
89.1 82.4% to 95.9% 
7.2% of the patients RS>31, tamoxifen: 60.5 46.2% to 
74.8% 
18% of the patients RS>31, chemotherapy: 88.1 
82.0% to 94.2% 
The RS assay predicts the magnitude 
of chemotherapy benefit in women with 
node-negative, ER–positive breast 
cancer 
 
If RS risk groups are considered: 
a minimal benefit from chemotherapy 
is seen in the low risk group, 
however with large intervals 
benefit is not assessable in the 
Intermediate risk group due to the 
uncertainty in the estimates 
a large chemotherapy benefit is seen 
in the high risk group 
 
LN = lymph node; TS = tumor size; TG = tumor grade; CMF = cyclophosphamide, methotrexate, and fluorouracil; DRFS= distant recurrence-free survival; ER = estrogen 
receptor; CI=confidence interval; RS = recurrence score; GEP=gene expression programming; HER = human epidermal growth factor receptor; NR = not reported; pCR=complete 
pathological response; INT= Italian National Cancer Institute of Milan, Italy; NSABP = The National Surgical Adjuvant Breast and Bowel Project; RT-PCR = reverse 
transcriptase polymerase chain reaction; PR = progesterone receptor; KM=Kaplan Meier.   
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Table 13. Risk classification of Oncotype DX™ against the St. Gallen criteria 
 
St. Gallen risk 
group 
10 yr. risk of 
distant relapse 
by St. Gallen 
Oncotype DX 
Risk group 
10 yr. risk of 
distant relapse 
% of St. Gallen 
stratum (n) 
Low  0% 72% (38) 





High 43% 6% (3) 
Low  5% 60% (134) 





High 21% 17% (37) 
Low  8% 42% (134) 


















10 yr. risk of 
distant relapse 
% of NCCN 
stratum (n) 
Low  0% 72% (38) 





High 43% 6% (3) 
Low  8% 49% (300) 





High 30% 29% (178) 
 




Table 15. Risk classification of Oncotype DX™ against the Adjuvant! guidelines 
 
Adjuvant! 
Online  risk 
group 















Medium- High 13% 39% (138) 












End points and 
Exclusion criteria 
Clinical validity and utility results Conclusions/Comments 
Buyse, 200659 
 
307/403 analyzed patients, all age 
< 60 y, all < 5cm (ER missing: 5 
patients) 
 
Clinical low risk/gene low risk 
n=52 (TS < 2cm: 67%, ER+: 
100%, TG-Good: 43%, TG-Poor: 
0%) 
 
Clinical low risk/gene high risk 
n=28 (TS < 2cm: 59%, ER+: 
100%, TG-Good: 43%, TG-Poor: 
0%) 
 
Clinical high risk/gene low risk 
n=59 (TS < 2cm: 29%, ER+: 91%, 
ER-: 9%, TG-Good: 12%, TG-
Poor: 18%) 
 
Clinical high risk/gene high risk 
n=163 (TS < 2cm: 25%, ER+: 




Exclusion criteria:  Age 
> 61 y, TS >5cm, 
previous malignancy 




End points: OS, RFS, 
TTM  
 
KM analysis stratified by MammaPrint and Adjuvant 
(% of patients with distant recurrence): 
Good(R>0.4), Adjuvant!Low: 52 patients 
OS(10years): 0.88 (0.74 to 0.95) 
Good(R>0.4), Adjuvant!High: 59 patients 
OS(10years): 0.89 (0.77 to 0.95) 
Poor(R<0.4), Adjuvant!Low: 28 patients  
OS(10years): 0.69 (0.45 to 0.84) 
Poor(R<0.4), Adjuvant!High: 163 patients 
OS(10years): 0.69 (0.61 to 0.76) 
 
Hazard Ratios (unadjusted), MammaPrint: 
TTM=2.32 (95% CI = 1.35-4.00) 
DFS=1.50 (95% CI = 1.04-2.16) 
OS=2.79 (95% CI = 1.60-4.87) 
 
MammaPrint adjusted by Adjuvant: 
TTM= 2.13 (95% CI = 1.19 to 3.82) 
DFS= 1.36 (95% CI = 0.91 to 2.03) 
OS= 2.63 (95% CI =1.45 to 4.79) 
 
Development of metastases within 5 years: 
Sensitivity for Gene signature 0.90 (0.78 to 0.95) 
Sensitivity for Adjuvant! 0.87 (0.75 to 0.94) 
Specificity for Gene signature 0.42 (0.36 to 0.48) 
Specificity for Adjuvant! 0.29 (0.24 to 0.35) 
 
ROC area under the curve: 
MammaPrint®: TTM: 0.681 
MammaPrint®: OS: 0.659 
Adjuvant: TTM: 0.648 
Adjuvant: OS: 0.576 
MammaPrint is a better predictor of 
TTM than Age, Size, Grade, ER, 
Adjuvant!, NPI, St Gallen 
 
St Gallen is a better predictor of DFS 
than MammaPrint  
 
MammaPrint is a better predictor for OS 
than Age, Size, Grade, ER, Adjuvant!, 
NPI, St Gallen 
 
The signature remained a statistically 
significant prognostic factor for TTM 
and OS even after adjustment for 
various risk classifications methods 
based on clinicopathologic factors 
 
The lack of statistical significance for 
DFS was explained by the fact that the 
signature was originally developed 
using TTM as the endpoint 
 
Overall the 70-gene signature adds 
independent prognostic information to 
clinicopathologic risk assessment for 
node-negative untreated patients with 
early breast cancer 
 
Clinical risk hazard ratios, adjusted for 
the gene signature were not significant, 
suggesting that most of their prognostic 
utility is subsumed by the gene 
signature 
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End points and 
Exclusion criteria 
Clinical validity and utility results Conclusions/Comments 
van't Veer, 200221 
 
Population: 78 + 19 patients, 
(mean age 44.9 y, TS < 2cm: 
41.2%, ER+: 70.2%. PR+: 57.7%, 




Hormonal (3 patients), 
Chemotherapy (3 patients) 
 
Exclusion criteria: Age 
>55 y, TS >5cm, 
metastases, previous 
malignancy, diagnosed 
before 1983, or after 
1996 
 
End point: distant 
metastases as first 
relapse event (5 years) 
 
Outcome: 
No metastases within 
5yrs: 51;  
Metastases within 5yrs: 
46 
65/78 correct predictions: 
5 poor in the 70-gene Good group 
8 good in the 70-gene Poor group 
 
17/19 correct predictions: 
1 poor in the 70-gene Good group 
1 good in the 70-gene Poor group 
 
Univariate OR=15, (95%CI=4-56, P =0.0000041) 
Multivariate OR = 18, (95%CI=3.3-94, P = 0.00014) 
The 70-genes signatures is a better 
predictor of the risk of distant 
metastases than standard clinical 
predictors 
van de Vijver, 200225 
 
Population: 295 patients, all age 
< 53 y, all < 5cm, 61 in common 
with van’t Veer 2002:21 
 
Poor Prognosis n=180, (TS < 
2cm: 647%, LN-: 51%, ER+: 
63%); 
Hormonal (13% patients), 
Chemotherapy (37% patients) 
 
 
Good Prognosis n=115, (TS < 
2cm: 62%, LN-: 52%, ER+: 97%); 
Hormonal (15% patients), 
Chemotherapy (38% patients) 
Exclusion criteria: Age 
>52 y, TS >5cm, 
previous malignancy, 
apical axillary LN 
involvement 
 
End point: distant 
metastases as first 
relapse event, OS 
 
The 70-genes association with age, tumor grade, 
ER (P value<0.001), and tumor size (P =0.012); 
 
67 LN- patients (not in van’t Veer 200221) OR = 
15.3, (95%CI = 1.8-127, P = 0.003) 
 
180 LN+ and LN- patients (not in van’t Veer 200221): 
OR = 14.6, (95%CI = 4.3-50, P < 0.0001) 
 
All patients, HR = 5.1, (95%CI = 2.9-9.0, P < 0.001) 
151 LN-, HR = 5.5, (95%CI = 2.5-12.2, P < 0.001) 
144 LN+, HR = 4.5, (95%CI = 2-10.2, P < 0.001) 
 
Multivariate HR = 4.6, 95%CI = 2.3-9.2, p value < 
0.001 
The authors demonstrate for the first 
time that microarray technology can be 
used as a reliable diagnostic tool 
 
The MammaPrint assay performed 
similarly to the original 70-genes 
signature and is, therefore, an excellent 
tool to predict outcome of disease in 
breast cancer patients 
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End points and 
Exclusion criteria 
Clinical validity and utility results Conclusions/Comments 
Glas, 200658 
 
Population: 162 LN-, untreated 
patients (<55 years), from the van 
de Vijver and van’t Veer cohorts 
 
All 78 patients form the van’t Veer 
were re-analyzed 
Exclusion criteria: 
See van’t Veer, 200225 
above 
 
End point: distant 
metastases as first 
relapse event 
 
78 patients from the van’t Veer21 series: 
MammaPrint OR = 13.95 (95%CI = 3.9-44); 
70-genes signature OR = 15, 95%CI = 2.1 to 19) 
7/78 differently classified by MammaPrint 
 
145 LN- patients from the van de Vijver25 series: 
MammaPrint HR = 5.6 (95%CI = 2.4-7.3, P = 
0.0001) 
 
Similar results were obtained for OS 
The authors demonstrate for the first 
time that microarray technology can be 
used as a reliable diagnostic tool 
 
The MammaPrint assay performed 
similarly to the original 70-genes 
signature and is, therefore, an excellent 
tool to predict outcome of disease in 
breast cancer patients 
 
ER = estrogen receptor; TS = tumor size; TG = tumor grade; OS=overall survival; RFS=relapse free survival; TTM=time to distant metastases; ROC = Receiver operating 
characteristic; NPI=Nottingham prognostic index; DFS=disease free survival; OR = odds ratio; CI = confidence interval; LN = lymph node; HR=hazard ratio; KM=Kaplan- Meier. 
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Table 17. MammaPrint® compared with traditional composite risk markers 
 
 Number classified as “high risk” 
Criteria Patients with metastases  
Sensitivity 
n=34 
Patients without metastases  
Specificity 
n=44 
St. Gallen5 33 (97%) 31 (30%) 
NIH3,4 32 (94%) 40 (9%) 




Table 18. Clinical Validity, two-gene signature and H/I ratio assays 
 
Study, Year Population size, N End Points and Major Findings Comments 
Goetz, 
200662 
Population: 206/256 eligible 
patients, from the randomized 
NCCTG 89-30-52 trial on 
tamoxifen treatment 
 
(TS < 3cm: 76%, LN-: 63%, ER+: 
100%, HER2, 0; 11%, HER2, 1; 
36%, HER2 2; 34%, TG-1: 26%, 
TG-3: 18%) 
 
Exclusion criteria: NR 
 
End points: RFS (any event of recurrence), DFS 
(recurrence, or death), and OS (death) 
 
Clinical validity and utility results: 
Nodal status, tumor size and Nottingham grade 
significantly associated with endpoints 
 
All patient in the study: 
RFS, Multivariate F-S 1.45 (95% CI 0.93, 2.27) 
DFS, Multivariate F-S 1.57 (95% CI 1.04, 2.38) 
OS, Multivariate F-S 1.29 (95% CI  0.81, 2.08) 
Node negative patients in the study (n=130): 
RFS, Multivariate F-S 1.73 (95% CI  0.92, 3.25) 
DFS, Multivariate F-S 1.77 (95% CI  0.99, 3.16) 
OS, Multivariate F-S 2.01 (95% CI  1.02, 3.99) 
According to the authors a high 2-gene 
expression ratio is associated with increased 
relapse and death in patients with node-
negative ER positive breast cancer treated with 
tamoxifen 
 
In this study the 2-gene ration was normalized 
by standard curve, and no reference genes 
were used; optimized cut-off points were 





Population: 1,252/1693 eligible 
patients, subsets: 
DFS: ER+, LN-, no Adjuvant (N 
= 468) 
PFS: ER+, first-line tamoxifen 
(N = 193) 
 
Exclusion criteria: distant 
recurrence within the first month 
of surgery, missing LN, ER, and 
HOXB13 and IL17B, < 30% tumor 
cells in specimens, poor RNA 
quality 
End points: disease-free survival (DFS), progression free 
survival (PFS), post-relapse survival (PRS), and overall 
survival (OS) 
 
Clinical validity and utility results: 
Multivariate analysis, ER+, LN-, no Adjuvant (N = 468): 
Dichotomized ratio with 3’ I17RB, DFS HR = 1.74; 95% 
CI = 1.17 to 2.59; P = 0.006 
Multivariate analysis, relapsing ER+, tamoxifen (N = 193): 
Optimal dichotomized ratio with 3’ I17RB, PFS HR = 
2.97; 95% CI = 1.82 to 4.86; P < 0.001 
Standard* dichotomized ratio with 3’ I17RB, PFS HR = 
1.95; 95% CI = 1.39 to 2.73; P < 0.001 
 
*as in Ma et 200661 
High HOXB13-to-IL17BR ratio expression levels 
associate with both tumor aggressiveness and 
tamoxifen therapy failure 
 
The ratio was significantly associated with DFS 
and PFS in the specific subsets of patients 
 
In multivariate analysis, the ratio was 
associated with a shorter DFS for node-
negative patients only 
 
Expression levels normalized to a different set 
of control genes respect to MA et al 200661 
using fresh frozen samples 
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Table 18. Clinical Validity, two-gene signature and H/I ratio assays (continued) 
 
Study, Year Population size, N End Points and Major Findings Comments 
Jerevall, 
200763 
Population: 357 patients 
analyzed, 264 post-menopausal, 
and 93 pre-menopausal. 
 
Postmenopausal patients: 
randomized clinical trial, 
comparing 2 years (163 
patients, 62%) and 5 years  




Exclusion criteria: NR 
End points: Correlation with clinical prognostic factors. 
 
The ratio was significantly associated to: 
Tumor size, P = 0.003; 
ER, P < 0.001; 
PR, P < 0.001; 
HER2, P = 0.003; 
NHG, P < 0.001; 
Ploidy, P < 0.001; 
S-phase, P = 0.005; 
ER, HER2, S-phase and NHG correlations are 
mostly due to IL17BT; 
PR and ploidy correlation have contribution from 
both genes 
Lower expression of IL17BR, but not HOXB13, 
was correlated to several factors related to 
poor prognosis, IL17BR might be an 
independent prognostic factor in breast cancer 
Ma, 200464 Population: by RT-PCR, Frozen 
specimens: 59/60, FFPE: 20/20 
eligible patients 
 
Frozen, recurrence, n=28, (mean 
age: 65.1, LN-: 57%, TS > 5cm: 9, 
ER+: 97%, TG-1: 7%, TG-3: 39%) 
 
Frozen, non recurrence, n=32, 
(mean age: 69.1, LN-: 47%, ER+: 
100%, TG-1: 3%, TG-3: 22%) 
 
FFPE, recurrence, n=10, (mean 
age: 65.5, LN-: 80%, ER+: 100%, 
TG-1: 10%, TG-3: 30%) 
 
FFPE, non recurrence, n=10, 
(mean age: 65.2, LN-: 100%, 
ER+: 100%, TG-1: 10%, TG-3: 
10%) 
 
Exclusion criteria: NR 
End points: DFS (months) was calculated from the date 
of diagnosis. 
 
Clinical validity and utility results: 
Frozen, recurrence, DFS: 54.8 (range: 5-137) 
Frozen, non recurrence, DFS: 115.6 (range: 61-169) 
FFPE, recurrence, DFS: 51.4 (range: 15-117) 
FFPE, non recurrence, DFS: 95.8 (range: 25-123) 
 
KM analysis, log-rank test, RT-PCR on the training set: P 
value = 0.0000058 
 
KM survival analysis, log-rank test, RT-PCR on the 
validation set: P value = 0.002 
 
Classification results in the validation set (RT-PCR data): 
16/20 correctly classified 
The authors concluded that HOXB13/IL17BR 2-
gene ratio predicts tumor recurrence in the 
setting of tamoxifen therapy 
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Table 18. Clinical Validity, two-gene signature and H/I ratio assays (continued) 
 
Study, Year Population size, N End Points and Major Findings Comments 
Ma, 200661 Population: 852/1002 eligible 
patients: 
All samples, n=852, (age > 50 
y: 82%, LN-: 72%, ER+: 
73%); 
Tamoxifen treated, 286, (age > 
50 y: 91%, LN-: 40%, ER+: 
89%); 
Untreated, 566, (age > 50 y: 
77%, LN-: 84%, ER+: 65%); 
 
Exclusion criteria: NR 
End points: Relapse-free survival (RFS), defined as the 
time from initial diagnosis to any recurrence. Optimal 
threshold for dichotomization of the 2-gene ratio was 
identified and applied in the analysis 
 
Clinical validity and utility results: 
Two-gene index on a continuous scale, 5-year recurrence 
risk for untreated patients: 
Index of -2.0 = 15% (95% CI, 9.8% to 20.5%) 
Index of +2.0 = 36% (95% CI, 26.5% to 45.2%) 
 
Multivariate Cox Regression Analysis; ER+ node 
negative, untreated test set and tamoxifen treated patients 
(n = 225), dichotomized HOXB13:IL17BR index (high 
versus low) 
 
HR = 3.9 (95% CI = 1.5 to 10.3) p value = 0.007 
According to the authors these results 
confirmed the significant correlations between 
mRNA and protein levels for ER and PR and 
provided validation of the FFPE gene 
expression assay platform 
 
The HOXB13:IL17BR index was only significant 
in node-negative patients 
 
Higher HOXB13:IL17BR index was associated 
with a higher risk of relapse 
 
Two-gene index was a significant predictor of 
clinical outcome in ER+, node-negative, 
patients irrespective of tamoxifen therapy 
Reid, 200569 Population: Tamoxifen 
20mg/day for 5 years: 58 
patients, (Age > 50yrs: 93.1%, TS 
≤2cm: 37.9%, LN-: 22.5%, 
HER2+: 20.7%, PR+: 79.3%, 
ER+: 100%) 
 
Exclusion criteria: NR 
End points: Disease Free Survival (DFS) 
 
Clinical validity and utility results: 
Univariate logistic regression: odds ratio: 
HOXB13 OR = 1.04, 95% CI = 0.92 to 1.16, P = 
0.54 
IL17BR OR = 0.69, 95% CI = 0.40 to 1.20, P = 0.18 
HOXB13/IL17BR OR = 1.30, 95% CI = 0.88 to 1.93, 
P = 0.18 
Similar results by the other methods 
 
Although the proposed predictive model is very 
appealing the use of the two-gene ratio 
signature in an independent population yielded 
statistically non significant results 
 
The authors failed to confirm the association of 
the 2-gene ratio with response to tamoxifen on 
their cohort (which is however different in terms 
of clinical characteristics from the original Ma 
2004 cohort) 
 
The authors also failed to classify patients 
using Discriminant Linear Analysis on two 
published data sets, including the Ma 2004 
original series 
 
NCCTG= North Central Cancer Treatment Group; TS = tumor size; LN=lymph node; ER= estrogen receptor; HER-2= Human epidermal growth factor receptor 2; TG = tumor 
grade; NR = not reported; RFS = relapse-free survival; DFS = disease-free survival; OS = overall survival; CI= confidence interval; RNA=ribonucleic acid; PFS = progression-free 
survival; PRS = post-relapse survival; NHG= Nottingham histologic grade; PR = progesterone receptor; RT-PCR = reverse transcriptase polymerase chain reaction; FFPE = 
formalin-fixed paraffin-embedded; KM = Kaplan Meier; HR= hazard ratio. 
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Table 19. Clinical Utility, Oncotype DX™ 
 
Study, Year Population size, N End Points and Major Findings Comments 
Chang, 
200755 
Population: 72/97 eligible 
patients, (mean age 48.5 y, ER+: 
69.1%;TG-Well: 2.8%; TG-Poor: 
56.9%, LN-: 90%, HER-2+: 
13.5%, treated with docetaxel) 
 
Exclusion criteria: NR 
End points: prediction of clinical response (by the RECIST 
method) to docetaxel treatment in women with breast cancer 
 
Clinical validity and utility results: 
Clinical CR was more likely in the high RS risk group (P = 
0.008); A 50 units increase in the RS showed an OR = 5 (95% 
CI = 1.3-6.0); AUROC = 0.73; 
The authors concluded that Oncotype DX 
can be potentially be used as a predictive 
test of chemosensitivity using small 




Population: 89/95 patients 
(mean age 49.9 y, stage-T4b: 
79%, stage-T4d: 18%, stage-T2: 
1%, stage-T3: 2%, ER+: 58%, 
TG-1: 24%, TG-3: 21%, LN-: 
16%, adjuvant with 
doxorubicin/paclitaxel followed by 
paclitaxel) 
 
Exclusion criteria: NR 
End points (goal): to examine the correlation between RS and 
pCR, and to identify additional genes associated with pCR 
 
Clinical validity and utility results: 
The global likelihood ratio test assessing probit regression 
based models with and without the incorporation of the RS 
resulted in a P value of 0.005 
The authors showed that the RS was 
strongly correlated with pCR, and 
identified a set of genes, whose 
expression correlated with pCR to 




220/234 eligible cases (TG-Well: 
11%, TG-Poor: 47%, TS < 2: 
64%, TS >2cm: 36%, ER+: 76%, 
ER-: 24%) 
 
570/631 eligible control patients 
(TG-Well: 31%, TG-Poor: 23%, 
TS < 2: 79%: TS >2cm: 21%, 
ER+: 90%) 
 
Exclusion criteria: LN+, age >75 
y, initially treated with 
chemotherapy, inflammatory or 
bilateral cancer, metastases, prior 
invasive cancer, 
unknown/unconfirmed tamoxifen 
End points: The risk of breast cancer-specific mortality among 
women with ER+, LN- breast cancer. Patients were matched by 
age, race, year of diagnosis and tamoxifen treatment. 
 
Clinical validity and utility results: 
10 y death risk according to RS (with tumor size and grade): 
RS <18 / ER+, tamoxifen: 2.8%, 95%CI: 1.7-3.9; 
RS <18 / ER+, no tamoxifen 6.2%, 95%CI: 4.5-7.9; 
RS 18-30 / ER+, tamoxifen 10.7%, 95%CI: 6.3-14.9; 
RS 18-30 / ER+, no tamoxifen 17.8%, 95%CI: 11.8-23.3; 
RS ≥31 / ER+, tamoxifen 15.5%, 95%CI: 7.6-22.8; 
RS ≥31 / ER+, no tamoxifen 19.9%, 95%CI: 14.2-25.2; 
The authors showed that the RS was 
strongly associated with risk of breast 
cancer death among : 
ER+ patients treated with tamoxifen ; 
ER+ patients not treated with tamoxifen  
ER- patients 
 
Such associations remained after 
accounting for tumor size and grade. 
Moreover the RS was able to identify a 
larger subset of patients with low risk of 
breast cancer death than it was possible 
with either of these standard prognostic 
indicators 
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Table 19. Clinical Utility, Oncotype DX (continued) 
 
Study, Year Population size, N End Points and Major Findings Comments 
Mina, 
200651 
Population: 45/70 eligible 
patients (mean age 49 y, median 
TS 6.8 cm, TG-Well: 24%, TG-
Poor: 49%, ER+: 57%, HER2+: 
18%, LN+: 47%, adjuvant with 
doxorubicin / docetaxel, 
tamoxifen in ER+); 
 
Exclusion criteria: NR 
End points: complete pathological response (pCR) to primary 
chemotherapy with anthracycline- and taxanes; 
 
Clinical validity and utility results: 
No correlation between Oncotype DX RS and pCR; 
Though the Oncotype DX RS correlated 
with pCR in the INT Milan cohort of the 
Gianni et al study,49 this association was 
not found in the present study 
Paik, 200653 Population: 651/670 eligible 
patients (TS < 2: 66%, TG-Well: 
13%, TG-Poor: 28%, TS >2cm: 
34%, ER+: 100%, LN-: 100%, 
tamoxifen treatment arm of 
NSABP B-20) 
 
Exclusion criteria: specimen 
shows <5% invasive tumor, 
insufficient RNA extracted from 
specimen, weak RT-PCR signal 
(average cycle threshold for 
reference genes >35) 
 
End points: freedom from distant recurrence in women with 
ER-positive, node-negative breast cancer from NSABP B-20. 
 
Clinical validity and utility results: 
20.6% of the patients RS<18, Tamoxifen, 96.8 93.7% to 99.9%; 
33.5% of the patients RS<18, Chemotherapy, 95.6 92.7% to 
98.6%; 
7% of the patients RS >18 <31, Tamoxifen: 90.9 82.5% to 
99.4%; 
13.7% of the patients RS >18 <31, Chemotherapy: 89.1 82.4% 
to 95.9%; 
7.2% of the patients RS>31, Tamoxifen: 60.5 46.2% to 74.8%; 
18% of the patients RS>31, Chemotherapy: 88.1 82.0% to 
94.2%; 
The RS assay predicts the magnitude of 
chemotherapy benefit in women with 
node-negative, ER–positive breast 
cancer; 
 
If RS risk groups are considered: 
a minimal benefit from chemotherapy is 
seen in the low risk group, however 
with large intervals; 
benefit is not assessable in the 
Intermediate risk group due to the 
uncertainty in the estimates; 
a large chemotherapy benefit is seen in 
the high risk group 
 
ER = estrogen receptor; TG = tumor grade; LN = lymph node; HER = human epidermal growth factor receptor; NR = not reported: RECIST = response evaluation criteria in solid 
tumors; CR = complete response; RS = recurrence score; OR = odd ratio; CI = confidence interval; AUROC = area under Receiver operator curve; pCR = pathological complete 
response; TS = tumor size;  RT-PCR = reverse transcriptase polymerase chain reaction; INT = Italian National Cancer Institute of Milan, Italy; NSABP = The National Surgical 
Adjuvant Breast and Bowel Project. 
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NCCN  Cost, QALY, 
DRFS, OS 
$2,028 in favor 
of RS 









RS = $4,272 vs. 
Tam 
RS = -$2,255 
vs. 
ChemoRx+Tam 
RS = +0.97 vs. 
Tam 
RS = +1.71 vs.  
ChemoRx+Tam 
Weak 
Oestreicher76 GEP NIH  Cost, QALY $2,882 in favor 
of GEP 




QALY = Quality Adjusted Life Years; NCCN = National Comprehensive Cancer Network; DRFS = Distant Recurrence-Free 
Survival; OS = Overall Survival; RS = Recurrence Score; LYS= Life Years Saved; C/E=Cost Effectiveness; Δ= Change in; 
ChemoRx= Chemotherapy; Tam=Tamoxifen; GEP = Gene Expression Profiling; NIH = National Institutes of Health. 
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Table 21. Clinical Utility, two-gene signature and H/I ratio 
 
Study, Year Population size, N End Points and Major Findings Comments 
Jerevall, 
200763 
Population: 357 patients analyzed, 




randomized clinical trial, 
comparing 2 years (163 
patients, 62%) and 5 years 
(101 patients, 38%) of adjuvant 
tamoxifen treatment. 
 




End points: Relapse-free survival (RFS), defined as the time from 
diagnosis to local, regional, or distant recurrence or death due to 
breast cancer; OS, defined as the time elapsed from diagnosis to the 
date of death due to breast cancer 
 
Clinical validity and utility results: 
Post-menopausal ER+ patients, low ratio: benefit from prolonged 
tamoxifen (P = 0.021; in KM analysis for RFS) due to the low 
expression of HOXB13 genes (P = 0.010, in KM analysis for 
RFS) 
 
Postmenopausal ER+ patients (n=179), multivariate Cox proportional 
hazard model analysis: 
Recurrence Rate (5y vs 2y), low ratio: 0.39 (CI 95% = 0.17–0.91), 
P value = 0.030 
Test for interaction: P value = 0.035 
Recurrence Rate (5y vs 2y) 
 
Postmenopausal ER+, node negative, patients (n=134), multivariate 
Cox proportional hazard model analysis: 
Recurrence Rate (5y vs 2y), low ratio: 0.27 (CI 95% = 0.10–0.72), 
P value = 0.0087 
In this study the expression levels 
were normalized to b-actin using 
fresh frozen samples. Patients 
were collected from two distinct 
institutions; of 373 tumor samples 
analyzed, RNA expression data 
were obtained from 357 tumors 
 
The ratio or HOXB13 alone can 
predict the benefit of endocrine 
therapy, with a high ratio or a high 
expression rendering patients less 
likely to respond 
 
 
BCP=breast cancer profiling; NR = not reported; RFS = relapse-free survival; OS = overall survival; ER= estrogen receptor; KM=Kaplan-Meier; CI= confidence interval. 
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Chapter 4. Discussion 
 
 Using the analytical framework described, we evaluated the evidence available on three 
commercially available gene expression based assays, and on the gene expression profiles 
underlying these tests. Specifically, our review focused on the MammaPrint® assay, based on the 
70-gene prognostic signature developed by van’t Veer and colleagues,21,25,58,59 on the Oncotype 
DX™ assay, based on the 21-gene profile developed by Paik and colleagues, 28,50,53 and on the 
Breast Cancer Profiling (BCP) assay, based on the two-gene ratio signature developed by Ma et 
al.61,64 
 The first question, (is there any direct evidence that these tests in breast cancer patients lead 
to improvement in outcomes?) is defined as randomized clinical trials comparing the outcomes 
of patients following standard management to those of patients managed with the aid of the 
expression-based assays. No such studies have been conducted. Two prospective randomized 
trials are in progress: TAILORx35 and MINDACT36 were recently initiated to prospectively 
evaluate the clinical utility of Oncotype DX and MammaPrint, respectively. As described in 
Chapter 3, TAILORx will provide information on the appropriate RS threshold for 
recommending adjuvant chemotherapy, and will not directly assess the effect of clinical 
decisionmaking with and without the test. The data generated may allow indirect inferences to be 
made. MINDACT will allow more direct inferences on the clinical utility, since its will be 
compared directly to the use of a conventional risk index. For both trials, patient health outcomes 
will be endpoints. 
 The evidence available on the subsequent key questions allowed us to draw conclusions 
about the specific tests, as well as about the methodology of test development and current and 
future clinical uses of gene expression assays.  Currently established methods for risk 
stratification of patients with breast cancer rely on a combination of prognostic factors like tumor 
size, grade, lymph node status, and presence of hormone receptors and the human growth factor 
receptor 2 (HER-2), such as the St. Gallen Consensus Guidelines5 or Adjuvant! Online.7 The 
latter also incorporates a nomogram to generate estimates of benefit from specific therapies. A 
critical question is how much gene expression-based tests add to standard risk assessment 
methods or guidelines. A second question is how clearly does the current evidence relate to the 
test’s proposed use in a decisionmaking context, i.e., how well defined or homogeneous are the 
patient populations, in terms of their current therapy and decisions about future therapy? Is it 
clear how the test information should be implemented, i.e., using cutoffs, as a continuous score, 
or in combination with other indices?  When viewed through the prism of clinical 
decisionmaking, the current evidence base for these technologies leaves many uncertainties. 
 Many aspects of expression-based predictors differ in qualitative ways from other kinds of 
risk predictors. First, the mechanism by which the expression of any particular gene, or 
combination thereof, is related to outcome is generally less well understood than with standard 
predictors, as are the methods by which the combinations are chosen. Gene expression levels are 
markers of activation or inactivation of complex biological processes. As Fan et al.79 
demonstrated, similar risk classifications can be achieved with predictors having few or no 
overlapping genes. Second, there is no “gold standard” for gene expression values; the 
technologies used here – RT-PCR and microarrays – represent the state of the art. In the end it is 
less analytic validity (i.e., proximity to a true value) but analytic variability (i.e., variation in the 
calculated value) that must be understood to predict whether investigational results are likely to 
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be similar to those produced in practice, and whether the results in practice are likely to be stable 
over time and with broader use. Third, we know little about the stability of the predictive value 
of such markers over populations with different genetic profiles. Arguments can be made that 
genetic predictors (particularly from tumors) are likely to be either more or less universal than 
physiologic ones, so there is still much to be learned about the generalizability of these rules. 
However, in spite of these differences, the latter half of the developmental pathway for these 
tests must follow the same principles and procedures as those for any multivariate clinical 
prediction rule. These have been outlined in detail in the clinical literature,94,95 enshrined in 
reporting guidelines,96 and articulated with specific respect to expression-based predictors in a 
series of articles by Simon.68,71, 97  
 The three signatures and assays considered differ not only in the technologies used and their 
implementations, but also in the nature of the validation studies. An important distinction for all 
expression-based tests is that between the signature and the licensed test, as offered to a patient. 
Data about the actual tests offered to the patients are available only for MammaPrint and 
Oncotype DX, albeit more limited for the former.  There is only one published study that used 
the two-gene index as it is implemented in its marketed version, the BCP assay,61 although it is 
not clear whether the lab performing the assay in this report was the same as the one with current 
rights to perform the test. The remaining reports considered the signature, with the expression of 
the two genes measured and combined in varying ways.61-63,72  
 Recent publications have begun to address the analytic validity of the tests. There is now 
evidence about several aspects of gene expression measurements for two of the tests 
(MammaPrint and Oncotype DX.44,45,57,58 The public release of these data is useful as it supports 
the rationale behind two of the currently available assays and encourages development and 
publication of similar information for future assays. However, evidence about analytic features 
of the assays does not obviate the need for continuous monitoring of the experimental procedures 
involved with such testing. In this regard it is worth mentioning that the U.S. FDA Office of In 
Vitro Diagnostic evaluation and Safety (OIVD) is developing a Guidance Document on In Vitro 
Diagnostic Multivariate Index Assays (IVDMIAs) that will affect the development of future 
assays in the U.S. Moreover, the laboratories offering such assays, as any other laboratory 
providing diagnostic services must adhere to the Clinical Laboratory Improvement Act (CLIA). 
 Below follows the discussion of the specific tests and key questions considered in the present 




 Oncotype DX, the basis for the “recurrence score,” was first developed, then applied and 
used as an assay in investigational settings. All evidence about the RS (apart from the 
comparison study by Fan and colleagues79 and the development studies44)48 were obtained using 
the same assay that is offered to patients, with sample processing done in the same manner by the 




 Analytic validity evidence now exists for some of the operational/laboratory 
characteristics/procedures of this test, as well as about its reproducibility, although information 
about this latter point is limited to a few repeated analyses. These studies demonstrated that the 
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reproducibility of the test across different samples of the same block, and samples from different 
blocks, is reasonably high.45 The test involves not only the simple assessment of the RNA levels 
by RT-PCR, but also the preparation of the RNA, following a central review of the specimens 
shipped to Genomic Health to check for tumor content. No direct evidence is available about the 
sample preparation aspect of the test, although there is indirect evidence from peer-reviewed 
literature in the form of the overall success rate of extracting analyzable mRNA, which appears 
to be fairly high. Centralization is a current strength of Oncotype DX with regard to 





 “Clinical validity” is defined here as the ability of a prediction test to accurately predict risk. 
Whether or not those risk predictions differ enough to justify its use in a clinical setting (i.e., 
whether discrimination is sufficient) is a second issue. The clinical validity of Oncotype DX has 
been evaluated in various settings. The first validation study28 used tamoxifen-treated women 
with ER positive, lymph node negative breast cancer, from the randomized clinical trial NSABP 
B-14. This study independently validated the prognostic value of the RS, which had been 
previously tested in the tamoxifen-treated population of NSABP B-20. Perhaps the most 
important aspect of this population is that it was clinically and prognostically well defined, in 
that everyone was presumed to be eligible for chemotherapy, and all subjects had similar 
treatment (i.e., tamoxifen), making for a relatively clear interpretation of the results in terms of 
both treatment biology and clinical decisionmaking. Predictors of response on a specified 
therapy are not necessarily prognostic factors independent of that therapy, so studies which mix 
treated and untreated patients, or patients differently treated, can produce results that do not 
apply well to either. While this study took place in the past, all measurements were done 
concurrently independently of the outcome, and so has evidential value quite close to that of a 
concurrent prospective study. The main issues raised by the non-concurrency are whether the 
668 subjects examined were a representative sample of the more than 2000 in the original study, 
and the degree to which the findings in tamoxifen-treated women will apply to aromatase 
inhibitor treated patients today, the role of HER-2 testing and treatment, and whether there was 
anything clinically relevant about how the early stage cancer was diagnosed (e.g., clinically or by 
mammogram) that might differ today.  
 While this study reported hazard ratios for the RS in the presence of clinical predictors, it did 
not provide predictions by the RS cross-classified by those of standardized combination risk 
predictors to see exactly how many women would be re-classified in risk strata that might 
change decisions regarding chemotherapy. This information was however presented in poster 
form in 200465  and it showed that the RS had considerable predictive power beyond that of the 
St. Gallen or NCCN risk stratification guidelines (n.b. St. Gallen did not include HER-2 at that 
time). Another poster66 showed the same information for Adjuvant! Online (Tables 13 and 14, 
Chapter 3). All of these cross-classifications showed that the greatest contribution of the test was 
likely to be in the reclassification of patients from high to low risk, i.e., in reducing the number 
of patients who might unnecessarily undergo chemotherapy.  It also showed that optimal 
predictions probably would be achieved with a combination of both expression and clinical 
predictors.   It must be stressed that the cross-classified risk of patients in the low-risk RS groups 
in these posters does not represent the lowest attainable risk; they are an artifact of the “low risk” 
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category threshold. Patients who had low absolute RS scores would be predicted to have lower 
risks than the “low risk” category average, and those lower risks are probably low enough for 
many women classified as high risk by other indices to change their treatment decisions. One 
very important remaining question is the degree to which the absolute observed risks in this 
population, particularly in these lowest risk groups, are similar to other populations, and to those 
whom it is currently being used, i.e. whether the calibration of the test predictions will vary. The 
low risk arm of the TAILORx trial, in which patients with a RS less than10 will not be treated 
with adjuvant chemotherapy, will help address this question. 
 A second large study looked at the clinical performance of the Oncotype DX assay to predict 
breast cancer death (at 10 years) in a community-based population of ER positive, node-negative 
patients treated with tamoxifen, confirming the B14 results among the tamoxifen treated patients, 
and showing predictive value, albeit lesser, in ER positive patients not treated with tamoxifen.50  
The Esteva study,48 which showed no predictive value of RS in a small population of patients 
who received neither tamoxifen nor chemotherapy, showed such anomalous results with standard 
predictors (i.e. higher grade predicting better prognosis) that its results cannot be regarded as 
reliable. Finally, the Fan study,79 while testing the RS signature measured by microarrays and not 
the actual Oncotype DX test based on RT-PCR, showed good discriminatory power in a 
relatively large, independent dataset, albeit with a heterogeneous mix of treatments, receptor and 
nodal status. This is the same dataset on which the MammaPrint signature was developed.  
 These studies in combination provide fairly strong support for the clinical validity of the 
Oncotype DX test over and above standard predictors, in a well defined population (ER positive, 
lymph node negative, tamoxifen treated) with clear treatment indication (adjuvant 
chemotherapy). Exactly how much it adds, however, exactly what proportion of these patients 
would benefit from its use, and the stability of the observed risk in the various risk categories in 
other (or current) populations, is not as clear. Discussion will continue below about its use in a 




 Clinical utility is the degree to which a test is predictive of treatment benefit, and hence is a 
critical foundation for the use of a test in clinical decisionmaking. Prognostic ability itself speaks 
to this to some degree, as it puts a ceiling on the degree of clinical benefit. For example, if the 10 
year distant relapse rate is 5 percent, by definition additional treatment cannot provide more than 
a 5 percent absolute benefit, and background knowledge about treatment efficacy tells us it will 
be less.  So if the risk of distant recurrence can be reliably established as low enough, this has 
clinical utility in itself. 
 However, it is of considerable value to have a direct estimate of the degree of treatment 
benefit. This can only be done reliably in the context of RCTs, prospectively or retrospectively, 
as they assess treatment effect in an unbiased manner. This was addressed by Paik et al. in their 
study of the correlation of the RS with the degree of adjuvant chemotherapy benefit in the 
context of the NSABP-20 trial.53 This showed that the chemotherapy benefit in ER positive, node 
negative patients randomized to tamoxifen versus tamoxifen plus chemotherapy was almost 
entirely restricted to those in the high risk RS category. The CIs in the low and intermediate risk 
categories were wide and included the possibility of benefit whereas the CI for the high risk 
group was narrow and showed clear benefit. A statistical interaction was also found with patient 
age, although those data were not reported. The only caveat is that the tamoxifen arm of this 
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population was part of the training set for the assay, although the outcome measure used in the 
training set was not treatment benefit. It is not clear whether the information in clinical predictors 
was optimally used (i.e., as continuous rather than dichotomous variables), but that is unlikely to 
have accounted for the degree of differential effect predicted by the RS. HER-2 positivity 
reportedly had no effect on the results. Several other studies evaluated the value of the RS 
information in different populations of patients to predict other correlates of treatment effect. For 
example,  evaluation of pathologic response after preoperative chemotherapy49,55 supports 
clinical utility, although that was evaluated in patients in whom chemotherapy was already 
determined to be necessary.  
 The NSABP-20 study probably represents as strong evidence as can be derived from already 
existing data regarding the clinical utility of the Oncotype DX test. While prospective 
confirmation of these findings are definitely needed as well as analysis of existing patient 
samples from other completed trials,  this provides reasonable justification in the interim for the 
use of the test by women in this specific population. 
 Use in clinical decisionmaking. One published study has reported the impact of using the 
RS on clinical management,56 and there have been examinations of the economic implications of 
testing.75 In general, studies showing that physicians change recommendations or that woman 
change treatment decisions in response to their Oncotype DX risk category are minimally 
informative if the study is not designed to specifically explore the woman’s risk thresholds for 
making that decision. The reported study does not specify what information was conveyed to the 
patients, i.e., a risk score, the risk category, or the risk itself. If the latter, the number they were 
told is important to know. In the absence of this information, it is not possible to know the 
threshold of risk below which most women (or any given proportion) would forego 
chemotherapy, or conversely, the risks at which they would choose it. In the absence of such 
information, it cannot be known whether the study is effectively examining compliance with 
physician recommendations, careful weighing of risks and benefits, or the effect of test 
marketing.  
 There are still uncertainties about the optimal use of this test in practice. First, while the cut-
offs are valuable for test validation purposes, it is not clear whether the current thresholds 
actually correspond to the cutoffs that would be derived using a formal decision-analytic 
approach based on utility assessments. For an individual woman, a risk based on her exact RS 
value would be preferable, since by definition, those with RS scores near the upper boundary of 
the “low risk” range have a predicted risk higher than the average of the group, and those with 
low scores have lower risk. The fact that the boundaries used in the studies may not be optimal 
for decisionmaking is seen in the different cut-offs used by the TAILORx trial, in which the low-
risk group is defined as RS less-than or equal-to10 instead of 18, and the high risk group is defined 
as greater than 25 instead of 30.  
 The second uncertainty is the optimal use of conventional predictors. While the RS has been 
shown to have more value than most predictors, the same studies show that clinical predictors 
retain predictive value, and clinical prediction models continue to evolve and improve. An 
improved prediction tool would involve a combination of the expression-based and clinical 
predictors, but this has not been systematically explored in any study, and absolute risks 
produced by regression models or stratified tables with all predictors included are generally not 
reported. As noted previously, cross-classification data using the most updated standardized 
clinical indices would be one form of such data, although those do not show the risk from 
combinations of the exact RS and clinical predictor score.  
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 Cost-effectiveness. While our review highlights many gaps in what is known about the 
clinical utility of using gene expression profiling in women diagnosed with breast cancer, the 
review also revealed that little is known about the cost-effectiveness of using these tests. Once 
studies have demonstrated the clinical utility of these gene expression profiles, policy makers 
and health care providers will need information about the cost-effectiveness of those tests that 
have proven utility. Such information will be particularly important given the relatively high 
expected costs of the tests. Oncotype DX, for example, costs more than $3000 for each use of the 
test.  
 In our review, we found three published studies that have addressed economic outcomes 
associated with use of the breast cancer gene expression tests. One study reported that using the 
21-gene RT-PCR assay to reclassify patients would be cost-effective for those who were defined 
by 2005 NCCN criteria as low risk ($31,452 per quality-adjusted life-year (QALY) gained) and 
would be cost-saving for those who were defined by NCCN criteria as high risk.67 The EPC team 
had only moderate confidence in these projections because the study did not provide enough 
information about potential sources of bias in the analysis, allied with the fact that the study was 
supported by the manufacturer, which may introduce conflict of interest. The 2007 NCCN 
guideline now indicates that use of chemotherapy in these patients is optional, further 
diminishing the value of these projections.  
 The second study reported that use of the 21-gene RT-PCR assay was associated with a cost-
utility ratio of $4432 per QALY compared with use of tamoxifen alone, and a gain of 1.71 
QALYs with net cost savings when compared with chemotherapy plus tamoxifen.75 The EPC 
team had little confidence in this analysis, which was supported by the manufacturer, because it 
did not meet many of the standards that were used for appraising the quality of the analysis.  
 The third study compared the cost-effectiveness of the Netherlands Cancer Institute gene 
expression profiling (GEP) assay (MammaPrint) to the U.S. National Institutes of Health (NIH) 
guidelines for identification of early breast cancer patients who would benefit from adjuvant 
chemotherapy. The GEP assay was projected to yield a poorer quality-adjusted survival than the 
NIH guidelines (9.68 vs. 10.08 QALYs) and lower total costs ($29,754 vs. $32,636). To improve 
quality-adjusted survival, the GEP assay would need to have a sensitivity of at least 95 percent 
for detecting high risk patients while also having a specificity of at least 51 percent. The EPC 
team had confidence in the results of this analysis because it met most of the standards for 
appraising the quality of an economic analysis. 
 Since the overall body of evidence is inconclusive about the economic outcomes associated 
with use of breast cancer gene expression tests, this is an area that will require further 
investigation. Future economic analyses of validated tests should take into consideration existing 
guidelines for the performance and reporting of such analyses.41 Ideally, the analyses should be 




Questions Regarding the Clinical Validity and Utility of the Oncotype 
DX Assay 
 
1. Better information is needed about the predictions from combining the RS with current 
versions of standardized risk predictors, both in the form of cross-classification tables, 
and perhaps of regression-based combinations that optimize individual risk predictions. 
Formal development of cutoffs to optimize patient utility are also needed. 
2. While Oncotype DX exhibits a fair bit of risk discrimination (i.e., separating patients into 
different risk groups), the stability across different populations of the observed absolute 
risk in patients with a given risk score (i.e., calibration) needs further study. Of greatest 
interest is the observed risk in the lowest risk groups, since the absolute level of this risk 
is critical for informed decisionmaking, and patients may forego chemotherapy on the 
basis of this information. 
3. Data are currently available mainly for tamoxifen-treated patients and for those treated 
with cyclophosphamide-methotrexate-5-fluorocil chemotherapy. It is important to assess 
whether RS applies to other hormonal treatments such as aromatase inhibitors, as well as 
more contemporary chemotherapy regimens using taxanes and anthracyclines. 
4. It is not clear whether RS can be used to help guide treatment of HER-2 positive patients 
and additional studies are needed, as most of these patients were classified in the high RS 
group in the initial trials. 
5. While awaiting the TAILORx results, the findings of the Paik 200653 study predicting 
treatment benefit need independent confirmation, particularly for low and intermediate 
risk groups. 
6. Studies examining the use of Oncotype DX should provide women and physicians with 
quantitative risk information and report how this alters clinical decisionmaking. The 




 Published evidence includes both reports about MammaPrint,57-59 as well as studies about the 
associated 70-gene signature. The manuscripts that used the signature provide useful information 
about the validity of the biological correlations underlying the profile and suggest that it can be 
used in a clinical setting, but cannot be considered to be a direct validation of the assay. 
 The assay is based on the gene signature first proposed in 200221 by investigators at the 
Netherlands Cancer Institute, using 789 lymph node negative patients, younger than 55 years old, 
who did not carry a breast cancer gene (BRCA) mutation, and whose tumors were less than 5 cm 
in diameter. This signature was validated in a second study by the same group, using a series of 
295 consecutive stage I or II breast cancer patients, who were either lymph node negative or 
positive, and who were younger than 53 years.25 This validation was only partial, since the 
investigators included 61 of the 78 patients used to develop the prognosis profile. The 
MammaPrint test itself was further validated in a multicenter European study of 302 patients not 
treated with chemotherapy or tamoxifen, showing that it provided prognostic information beyond 
that of standard clinical-pathologic indices for those patients.59 Recently, this signature was 
implemented as a commercial assay, and RNA available from the original cohorts were 
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reanalyzed, yielding consistent results.58 It is the first prognostic test submitted to the FDA under 




 This assay is the first microarray-based test introduced in the field. Two recent papers 
addressed issues related to the reproducibility of the test within laboratories, as well as across 
laboratories. Such evidence however was obtained from a limited number of patients and using a 
moderate number of replication experiments. Results showed a good reproducibility within a 
laboratory, and a good degree of agreement across laboratories, although RNA labeling emerged 
as a possible source of variation capable of affecting the results. Whether this issue has an impact 
on risk classification was not thoroughly investigated, and thus the portability of the result of the 
assay from one laboratory to another still remains open. A second relevant point is the fact that 
the only validation study using the MammaPrint assay showed that only about 80 percent of 
specimens from the field (in this case 5 different European institutions) were analyzable, raising 
some concern about the analysis of fresh-frozen specimens. As more patients are analyzed by 
this test, the overall success rate may change. Finally, it must be noted that although this 
technology requires fresh rather than paraffin embedded specimens, Agendia performs a central 
pathologic review of the specimens as is performed with FFPE samples at Genomic Health, 




 Overall, published evidence supports MammaPrint as a better predictor of the 5-year risk of 
distant recurrence than traditionally used tumor characteristics or algorithms. However, the 
cohorts in whom it was developed and validated are more clinically heterogeneous than those 
used for the Oncotype DX test, with a mix of lymph node status, ER status and current treatment.  
Additionally, evidence was derived only from patients younger than 55 to 60 years of age. Even 
so, it is interesting that it had 80 percent concordance with the array-based RS classification 
when applied to the same patients, although it remains to be seen how well it predicts in cohorts 
with the same degree of clinical and treatment homogeneity as used in the Oncotype DX 
development, and which differ from its training set. Evidence about its value in comparison with 
clinical predictors was assessed in a collaborative study among 5 different institutions in Europe, 
where data were compared to standard clinical predictors like Adjuvant!.59 The area under the 
receiver operating characteristic curves was 0.68 for MammaPrint and 0.66 for the Adjuvant! 
Score. Such estimates indicate that both methods have apparently similar and modest 
discriminatory power in absolute terms. Similar results were obtained also using the ten year 
overall survival end point. However, when Adjuvant! and MammaPrint were cross-classified 
against each other, Adjuvant! had no additional predictive value. Adjustment for other predictors 
(St. Gallen and the Nottingham Prognostic Index) had a minimal effect on the regression 
coefficient of MammaPrint score or its significance, but no other data were reported on their 
incremental value.  Of note, no significant heterogeneity in the hazard ratio estimates was shown 
among centers, although original hazard ratio estimates were significantly higher than those 
obtained in this validation study. The validation cohort had longer time of observation, included 





 No studies evaluated clinical utility of this test. 
 Use in clinical practice. No studies explored the use of this test in clinical practice.  
 In summary, MammaPrint is the first commercialized microarray-based gene expression 
profile with a prognostic purpose. The underlying signature has been evaluated in approximately 
700 patients, although MammaPrint itself has only been evaluated in one study of 307 untreated 
patients. A reanalysis of the original training data of the signature using the marketed test 
showed a net reclassification of only one patient of 78.58  It is unclear what population of patients 
would derive benefit from use of the test, and what the magnitude of that benefit would be. 
Prospective data from trials like MINDACT will be extremely valuable. Overall, published 
evidence supports MammaPrint as a better predictor of the risk of distant recurrence than 
traditionally used tumor characteristics or algorithms, but its performance in therapeutically 
homogeneous populations is not yet known with precision, and it is unclear for how many 
women the lowest predicted risks are low enough to forgo chemotherapy. No evidence is 
available to permit conclusions regarding the clinical utility of MammaPrint to select women 
who will benefit from chemotherapy. 
 To conclude, the literature on the 70-gene signature includes numerous studies that focused 
more on its biological underpinning and less on the clinical implications of this gene expression 
profile, although it has now received FDA approval for clinical use. It has been shown that this 
signature is maintained along the cancer progression process.82 This profile was directly 
investigated by two different platforms (microarray and RT-PCR,48), and was successfully re-
implemented in two distinct microarray platforms, showing that it has a fair degree of analytic 
robustness. 
 Here we summarize open questions as well as research gaps found in the evidence about the 
clinical validity and utility of the MammaPrint assay and the 70-gene signature. 
 
1. The prognostic value of the 70-gene signature has been assessed in different populations 
facing different therapeutic choices. In the analysis by van de Vijver and colleagues, 130 
of the 295 patients received adjuvant therapy in a non-randomized fashion. Patients in the 
original development cohort were not treated, and Buyse validated the marketed assay in 
untreated patients. It is not yet clear which are the optimal patient populations for the use 
of this test, exactly what its performance is in those populations, and how many of its 
predictions would result in different therapeutic decisions. Larger independent validation 
studies in therapeutically homogeneous groups would be very valuable. 
2. Previous comments noted in the Oncotype DX summary apply here as well, including the 
presentation of data regarding the test in combination with standard predictors, the use of 
risk categories instead of a continuous risk measure, and the importance of confirming 
the stability of the test’s calibration in different populations.  
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H/I Ratio Signature and Breast Cancer Profiling (BCP)  
 
 This test, licensed by AviaraDX to Quest Diagnostic, Inc. is based on the two-gene ratio 
signature originally proposed by Ma and colleagues.64 Specifically, the assay is based on the 
two-gene index that includes normalization to specific reference genes followed by a 
mathematical transformation.61 Overall, large collections of patients have been investigated using 
the signature, but its prognostic and predictive value has been inconsistent; strong in some 
studies, weak or absent in others. In the Fan study, in which the ratio based on the signature (not 
the marketed BCP test), it was completely non-predictive where both Oncotype DX and the 
MammaPrint signatures were. The reason for that may have been a technical failure of the array 
technology used to simulate the test,98 or the test’s value may be restricted to certain populations. 
The populations in which it has been developed have been heterogeneous, although stratified 
analyses were used. Differences have been found in its ability to predict in various subgroups of 
those populations, differences that are not consistent across studies. A major limitation of the 
evidence is that the signature has been formulated in a variety of ways, as a simple ratio, as an 
index, by normalizing to a different set of reference genes, or to a standard calibration RNA. In 
the 2006 study in which the index as is currently marketed was tested,61 statistical methods to 
find optimal cutoffs were applied,  meaning that this assay still requires further external 
validation. We found no analytic validity data for the BCP assay. 
 In summary, while this test shows some promise, it must be regarded as being in a 
developmental phase. It was not clear in the Ma 200661 study whether samples were processed 
by Quest Diagnostics, Inc. which holds the current license. There are a number of intriguing 
biological insights and plausible mechanisms to support the rationale for the test, but its 
consistent value in well-defined clinical settings has not yet been firmly established. 
 
General Comments on Analytic Validity 
and Laboratory Quality Control 
 
 Until recently there were no multi-gene RNA-expression-based assay kits approved by the 
FDA for use in breast cancer. Such tests are currently offered as laboratory services (“home-
brew test”) subject to CLIA general laboratory standards. In February 2007, and again in July 
2007, the FDA published draft guidelines on regulation of IVDMIAs, which cover tests 
combining complex algorithms and data from multiple laboratory tests. The release of these draft 
guidelines suggests that in the future these tests will be subject to FDA evaluation. Under this 
model, all the assays to be used to make medical decisions about therapeutic options will be 
regarded as Class II or III devices and will go through a Pre-Market Approval (PMA) process, 
and will require specific post-market revision. Based on such draft guidelines, MammaPrint 
receive IVDMIA approval upon their voluntary submission of data.38,39 
 Nevertheless, analytic validity is an issue related to quality control in the laboratories where 
the test is carried out, and these data are not in the literature, but in the laboratories’ log books. 
An effort has been made by Genomic Health, Inc. and Agendia to clarify the laboratory 
procedures and acknowledge critical issues, but periodic review and reporting of the procedures 
needs to be established to monitor the reproducibility of the procedures, success rates, and 
quality control indices. 
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 A critical and often underappreciated analytic issue for the success of these tests is the way 
specimens are handled. Unlike DNA, RNA is unstable, so the length of time from excision to 
freezing or fixation, prolonged storage, and other factors related to specimen processing can lead 
to significant variability in the quality of mRNA available for expression profiling. Even if 
central labs offering the test are certified and use reliable procedures, preanalytic issues at the 
sending sites such as specimen acquisition and handling can potentially affect the results of the 
testing. Both the Oncotype DX and BCP use standard formalin fixed specimens, which tends to 
be stable, whereas MammaPrint requires fresh tissue. The use of fresh tissue required for gene 
array testing is challenging and, according to on-line information available from the Agendia 
website, careful procedures must be used when sampling the tumor to avoid necrotic parts and 
stromal tissue. Samples are reviewed centrally at Genomic Health and Agendia for tumor 
content, and BCP is performed after laser capture microdissection. Regardless of the technology 
used, standardized protocols, use of new reagents specifically designed to preserve mRNA for 
gene expression profiling, and reduction in RNA degradation (during sample processing, storage, 
and preparation) are important to assuring reliable measurements of mRNA levels for use in gene 
expression profiling.  
 
Overall Implications and Recommendations 
 
 The discussion above covers issues specific to the tests under examination, but there are 
some larger issues whose consideration is motivated by this analysis that groups involved in 




 In general, it is clear that validation studies need to deal with populations for whom the 
decision-making implications of various risk groupings are clear. The studies examined herein 
have established the proof-of-concept that tumor gene expression has prognostic value, but for 
all tests except Oncotype DX, both validation and development studies have been on mixed 
populations, without sufficient sample sizes to stratify into large enough homogeneous groups to 
guide clinical decisionmaking. In addition, validation samples are often re-used by other 
investigators; the pool of such samples in the public domain needs to be greatly expanded. 
 
Potential for Scale Problems 
 
 One problem that may be faced in the future is that of the consequences of an increase in 
demand for these tests. Scaling up the production could represent a challenge for the 
reproducibility and reliability of the tests in any setting, especially if more than one laboratory 
will offer the assays, since procedures to warrant inter-lab reproducibility will be needed. Not 
only analytical aspects will need monitoring, but also procedures involving specimen evaluation 
prior to testing. With a larger number of tests, for instance, the ability to reliably perform the 
central pathologic review might become an issue, while in the case of MammaPrint the 
availability of the current reference RNA could potentially become a limiting factor. 
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Genetic Variability and Gene Expression 
 
 It is unknown whether gene expression profiles are more or less likely than more traditional 
biomarkers to be generalizable beyond the populations in which they were initially developed. 
Gene expression may reflect fundamental biological tumor features, and thus be relatively stable 
across ethnic groups. However, gene expression patterns have also been associated with specific 
genetic mutations (i.e., BRCA1), indicating that specific DNA mutations or polymorphisms21,99 
may affect the performance of a signature. This speaks to the importance of validating these tests 
in populations with varying genetic background. Biological and genetic evidence potentially 
addressing these issues is expected to become available in the form of single nucleotide 
polymorphism (SNP) arrays coupled to expression arrays. 
 
The Need for Databases, Reproducibility, and Standards 
 
 MammaPrint® is the first assay based on microarrays that has completed the path from the 
bench to FDA approval for clinical application.  For data storage, the MIAME standards32 
represent the basis for the proper collection and storage of microarray data, and should be used to 
develop procedures going forward for the archiving of the tests performed in real patients , much 
as databases have been developed to facilitate outcomes research to complement clinical trials. 
Consideration should be given to the development of databases with complete data on each 
patient (absent identifiers), including all the analyses performed, laboratory logs, the raw and 
processed data, and all the information about procedures and analyses that have been performed 
to produce a risk estimate from a tumor sample. These apply equally to the other two assays, 
differing only in the type of data that would be stored. 
 
Where Is the Field Going? 
 
 The current evidence for the feasibility of such gene expression based tests in clinical 
settings, along with the demand for better tools to manage patients, is leading to both an 
evolution of the available tests, and the addition of novel alternative tests. The number of 
publications is growing, and several alternative signatures not considered here have already been 
proposed for breast cancer as well as for other neoplasms. We can expect many new tests, as 
well as new uses for the assays that already exist. More genes might be added to the signatures, 
and in the particular case of MammaPrint this will be possible without changing the experimental 
procedures, since the array contains thousands more genes than the ones that are incorporated in 
the 70-gene signature. In this regard, we might also expect other modifications: subsets of the 
current signatures might be proposed as alternatives to current clinical risk factors, or be 
proposed in different populations or for different purposes. For Oncotype DX, a natural evolution 
could be related to its use as an alternative to immunohistochemistry and/or pathology to 
evaluate tumor Grade, S-phase index, ER, PR, and HER-2 expression, since such genes are part 
of the set included in the assay.  Reporting of individual gene expression results may also prove 
useful. A great deal more work needs to be done on the prediction of therapeutic benefit, which 
is the ultimate goal of all such tests. 
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“Comparative Effectiveness” Studies 
 
 The emphasis in virtually all of the papers and in our evidence assessment is on the 
establishment of the value of each of these predictors over standard clinical predictors. However, 
as gene expression tests mature and proliferate, an important question will be how they compare 
to each other, and whether there is value in their combination. In the therapeutic domain, this has 
been called “comparative effectiveness” research. Such research has traditionally been difficult 
to fund by government or by industry, because it may not hold out as much therapeutic promise 
as new discoveries, and because industry understandably is not anxious to fund head-to-head 
comparisons with competitive products. This same dynamic could easily take hold in the risk 
prediction arena, with a proliferation of licensed prediction indices without any clear notion of 
what new ones are contributing over previous tests. Development of future expression-based 
predictors should make clear their incremental value over pre-existing methods. In the absence of 
better oversight of test development, physicians and patient are likely to be awash in new tests 
that all claim to offer similar guidance, or perhaps new guidance in previously neglected clinical 




 The introduction of these gene-expression tests have ushered in a new era in which many 
conventional clinical markers and predictors may be seen merely as surrogates for more 
fundamental genetic and physiologic processes. The multidimensional nature of these predictors 
demands both large numbers of clinically homogeneous patients to the used in the validation 
process, and exceptional rigor and discipline. Every study provides an opportunity to tweak a 
genetic signature, but we must find the right balance between speed of innovation and 
development of scientifically and clinically reliable tools. Going forward, it will be important to 
harness, if possible, as much genetic and clinical information on patients who undergo these tests 
to facilitate each goal without unduly sacrificing the other.  
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Appendix A: List of Acronyms 
 
Acronym Definition 
AHRQ Agency for Healthcare Research and Quality 
ANOVA Analysis of variance 
AUC Area under the receiver-operating-characteristic curve 
BCP Breast Cancer Profiling 
BCT Breast conserving therapy 
BIG Breast International Group 
BRCA Breast cancer gene 
CCD Charge Coupled Devices 
CDC Centers for Disease Control and Prevention 
cDNA Complementary DNA 
CENTRAL The Cochrane Central Register of Controlled Trials 
CI Confidence Interval 
CLIA Clinical Laboratory Improvement Act 
CMTP Center for Medical Technology Policy 
CR Complete response 
CT Cycle threshold 
CV Coefficient of variation 
DFS Disease free survival 
DNA Deoxyribonucleic acid 
DRFS Distant recurrence-free survival 
EGAPP Evaluation of Genomic Applications in Practice and Prevention 
EPC The Evidence-based Practice Center 
ER Estrogen receptor 
FDA Food and Drug Administration 
FFPE Formalyn-fixed paraffin-embedded 
FISH Fluorescent in situ hybridization 
FRET Förster Resonance Energy Transfer 
GEP Gene expression profiling 
HER2 Human epidermal growth factor receptor 2 
HR Hormone Receptors 
IHC Immunohistochemical 
INT Italian National Cancer Institute of Milan, Italy 
IVDMIAs In Vitro Diagnostic Multivariate Index Assays 
JHU Johns Hopkins University 
LCM Laser-capture micro dissected 
LMC Laser micro-dissection 
LOD Limit of detection 
LOQ Limit of quality 
MeSH Medical subject heading 
MIAME Minimum Information About a Microarray Experiment 
MINDACT Microarray for Node-Negative Disease may Avoid Chemotherapy 
mRNA Messenger ribonucleic acid 
A-2 
Acronym Definition 
NCCN National Comprehensive Cancer Network 
NCCTG North Central Cancer Treatment Group 
NCI National Cancer Institute 
NHG Nottingham Histologic Grade 
NIH National Institutes of Health 
NPI Nottingham Prognostic Index 
NSABP National Surgical Adjuvant Breast and Bowel Project 
OR Odds Ratio 
OS Overall survival 
OVID Office of In Vitro Diagnostic evaluation and Safety 
pCR Complete pathological response 
PCR Polymerase chain reaction 
PD Progressive disease 
PFS Progression free survival 
PMA Pre-Market Approval 
PR Progesterone receptor 
PR Partial response 
QALY Quality-adjusted life-year 
RCT Randomized Controlled Trial 
RECIST Response Evaluation Criteria in Solid Tumors 
REMARK Reporting recommendations for tumour MARKer prognostic studies 
RFS Relapse Free Survival 
RNA Ribonucleic acid 
ROC Receiver operating characteristic 
RR Relative risk 
RS Recurrence Score 
RT-PCR reverse transcriptase polymerase chain reaction 
SD Standard deviation 
SNP Single nucleotide polymorphisms 
STARD Standards for Reporting of Diagnostic Accuracy 
TAILORx Trial Assigning Individualized Options for Treatment 
TBCI The North American Breast Cancer Intergroup 
TRANSBIG Translating molecular knowledge into early breast cancer management: 
building on the BIG (Breast International Group) network for improved 
treatment tailoring 
TTM Time to distant metastases 





Appendix B:  Glossary 
 
Cycle Threshold (Ct, CT, Ct) 
In an RT-PCR reaction template, the relative ratios of products and reagents vary. At the 
beginning of the process, reagents are in excess, and template and products are at low 
concentrations and do not compete with primer binding, so that the amplification proceeds at a 
constant, exponential rate. After this initial phase, the process enters a linear phase of 
amplification, due to competition of product renaturation with primer binding. In late reaction 
cycles, the amplification reaches a plateau phase and no more products accumulate. To achieve 
accuracy and precision, it is necessary to collect quantitative data during the exponential phase of 
amplification, since in this phase amplification is extremely reproducible. In RT-PCR, this 
process is automated and measurements are made at each cycle. The ‘cycle threshold’ is the 




A DNA microarray (also commonly referred to as “gene chip,” “DNA chip”) is a collection of 
microscopic DNA spots (defined “features”), commonly representing single genes or transcripts, 
arrayed on a solid surface by covalent attachment to chemically suitable matrices, or directly 
synthesized on them. DNA microarrays use DNA as part of their detection system. Qualitative or 
quantitative measurements with DNA microarrays use the selective nature of DNA-DNA or 
DNA-RNA hybridization under high-stringency conditions and fluorophore-based detection. 
DNA arrays are commonly used for gene expression profiling, i.e., monitoring expression levels 
of thousands of genes simultaneously, or for comparative genomic hybridization. 
 
Gene Annotation 
Gene annotation is the body of information that is associated with genes, as well as the process 
involved with the generation and maintenance of such information. Molecular biology and 
bioinformatics have faced the need for DNA annotation since the 1980s. Today a number of 
genomic and proteomic annotation projects have made this information publicly available.  
 
Gene Expression 
Gene expression refers to the translation of the information encoded in a gene into an RNA 
transcript. Expressed transcripts include messenger RNAs (mRNA) translated into proteins, as 
well as other types of RNA, such as transfer RNA (tRNA), ribosomal RNA (rRNA), micro RNA 
(miRNA), and non-coding RNA (ncRNA), that are not translated into protein. Gene expression is 
a highly specific process by which cells switch genes on and off in a timely manner, according to 
their state. The study of mRNA expression in a cell is an indirect way to study the proteins 
counterpart. 
 
Gene Expression Classifier 
The term classifier is derived from the field of machine learning. The goal of classification is to 
group items that have similar feature values into groups. Usually, in the context of gene 
expression analysis, a classifier is a composite algorithm that achieves patients classification by 





Gene Expression Profiling 
This term refers to any genomic techniques that measure the fraction of the genes that is 
expressed in a specific sample. This definition refers to techniques that allow the assessment of 
more than one gene at a time, especially microarray and real time RT-PCR. 
Gene expression profile: This is any set of genes for which the expression in a specific sample 
is known. A gene expression profile may account for a variable number of genes, and the 
corresponding expression values may be obtained by different techniques. Gene expression 
profiles can be associated, by various techniques, to phenotypes. 
Gene expression pattern: This is an equivalent term currently in use to refer to “gene 
expression profile.” 
Gene expression signature: This is an equivalent term currently in use to refer to a specific 
“gene expression profile,” usually associated with a specific phenotype. 
 
Genome 
In biology the genome of an organism is its whole hereditary information and is encoded in the 
DNA (for some viruses, RNA). This includes both the genes encoding for proteins, as well as the 
non-coding sequences of the DNA. The term, coined in 1920 by Hans Winkler, is the fusion of 
the words gene and chromosome. The study of the global properties of genomes is usually 
referred to as ‘genomics’, which distinguishes it from genetics, which generally studies the 
properties of single genes or groups of genes. 
 
Laser Capture Microdissection 
Laser Capture Microdissection (LCM) is a method for isolating pure cells of interest from 
specific regions of tissue sections. In this procedure a special film is applied on tissue sections 
that are analyzed under the microscope. When the cells of choice are identified, the operator can 
use a laser to dissect the cells and transfer them off of the film leaving all unwanted cells behind 
in the tissue section. LCM does not alter or damage the morphology and chemistry of the sample 
collected from which is possible to prepare DNA, RNA and/or protein. LCM can be performed 
on a variety of tissue samples, including blood smears, cytologic preparations, cell cultures and 
frozen and paraffin embedded archival tissue. 
 
MIAME 
MIAME (Minimum Information About a Microarray Experiment) is a standard for reporting 
microarray experiments. It is intended to specify all the information necessary to interpret the 
results of the experiment unambiguously and to reproduce the experiment. While the standard 
defines the content desired for reports, it does not specify the format in which this data should be 
presented. There are a number of file formats for representing this data, and both public and 
subscription-based repositories for such experiments. 
 
Normalization 
In an experimental context, normalizations are used to standardize data to enable differentiation 
between real (biological) variations and variations due to the measurement process. In gene 
expression analysis (by DNA microarray or RT-PCR), normalization refers to the process of 




common scale. Several alternative methods and approaches to perform normalization exist both 
for RT-PCR and DNA microarray.  
 
Oligonucleotide 
Oligonucleotides are short sequences of nucleotides (RNA or DNA), typically with twenty or 
fewer bases, although automated synthesizers allow the synthesis of oligonucleotides up to 200 
bases. The length of a synthesized base is usually denoted by the suffix 'mer': for example, a 
fragment of 25 bases would be called a 25-mer. Oligonucleotides are used as probes to detect 
complementary DNA or RNA molecules. Specific DNA oligonucleotides are used in the PCR, 
and in this instance, they are referred to as “primers,” since they generate a place for the DNA 
polymerase to bind and extend the primers themselves, by the addition of nucleotides to make a 
copy of the target sequence. Oligonucleotides are may be referred to as “oligos.” 
 
Platform 
In the context of gene expression profiling analysis the term “platform” is often used to refer to 
the technology, instruments, and protocols used to measure gene expression. In this sense real 
time RT-PCR, cDNA microarrays, and oligonucleotide microarrays represent different 
platforms. 
 
Polymerase Chain Reaction (PCR) 
PCR is a molecular biology technique for isolating and exponentially amplifying a DNA 
sequence of interest in vitro via enzymatic replication. This technique has been extensively 
modified to perform a wide array of tasks, and it is now a common tool used in medical and 
biological research. PCR is now used to obtain the sequence of genes, to diagnose hereditary 
diseases, identify genetic fingerprints (forensics medicine), detect infectious diseases, and create 
transgenic organisms. Coupled to “reverse transcription” it is used to amplify RNA molecules. 
 
Primer 
A primer is a nucleic acid strand or a related molecule that serves as a starting point for DNA 
replication. A primer is required because most DNA polymerases cannot begin synthesizing a 
new DNA strand from scratch, but can only add to an existing strand of nucleotides. In most 
natural DNA replication, the ultimate primer for DNA synthesis is a short strand of RNA. This 
RNA is produced by “primase,” and is later removed and replaced with DNA by a DNA 
polymerase. Many laboratory techniques of biochemistry and molecular biology that involve 
DNA polymerases, such as DNA sequencing and polymerase chain reaction, require primers. 
The primers used for these techniques are usually short, chemically synthesized DNA molecules 






In molecular biology, a hybridization probe is a fragment of DNA of variable length, which is 
used to detect the presence of nucleotide sequences that are complementary to the sequence in 
the probe. The complementary sequences are referred to as “targets.” The hybridization probe is 
usually labeled radioactively, or with immunological or fluorescent markers. The labeled probe 
is then denatured (by heating) into single DNA strands and hybridized to target DNA (Southern 
blotting) or RNA (Northern blotting) immobilized on a membrane or in situ. In a DNA 
microarray the hybridization scheme is reversed and the probes are attached to a solid surface, 
while the labeled targets are in the reaction solution. Similarly, in real time RT-PCR, probes are 




The term proteome was coined by Mark Wilkins in 1994, as the fusion between proteins and 
genome. This term refers to the entire set of proteins expressed by a genome, cell, tissue or 
organism at a given time under defined conditions. The proteome is larger and more complex 
than the genome, especially in eukaryotes, in the sense that there are more proteins than genes. 
This is due to alternative splicing of genes and post-translational modifications like glycosylation 
or phosphorylation. 
 
Real Time Reverse Transcriptase Polymerase Chain Reaction (RT-
PCR) 
Real-time RT-PCR is a molecular biology technique that allows the amplification and the 
quantification in real time of defined RNA molecules from specific specimens. This technology 
has been used for several years in research and clinical settings to measure RNA molecules. 
In the first step DNA, copies of the investigated RNA molecules present in the template are 
obtained by a reaction named reverse transcription. Then DNA amplification is obtained using 
PCR, while the quantification of the accumulating DNA product is accomplished by the use of 
specific fluorescent reagents. The quantification of the target RNA molecule is based on the 
analysis of the accumulation curve of the complementary DNA, as measured by the fluorescence 
detected at each cycle of the reaction. 
 
Reverse Transcription 
In biochemistry, reverse transcription is the enzymatic reaction induced on by the RNA-
dependent DNA polymerase. This enzyme, also known as reverse transcriptase, is a DNA 
polymerase enzyme that copies single-stranded RNA into DNA. This process is the reverse of 
normal transcription, which involves the synthesis of RNA from DNA. 
 
Ribonuclease 
This type of enzyme, abbreviated commonly as RNase, is a nuclease that catalyzes the hydrolysis 
of RNA molecules into smaller components. They are divided into endonucleases (can cut RNA 







In gene expression profiling analysis, a target is the RNA transcript that is under investigation 
using its complementary counterpart, the probe. 
 
Tissue Microarrays 
Tissue microarrays (TMA) consist of paraffin blocks in which can be embedded with up to 1000 
separate tissue cores, assembled in array fashion to allow simultaneous histological analysis. 
 
Transcription 
Transcription is the process by which DNA sequences are copied into complementary RNA 
molecules by the enzyme RNA polymerase. This reaction represents the transfer of genetic 
information from DNA into RNA, which is from “storing” to “function.” The DNA sequence 
that is transcribed into an RNA molecule is called a “transcript.” 
 
Trascriptome 
The transcriptome is the set of all RNA molecules, or “transcripts,” produced in one or a 
population of cells. The term can be applied to the total set of transcripts in a given organism, or 
to the specific subset of transcripts present in a particular cell type. Unlike the genome, which is 
roughly fixed for a given cell line (excluding mutations), the transcriptome can vary from cell to 
cell, and with external environmental conditions. Because it includes all RNA transcripts in the 
cell, the transcriptome reflects the genes that are being actively expressed at any given time. The 
study of the trascriptome examines the expression level of RNAs in a given cell population, often 
using high-throughput techniques based on DNA microarray technology, or RT-PCR. 
 
C-1 
Appendix C:  Description of Genes 
 
ONCOTYPE™: the 21-gene signature 
 
Acc UGCluster Name Symbol EGID UGRepAcc LLRepProtAcc Chromosome Cytoband 
NM_001101 Hs.520640 Actin, beta ACTB 60 AK125561 NP_001092 7 7p15-p12 
NM_002046 Hs.544577 Glyceraldehyde-3-phosphate dehydrogenase GAPDH 2597 BF983396 NP_002037 12 12p13 
NM_001002 Hs.546285 Ribosomal protein, large, P0 RPLP0 6175 BQ051850 NP_444505 12 12q24.2 
NM_000181 Hs.255230 Glucuronidase, beta GUSB 2990 AK096764 NP_000172 7 7q21.11 
NM_003234 Hs.529618 Transferrin receptor (p90, CD71) TFRC 7037 BC001188 NP_003225 3 3q29 
NM_002417 Hs.80976 Antigen identified by monoclonal antibody Ki-67 MKI67 4288 NM_002417 NP_002408 10 10q25-qter 
NM_003600 Hs.250822 Aurora kinase A AURKA 6790 NM_198433 NP_940839 20 20q13.2-q13.3 
NM_001168 Hs.514527 Effector cell peptidase receptor 1 EPR1 8475 NM_001012271  17 17q25 
NM_031966 Hs.23960 Cyclin B1 CCNB1 891 NM_031966 NP_114172 5 5q12 
NM_002466 Hs.179718 V-myb myeloblastosis viral oncogene homolog (avian)-like 2 MYBL2 4605 BX647151 NP_002457 20 20q13.1 
NM_004448 Hs.446352 
V-erb-b2 erythroblastic leukemia viral 
oncogene homolog 2, 
neuro/glioblastoma derived oncogene 
homolog (avian) 
ERBB2 2064 NM_001005862 NP_004439 17 17q11.2-q12|17q21.1
NM_005310 Hs.86859 Growth factor receptor-bound protein 7 GRB7 2886 NM_005310 NP_005301 17 17q12 
NM_000043 Hs.244139 Fas (TNF receptor superfamily, member 6) FAS 355 AB209361 NP_690616 10 10q24.1 
NM_000926 Hs.368072 Progesterone receptor PGR 5241 X51730 NP_000917 11 11q22-q23 
NM_000633 Hs.150749 B-cell CLL/lymphoma 2 BCL2 596 NM_000633 NP_000648 18 18q21.33|18q21.3 
NM_020974 Hs.523468 Signal peptide, CUB domain, EGF-like 2 SCUBE2 57758 NM_020974 NP_066025 11 11p15.3 
NM_005940 Hs.143751 Matrix metallopeptidase 11 (stromelysin 3) MMP11 4320 NM_005940 NP_005931 22 22q11.2|22q11.23 
NM_001333 Hs.660866 Cathepsin L2 CTSL2 1515 BC067289 NP_001324 9 9q22.2 
NM_000561 Hs.301961 Glutathione S-transferase M1 GSTM1 2944 BQ880398 NP_666533 1 1p13.3 
C-2 
NM_001251 Hs.647419 CD68 molecule CD68 968 NM_001251 NP_001242 17 17p13 
NM_004323 Hs.377484 BCL2-associated athanogene BAG1 573 NM_004323 NP_004314 9 9p12 
 
MAMMAPRINT®: the 70-gene signature 
 
ORIGINALID Acc UGCluster Name Symbol LLID UGRepAcc LLRepProtAcc Chromosome Cytoband 
AA555029_RC AA555029 Hs.100691 Hypothetical protein LOC286052 LOC286052 286052 AK095104  8 8q24.13 
AF052162 AF052162 Hs.368853 Acyltransferase like 2 AYTL2 79888 AK090444 NP_079106 5 5p15.33 
NM_007203 NM_007203 Hs.591908 PALM2-AKAP2 protein PALM2-AKAP2 445815 NM_053016 NP_671492 9 9q31-q33 
AL080059 AL080059 Hs.173094 TSPY-like 5 TSPYL5 85453 NM_033512 NP_277047 8 8q22.1 
AL137718 AL137718 Hs.283127 Diaphanous homolog 3 (Drosophila) DIAPH3 81624 NM_001042517 NP_112194 13 13q21.2 
NM_003748 NM_003748 Hs.77448 Aldehyde dehydrogenase 4 family, member A1 ALDH4A1 8659 NM_003748 NP_733844 1 1p36 
NM_001282 NM_001282 Hs.514819 Adaptor-related protein complex 2, beta 1 subunit AP2B1 163 NM_001030006 NP_001273 17 17q11.2-q12 
U82987 U82987 Hs.467020 BCL2 binding component 3 BBC3 27113 AF332558 NP_055232 19 19q13.3-q13.4
NM_004702 NM_004702 Hs.567387 Cyclin E2 CCNE2 9134 NM_057735 NP_477097 8 8q22.1 
NM_020974 NM_020974 Hs.523468 Signal peptide, CUB domain, EGF-like 2 SCUBE2 57758 NM_020974 NP_066025 11 11p15.3 
NM_001809 NM_001809 Hs.1594 Centromere protein A CENPA 1058 BM911202 NP_001800 2 2p24-p21 
AF201951 AF201951 Hs.530735 Membrane-spanning 4-domains, subfamily A, member 7 MS4A7 58475 NM_032597 NP_996823 11 11q12 
X05610 X05610 Hs.508716 Collagen, type IV, alpha 2 COL4A2 1284 NM_001846 NP_001837 13 13q34 
Contig20217_RC AA834945 Hs.604604 
Transcribed locus, moderately 
similar to XP_001091104.1 
similar to lin-9 homolog [Macaca 
mulatta] 
AA834945  AA834945  1  
Contig24252_RC AW024884 Hs.528605 PP12104 LOC643008 643008 XM_928053  17 17q25.1 
Contig28552_RC AA992378 Hs.283127 Diaphanous homolog 3 (Drosophila) DIAPH3 81624 NM_001042517 NP_112194 13 13q21.2 
Contig32125_RC AA404325 Hs.523036 CDNA FLJ38245 fis, clone FCBBF2007186 AA404325  AK095564  1  
Contig32185_RC AI377418 Hs.657472 G protein-coupled receptor 180 GPR180 160897 NM_180989 NP_851320 13 13q32.1 
Contig35251_RC AI283268 Hs.634333 CDNA: FLJ22719 fis, clone HSI14307 AI283268  AK026372  7  
Contig38288_RC AI554061 Hs.657864 Quiescin Q6 sulfhydryl oxidase 2 QSOX2 169714 AJ318051 NP_859052 9 9q34.3 
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ORIGINALID Acc UGCluster Name Symbol LLID UGRepAcc LLRepProtAcc Chromosome Cytoband 
Contig40831_RC AI224578 Hs.595493 
Full-length cDNA clone 
CS0DI029YM01 of Placenta Cot 
25-normalized of Homo sapiens 
(human) 
AI224578  BF675485  8  
Contig46218_RC AI813331 Hs.283127 Diaphanous homolog 3 (Drosophila) DIAPH3 81624 NM_001042517 NP_112194 13 13q21.2 
Contig46223_RC AA528243 Hs.22917 Reticulon 4 receptor-like 1 RTN4RL1 146760 NM_178568 NP_848663 17 17p13.3 
Contig48328_RC AI694320 Hs.655005 Zinc finger protein 533 ZNF533 151126 BC092423 NP_689733 2 2q31.2-q31.3
Contig51464_RC AI817737 Hs.567582 F-box protein 31 FBXO31 79791 AF318348 NP_079011 16 16q24.2 
Contig55377_RC AI918032 Hs.632255 RUN domain containing 1 RUNDC1 146923 BC039247 NP_775102 17 17q21.31 
Contig55725_RC AI992158 Hs.470654 Cell division cycle associated 7 CDCA7 83879 AL834186 NP_665809 2 2q31 
Contig56457_RC AI741117 Hs.530272 Chromosome 9 open reading frame 30 C9orf30 91283 AK092292 NP_542386 9 9q31.1 
Contig63102_RC AI583960 Hs.55918 Likely ortholog of mouse D11lgp2 LGP2 79132 AK021416 NP_077024 17 17q21.2 
Contig63649_RC AW014921 Hs.446388 CDNA FLJ41489 fis, clone BRTHA2004582 AW014921  AK123483  11  
NM_020188 NM_020188 Hs.388255 Chromosome 16 open reading frame 61 C16orf61 56942 BM463756 NP_064573 16 16q23.2 
NM_000788 NM_000788 Hs.709 Deoxycytidine kinase DCK 1633 CD014015 NP_000779 4 4q13.3-q21.1
AL080079 AL080079 Hs.318894 G protein-coupled receptor 126 GPR126 57211 NM_020455 NP_940971 6 6q24.1 
Contig25991 AI738508 Hs.518299 Epithelial cell transforming sequence 2 oncogene ECT2 1894 AY376439 NP_060568 3 3q26.1-q26.2
NM_007036 NM_007036 Hs.129944 Endothelial cell-specific molecule 1 ESM1 11082 X89426 NP_008967 5 5q11.2 
NM_000127 NM_000127 Hs.492618 Exostoses (multiple) 1 EXT1 2131 NM_000127 NP_000118 8 8q24.11-q24.13 
NM_003862 NM_003862 Hs.87191 Fibroblast growth factor 18 FGF18 8817 AF075292 NP_387498 5 5q34 
NM_018354 NM_018354 Hs.516834 Chromosome 20 open reading frame 46 C20orf46 55321 AK126837 NP_060824 20 20p13 
NM_002019 NM_002019 Hs.654360 
Fms-related tyrosine kinase 1 
(vascular endothelial growth 
factor/vascular permeability 
factor receptor) 
FLT1 2321 NM_002019 NP_002010 13 13q12 
NM_003875 NM_003875 Hs.591314 Guanine monphosphate synthetase GMPS 8833 NM_003875 NP_003866 3 3q24 
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ORIGINALID Acc UGCluster Name Symbol LLID UGRepAcc LLRepProtAcc Chromosome Cytoband 
NM_002073 NM_002073 Hs.584760 
Guanine nucleotide binding 
protein (G protein), alpha z 
polypeptide 
GNAZ 2781 BC037333 NP_002064 22 22q11.22 
NM_000849 NM_000849 Hs.2006 Glutathione S-transferase M3 (brain) GSTM3 2947 NM_000849 NP_000840 1 1p13.3 
NM_006101 NM_006101 Hs.414407 
NDC80 homolog, kinetochore 
complex component (S. 
cerevisiae) 
NDC80 10403 NM_006101 NP_006092 18 18p11.32 
NM_018401 NM_018401 Hs.133062 Serine/threonine kinase 32B STK32B 55351 AY358353 NP_060871 4 4p16.2-p16.1
AF055033 AF055033 Hs.635441 Insulin-like growth factor binding protein 5 IGFBP5 3488 NM_000599 NP_000590 2 2q33-q36 
NM_000599 NM_000599 Hs.635441 Insulin-like growth factor binding protein 5 IGFBP5 3488 NM_000599 NP_000590 2 2q33-q36 
NM_014791 NM_014791 Hs.184339 Maternal embryonic leucine zipper kinase MELK 9833 NM_014791 NP_055606 9 9p13.2 
AK000745 AK000745 Hs.377155 Metadherin MTDH 92140 BC045642 NP_848927 8 8q22.1 
AB037863 AB037863 Hs.471955 Early B-cell factor 4 EBF4 57593 XM_044921  20 20p13 
NM_016448 NM_016448 Hs.656473 Denticleless homolog (Drosophila) DTL 51514 NM_016448 NP_057532 1 1q32.1-q32.2
NM_016359 NM_016359 Hs.615092 Nucleolar and spindle associated protein 1 NUSAP1 51203 AK222819 NP_060924 15 15q15.1 
NM_020386 NM_020386 Hs.36761 HRAS-like suppressor HRASLS 57110 BC048095 NP_065119 3 3q29 
NM_005915 NM_005915 Hs.444118 Minichromosome maintenance complex component 6 MCM6 4175 NM_005915 NP_005906 2 2q21 
NM_004994 NM_004994 Hs.297413 
Matrix metallopeptidase 9 
(gelatinase B, 92kDa gelatinase, 
92kDa type IV collagenase) 
MMP9 4318 NM_004994 NP_004985 20 20q11.2-q13.1
NM_014889 NM_014889 Hs.528300 Pitrilysin metallopeptidase 1 PITRM1 10531 CR749279 NP_055704 10 10p15.2 
NM_006681 NM_006681 Hs.418367 Neuromedin U NMU 10874 BF034907 NP_006672 4 4q12 
NM_014321 NM_014321 Hs.49760 Origin recognition complex, subunit 6 like (yeast) ORC6L 23594 NM_014321 NP_055136 16 16q12 
NM_000436 NM_000436 Hs.278277 3-oxoacid CoA transferase 1 OXCT1 5019 NM_000436 NP_000427 5 5p13.1 
NM_006117 NM_006117 Hs.15250 Peroxisomal D3,D2-enoyl-CoA isomerase PECI 10455 AB209917 NP_996667 6 6p24.3 
AF257175 AF257175 Hs.15250 Peroxisomal D3,D2-enoyl-CoA isomerase PECI 10455 AB209917 NP_996667 6 6p24.3 
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MAMMAPRINT®: the 70-gene signature (continued) 
 
ORIGINALID Acc UGCluster Name Symbol LLID UGRepAcc LLRepProtAcc Chromosome Cytoband 
NM_003607 NM_003607 Hs.35433 CDC42 binding protein kinase alpha (DMPK-like) CDC42BPA 8476 NM_003607 NP_055641 1 1q42.11 
NM_003981 NM_003981 Hs.567385 Protein regulator of cytokinesis 1 PRC1 9055 NM_003981 NP_955446 15 15q26.1 
NM_016577 NM_016577 Hs.12152 RAB6A, member RAS oncogene family RAB6A 5870 NM_016577 NP_942599 3 11q13.3 
NM_002916 NM_002916 Hs.518475 Replication factor C (activator 1) 4, 37kDa RFC4 5984 NM_002916 NP_853551 3 3q27 
AF073519 AF073519 Hs.658079 Small EDRK-rich factor 1A (telomeric) SERF1A 8293 AF073519 NP_068802 5 5q12.2-q13.3
NM_006931 NM_006931 Hs.419240 Solute carrier family 2 (facilitated glucose transporter), member 3 SLC2A3 6515 AB209607 NP_008862 12 12p13.3 
Contig2399_RC W90004 Hs.444450 Egl nine homolog 1 (C. elegans) EGLN1 54583 AF229245 NP_071334 1 1q42.1 
NM_003239 NM_003239 Hs.592317 Transforming growth factor, beta 3 TGFB3 7043 AK122902 NP_003230 14 14q24 
NM_015984 NM_015984 Hs.591458 Ubiquitin carboxyl-terminal hydrolase L5 UCHL5 51377 AK225794 NP_057068 1 1q32 




BCP – H/I assay: 2-gene signature and normalizing genes 
 
Symbol UGCluster Name EGID UGRepAcc LLRepProtAcc Chromosome Cytoband 
ACTB Hs.520640 Actin, beta 60 AK125561 NP_001092 7 7p15-p12 
HMBS Hs.82609 Hydroxymethylbilane synthase 3145 BU168137 NP_000181 11 11q23.3 
SDHA Hs.440475 
Succinate dehydrogenase complex, 
subunit A, flavoprotein (Fp) 6389 AK131478 NP_004159 5 5p15 
UBC Hs.520348 Ubiquitin C 7316 AB209436 NP_066289 12 12q24.3 
HOXB13 Hs.66731 Homeobox B13 10481 AY937237 NP_006352 17 17q21.2 
IL17RB Hs.654970 Interleukin 17 receptor B 55540 NM_018725 NP_758434 3 3p21.1 
 
 
Symbol: official gene symbol 
UGCCluster: Unigene cluster identifier 
Name: gene name according to Unigene 
EGID: Entrez Gene identifier 
UGRepAcc: representative GeneBank accession number according to Unigene 
LLRepProtAcc: representative Protein accession number according to Entrez Gene 
Chromosome: chromosomal location 
Cytoband: cytogenetic band 
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Appendix D:  Technologies 
 
Reverse Transcription-Polymerase Chain Reaction (RT-PCR) and 
Real-Time RT-PCR 
 
 Reverse transcription polymerase chain reaction (RT-PCR) is a molecular biology technique for 
amplifying a specific piece of a ribonucleic acid (RNA) molecule. The RNA molecule is first reverse 
transcribed into complementary DNA (cDNA), followed by amplification of the resulting DNA by 
polymerase chain reaction (PCR), which is the common method used to amplify specific parts of a DNA 
molecule, via the temperature-mediated enzyme DNA polymerase. PCR uses specific short 
oligonucleotides, defined as primers, complementary to the target sequence to be amplified that serve to 
prime the polymerase reaction. The sequence of such oligonucleotides is responsible for the specificity of 
the reaction for the target nucleic acid fragment under analysis. PCR proceeds through subsequent 
amplification cycles determined by controlled temperature shifts of the reaction mixture. 
Real-time polymerase chain reaction is a laboratory technique that allows amplifying and quantifying 
simultaneously the specific part of the nucleic acid sequence under analysis. In this technique, the DNA 
quantity produced after each round of amplification is obtained by alternative methods. The most 
common quantification protocols are based on the use of fluorescent dyes that intercalate with double-
strand DNA, or on modified DNA oligonucleotide probes that fluoresce when hybridized with the 
complementary DNA. 
Real-time RT-PCR is the combination of the described techniques and enables gene expression 
evaluation at a particular time, or in a particular cell or tissue type. This technique is extremely sensitive 
and has been used to measure RNA from a single cell. The development of novel chemistries and 
instrumentation platforms has led to widespread use of this approach to measure gene expression changes. 
Moreover, this technique has become the preferred way to validate results obtained from microarray 
analyses and other techniques that evaluate gene expression changes on a global scale. 
 
RT-PCR procedures 
During PCR amplification, template, product and reagent relative ratios vary. At the beginning of the 
reaction, reagents are in excess, template and products are at low concentrations. In this phase they do not 
compete for primer binding, so that the amplification proceeds at an exponential rate. Following this 
initial phase the reaction enters a linear phase of amplification, in which annealing of the PCR products 
competes with primers for binding. Following this phase, in late reaction cycles, the amplification reaches 
a plateau and no more PCR products accumulate. Accurate and precise quantitative data are collected 
during the exponential phase of the amplification, in which amplification is extremely reproducible. In 
real-time PCR this process is automated and measurements are made at each cycle. 
Several options are currently available to perform RT-PCR and real time RT-PCR: TaqMan® 
(Applied Biosystems, Foster City, CA, USA), Molecular Beacons, Scorpions® and the use of SYBR® 
Green (Molecular Probes). In all of these technologies PCR products are detected by generation of a 
fluorescent signal. TaqMan® probes, Molecular Beacons and Scorpions® rely on Förster Resonance 
Energy Transfer (FRET): a dye molecule and a quencher moiety are bound to the same or different 
oligonucleotide substrates and fluorescence is emitted when they are separated. SYBR Green is a 
fluorogenic dye that emits a strong fluorescent signal upon binding to double-stranded DNA. 
 
TaqMan probes 
 TaqMan technology depends on the 5'- nuclease activity of the DNA polymerase used for PCR. This 
activity is used to separate the quencher and the dye, releasing FRET and thus producing fluorescence. 
During the reaction, this enzyme hydrolyzes the oligonucleotide probes that are hybridized to the target 
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sequence, decoupling occurs, and fluorescence arises, increasing at each cycle, proportional to the amount 
of probe cleavage. 
 
Molecular beacons 
 Molecular Beacons also is based on FRET, although the design of the probes is different. In this 
chemistry, a dye is attached to the 5' end and a quencher is bound to the 3' end of an oligonucleotide 
substrate. The 5'- nuclease activity of the DNA polymerase is not required since Molecular Beacons 
probes in solution form a loop structure that prevents fluorescing, while after hybridization to the target 
sequence, the dye and quencher are separated, FRET is release, and light is emitted upon irradiation. 
 
Scorpions 
 Scorpion technology assembles the amplification primer and the reporter sequence into the same 
oligonucleotide. In solution, the dye is attached to the 5' end of the probe and is quenched by a moiety 
coupled to a complementary sequence, linked to the primer at the 3’ end, through a non-amplifiable 
monomer. During PCR, after extension of the Scorpion primer, the two specific probe sequences are able 
to bind each other, thus opening up the hairpin loop, releasing quenching and causing signal emission. 
 
SYBR Green 
 SYBR Green binds double-stranded DNA, and upon excitation fluoresces. The more PCR products 
accumulate, the more light emission increases. SYBR® Green is sensitive, inexpensive, and easy to use. 
However it binds to any double-stranded DNA molecule in the reaction, including primer-dimers and 
other non-specific reaction products, and this may result in an overestimation of the target molecule 
concentration. Since this dye binds to double-stranded DNA, there is no need to design specific probes for 
any particular target under analysis. 
 
Real-time reporters for Multiplex PCR 
 Several implementations of this technique (TaqMan, Molecular Beacons and Scorpions) allow 
multiple DNA species to be measured in the same sample (multiplex PCR). Fluorescent dyes with 
different emission spectra, indeed, may be coupled to the different probes assaying different targets. This 
approach allows the use of internal controls, which can be co-amplified along with the target sequence 
under analysis in the same reaction tube. Multiplex is not possible with SYBR Green. 
 
Quantitation of results 
 Two methods are commonly used to quantify the results obtained by real-time RT-PCR: 
1. The standard curve method; 
2. Comparative threshold method; 
 
The standard curve method 
 In this method, a standard curve is obtained from a nucleic acid template of known concentration, 
serially diluted. This curve is subsequently used as a reference to extrapolate quantitative information 
about mRNA targets of unknown concentrations. Such standards can be RNA molecules transcribed in 
vitro from cDNA plasmids, or other nucleic acid templates prepared at the purpose. cDNA plasmids are 
the preferred standards used to obtain the standard curve, however, their use will not allow inferences 
about the efficiency of the reverse transcription reaction, or about possible differences in the RNA 
template inputs. For this reason normalization to one or more housekeeping genes is often used. 
 
Comparative threshold method 
 This approach involves the comparison of the cycle threshold (CT) values of the samples of interest 
to the CT values of a control RNA sample, after internal normalization of each CT to an appropriate 
endogenous housekeeping gene. For this method to be valid, the amplification efficiencies of the target 
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and the endogenous reference must be similar. If a housekeeping gene cannot be found, whose 
amplification efficiency is similar to the target, then the standard curve method is better. 
 
Instrumentation for Real-time RT-PCR 
 Real-time RT-PCR requires platforms consistency of a thermal cycler, a computer, optics for 
fluorescence excitation and emission collection, and data acquisition and analysis software. Such 
instrumentation, available from several manufacturers, varies in term of sample capacity (single tubes, 96-




 The introduction of automated large scale sequencing, supported by adequate computational 
tools and bioinformatics development, has greatly increased our general knowledge on genomic 
sequences organization and function. This knowledge is the basis for gene expression 
investigation on a global scale by parallel analysis of thousands of genes in a single assay. In 
microarray analysis, the Northern blotting scheme is reversed: the labeled moiety is obtained 
from the RNA sample and a certain number of immobilized known sequences are used as probes 
(Baldwin, Crane et al. 1999). The advances made in attaching nucleic acid sequences to glass 
supports and robotics allowed investigators to miniaturize the scale of the reactions. Modified 
microscope slides could be used to deposit thousands of nucleic acid sequences. The same result 
was also obtained by borrowing photolithography techniques from semiconductor manufacturing 
to synthesize oligonucleotides directly onto a solid support (Watson, Mazumder et al. 1998). 
Altogether, these advances led to in 1995, to the first papers in which the term “microarray” was 
used in its current meaning (Schena, Heller et al. 1998). 
 
Principles of microarray analysis 
 All the different technical solutions that have been so far developed to perform microarray 
analysis are miniaturized hybridization assays that allow investigators to simultaneously query 
thousands of nucleic acid fragments. All microarray systems share the following key 
components: 
• The array, which contains the immobilized nucleic acid sequences, known as “probes”; 
• One or more labeled samples or “targets”, that are hybridized against the microarray; 
• A detection system that quantify the hybridization signals 
 
Microarrays and DNA-chips 
 Spotted microarrays consist of a collection of preformed nucleic acid sequences immobilized 
onto the solid support so that each unique sequence forms a tiny feature called “spot” or feature. 
These nucleic acids are obtained in numerous ways, and there are different methods for 
depositing them onto microarray slides (by simple contact, by ink-jet technology, or by micro-
syringe pumping for instance). In general, nucleic acid prepared for deposition on microarrays 
consist of cDNA clones amplified by polymerase chain reaction (cDNA microarrays), or of 
synthesized oligonucleotides of various length (oligonucleotide microarrays, i.e., microarrays 
from Agilent Technologies). The size of the spots differs from one system to another, but it is 
usually less than two hundred micrometers in diameter. A modified glass slide or glass wafer 
acts as the solid support onto which up to tens of thousands of spots can be arrayed in a total area 
of a few square centimetres. On the contrary, DNA-chips are produced by a proprietary 
technology (GeneChip®, Affymetrix) quite different from the spotted one, as it is based on 
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 Whatever the kind of microarray used, DNA probes present on the arrays are interrogated by 
nucleic acid hybridization with a labeled target. The sample may be mRNA for a gene expression 
study or genomic DNA for other purposes (promoter usage analysis: CHIP-on-Chip, genomic 
rearrangements: FISH-on Chip). The sample is converted to a labeled population of nucleic 
acids, known as the target. These moieties consist of several thousands of different labeled 
nucleic acid fragments and the final complexity is much greater than the one usually encountered 
in other routine molecular biology experiments. Therefore, these hybridizations should be carried 
out under conditions that do not promote annealing of non-complementary fragments. 
Fluorescent dyes, and especially the cyanine dyes Cy3 and Cy5, have been widely adopted as the 
predominant labels in microarray analysis. Fluorescence has the advantage of permitting the 
detection of two or more different signals in one experiment. This has thus allowed investigators 
to perform comparative analysis of two or more samples on one microarray. The described 
scheme is usually adopted for cDNA microarray analysis, while single channel experiments are 
the best-suited choice for GeneChip® technology, thanks to the high manufacturing 
reproducibility of the chips. The use of fluorescence has also increased the accuracy and 
throughput of microarray analysis over filter-based macroarrays, in which only one radioactively 
labeled sample can be conveniently analyzed at a time. 
 
Microarray hybridization 
 In a microarray hybridization, the labeled fragments in the target are expected to form 
duplexes with their immobilized complementary probes. This requires that the nucleic acids are 
single-stranded and accessible to each other. The number of duplexes formed reflects the relative 
number of each specific fragment in the target, as long as the amount of immobilized nucleic 
acid probe is in excess and not restraining the kinetics of hybridization. Two or more samples 
labeled with different fluorescent dyes can be hybridized simultaneously, resulting in 
simultaneous hybridization taking place at each spot. By measuring the different fluorescent 
signals associated with each feature, the relative abundance of specific sequences in each of the 
samples can be determined. 
 
Scanning and data analysis 
 Microarray scanners typically contain two different lasers that emit light at wavelengths that 
are suitable for exciting the fluorescent dyes used as labels. A detector system attached to a 
confocal microscope records the emitted light from each feature of the array, permitting high-
resolution detection of the hybridization signals. Alternative solutions use CCD-camera devices 
to detect the fluorescence. Despite their small size, microarrays allow the generation of a large 
amount of data even from a single hybridization. For these reasons the use of computerized data 
processing is necessary in order to handle the amount of generated data and to gain maximum 
information from the experiment. This is usually achieved by specialized software that extracts 
primary data from scanned microarray slide images, normalizes this data to remove the influence 
of experimental variation, and finally manipulates the data so that biologically meaningful 
conclusions can be made. 
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Applications of microarray analysis 
 The versatility of microarray analysis is confirmed by its rapid emergence as a general 
molecular biology analytical technique. An increasing number of researchers are now exploiting 
this technology in diverse biomedical disciplines. In fact, microarrays have not replaced 
established techniques, but rather represent a high-power approach to perform analyzes that were 
previously time consuming. By using information derived from the several complete or near 
complete genome sequences, including the human genome, it is now possible to perform 
genome-wide experiments using microarray technology. This has already been demonstrated for 
Saccaromyces Cerevisiae where all the expressed genes are known (Chu, DeRisi et al. 1998; 
Spellman, Sherlock et al. 1998). Due to the availability of millions of data points at once, 
microarrays enabled global analysis of fundamental biological processes: gene expression 
analysis, genome analysis, and drug discovery have been three of the main areas in which 
microarray analysis has been applied so far. 
 
Gene expression analysis 
 Gene expression analysis examines the composition of cellular messenger RNA populations. 
The identity of transcripts that make up these populations and their expression levels are 
informative of the cell state and of the activity of the genes and, as the precursors of translated 
proteins, changes in mRNA levels are related to changes in the proteome. In the simplest scheme 
a typical microarray gene expression experiment compares the relative expression levels of 
specific transcripts in two samples. Usually one of the samples is a control while the other is 
obtained from cells whose response or status is being explored. Each one of the two samples is 
labeled with a different fluorescent dye, and equal amounts of the labeled samples are combined 
and hybridized with the microarray. After hybridization, two grey scale images (usually in a 16-
bit TIFF format) corresponding to the fluorescent signals of the two dyes are independently 
obtained by scanning the microarray and fluorescence intensity from each feature is subsequently 
quantified by a specific software. After normalization, the intensity of the two hybridization 
signals can be compared: equal signal from both samples suggests equal expression of the 
considered genes in both samples, while signals’ disparity is suggestive of differential 
expression. 
 One of the most important remarks that has to be taken into account is that microarray 
analysis does not give any information about absolute gene expression levels in the samples. 
This is because the intensity of the fluorescent signals is not only proportional to the number of 
hybridized fragments, but also to the length of these fragments and the number of fluorescent 
labels each fragment carries (specific activity of the target or labeling density). These parameters 
are determined by the unique nucleotide sequence of each transcript, so that they will vary from 
gene to gene. If the two samples have been labeled under similar conditions, the length and 
labeling density of specific transcripts will be similar, allowing the comparison of the relative 
abundance of the transcripts in the analyzed targets. For these reasons a strong hybridization 
signal from microarray analysis does not necessarily correspond to a highly expressed gene, as it 
could be derived, for instance, from a gene that is expressed at a relatively low level but yields 
highly labeled target fragments. 
 Gene expression analysis with microarrays has been applied to numerous mammalian tissues, 
plants, yeast, and bacteria (Braxton and Bedilion 1998; Mirnics 2001; Mirnics, Middleton et al. 
2001; Schulze and Downward 2001; van Berkum and Holstege 2001). These studies have 
examined the effects of treating cells with chemicals, the consequences of over-expression of 
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regulatory factors in transfected cells, and compared mutant strains with parental strains to 
delineate functional pathways. In cancer research, microarrays have been used to find gene 
expression changes in transformed cells and metastases, to identify diagnostic markers, and to 
classify tumors based on their gene expression profiles (DeRisi, Penland et al. 1996; Alizadeh, 
Eisen et al. 1999; Alizadeh, Ross et al. 2001; Rew 2001, van't Veer et al. 2002). 
 
Genomic analysis 
 In addition to gene expression analysis, microarrays are now also established tools for 
genomic analysis (Shoemaker, Schadt et al. 2001). Microarrays, in fact, can be used to reveal 
transcription factor interactions with specific sequences and motifs regulating gene expression. 
For example, by combining immunoprecipitation of transcription factor-DNA complexes to 
microarray identification of DNA fragments on a genomic microarray, it was possible to identify 
functional regulatory elements in the yeast genome (Lieb, Liu et al. 2001). Furthermore, 
microarrays were used to predict splice variants of transcripts and investigate genomic fragments 
derived from genetic analysis methods, such as genomic mismatch scanning and representational 
difference analysis (Hu, Madore et al. 2001; Meltzer 2001) and specific oligonucleotide 
microarrays have been applied to the analysis of known single nucleotide polymorphisms (SNPs) 
and mutations (Sapolsky, Hsie et al. 1999; Larsen, Christiansen et al. 2001). Moreover, 
microarray hybridization can also be used to sequence DNA samples, thus providing a suitable 
mean for identifying new genetic variants (Drobyshev, Mologina et al. 1997). 
 
Drug discovery 
 A typical drug discovery process needs several years of research and only a few candidate 
compounds result at the end in approved drugs. For these reasons methods that increase the 
efficiency of the process and improve the probability of developing effective drugs are needed. 
In this perspective microarray analysis proved useful in different stages of drug discovery 
(Lockhart and Winzeler 2000; Meltzer 2001; van Berkum and Holstege 2001). For instance, the 
identification of potential therapeutic compounds can be achieved by elucidating metabolic 
pathways by looking for co-expressed. Once the drug candidates have been selected, microarrays 
can be subsequently used to define their toxic properties by examining expression profiles 
induced by drug treatments (Jain 2000). Moreover, the gene expression changes elicited by 
different drug treatments were also recently used to recognize their mechanisms of action (Jain 
2000). 
 
Specific Gene Expression Based Assays 
 
Oncotype DX™ process 
 Oncotype DX is a multi-gene assay, designed to provide a quantitative assessment of the 
likelihood of breast cancer distant recurrence. Oncotype DX is offered by Genomic Health, 
where the assay was developed. The assay accounts for the following procedures: RNA is 
extracted and purified from the tumor specimen, then the level of expression of 21 genes (16 
cancer related and 5 control genes) is obtained by RT-PCR, finally the Recurrence Score™ is 
calculated from the gene expression results. 
 In the current implementation of the assay, a pathologist at Genomic Health reviews the 
tumor content of the specimens to be processed, then RNA is extracted from formalin-fixed, 
paraffin-embedded (FFPE) specimens and contaminant DNA is removed by DNase I treatment. 
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Total RNA yield is measured and the absence of DNA contamination is verified. Real time RT-
PCR is the performed by TaqMan® technology in 384-well plates. The expression of the 16 
cancer genes is measured in triplicate then normalized to the expression levels of the 5 reference 
genes. Finally, normalized gene expression levels of the 16 cancer related genes are used to 
compute the Recurrence Score (RS), on a scale form 1 to 100. Clinical studies showed the 
correlation of the RS with the likelihood of distant recurrence at 10 years, which increases 
continuously with increase of the RS, however three distinct group of risk were defined: low-risk 
(RS < 18), intermediate-risk (RS 18-30), and high-risk (RS ≥ 31) (Paik, Shak et al. 2004). 
The Oncotype DX test is offered to patients who meet the following criteria: 
• Newly diagnosed 
• Will be treated with tamoxifen; 
• Stage I invasive breast cancer with ER positive; 
• Stage II invasive breast cancer with ER positive and lymph node negative. 
 
MammaPrint® 
 MammaPrint is a multi-gene microarray-based, diagnostic assay, designed to provide a 
quantitative prediction of risk of metastasis in breast cancer patients. The assay measures in 
triplicate the expression levels of 70 distinct genes, which were originally identified in a research 
performed at the Netherlands Cancer Institute (Amsterdam, The Netherlands) (van 't Veer, Dai et 
al. 2002; van de Vijver, He et al. 2002). According to this test, patients are divided into two risk 
groups, with different prognosis, by measuring the cosine correlation between the 70-gene 
expression profile of each individual patient to the original signature developed, according to a 
pre-specified threshold. 
 The CE-marked, FDA cleared assay is offered by the certified (QSR/GMP, ISO 17025, CLIA 
(#99D1030869) and CAP) Agendia laboratory (Amsterdam, The Netherlands), with the 
following features: 
• The assay is performed from fresh (non-FFPE) specimens; 
• A validated sampling and transportation method of fresh tissue on ambient temperature; 
• A histologic review of the shipped specimens; 
• RNA extraction and quality evaluation prior to microarray analysis; 
• Triplicate gene expression measurements and duplicate sample measurements, in a dye-
swap design; 
• Use of a constant, standardized reference RNA in each hybridization; 
  
 The MammaPrint test is offered to patients who meet the following criteria: 
• Below age 61; 
• Stage I invasive breast cancer with ER positive or ER negative; 
• Stage II invasive breast cancer with ER positive or ER negative and lymph node 
negative; 
• Tumor size less than 5 cm. 
 
Breast Cancer Profiling (BCP or H/I ratio) 
 The Breast Cancer Profiling (BCP) assay is based on the two-gene expression index 
(HOXB13/IL17BR) developed by Ma and colleagues (Ma, Wang et al. 2004; Ma, Hilsenbeck et 
al. 2006). Gene expression levels for the two genes are measured by real time RT-PCR, 
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normalized to a specific set of reference genes, prior the index computation. The two-gene index 
is a continuous marker of recurrence risk in untreated ER-positive, node negative patients. 
This assay is licensed by AviaraDX to Quest Diagnostic, and it is offered as a laboratory service, 
with the following features: 
• The assay is performed from FFPE specimens; 
• Laser capture microdissection is performed if the specimen content is <30% cancer cells; 
• RNA preparation and quality evaluation; 
• Real-time PCR analysis of HOXB13 and IL-17BR gene expression; 
• Formulation of the normalized two-gene expression index; 
• Result formulation with 5-year recurrence risk; 
 
 The BCP assay is offered to patients who meet the following criteria: 
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Appendix I: Evidence Tables 
 
Evidence Table 1. Study design, Oncotype DX™ 
 











Chang,200755 UK and 
USA 
2000-2004 retrospective 72 NR Validation 
Cobleigh, 200547 USA 1979-1999 retrospective 78 NR Development 
Cronin, 200444 USA NR retrospective 62 NR Protocols 
development 
Cronin, 200745 USA NA Analytic 
validity 
NR NR Analytic validity 










Gianni, 200549 Italy 1998-2002 prospective INT-Milan, 95 NA Validation 

















Mina, 200651 NR NR retrospective 
Parent trial, 70 
NA Validation 
Oratz, in press56 NR NR retrospective 74 NR Validation  
Paik, 2004*28 USA 1982-1988 retrospective 668 NR Validation  
Tamoxifen 
treated, 227 






* Supplemental information 
 
NR = not reported; INT= Italian National Cancer Institute of Milan, Italy; NA = not applicable; NSABP = The National Surgical 
Adjuvant Breast and Bowel Project 
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Evidence Table 2. Study population characteristics, Oncotype DX™ 
 
Study, 
Year Intervention General Characteristics Diagnosis(es) Treatments and Outcomes 
Chang,2007
55 
 Age: mean 49 y 
Menopausal status:  
pre: n=26 (53.1%) 
post: n=23 (46.9) 
Race, n (%):  
W: 37 (52) 
B: 19 (27) 
H: 11 (16) 
A: 4 (6) 
UK: 1 
Exclusion criteria: NR 
TG: Well 2 (2.8%)  
TG: Moderate 29 (40.3%) 
TG: Poor 41 (56.9%)  
H:  Ductal 67 (93.1%) 
H: Lobular 4 (5.6%) 
H: Mucinous 1 (1.4%)  
ER+: 47 (69.1%) 
ER-: 21 (30.9%)  
PR+: 38 (58.5%) 
PR-: 27 (41.5%) 
PR Unknown: 7 ;  
HER-2+: 7 (13.5%) 
HER-2-: 45 (86.5%) 
HER-2 Unknown: 20   
Palpable nodes: Yes 7 (10.0%) 
Palpable nodes: No 63 (90.0%) 
Palpable nodes: Unknown 2  
 
Treatments: 
a: Docetaxel at 100 mg/m 128 2 was 
given every 3 weeks for a total of 4 
cycles, and clinical response was 
assessed after the fourth cycle, at 12 
weeks.  
s, a: Primary surgery and standard 
adjuvant therapy were then 
administered 
Outcome: 
CR (complete disappearance of the 
tumor), 12 (16.7%) 
PR (decrease in unidimensional size 
by at least 30%), 41 (56.9%) 
PD (an increase of more than 25%), 
2 (2.8%) 
SD (any response that does not meet 
the definition of CR, PR, or PD), 17 
(23.6%)  
Complete pathologic response 2 
(3.2%) ; Others 61 (96.8%) 
Unknown 9 ;  
Relapse: Yes 13 (20.0%) ; No 52 
(80.0%) Unknown 7 
Cobleigh, 
200547 
  Age, mean y (range) SD: 57 (33-
86) 13 
Menopausal status: NR 
Race, n (%): NR 
Exclusion criteria: 
● evidence of metastatic 
disease 
● <10 positive nodes 
● <5% of specimen shows 
tumor involvement 
● no evidence of invasive 
breast cancer 
TS 0-2; 26/78 (33%) 
TS 2-5; 28/78 (36%) 
TS >5; 24/78 (31%) 
Rush (B-R) TG 1; 22/78 (29%) 
Rush (B-R) TG 2; 28/78 (36%) 
Rush (B-R) TG 3; 28/78 (36%) 
Genomic Health (B-R) TG 1; 11/78 (14%) 
Genomic Health (B-R) TG 2; 37/78 (47%) 
Genomic Health (B-R) TG 3; 30/78 
(38%)LN# 0-9; 0/78 (0%) 
LN# 10-15; 40/78 (51%) 
LN# 15-20; 18/78 (23%) 
LN# 20-30; 12/78 (15%) 
LN# >30;  8/78 (10%) 
Treatments: 
h: tamoxifen Yes; 42/78 (54%) 
h: tamoxifen No; 36/78 (46%) 
a: chemotherapy (cyclophosphamide, 
methotrexate, fluorouracil) Yes; 62/78 
(80%) 
a: chemotherapy No; 16/78 (20%) 
Outcomes: NR 
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Evidence Table 2. Study population characteristics, Oncotype DX (continued) 
 
Study, 
Year Intervention General Characteristics Diagnosis(es) Treatments and Outcomes 
Cronin, 
2004 44 
There are no patient characteristics reported in this article. This is a study of analytic validity. 
Cronin, 
2007 45 
There are no patient characteristics reported in this article. This is a study of analytic validity. 
Esteva, 
200548 
None Age, mean y, SD, median y: 
58.0, 11.5, 59.0 
Menopausal status:  
Pre; 122/149 (84.6%) 
Post; 27/149 (18.1%) 
Race, n (%): 
W, 126 (84.6) 
H, 8 (5.4) 
B 10 (6.7) 
A 5 (3.4) 
Exclusion criteria: 
● specimen shows <5% 
invasive tumor 
● insufficient RNA extracted 
from specimen 
● RT-PCR signal for genes 
outside the specifications for 
the assay 
● evidence of axillary lymph 
node involvement 
● use of adjuvant systemic 
therapy 
● follow up for <5 years 
mean TS(cm) 2.3 
median TS(cm) 2.0 
standard deviation(cm) 1.1 
B-R TG 1; 18/149 (12.1%) 
B-R TG 2; 86/149 (57.5%) 
B-R TG 3; 45/149 (30.2%) 
ER -; 46/149 (30.9%) 
ER +; 103/149 (69.1%)  
(HER2) -; 124/149 (83.2%) 
(HER2) +; 25/149 (16.8%) 
PR -; 99/149 (66.4%) 




Evidence Table 2. Study population characteristics, Oncotype DX. (continued) 
 
Study, 
Year Intervention General Characteristics Diagnosis(es) Treatments and Outcomes 
Poor prognosis Age, n (%) 
<40yrs 52 (29) 
40-44yrs, 41 (23) 
45-49yrs, 55 (31) 
≥50yrs; 32 (18) 
Menopausal status: NR 
Race: NR 
Exclusion criteria:  
● Previous history of cancer 
(except non-melanoma skin 
cancer) 
● Apical axillary lymph node 
involvement 
● Age at diagnosis >52 years 
● Tumor >5 cm in diameter at 
pathological examination 
H I (good); 19/180 (11%) 
H II (intermediate); 56/180 (31%) 
H III (poor); 105/180 (58%) 
TS ≤20mm; 84/180 (47%) 
TS >20mm; 96/180 (53%) 
LN# 0; 91/180 (51%) 
LN#1-3; 63/180 (35%) 
LN# ≥4; 26/180 (14%) 
ER -; 66/180 (37%) 
ER +; 114/180 (63%) 
VI Absent; 108/180 (60%) 
VI 1-3 vessels; 18/180 (10%) 
VI >3 vessels; 54/180 (30%) 
 
Diagnostic method: RT-PCR 
Treatment: 
h Yes; 23/180 (13%) 
h No; 157/180 (87%) 
a Yes; 66/180 (37%) 
a No; 114/180 (63%) 
s Breast conserving; 97/180 (54%) 




Good prognosis Age, n (%) 
<40yrs, 11 (10) 
40-44yrs, 44 (38) 
45-49yrs, 43 (37) 
≥50yrs, 17 (15) 
Menopausal status: NR 
Race: NR 
Exclusion criteria: see poor 
prognosis 
H I (good); 56/115 (49%) 
H II (intermediate); 45/115 (39%) 
H III (poor); 14/115 (12%) 
TS ≤20mm; 71/115 (62%) 
TS >20mm; 44/115 (38%) 
LN# 0; 60/115 (52%) 
LN# 1-3; 43/115 (37%) 
LN# ≥4; 12/115 (10%) 
ER-; 3/115 (3%) 
ER +; 112/115 (97%) 
VI Absent; 77/115 (67%) 
VI 1-3 vessels; 12/115 (10%) 
VI >3 vessels; 26/115 (23%) 
 
Diagnostic method: RT-PCR 
Treatment: 
h: Yes; 17/115 (15%) 
h: No; 88/115 (85%) 
a: Yes; 44/115 (38%) 
a: No; 71/115 (62%) 
s: Breast conserving; 64/115 (56%) 
s: mastectomy; 51/115 (44%) 
Outcome: NR 
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Evidence Table 2. Study population characteristics, Oncotype DX (continued). 
 
Study, 













Age, mean y (range) SD: 49.9 
(29-65) 9.0 
Menopausal status: NR 
Race, n (%): NR 
Exclusion criteria: NR 
T1 0/89 (0%) 
T2 1/89 (1%) 
T3 2/89 (2%) 
T4a 0/89 (0%) 
T4b 70/89 (79%) 
T4d (inflammatory breast Ca) 16/89 (18%)
LNO 14/89 (16%) 
LN1 51/89 (57%) 
LN2 24/89 (27 %) 
Supraclavicular LN 14/89 (16%) 
TG 1; 21/80 (24%) 
TG 2; 49/89 (55%) 
TG 3; 19/89 (21%) 
ER -; 31/89 (35%) 
ER +; 52/89 (58%) 
ER Not Assessable 6/89 (7%) 
Treatments: 
s: Mastectomy; 79/89 (89%) 
s: Quadrantectomy; 8/89 (9%) 
No surgery; 2/89 (2%) 
Outcomes: 
CR; 17/89 (19%) 
PR; 57/89 (64%) 
SD; 13/89 (15%) 
PD; 2/89 (2%) 












(FAC) X4 courses 
Age, mean y (range) SD: 53.1 
(29-79) 11.7 
Menopausal status: NR 
Race, n (%): NR 
Exclusion criteria: NR 
T1 7/82 (9%) 
T2 46/82 (56%) 
T3 15/82 (18%) 
T4a 1/82 (1%) 
T4b 6/82 (7%) 
T4d (inflammatory breast Ca) 7/82 (9%) 
Nodal status 
N0 28/82 (34%) 
N1 38/82 (46%) 
N2 8/82 (10 %) 
Supraclavicular LN 8/82 (10%) 
TG 1; 2/82 (3%) 
TG 2; 31/82 (37%) 
TG 3; 50/82 (60%) 
ER -; 48/82 (58%) 
ER +; 32/82 (39%) 
ER Not Assessable 3/82 (4%) 
Treatments:  
s: Mastectomy; 48/89 (59%) 
s: Quadrantectomy;33/89 (40%) 
No surgery; 1/89 (1%) 
Outcomes: 
CR; 28/82 (34%) 
PR; 40/82 (49%) 
SD; 13/82 (16%) 
PD; 1/82 (1%) 
pCR; 21/82 (26%) 
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Evidence Table 2. Study population characteristics, Oncotype DX (continued). 
 
Study, 
Year Intervention General Characteristics Diagnosis(es) Treatments and Outcomes 
 Cases Age, n (%): 
<40, 17 (8) 
40-49, 42 (19) 
50-59, 64 (29) 
60-74, 97 (44) 
Menopausal status: NR 
Race, n (%) 
W, 172 (78) 
H, 7 (3) 
B, 20 (9) 
A, 21 (10) 
Exclusion criteria: 
● positive node status 
● diagnosed at or after 75 
years of age 
● initial disease treated with 
chemotherapy 
● inflammatory or bilateral 
breast cancer or evidence of 
metastases 
● prior invasive cancer 
● unknown/unconfirmed 
treatment with tamoxifen 
TS < 1 cm, 49 (22) 
TS 1.1-2 cm, 93 (42) 
TS 2.1-4 cm, 72 (33) 
TS > 4 cm, 6 (3) 
TG well diff, 25 (11) 
TG mod diff, 92 (42) 
ER+, 168 (76) 
ER-, 52 (24) 
Poor diff, 103 (47) 
Treatments:  
h: Tamoxifen, 64 (26) 
Outcomes: 
RS <18, 57 (26%) 
RS 18-3, 54 (25%) 
RS > 31, 109 (50%) 
Habel, 
200650 
 Controls Age, n (%): 
<40, 23 (4) 
40-49, 127 (22) 
50-59, 152 (27) 
60-74, 268 (47) 
Menopausal status: NR 
Race, n (%) 
W, 457 (810) 
H, 13 (2) 
B, 47 (8) 
A, 53 (9) 
Exclusion criteria: see cases 
TS < 1 cm, 193 (34) 
TS 1.1-2 cm, 255 (45) 
TS 2.1-4 cm, 114 (20) 
TS > 4 cm, 8 (1) 
TG well diff, 175 (31) 
TG mod diff, 261 (46) 
ER+, 514 (90) 
ER-, 56 (10) 
Poor diff, 134 (23) 
Treatments: 
h: Tamoxifen, 177 (31) 
Outcomes: 
RS <18, 322 (56%) 
RS 18-3, 108 (19%) 
RS > 31, 140 (25%) 
Hornberger, 
2005 67 
There are no patient characteristics reported in this article. This was a study on the economics of using a recurrence score to predict distant 
recurrence-free survival in patients with early-stage breast cancer.  
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Evidence Table 2. Study population characteristics, Oncotype DX (continued). 
 
Study, 
Year Intervention General Characteristics Diagnosis(es) Treatments and Outcomes 
High RS (>31) DR: Tamoxifen alone, 38.3%; Tamoxifen 
+ chemo, 11.1% 
Intermediate RS 
(18-30) 
DR: Tamoxifen alone, 17.8%; Tamoxifen 
+ chemo, 10.1% 
Lyman, 
2007 75 
Low RS (<18) 
Age: NR 
Menopausal status: NR 
Race: NR 
Exclusion criteria: NR 
DR: Tamoxifen alone, 3.7%; Tamoxifen + 
chemo, 5% 
NR  
Parent trial (Miller, 
2005), n=70 
Age, mean y (range): 50 (30-65) 
Menopausal status: NR 
Race/ethnicity, n (%): NR 
Exclusion criteria: NA 
TS: 6 cm 
TG: NR 
ER+: 40 (57) 
HER2+: 14 (20) 
pCR: 9 (13) 
Pathologically negative nodes: 37 (53) 
Inflammatory disease 14 (20) 
Palpable lymph nodes: 33 (47) 




Age, mean y (range): 49 (29-64) 
Menopausal status: NR 
Race/ethnicity, n (%): NR 
Exclusion criteria: NR 
TS: 6.8 cm (2.3-21) 
TG: well differentiated 11 (24); mod 
differentiated 12 (27); poor differentiated 
22 (49) 
ER+: 26 (57) 
HER2+: 8 (18) 
pCR: 6 (13) 
Pathologically negative nodes: 23 (51) 
Inflammatory disease 9 (20) 
Palpable lymph nodes: 21 (47) 
 
Treatments: 
a: sequential doxorubicin a:, 75 mg/M2 
ea 2weeks for 3 cycles; docetaxel (T) 40 
mg/M2 1weeks for 6 cycles 
a: definitive surgery was at the 
completion of all chemotherapy 
r: at the discretion of the treating 
oncologist 





 Median age (range): 54 (35-77) 
Menopausal status: NR 
Race, n (%): NR 
Exclusion criteria: NR 
TS (cm) 0-1.0; 32/68 (47%) 
TS (cm) 1.1-2.0; 28/68 (41%) 
TS (cm) 2.1-3.0; 8/68 (12%) 
TG 1; 30/68 (44%) 
TG 2; 24/68 (35%) 





Evidence Table 2. Study population characteristics, Oncotype DX (continued). 
 
Study, 
Year Intervention General Characteristics Diagnosis(es) Treatments and Outcomes 
NSABP B-14, 
Genomic Health 
populations: n = 
668  
Age, n (%): 
<50y, 194 (29) 
50 to 60y, 173 (26) 
>60y, 301 (45) 
Menopausal status: NR 
Race/ethnicity, n (%): 
W, 615 (92) 
B, 31 (5) 
O, 22 (3) 
Exclusion criteria:   
● insufficient tumor as 
assessed by histopathology 
<5% overall tissue 
● insufficient RNA < 0.5µg 
● weak TR-PCR signal (avg 
cycle threshold for the 
reference genes >35) 
TS 0-1.0; 109 (16%) 
TS 1.1-2.0; 305 (46%) 
TS 2.1-4.0; 220 (33%) 




population, n = 
1949 
Age, n (%): 
<50y, 618 (32) 
50 to 60y, 583 (30) 
>60y, 748 (38) 
Menopausal status: NR 
Race/ethnicity, n (%): 
W, 1763 (90) 
B, 87 (5) 
O, 99 (5) 
Exclusion criteria: NR 
TS 0-1.0; 366 (19%) 
TS 1.1-2.0; 877 (45%) 
TS 2.1-4.0; 635 (32%) 
TS >4.1; 71 (4%) 
NR 
Paik, 200428  
All B-14 patients, n 
= 2617 
Age, n (%): 
<50y, 812 (31) 
50 to 60y, 756 (29) 
>60y, 1049 (40) 
Menopausal status: NR 
Race/ethnicity, n (%): 
W, 2378 (91) 
B, 118 (4) 
O, 121 (5) 
Exclusion criteria: NR 
TS 0-1.0; 475 (18%) 
TS 1.1-2.0; 1182 (45%) 
TS 2.1-4.0; 855 (33%) 
TS >4.1; 105 (4%) 
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Evidence Table 2. Study population characteristics, Oncotype DX (continued) 
 
Study, 
Year Intervention General Characteristics Diagnosis(es) Treatments and Outcomes 





Age, n (%):  
<40, 63 (10) 
40-49, 226 (35) 
50-59, 166 (25) 
>60, 196 (30) 
Menopausal status: NR 
Race/ethnicity, n (%): NR 
Exclusion criteria:   
● insufficient tumor as 
assessed by histopathology 
<5% overall tissue 
● insufficient RNA < 0.5µg 
● weak TR-PCR signal (avg 
cycle threshold for the 
reference genes >35) 
TS 0-1 cm, 110 (17) 
TS 1.1-2 cm, 318 (49) 
TS 2.1-4 cm, 196 (30) 
TS >4 cm, 24 (4) 
TG well diff, 77 (13) 
TG mod diff, 339 (59) 
TG poor diff, 163 (28) 
ER 10-49 fmol/mg, 261 (40) 
ER 50-99 fmol/mg, 153 (23) 
ER 100-199 fmol/mg, 122 (19) 
ER >200 fmol/mg, 115 (18) 
PR 0-9 fmol/mg, 105 (16) 
PR 10-49 fmol/mg, 113 (17) 
PR 50-99 fmol/mg, 97 (15) 
PR 100-199 fmol/mg, 110 (17) 
PR >200 fmol/mg, 226 (35) 
Treatments: NA 
Outcomes: 
RS <18, 353 
RS 18-3, 134 
RS > 31, 164 
TAM treated, 
n=227 
Age, mean y (range): NR  
Menopausal status: NR 
Race/ethnicity, n (%): NR 




RS <18, 135; RFS 10 year-96.8% 
RS 18-3, 45; RFS 10 year-90.9% 





Age, mean y (range): NR  
Menopausal status: NR 
Race/ethnicity, n (%): NR 
Exclusion criteria: see all patients 
NR Treatments: 
h: Tamoxifen 
a: cyclophosphamide, methotrexeate, 
and fluorouracil (CMF) OR 
methotrexeate and fluorouracil (MF) 
Outcomes:  
RS <18, 218; RFS 10 year-95.6% 
RS 18-3, 89; RFS 10 year-89.1% 
RS > 31, 117; RFS 10 year-88.1% 
 
* Diagnoses: H = histology/histologic type; TS = tumor size/diameter; LN# = # of Lymph nodes at primary diagnosis; LN = lymph node status; TG = tumor grade;  ER = estrogen 
receptor status; HER = HER neu status; PR = Progesterone receptor status;  SP = S-phase fraction; Pl = ploidy; VI = vascular invasion; PTS = site of primary tumor; HR = 
hormonal status, ER or PR or both; DR = distant recurrence; LI lymphatic infiltrate 
† Treatments: H = hormonal; A = adjuvant; S = surgical; R = radiation 
‡ Treatment outcomes: OS = overall survival; RFS = relapse-free survival (first disease relapse, irrespective of site); CR = complete response; PR = partial response; RS: recurrence 
score; SD = stable disease; PD = progressive disease; pCR = complete pathologic response; D = death 
W=white; B=black; H=Hispanic; A=Asian; NR=not reported; RNA=ribonucleic acid; NSABP= National Surgical Adjuvant Breast and Bowel Project; CMF= cyclophosphamide, 
methotrexeate, and fluorouracil; MF= methotrexeate and fluorouracil; TAM=tamoxifen 
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Evidence Table 3. Analytic validity, Oncotype DX™ 
 
Study, year Measure Conclusions 
Chang, 
200755 
Context: This study used the Oncotype DX assay analyzing FFPE specimens. Out of the 97 
eligible samples the analysis was carried on 80 samples* 
 
Methods: 
●   Standard Oncotype DX assay protocols were developed 
●   Methods for IHC not described 
●   The degree of concordance between IHC and RT-PCR with respect to ER, PR, and HER-
2 was assessed graphically and by the kappa statistic 
●   Positivity from RT-PCR analysis was assigned by the following expression levels: 
ER, >6.5.0 CT 
PR, > 5.5 CT 
HER2, > 11.5 CT 
 
Results: 
●   80 patients out of 97 successfully analyzed, for the following reasons*: 
Tumor content < 5%: 16 /97 patients (16.5%) 
Poor RNA yield: 1/80 patient (1.2%) 
Successful assays: 80 /97 (82.4%) 
●   Agreement between IHC vs RT-PCR: 
ER, k = 1.00, (95% CI = 1.00 to 1.00) 
PR, k= 0.57, (95% CI = 0.37 to 0.77) 
HER2, k= 0.74, (95% CI = 0.45 to 1.00) 
 
*Of the 80 patients that were assayed however clinical information was available for 72 cases 
The RT-PCR technology provides a potential 
platform for a predictive test using small amounts 
of routinely processed specimens (core biopsies) 
 
I-11 
Evidence Table 3. Analytic validity, Oncotype DX (continued) 
 
Study, year Measure Conclusions 
Cobleigh, 
200547 
Context: This study used the Oncotype DX assay analyzing FFPE specimens. Out of the 86 
eligible samples the analysis was carried on 78 samples. 
 
Methods: 
●   Standard Oncotype DX assay protocols were used 
●   Immunohistochemistry (IHC) of ER, PR, HER2/neu and Ki-67 by standard biotin-
streptavidin method with the appropriate antibodies (DAKO, CA, USA): 
●   The ER staining were defined as positive if staining of any intensity was seen in more than 
10% of cells 
●   ER positivity from RT-PCR analysis was assigned to expression levels > 6.5 CT 
●   Pearson’s correlation for co-expressed genes evaluation 
 
Results: 
●   78 patients out of 86 successfully analyzed, for the following reasons: 
Clinically ineligible: 1 stage VI;  
Tumor content < 5%: 7 patients 
Successful assays: 78/85 (91.7%) 
●   Correlation between two distinct probe-prime sets for ER in  RT-PCR: r =0.96 
●   Agreement between IHC vs RT-PCR: 
ER, k = 0.83 
PR, k= 0.40 
HER2, = 0.67 
Ki-67/MIB1, = 0.22 
●   Pearson’s correlation for gene pairs: 
KRT5 and KRT17 (r = 0.86) 
LPL and RBP4 (r = 0.82) 
HER2 and GRB7 (r = 0.82);  
The accuracy and specificity of this RT-PCR 
assay of formalin-fixed, paraffin embedded tumor 
tissue was supported by comparison of the 
results of RT-PCR assay of RNA and IHC assay 




Evidence Table 3. Analytic validity, Oncotype DX (continued) 
 
Study, year Measure Conclusions 
Cronin, 
200444 
Context: This study used the Oncotype DX assay analyzing FFPE specimens. 
 
Methods: 
●   Standard Oncotype DX assay protocols were developed 
●   Methods for IHC an d FISH not described 
●   ER positivity from RT-PCR analysis was assigned to expression levels > 8 CT 
●   Pearson’s correlation for co-expressed genes evaluation and correlation between FFPE 
and frozen specimen 
 
Results: 
●   ER status by RT-PCR: 
ER-positive: 79% (49 out of 62 tumors) 
ER-negative: 21% (13 out of 62 tumors) 
●   ER status, IHC vs RT-PCR comparison: 
58 concordant samples 
24ER positive by RT-PCR were negative by IHC 




●   Pearson’s correlation for gene pairs: 
KRT5 and KRT17 (r = 0.85) 
LPL and RBP4 (r = 0.84) 
HER2 and GRB7 (r = 0.71) 
ER1 and GATA23(r = 0.60) 
●   Comparison between FFPE and frozen specimens, 48 genes: 






Evidence Table 3. Analytic validity, Oncotype DX (continued) 
 
Study, year Measure Conclusions 
Cronin, 
200745 
Context: This study used the Oncotype DX assay 
●   The following analytic components of the assay were addressed: 
Limits of detection (LOD) 
Limits of quantification (LOQ) 
Amplification efficiency 
Dynamic range linearity 




●   Repeated negative sample measurement and a serial dilutions experiment, using a pooled 
reference RNA were performed for each gene, to assess LOD, LOQ, amplification efficiency, 
dynamic range linearity, and accuracy and precision 
●   Repeated measurements of 2 aliquots of a single RNA sample across multiple days, 
operators, RT-PCR plates, 7900HT instruments, and liquid-handling robots were performed 
to assess individual gene and RS reproducibility 
●   In the linearity study cDNA input varied over RNA equivalents between 2e-10 and 2000 ng 
per reaction; in all other experiments cDNA input was equivalent to 2 ng RNA 
●   The linearity response was assessed for each individual gene in the assay, by examining 
the SE from nonlinear polynomial regression 
●   ANOVA was used to asses precision variability due to plate and well within plate, treating 
plates and wells within plates at random 
●   Mixed-effect ANOVA was used to estimate components of variance due to days, plates 
within days, and within plates by treating operator, 7900HT instrument, and liquid-handling 
robot as fixed effects 
 
Results: 
●   The LOD and the LOQ for all the genes proved to be well above the pre-specified limits of 
CT units (40 cycles): 
LOD ranged from 38.7 CT (RPLPO) to 40.0 CT (most of the genes in the assay) 
LOQ ranged from 36.9 CT (ERBB2) to 39.5 CT (GAPDH) 
●   Amplification efficiencies for all the genes ranged from 75.3% (GAPDH) to 112.1% 
(BAG1), with values exceeding 100% due to the cumulative nature of the analysis along 
the sample-dilution series 
Authors reported that  the following procedures a 
currently performed to assure  the reproducibility 
of the assay: 
A standard RNA control sample is assayed at 
least once per batch of patient (46 samples) 
PCR controls are run in every assay plate 
RT-PCR failures are excluded from analysis 
Expression values are assigned when at least 
2 of 3 assay wells provide acceptable RT-
PCR results 
All 21 genes must have an expression value 





Evidence Table 3. Analytic validity, Oncotype DX (continued) 
 
Study, year Measure Conclusions 
Cronin, 2007 
(con’t) 
●   Assay linearity and dynamic range: 
6 genes (ACTB, BAG1, CD68, ESR1, RPLP0, and TFRC), were linear over the entire 
RNA range 
6 genes (BCL2, SCUBE2, GRB7, ERBB2, MMP11, and GAPDH), were linear over the 
entire RNA range tested, with an estimated maximal deviation from linearity below 1 
CT over a linear range > 2000-fold, as specified by CLSI 4 genes (MYBL2, AURKA, 
BIRC5, MYBL2) were linear over a more restricted RNA concentration range of 2e-8 
to 2000 ng, with an estimated maximal deviation from linearity below 1 CT over a 
linear range > 2000-fold, as specified by CLSI 
1 gene (PR) was linear over a more restricted RNA concentration range of 2e-9 to 2000 
ng 
2 genes (CCNB1, GSTM1) were linear over a more restricted RNA concentration range 
of 2e-8 to 2000 ng 
2 genes (CTSL2, GUSB) were linear over a more restricted RNA concentration range 
of 2e-7 to 2000 ng 
●   Assay quantitative bias and precision at the 2-ng/well for the 16 cancer-related genes: 
range = -10% (BAG1) to 6% (CTSL2) 
estimated mean deviation = 0.3% 
CV of 5.7% 
●   Assay quantitative bias and precision at the 2-ng/well for the 5 reference genes: 
range = -1.5% (GUSB) to 3.3% (ACTB) 
estimated mean deviation = 0.7% 
CV of 3.2% 
●   Reproducibility, CT measurements SD for the individual genes: 
Total SD ranged from 0.06 to 0.15 CT units 
Between day SD ranged from 0 to 0.055 CT units 
Between plated SD ranged from 0 to 0.090 CT units 
Within plated SD ranged from 0.057 to 0.147 CT units 
At a CT of 30 a maximum SD of 0.15 translate into a CV of 0.5% 
The largest differences between operators, liquid handling robots, and 7900HT 
instruments, were < 0.5 CT 
●   Reproducibility, CT measurements SD for the RS: 
Total SD was 0.792 RS units 
Between day SD was 0 RS units 
Between plated was 0 RS units 
●   Within plated was 0.792 RS units 
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Evidence Table 3. Analytic validity, Oncotype DX (continued) 
 
Study, year Measure Conclusions 
Esteva, 
200548 
Context: This study used the Oncotype DX assay analyzing FFPE specimens. Out of the 220 
eligible samples the analysis was carried on 149 samples 
 
Methods: 
●   Standard Oncotype DX assay protocols were used 
●   IHC methods in Esteva et al., 200348 and Wang et al., 200289 
●   Positivity from RT-PCR analysis was assigned by the following expression levels: 
ER, >7.0 CT 
PR, > 6.0 CT 
HER2, > 11.5 CT 
●   Concordance between RT-PCR and IHC results by Cohen’s k statistics 
●   Logistic model for HER2 measurement by RT-PCR, IHC as a quantal response 




●   149 patients out of 220 successfully analyzed, for the following reasons: 
Tumor content < 5%: 42 /220 patients (19.0%)* 
Poor RNA yield: 4/220 patients (1.8%) 
RT-PCR not within the specifications; 3 /220(1.3%) 
Low reference genes RT-PCR signal: 22/220 (10%) 
●   Successful assays: 149 /220 (67.7%) 
●   Agreement between IHC vs RT-PCR: 
ER, k = 0.80, (=+ 0.05) 
PR, k = 0.48 
HER2, k = 0.6, (=+ 0.08) 
●   Agreement between IHC vs RT-PCR: 
Logistic model p value: < 0.001 
●   HER2, RT-PCR > 11.50CT: 
Specificity: 77% 
Sensitivity: 84% 
●   HER2, RT-PCR > 11.5 CT: 
Specificity: 89% 
Sensitivity: 84% 






Evidence Table 3. Analytic validity, Oncotype DX (continued) 
 
Study, year Measure Conclusions 
Gianni, 
200549 
Context: This study used the Oncotype DX assay analyzing FFPE specimens. Out of the 95 
eligible samples the analysis was carried on 89 samples. 
 
Methods:  
●   Standard Oncotype DX assay protocols were used; 
●   Immunohistochemistry (IHC) of ER, PR by reagents from Lab Vision-Neomarkers 
(Fremont, CA) 
●   The ER staining were defined as positive if staining of any intensity was seen in more than 
10% of cells; 
●   ER positivity from RT-PCR analysis was assigned to expression levels > 6.5 CT; 
 
Results: 
●   89 patients out of 95 successfully analyzed, for the following reasons: 
Poor RNA yield: 4 patients (4.2%); 
Tumor content < 5%: 2 patients (2.1%); 
Successful assays: 89/95 (93.7%); 
●   Agreement between IHC vs RT-PCR: 
ER, k = 0.84, (95% CI = 0.71 to 0.96); 
PR, k= 0.71, (95% CI = 0.56 to 0.86); 
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Evidence Table 3. Analytic validity, Oncotype DX (continued) 
 
Study, year Measure Conclusions 
Habel, 
200650 
Context: This study used the Oncotype DX assay, analyzing FFPE specimens; data about 
the success rate of the assay were reported. 
 
Methods:  
●   Standard Oncotype DX assay protocols were used 
●   Pearson’s correlation and ANOVA to assess within patients correlation and variability: 
60 blocks that did not undergo macro-dissection from 20 (2 to 5 blocks per patient) 
49 core biopsies or tumor resection blocks 
●   ER positivity from RT-PCR analysis was assigned to expression levels > 6.5 CT 
 
Results: 
●   After medical history review, FFPE blocks were available for 234 cases and 631 controls, 
for a total of 865 patients, who underwent pathological review: 
59 patients needed macro-dissection 
19 patients showed tumor content < 5% and were excluded from the study 
●  The final analysis considered 220 cases and 570 controls, for a total 790 patients, resulting 
form a 7.9% loss due to insufficient tumor content and 1% failure rate of the RT-PCR 
assay; it is not clear which is the total with respect these percentage are expressed, since 
it was not reported 
●   RS (as a continuous value) standard deviation (SD) and Pearson’s correlation observed in 
two unpublished study: 
Overall between blocks SD was 3.0 RS units 
For 16 of the 20 patients, the between blocks SD was < 2.5 RS units 
Pearson’s correlation = 0.86 
Similar results from the second study 
●   The concordance of ER status between RT-PCR and medical chart information: 
kappa = 0.49, 95% CI 0.41–0.56 
115/122 of the discordances were patients classified as ER+ based on RT-PCR 
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Evidence Table 3. Analytic validity, Oncotype DX (continued) 
 
Study, year Measure Conclusions 
Mina, 200651 Context: This study used the Oncotype DX assay, analyzing FFPE specimens. Out of the 70 
eligible samples the analysis was carried on 45 samples. 
 
Methods: 
●   Standard Oncotype DX assay protocols were used 
●   Immunohistochemistry (IHC) of ER, PR, HER2/neu and Ki-67 by standard biotin-
streptavidin method with the appropriate antibodies (DAKO, CA, USA): 
anti-ER: mouse monoclonal 1 D5; 
anti-PR: mouse monoclonal PR636 
anti-Ki-67: mouse monoclonal MIB-1; 
HER2/neu: HercepTest; 
●   The ER staining were defined as positive if staining of any intensity was seen in more than 
10% of cells 
●   ER positivity from RT-PCR analysis was assigned to expression levels > 6.5 CT 
 
Results:  
●   45 patients out of 70 successfully analyzed, for the following reasons: 
No consent: 3 patients 
No specimen available: 10 patients 
Poor RNA yield: 9/57 patients (15.8%) 
Tumor content < 20%: 3/57 patients (5.3%) 
Successful assays: 45/57 patients (78.9%) 
●   Reference genes showed smaller ranges of expression across samples, than the 16 
cancer-related genes, especially the ER-related group (standard deviation in CT is 
reported: 
Normalization genes: b-actin = 0.56, GAPDH = 0.71, GUS = 0.75, RPLPO = 0.53, and 
TFRC = 0.64 
ER-related genes: ER = 2.72, PR = 2.27, Bcl2 = 1.41, and SCUBE2 = 2.45 
●   ER status by RT-PCR: 
ER-positive: 64% (29 out of 45 tumors) 
ER-negative: 36% (16 out of 45 tumors) 
●   ER status, IHC vs RT-PCR comparison: 
41 concordant samples 
2 ER positive by IHC were negative by RT-PCR 
2 ER positive by RT-PCR were negative by IHC 
●   Agreement data for PR, KI-67 and HER2/neu were not reported 
Gene expression analysis on core biopsy 
samples is feasible; 
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Evidence Table 3. Analytic validity, Oncotype DX (continued) 
 
Study, year Measure Conclusions 
Oratz, in 
press56 
Context: This study used the Oncotype DX assay analyzing FFPE specimens. Out of the 74 
eligible samples the analysis was carried on 72 samples 
 
Methods: 
●   Standard Oncotype DX assay protocols were developed 
 
Results: 
●   72 patients out of 74 successfully analyzed, for the following reasons: 
Tumor content < 5%: 2 /74 patients (2.7%) 
Successful assays: 72 /74 (97.3%) 
 
Paik, 2004*28 Context: This study used the Oncotype DX assay analyzing FFPE specimens. FFPE 




●   Standard Oncotype DX assay protocols were used 
●   ER and PR receptors proteins were measured by ligand-binding assays 
●   HER2 DNA was measured by a fluorescence in situ hybridization assay (PathVysion, 
Vysis) 
●   Reproducibility within and between blocks was assessed by performing the 21-gene assay 
in five serial sections from six blocks in two patients 
 
Results: 
●   675 patients out of 754 successfully analyzed, for the following reasons: 
Tumor content < 5%: 79 /754 patients (89.5%)* 
Successful assays: 668 /675 (98.9%) 
●   Reproducibility evaluation: 
16 Cancer genes SD ranged from 0.07 to 0.21 CT units 
Within-block RS SD = 0.72 RS unit (95% CI = 0.55 to 1.04) 
Total within-patient SD (including between and within-block SD) = 2.2 RS units 
Similar variability in the RS was observed in reanalysis of clinical trial samples on 
separate days with different reagent lots (data not shown). 
 






Evidence Table 3. Analytic validity, Oncotype DX (continued) 
 
Study, year Measure Conclusions 
Paik, 2006*53 Context: This study used the Oncotype DX assay analyzing FFPE specimens. Out of the 670 
eligible samples the analysis was carried on 651 samples 
 
Methods: Standard Oncotype DX assay protocols were used. 
 
Results: 
●   A successful assay was obtained for 651 patients out of 670 for which a specimen block 
was available: 
Successful assays: 651/670 (97.2%) 
 
 
FFPE = formalin fixed paraffin embedded; IHC = immunohistochemistry; RT-PCR = real time polymerase chain reaction; ER = estrogen receptor; PR = progesterone receptor; 
HER-2 = human epidermal growth factor receptor 2; CT = cycle threshold; RNA= ribonucleic acid; CI=confidence interval; FISH = Fluorescence In Situ Hybridization; 
LOD=limits of detection; LOQ=limits of quantification; ANOVA= analysis of variance; CLSI= Clinical and Laboratory Standards Institute; SD = standard deviation; RS = 
recurrence score; CV= coefficients of variation; 
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Evidence Table 4. Clinical utility and validity, Oncotype DX™ 
 
Study, year Measure Conclusions 
Chang,2007 
55 
Context: This study used the Oncotype DX assay and assessed its predictive utility 
 
End points: prediction of clinical response (by the RECIST method) to docetaxel treatment in 
women with breast cancer 
 
Methods: 
●  The degree of concordance between IHC and RT-PCR with respect to ER, PR, and HER-2 
was assessed graphically and by the kappa statistic; 
●  Logistic regression was used to evaluate the association between clinical complete response 
with: 
Various clinical variables; 
The expression levels of individual genes; 
The average expression levels for Oncotype DX gene groups; 
The Oncotype DX RS 
●  Statistical significance in logistic regression analyses was determined by the likelihood ratio 
test; 
●  Area under the receiver operating characteristic curve (AUROC) was used to measure the 
accuracy of predictions from the logistic model; 
●  Expression relationships among genes were investigated through hierarchical cluster 
analysis using 1-Pearson r as the distance measure and pair-group average amalgamation 
 
Results: 
●  Clinical CR was associated with lower expression of the ER gene group and higher 
expression of the proliferation gene group from the 21 gene assay; 
●  Clinical CR was more likely in the high RS risk group (P = 0.008); 
●  A 50 units increase in the RS showed an OR = 5 (95% CI = 1.3-6.0); 
●  A14 units increase in the RS showed an OR for a clinical complete response = 1.7 (95% CI = 
1.15, 2.60); 
●  The accuracy with which RS predicted the response to adjuvant chemotherapy throughout 
the range of RS values was moderate (AUROC = 0.73) 
The authors have established molecular 
profiles for sensitivity to docetaxel adjuvant 
chemotherapy. 
 
The RT-PCR technology provides a potential 
platform for a predictive test of chemosensitivity 




Evidence Table 4. Clinical utility and validity, Oncotype DX (continued) 
 
Study, year Measure Conclusions 
Cobleigh, 
200547 
Context: This is one of the development studies of the Oncotype DX assay; 
 
End points: the likelihood of distant recurrence free survival in lymph nodes positive (> 10 
nodes), ER positive and negative breast cancer patients 
 
Methods: Univariate and multivariate Cox proportional hazards models with stepwise 
variable selection and bootstrap resampling 
 
Results: 
Recurrence score classification: 
Low -risk group (RS < 18): 
11 /78 patients (14%), rate of distant recurrence at 10 years of 29% (95% confidence 
interval, 0-53%) 
Intermediate-risk group (RS >18 and RS < 31):  
19/78 patients (24%), rate of distant recurrence at 10 years of 72% (95% confidence 
interval, 38-88%) 
High-risk group (RS > 31):  
48/78 patients (62%), rate of distant recurrence at 10 years of 80% (95% confidence 
interval, 63-89%). 
This study found that tumor gene expression was 
correlated with the likelihood of distant 
recurrence in patients who have invasive breast 
cancer and more than 10 positive nodes. 
 
Tumor gene expression quantified by RT-PCR for 
22 /203 genes was significantly correlated with 
distant relapse free survival (DRFS): unadjusted 
P-value < 0.05. 
 
The data generated in this study contributed to 
the development of the 21-gene assay  and 




Context: This study used the Oncotype DX assay and assessed its prognostic utility. 
 
End points (goals): 
●  Assess prognosis inpatients with node-negative breast cancer who did not receive 
systemic therapy using formalin-fixed, paraffin-embedded tissue 
●  Determine whether the quantitative RT-PCR data correlated with immunohistochemistry 
assay data regarding estrogen receptor, progesterone receptor, and HER 2 status. 
 
Methods: The Fleming and Harrington log-rank test and the Cox proportional hazards model, 
with the covariates age and tumor size, were used to test differences in distant recurrence 
among the distinct RS groups 
 
Results: 
●  No significant correlation was found between age, tumor size, or RS and distant 
recurrence-free survival 
●  No significant difference was found between the low-, intermediate-, and high risk groups 
in terms of 10-year distant recurrence free survival 
The lack of validation of the assay observed in 
this study could be due to the following 
differences between the considered population 
and the NSABP B-14 population used in Paik et 
al 2004: 
ER-positive and ER-negative patients were 
used; 
ER-positive patients were not treated with 
tamoxifen; 
An association between high nuclear grade 
and improved outcome was observed; 
Patients were from a single institution and the 




Evidence Table 4. Clinical utility and validity, Oncotype DX (continued) 
 
Study, year Measure Conclusions 
Fan, 200679 Context: The study is a comparison of classification agreement among 5 different gene 
expression based predictors (70-genes, Oncotype DX, Wound-response, Intrinsic subtypes 
and two-gene ratio) using the 295 samples from the consecutive cohort originally used by van 
de Vijver, 2002,25 
 
Methods: 
●  Cramer V statistics 
●  Kaplan-Meier survival analysis 
●  Multivariate Cox proportional hazards analysis, adjusting for age, tumor size, tumor grade, 
ER status, number of lymph node involved 
●  All analyses were performed using all the patients, as well as the ER positive patients 
subset (N=225) 
●  NB: coefficients of clinical predictors were allowed to vary between models 
 
Results: 
●  In multivariate Cox proportional hazards analysis all tests except the two-gene ratio were 
highly significant predictors of OS and DFS: 
70 genes DFS HR = 3.4 (95%CI = 2.0-6.0), P value < 0.001 
Two-gene ratio DFS HR = 0.91 (95%CI = 0.6-1.3), P value = 0.62 
Oncotype OS HR = 4.3 (95%CI = 2.1-8.9), P value < 0.001 
70 genes OS HR = 4.71 (95%CI = 2.02-11.0), P value < 0.001 
Two-gene ratio OS HR = 1.00 (95%CI = 0.61-1.63), P value = 0.99 
Oncotype DFS HR = 6.14 (95%CI = 1.84-20.4), P value = 0.003 
●  ER status, tumor grade, tumor size, and lymph nodes were also significant predictors. 
●  Patients classification into dichotomized risks groups proved to be roughly similar, ranging 
from ~80% to ~40%: 
70-genes and RS yielded a V= 0.60 
70-genes and RS yielded an agreement of ~81% (239/295) 
Good but not perfect correlation between 
predictions, albeit surprising with different 
gene sets. Degree of prediction over and 
above “standard” clinical stratifiers is not clear 
– reclassification not done. 
Gianni, 
200549  
Context: This study used the Oncotype DX assay and assessed its predictive utility 
 
End points (goal): to directly examine the correlation between RS and pCR, and to identify 
additional genes associated with pCR 
 
Methods:  
●  Univariate analysis by logistic and probit regression was used to evaluate the association of 
gene expression and pCR 
●  Forward stepwise regression and bootstrap resampling were performed to assess 
robustness 
 
Results: The global likelihood ratio test assessing probit regression based models with and 
without the incorporation of the RS resulted in a P value of 0.005, showing a good 
discrimination of pCR by RS; 
The authors identified a set of genes, which 
expression correlated with pCR to neoadjuvant 
doxorubicin and paclitaxel. 
 
The authors showed that the RS was strongly 
correlated with pCR. 
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Evidence Table 4. Clinical utility and validity, Oncotype DX (continued) 
 
Study, year Measure Conclusions 
Habel, 200650 Context: This study used the Oncotype DX assay to assess its prognostic utility. 
 
End points: The risk of breast cancer-specific mortality among women with ER-positive, 




●  Conditional logistic regression analysis was performed, adjusting for tumor size and grade 
●  Relative risks for RS, used as a continuous variable, was calculated for increments of 50 
units 
●  Standard low (RS<18), intermediate (RS=19-31), and high (RS>31) risk groups were used 
●  Alternative RS risk stratification was obtained by RS quartiles 
●  RS was also used as a continuous variable in the models, assessing the association with 
the 10-years risk of death using increments of 50 RS units 
 
Results: 
●  Multivariate analysis with continuous RS, tumor size and grade 
Tamoxifen treated (55 cases and 150 controls): RR = 5.3 (95% CI = 1.6–17.2), P value = 
0.003 
Tamoxifen untreated (110 cases and 251 controls): RR = 2.4 (95% CI = 1.1–5.2), P value = 
0.025 
●  Overall the patients reclassification analysis according to RS, in combination with tumor 
size and grade, showed that RS is able to further stratify patients’ risk beyond size and 
grade (see below) 
10 yr risk of death with 95% CI in the Low risk group (RS <18): 
ER+, tamoxifen treated 2.8%, 95%CI (1.7-3.9) 
ER+, tamoxifen untreated 6.2%, 95%CI (4.5-7.9) 
10 yr risk of death with 95% CI in the Intermediate risk (RS 18-30): 
ER+, tamoxifen treated 10.7%, 95%CI (6.3-14.9) 
ER+, tamoxifen untreated 17.8%, 95%CI (11.8-23.3) 
ER+, tamoxifen treated: RR (Intermediate vs low) = 4.0 (1.8-8.8) 
ER+, tamoxifen untreated: RR (Intermediate vs low) = 2.7 (1.5-5.0) 
10 yr risk of death with 95% CI in the High risk (RS ≥31): 
ER+, tamoxifen treated 15.5%, 95%CI (7.6-22.8) 
ER+, tamoxifen untreated 19.9%, 95%CI (14.2-25.2) 
ER+, tamoxifen treated: RR (high vs low) = 6.2 (2.4-15.8) 
ER+, tamoxifen untreated: RR (high vs low) = 3.3 (1.8-5.9) 
The RS was strongly associated with risk of 
breast 
cancer death among : 
ER-positive patients treated with tamoxifen  




Such associations remained after accounting for 
tumor size and grade. 
 
The RS was able to identify a larger subset of 
patients with low risk of breast cancer death 
than it was possible with either of these 
standard prognostic indicators. 
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Evidence Table 4. Clinical utility and validity, Oncotype DX (continued) 
 








See evidence table 5 
Mina, 
200651 
Context: This study used the Oncotype DX assay to assess its predictive utility; 
 
End points: complete pathological response (pCR) to primary chemotherapy 
with anthracycline- and taxanes; 
 
Methods:  
●  Generalized linear models with a logistic link function were used to assess 
the correlation of gene expression measurements with pCR. 
●  Logistic regression was used to examine the correlation RS with pCR. 
●  Logistic regression analysis was also performed to identify genes that 
correlated with inflammatory breast cancer (IBC). 
●  Correlation analyses of gene expression used Pearson linear correlation. 
●  Cluster analysis used 1-Pearson R squared as the distance metric and single 
linkage hierarchical clustering. 
 
Results: 
●  No correlation between Oncotype DX  RS and pCR was demonstrated  (p = 
0.67); 
●  The expression of 22 individual genes, out of 274, proved to be correlate with 




Invasion related genes 
Although 22 genes were identified as being associated with 
pCR, given the large number of candidate genes tested, the 
likelihood of false discovery is high (13 genes were expected by 
chance alone). 
 
The 22 predictive genes contain three major predefined clusters, 
angiogenesis-related genes, proliferation-related genes and 
invasion-related genes. 
 
Though the Oncotype DX RS correlated with pCR in the INT 
Milan cohort of the Gianni et al study, this association was not 
found in the present study. 
 
The authors failed to find a correlation between ER and pCR. 
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Evidence Table 4. Clinical utility and validity, Oncotype DX (continued) 
 
Study, year Measure Conclusions 
Oratz, in 
press56 
Context: Investigation of the impact of the Oncotype DX RS assay results on 
clinicians’ treatment recommendations and on the actual treatment 
administered in patients with ER+, LN–, early (stage I or II) breast cancer; 
 
End points: treatment recommendations prior to the RS knowledge were 
compared with recommendations after the results of the assay were known and 
to the treatment eventually administered; 
 
Methods: 
●  Patients were stratified by: 
Standard RS risk categories; 
Treatment recommendation before knowledge of the RS; 
Treatment recommendation post knowledge of the RS; 
Actual administered treatment; 
●  The odds ratio were computed to:  
Compare the likelihood of a change in the treatment recommendation 
given a low versus a high RS risk group; 
Evaluate the influence of the RS on the treatment actually administered. 
●  Exact inference methods were used for significance testing of the odds ratio; 
 
Results:  
●  The knowledge of the RS changed the clinicians’ treatment 
recommendations in for 14 patients (20%): 
The odds of the physician treatment recommendation changing from 
hormonal therapy (HT) to chemotherapy (CT) were significantly higher (P 
= 0.0011) if the RS was high (odds 4:0) versus low (odds 1:18); 
The odds of the physician treatment recommendation changing from CT to 
HT were significantly higher (P = 0.0340) if the RS was low (odds 6:7) 
versus high (odds 0:10); 
●  The knowledge of the RS changed the actual administered treatment in 17 
patients (25%): 
The odds of CT treatment, given an initial physician treatment 
recommendation for HT, were significantly higher (P = 0.0474) if the RS 
was high (odds 2:2) versus low (odds 0:19); 
The odds of HT treatment, given an initial physician treatment 
recommendation for CT, were 20.3 times higher (P = 0.0130) if the RS 
was low (odds 9:4) versus high (odds 1:9); 
The knowledge of the RS changed treatment recommendations 
and administration in patients with ER+, LN–, early breast 
cancer. 
 
An important finding is that the direction of the change was 




Evidence Table 4. Clinical utility and validity, Oncotype DX (continued) 
 
Study, year Measure Conclusions 
Paik, 2004*28 Context: This study used the Oncotype DX assay and assessed its prognostic 
utility. 
 
End points: the likelihood of distant recurrence and the Overall Survival in 
lymph nodes negative, ER positive breast cancer patients was considered 
 
Methods: 
●  Comparison of the high and low risk groups by Kaplan–Meier analysis with 
Greenwood variance estimates 
●  Cox proportional-hazards models accounting for: 
Age (less than 50 years), clinical tumor size (less than 2cm), and RS (as 
continuous variable, hazard ratio for bins of 50 units); 
PR (as ordinal variable), ER (as ordinal variable), HER (as binary 
variable), age, clinical tumor size, tumor grade (1 pathologist), and RS; 
 
Results: 




High =30.5-95%CI=23.6–37.4) , 27%; 
P<0.001 for the comparison high versus  low-risk category; 
●  Overall survival, number of patients with death event over the total number 
of patients at risk: 
Low=70/338; 
Intermediate=48/149; 
 High =71/181; 
●  Age, size and RS: 
p-Value=0.001, Hazard Ratio =3.21 (95%CI=(2.23–4.61) ;  
●  PR, ER, HER, age, size, grade, and RS: 
p-Value=0.001, Hazard Ratio =2.81 (95%CI=(1.70–4.64); 
Similar results with more than two categories of age and tumor size  (data 
not shown); 
The assay  prognostic  capability to quantify the likelihood of 
distant recurrence has been validated  in tamoxifen-treated, 
lymph  node-negative, ER-positive breast cancer. 
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Evidence Table 4. Clinical utility and validity, Oncotype DX (continued) 
 
Study, year Measure Conclusions 
Paik, 2006*53 Context: This study used the Oncotype DX assay and validated the assay by 
assessing its predictive utility (prediction of chemotherapy benefit magnitude 
by RS). 
 
End points: freedom from distant recurrence in women with ER-positive, 
node-negative breast cancer from NSABP B20. 
 
Methods:  
●  Kaplan-Meier analysis with disease recurrence free survival (DRFS). 
●  Multivariate Cox proportional hazards models to evaluate the interaction 
between chemotherapy treatment and RS as a continuous variable. 
●  Models included RS, individual and grouped gene expression variables, 
patients’ age, tumor size and grade, ER status, PR status. 
●  RS was used as a continuous variable, age size, grade, ER and PR were 
dichotomized 




●  Kaplan-Meier Estimates of 10 Years DRFS for Tamoxifen-Treated Patients 
and Tamoxifen Plus Chemotherapy-Treated Patients (10-Year DRFS (%), 
95% CI, number of patients): 
All patients : 
Tamoxifen alone: 87.8, 83.3% to 92.3%, 227 
Tamoxifen Plus Chemotherapy : 92.2, 89.4% to 94.9% 424 
Low risk (RS<18): 
Tamoxifen alone: 96.8 93.7% to 99.9%, 135 
Tamoxifen Plus Chemotherapy :  95.6 92.7% to 98.6%,218 
Intermediate risk (RS 18-30): 
Tamoxifen alone: 90.9 82.5% to 99.4% 45 
Tamoxifen Plus Chemotherapy :  89.1 82.4% to 95.9% 89 
High risk (RS>31): 
Tamoxifen alone: 60.5 46.2% to 74.8% 47 
Tamoxifen Plus Chemotherapy :  88.1 82.0% to 94.2% 117 
The RS assay predicts the magnitude of chemotherapy benefit in 
women with node-negative, ER–positive breast cancer. 
 
If RS risk groups are considered: 
a minimal benefit from chemotherapy is seen in the low risk 
group,  however with large intervals; 
benefit is not assessable in the Intermediate risk group due 
to the uncertainty in the estimates; 
a large chemotherapy benefit is seen in the high risk group. 
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Study, year Measure Conclusions 
Paik, 2006 
(con’t) 
●  Likelihood Ratio Tests for the Interaction of Chemotherapy Treatment With 
the Clinical Variables and the Gene Expression Variables, Assessable 
NSABP  B20 Patients (n = 651) 
RS HR = 0.32 0, 95%CI = 11 0.94 , P-value = 0.038 
●  Benefit from chemotherapy usage by RS risk groups: 
Low risk (RS<18): RR = 1.31; 95% CI, 0.46 to 3.78, with a mean absolute 
decrease in distant recurrence rate at 10 years of 1.1% (SE, 2.2%) 
Intermediate risk (RS 18-31): RR = 0.61; 95% CI, 0.24 to 1.59, with a mean 
absolute  increase in absolute risk of 1.8% 
High risk (RS>31): RR = 0.26; 95% CI, 0.13 to 0.53, with a mean absolute 
decrease in distant recurrence rate at 10 years of 27.6% (SE, 8.0%) 
●  Similar trends were observed for freedom from locoregional and/or distant 
recurrence and overall survival (Figs A1 and A2, online-only appendix) 
●  Similar results were observed when chemotherapy benefit was analyzed in 
the CMF and MF groups separately (data not shown); 
 
 
RECIST = Response Evaluation Criteria in Solid Tumors; IHC = immunohistochemistry; RT-PCR = real time polymerase chain reaction; ER = estrogen receptor; PR = 
progesterone receptor; HER-2 = human epidermal growth factor receptor 2; AUROC=area under the receiver operating characteristic curve; CR = complete response; RS = 
recurrence score; OR = odds ratio; CI = confidence interval; DRFS = distant recurrence free survival; NSABP = The National Surgical Adjuvant Breast and Bowel Project; OS= 
overall survival; HR= hazard ratio; pCR = pathologic complete response; RR= relative risk; IBC= inflammatory breast cancer; INT= Italian National Cancer Institute of Milan, 
Italy; LN= lymph node; HT = hormonal therapy; CT = chemotherapy; KM= Kaplan Meier; SE = standard error; CMF= cyclophosphamide, methotrexeate, and fluorouracil; MF= 
methotrexeate and fluorouracil. 
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Answers Dimension of 
Quality 
Questions for Critical 





Is there a clear statement of 
the decision problem? 
Yes; Is a 21-Gene RT-PCR 
assay economically and clinically 
useful in assisting in 
classification of ER+, LN- early 
stage breast cancer patients and 
in determination of 
chemotherapy? 
Yes; Is the use of a 21-Gene RT-
PCR assay to assist in the risk 
classification and chemotherapy 
recommendation of early-stage 
breast cancer patients clinically and 
economically beneficial?  
Yes; Is using the Netherlands 
Cancer Institute GEP assay 
versus NIH guidelines cost-
effective for the identification of 
early stage breast cancer 
patients who would benefit from 
adjuvant chemotherapy? 
  Is the objective of the 
evaluation and of the model 
specified and consistent 
with the stated decision 
problem? 
Yes; to estimate the incremental 
benefits, costs, and cost-
effectiveness of using a 
recurrence score based on the 
21-Gene RT-PCR assay that 
would assign risk more 
accurately and help guide the 
decision to prescribe 
chemotherapy 
Yes; to incorporate and extend 
validation results from previous 
studies of NSABP B-14 and B-20 
into an economic model of the 21-
gene expression signature to guide 
the use of adjuvant chemotherapy 
and hormonal therapy in patients 
with ER+, LN- early stage breast 
cancer 
Yes; to assess the incremental 
coast and QALYs associated 
with use of the GEP assay 
compared to use of the NIH 
guidelines. 
  Is the primary decision-
maker specified? 
Yes; physician Yes; physician Yes; physician 
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Answers Dimension of 
Quality 
Questions for Critical 





Is the perspective for the 
model stated clearly? 
Yes; Authors state that the model 
takes a “societal perspective 
considering survival, quality of 
life, and relevant costs.”  
No.  Yes; Authors state that the model 
takes a “societal perspective for 
this analysis and follows the 
recommendations of the Panel 
on Cost-Effectiveness in Health 
and Medicine.” 
  Are the model inputs 
consistent with the stated 
perspective? 
Not entirely; the model does not 
include all costs that are relevant 
to a societal perspective, and 
specifically does not include 
direct non-medical costs (other 
than patient time) and indirect 
costs. 
Not applicable since perspective is 
not stated.  
Yes; the model includes costs 
that are relevant to a societal 
perspective, including direct 
medical costs and non-medical 
costs (e.g., lost wages from time 
spent traveling to treatment 
facilities and in treatment). 
  Has the scope of the model 
been stated and justified? 
Partly; Authors state the model 
includes survival, quality of life, 
and relevant costs, and forecasts 
outcomes over the patient’s 
lifetime. Authors do not justify 
exclusion of some types of 
societal costs, and do not justify 
using a timeframe beyond the 
10-year period for which 
recurrence data is available.  
Partly; Authors indicate that the 
model includes clinical, economic, 
and quality of life outcomes, and 
projects the impact on life 
expectancy. Authors do not justify 
exclusion of some types of costs, 
and do not justify using a timeframe 
beyond the 10-year period for 
which recurrence data was 
available. 
Yes; Authors state the model 
includes survival, quality of life, 
and relevant costs, and forecasts 
outcomes over the patient’s 
lifetime. However, the model is 
based on a 6.7-year period for 
which recurrence data is 
available yet is projected over 
the patients’ lifetime.  
  Are the outcomes of the 
model consistent with the 
perspective, scope, and 
overall objective of the 
model? 
Yes; Outcomes include survival 
in life-years, QALYs, and overall 
costs for breast cancer.  
Yes; Outcomes include life-years 
saved, QALYs, and costs of cancer 
care. 
Yes; Outcomes include expected 
proportion of distant recurrences 
prevented, QALYs, and overall 
costs for breast cancer.  
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Answers Dimension of 
Quality 
Questions for Critical 




Is the structure of the model 
consistent with a coherent 
theory of the health 
condition under evaluation? 
Yes; The authors use a Markov 
model with transition states for: 
no recurrence; recurrence 
without metastatic progression; 
recurrence with metastatic 
progression; and death.  
Uncertain; The authors do not 
provide sufficient information about 
the structure of the model. The 
model seems to be based on 
comparing outcomes for 3 adjuvant 
treatment strategies. Patients are 
classified based on RS score and 
then a treatment strategy is 
applied: Strategy 1 (all patients 
receive tamoxifen), Strategy 2 (all 
patients receive chemotherapy and 
tamoxifen), Strategy 3 (if RS 
classification = low risk, then only 
tamoxifen; if RS classification = 
intermediate or high risk, then 
chemotherapy and tamoxifen). 
Yes; The authors use a Markov 
model with transition states for: 
no evidence of disease; distant 
recurrence; and death.  
  Are the sources of data 
used to develop the 
structure of the model 
specified? 
Yes Uncertain because the structure of 
the model is not specified  
Yes 
  Are the causal relationships 
described by the model 
structure justified 
appropriately? 
Yes; Authors use clinical data to 
determine recurrence rates and 
assume that all high risk patients 
will receive chemotherapy and all 
low risk patients will not receive 
chemotherapy. 
Uncertain because the structure of 
the model is not specified 
Yes; Authors use clinical data to 
determine recurrence rates and 
assume that all women classified 
as “poor prognosis” will receive 
chemotherapy and all women 
classified as “good prognosis” 
will not receive chemotherapy. 
Structural 
Assumptions 
Are the structural 
assumptions transparent 
and justified? 
Yes No Yes 
  Are the structural 
assumptions reasonable 
given the overall objective, 
perspective, and scope of 
the model? 
Yes Uncertain Yes 
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Answers Dimension of 
Quality 
Questions for Critical 




Is there a clear definition of 
the options under 
evaluation? 
Yes; NCCN system as current 
standard versus the RT-PCR 
assay 
Yes; clear description of treatment 
strategies as noted above 
Yes; NIH clinical guidelines as 
the standard versus the 
Netherlands Cancer Institute 
GEP  assay. 
  Have all feasible and 
practical options been 
evaluated? 
No; This analysis focuses only 
on comparing use of one test, 
the RT-PCR assay, to use of the 
NCCN guidelines. 
No: This analysis focuses only on 
comparing outcomes of treatment 
guided by one test, the 21-gene 
expression signature, to outcomes 
associated with using tamoxifen 
alone or chemotherapy followed by 
tamoxifen.  
No; This analysis focuses only 
on comparing use of one test, 
the Netherlands Cancer Institute 
GEP assay, to use of the NIH 
guidelines. A stated limitation by 
the authors is that other 
guidelines (e.g., NCCN) are 
available but were not used in 
this comparison.  
  Is there justification for the 
exclusion of feasible 
options? 
No No Partly; the authors state that the 
NCCN criteria are more 
conservative; they would have 
yielded higher cost and would 
have had higher sensitivity than 
the NIH guidelines. They suggest 
that using NCCN criteria would 
be unlikely to change the 
outcome of the model. 
Model type Is the chosen model type 
appropriate given the 
decision problem and 
specified causal 
relationships within the 
model? 
Yes Uncertain Yes 
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Answers Dimension of 
Quality 
Questions for Critical 
Appraisal Hornberger, 2005 Lyman, 2007 Oestreicher, 2005 
Structure (continued) 
 Time horizon Is the time horizon of the 
model sufficient to reflect all 
important differences 
between options? 
Yes Yes Yes 
  Are the time horizon of the 
model, the duration of the 
treatment, and the duration 
of the treatment effect 
described and justified? 
Yes; The model forecasts 
outcomes over the patient’s 
lifetime and assumes treatment 
time of 6 months, but does not 
explicitly state any assumption 
regarding the duration of the 
treatment effect. 
Yes; The model estimates the 
impact on life expectancy and 
presents the assumed duration of 
treatment options, the longest of 
which was 24 weeks. 
Yes; The model forecasts 
outcomes over the patient’s 
lifetime and assumes initial 
treatment time of 6 months, but 
does not explicitly state any 
assumption regarding the 
duration of the treatment effect. 
Disease states/ 
pathways 
Do the disease states (state 
transition model) or the 
pathways (decision tree 
model) reflect the underlying 
biological process of the 
disease in question and the 
impact of interventions? 
Yes Uncertain Yes 
Cycle length Is the cycle length defined 
and justified in terms of the 
natural history of disease? 
Yes; Cycle length is defined as 1 
year. 
No; Cycle length is not specified. Yes; Cycle length is defined as 1 
year. 
I-35 
Evidence Table 5. Critical appraisal of economic analyses of breast cancer gene expression testing (continued) 
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Questions for Critical 




Are the data identification 
methods transparent and 
appropriate given the 
objectives of the model? 
Yes; The studies and cases used 
in the model are clearly 
referenced. 
Yes; The authors cite previous 
work for some of the details.  
Yes; The studies and 
assumptions used in the model 
are clearly referenced. 
  Where choices have been 
made between data 
sources, are these justified 
appropriately? 
Yes; Only NSABP B-14 data are 
used. This is justified by the 
limited amount of comparable 
sources of data with adequate 
followup.  
Yes; The authors explain their use 
of data from NSABP B-20 and 
NSABP B-14. 
Yes; The Netherlands Cancer 
Institute cohort data are used. 
  Has particular attention 
been paid to identifying data 
for the important parameters 
in the model? 
Yes; Authors focus on: 1) 
propensity to change 
chemotherapy decision based on 
recurrence score, 2) relative risk 
reduction of chemotherapy and 
tamoxifen versus tamoxifen only, 
3) cost of chemotherapy, and 4) 
proportion of patients defined by 
NCCN as low risk. 
Uncertain given the lack of 
information about the structure of 
the model 
Yes; Authors focus on propensity 
to make chemotherapy decision 
based on the classification of low 
risk versus high-risk, relative risk 
reduction of chemotherapy, cost 
of chemotherapy, and proportion 
of patients defined by NIH criteria 
as low risk. 
  Has the quality of the data 
been assessed 
appropriately? 
Not reported Not reported Not reported 
  Where expert opinion has 
been used, are the methods 
described and justified? 
Not applicable Not applicable Not applicable 
Data modeling Is the data modeling 
methodology based on 
justifiable statistical and 
epidemiological techniques? 
Yes Uncertain given the lack of 




Evidence Table 5. Critical appraisal of economic analyses of breast cancer gene expression testing (continued) 
 
Answers Dimension of 
Quality 
Questions for Critical 
Appraisal Hornberger, 2005 Lyman, 2007 Oestreicher, 2005 
Data (continued) 
Baseline Data Is the choice of baseline 
data described and 
justified? 
Yes; Percent chance of 
recurrence and treatment plans 
are cited and described. 
Yes; Table 1 describes most of the 
baseline data. Other values are 
described throughout the paper 
Yes; Probabilities of recurrence 
and treatment plans are 
described and justified. 
  Are transition probabilities 
calculated appropriately? 
Yes; Probabilities appear to be 
obtained from prior meta-
analyses. 
Uncertain, given the lack of 
information about the structure of 
the model. However, probabilities 
are taken from previous analysis of 
the 21-Gene RT-PCR assay 
Yes; Probabilities were estimated 
from empirical analyses 
performed on patient level data 
from the Netherlands Cancer 
Institute cohort, which was also 
the population for a validation 
study of GEP. 
  Has a half-cycle correction 
been applied to both cost 
and outcome? 
Not reported Not reported Not reported 
  If not, has this omission 
been justified? 
No No No 
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Answers Dimension of 
Quality 
Questions for Critical 




If relative treatment effects 
have been derived from trial 
data, have they been 
synthesized using 
appropriate techniques? 
Yes; The authors use meta-
analyses of clinical trials to 
estimate the relative risk 
reduction associated with 
chemotherapy plus tamoxifen 
versus tamoxifen alone.  
Uncertain; Table 1 suggests that a 
single study is used as the source 
of estimates for relative effects of 
tamoxifen, chemotherapy plus 
tamoxifen, and RS-guided therapy.  
Yes; The authors use the meta-
analysis from the Early Breast 
Cancer Trialists’ Group trial to 
estimate the relative risk 
reduction associated with 
chemotherapy.  
  Have the methods and 
assumptions used to 
extrapolate short-term 
results to final outcomes 
been documented and 
justified? 
Partly; The authors assume a 
constant recurrence rate over 10 
years, but do not justify 
extrapolation beyond 10 years.  
Not reported Partly; The authors assume a 
constant recurrence rate over 6.7 
years, but do not justify 
extrapolation beyond 6.7 years.  
  Have alternative 
assumptions been explored 
through sensitivity analysis? 
Yes, using sensitivity analysis 
and Monte Carlo simulation 
Uncertain; Ranges for costs, 
healthy life expectancy, and utility 
with chemotherapy are given in 
Table 1. Although the authors do 
not state whether a sensitivity 
analysis was performed for these 
assumptions in particular, they 
indicate that a Monte Carlo 
analysis was performed. 
Yes, a wide variety of 
assumptions has been explored 
using sensitivity analysis and 
Monte Carlo simulation 
  Have assumptions 
regarding the continuing 
effect of treatment once 
treatment is complete been 
documented and justified? 
Have alternative 
assumptions been explored 
through sensitivity analysis? 
Yes Yes; The introduction also 
mentions ongoing investigations 
into the long-term effects of 
chemotherapy, particularly 
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Answers Dimension of 
Quality 
Questions for Critical 
Appraisal Hornberger, 2005 Lyman, 2007 Oestreicher, 2005 
Data (continued) 
Quality of life 
weights (utilities) 
Are the utilities incorporated 
into the model appropriate? 
Yes; Table 3 lists several health-
state utilities that are appropriate 
to include in the analysis. One 
limitation is that the sensitivity 
analysis considered only a 
relatively narrow range of 
estimates for each utility value. 
Uncertain: The only health-state 
utility mentioned in this report is for 
“utility with chemotherapy.” No 
mention is made of any other 
relevant health-state utilities. 
Yes; Table 1 listed several 
utilities that are appropriate to 
include in the analysis. These 
included: utilities for no adjuvant 
chemotherapy; adjuvant 
chemotherapy; no evidence of 
disease and distant recurrence 
 Are the methods of 
derivation for the utilities 
justified? 
Uncertain; The authors cite 
several references from peer-
reviewed journals as the sources 
for the utility estimates, but they 
do not discuss any of the 
potential limitations of how those 
utilities were originally derived.   
Partly: The authors report that they 
used a time trade-off method to 
estimate the impact of treatment 
strategies on health-related quality 
of life, but they provide no details 
about how the estimates were 
derived.  
Unclear; The authors discuss 
their derivation of utilities and cite 
several references from peer-
reviewed journals as the sources 
for the utility estimates. But they 
gave no explanation of the 
methods or scaling techniques 
that were used to derive the 
utility estimates. The utility 
values generally seemed very 
low when compared to the 
values typically assigned to 
serious health conditions. 
Costs Are the costs incorporated 
into the model justified? 
Yes, but see the comment above 
regarding exclusion of some 
types of societal costs 
Yes, but they provide no details 
about how the estimates were 
derived. 
Yes, although it is unclear 
whether all relevant societal 
costs have been included. 
  Has the source for all costs 
been described? 
Yes Yes; Most costs have been cited in 
Table 1. A reference is given for 
additional details. 
Yes 
  Have discount rates been 
described and justified given 
the target decision-maker? 
Yes; The investigators discount 
both costs and survival by an 
annual rate of 3%.  
Not reported Yes; The investigators 
discounted costs and QALYs by 
an annual rate of 3%.  
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Questions for Critical 




Have all data incorporated 
into the model been 
described and referenced in 
sufficient detail? 
Yes; Data inputs have been 
referenced and most have been 
described in sufficient detail. 
No; The individual costs and 
recurrence probabilities have been 
justified and referenced. However, 
not all data inputs have been 
described. 
Yes; Data inputs have been 
referenced and have been 
described in sufficient detail. 
  Has the use of mutually 
inconsistent data been 
justified (i.e., are 
assumptions and choices 
appropriate?) 
Not applicable Not applicable Not applicable 
  Is the process of data 
incorporation transparent? 
Yes; The incorporation of most 
costs into the model are 
described. However, calculation 
of the "follow-up" number is not 
described, although it seems to 
be incorporating treatment side-
effects, monitoring for side-
effects and end-of-life costs. 
No; Not enough information is 
given to understand how the 
authors derived the estimates of 
"Costs" and "LYS" in Table 2 and 
"Expected Costs" from Figure 2. 
Yes; The incorporation of costs 
into the model is described.  
  If data have been 
incorporated as a 
distribution, has the choice 
of distribution for each 
parameter been described 
and justified? 
Generally, point estimates are 
used, not distributions. As part of 
the sensitivity analysis, the 
investigators used a Monte Carlo 
probabilistic analysis, and 
referred to a technical appendix 
for the details.  
Yes; The authors use a figure to 
show the distribution of distant 
recurrence estimates by RS.  
Yes. The investigators conducted 
one-way sensitivity analysis 
varying the values of 
probabilities, costs and utilities 
on model results. As part of the 
sensitivity analysis, the 
investigators used a Monte Carlo 
probabilistic analysis. 
  If data have been 
incorporated as 
distributions, is it clear that 
second order uncertainty is 
reflected? 
Not reported Not reported Yes. 
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Answers Dimension of 
Quality 
Questions for Critical 
Appraisal Hornberger, 2005 Lyman, 2007 Oestreicher, 2005 
Data (continued) 




addressed by running 
alternative versions of the 
model with different 
methodological 
assumptions? 
Not reported Not reported Yes. A number of alternative 
testing hypotheses and 
alternative testing strategies 
were considered in the model. 
 Is there evidence that 
structural uncertainties have 
been addressed via 
sensitivity analysis? 
Not reported Not reported Not reported. 
 Has heterogeneity been 
dealt with by running the 
model separately for 
different subgroups? 
Yes; The model considers NCCN 
low risk and NCCN high risk 
groups, and is applied to a cohort 
of 100 patients similar to those in 
the B-14 trial. 
Yes; The model considers the B-14 
and B-20 studies/ 
Yes; The model considers low 
risk and high risk groups, and is 
applied to a hypothetical cohort 
of patients similar to those in the 
Netherlands Cancer Institute 
cohort. Additional prognostic 
groups using different 
combinations of GEP and NIH 
results were also considered.  
 Are the methods of 
assessment of parameter 
uncertainty appropriate? 
Yes Yes Yes 
  If data are incorporated as 
point estimates, are the 
ranges used for sensitivity 
analysis stated clearly and 
justified? 
Yes; The ranges are stated in 
Table 3, but are not fully justified. 
Yes; The ranges for most data 
points are clearly stated in Table 1. 
Yes; The ranges are stated in 
Table 1, but are not fully justified. 
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Is there evidence that the 
mathematical logic of the 
model has been tested 
thoroughly before use? 
Not reported Not reported Yes; the analysis was performed 
using a Microsoft Excel 
spreadsheet and then validated 
using decision analysis software. 
External 
consistency 
Are any counterintuitive 
results from the model 
explained and justified? 
Not applicable Not applicable Not applicable 
  If the model has been 
calibrated against 
independent data, have any 
differences been explained 
and justified? 
Not reported Not reported Not reported 
  Have the results of the 
model been compared with 
those of previous models 
and any differences in 
results explained? 
Not reported Not reported Not reported 
 
RT-PCR= reverse transcriptase polymerase chain reaction; ER=estrogen receptor; LN= lymph node; NSABP= National Surgical Adjuvant Breast and Bowel Project; GEP= gene 
expression programming; NIH= National Institute of Health; QALY= quality-adjusted life-year; RS= recurrence score; NCCN= National Comprehensive Cancer Network; LYS= 
life years saved. 
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* Supplemental information 
 
NR = not reported; NA = not applicable 
 
I-43 
Evidence Table 7. Study population characteristics, MammaPrint® 
 
Study, Year Intervention General Characteristics Diagnosis (es) [include details] Treatments and Outcomes 
Ach, 2007 57 There are not patient characteristics reported in this article. This is a study of analytic validity 
Clinical low 
risk/gene low risk§ 
n=52 
Age, n (%) 
< 41, 8 (15) 
41-50, 36 (69) 
51-60, 8 (15) 
Menopausal status: NR 
Race: NR 
Exclusion criteria:  
● >61yearsOld 
● >T1-T2(>5cm) 
● previous malignancy 
(except basal cell carcinoma) 
● bilateral synchronous 
breast 
TS <1 cm, 5 (9) 
TS 1-2 cm, 30 (58) 
TS 2-5 cm, 17 (33) 
TG good diff, 22 (43) 
TG Int diff, 29 (56) 
TG poor diff, 0  (0) 
TG UK, 1 (2) 
ER+, 52 (100) 
ER-, 0 (0) 
 
Diagnostic method: clinical and 
microarray 
Treatment: NR 
Outcome: Proportion alive at 10y (95% 
CI), 0.88 (0.74 to 0.95) 
Clinical low 
risk/gene high risk 
n=28 
Age, n (%) 
< 41, 1 (4) 
41-50, 22 (78) 
51-60, 5 (18) 
Menopausal status: NR 
Race: NR 
Exclusion criteria: see clinical 
low risk/gene low risk 
TS <1 cm, 4 (14) 
TS 1-2 cm, 12 (43) 
TS 2-5 cm, 12 (43) 
TG good diff, 12 (43) 
TG Int diff,16 (57) 
TG poor diff, 0  (0) 
TG UK, 0 (0) 
ER+, 28 (100) 
ER-, 0 (0) 
 
Diagnostic method: clinical and 
microarray 
Treatment: NR 
Outcome: Proportion alive at 10y (95% 




risk/gene low risk§ 
n=59 
Age, n (%) 
< 41, 9 (15) 
41-50, 20 (34) 
51-60, 30 (51) 
Menopausal status: NR 
Race: NR 
Exclusion criteria: see clinical 
low risk/gene low risk 
TS <1 cm, 0 (0) 
TS 1-2 cm, 17 (29) 
TS 2-5 cm, 42 (71) 
TG good diff, 7 (12) 
TG Int diff, 41 (69) 
TG poor diff, 11 (18) 
TG UK, 0 (0) 
ER+, 54 (91) 
ER-, 5 (9) 
 
Diagnostic method: clinical and 
microarray 
Treatment: NR 
Outcome: Proportion alive at 10y (95% 
CI), 0.89 (0.45 to 0.95) 
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risk/gene high risk§ 
n=163 
Age, n (%) 
< 41, 40 (24) 
41-50, 67 (41) 
51-60, 56 (34) 
Menopausal status: NR 
Race: NR 
Exclusion criteria: see clinical 
low risk/gene low risk 
TS <1 cm, 2 (1) 
TS 1-2 cm, 40 (24) 
TS 2-5 cm, 121 (74) 
TG good diff, 6 (3) 
TG Int diff, 39 (23) 
TG poor diff, 113 (69) 
TG UK, 5 (3) 
ER+, 78 (48) 
ER-, 85 (52) 
 
Diagnostic method: clinical and 
microarray 
Treatment: NR 
Outcome: Proportion alive at 10y (95% 
CI), 0.69 (0.61 to 0.76) 
Fan, 200679§ Poor prognosis Age, n (%) 
<40yrs 52 (29) 
40-44yrs, 41 (23) 
45-49yrs, 55 (31) 
≥50yrs; 32 (18) 
Menopausal status: NR 
Race: NR 
Exclusion criteria:  
● Previous history of cancer 
(except non-melanoma skin 
cancer) 
● Apical axillary lymph node 
involvement 
● Age at diagnosis >52 
years 
● Tumor >5 cm in diameter 
at pathological examination 
H I (good); 19/180 (11%) 
H II (intermediate); 56/180 (31%) 
H III (poor); 105/180 (58%) 
TS ≤20mm; 84/180 (47%) 
TS >20mm; 96/180 (53%) 
LN# 0; 91/180 (51%) 
LN#1-3; 63/180 (35%) 
LN# ≥4; 26/180 (14%) 
ER -; 66/180 (37%) 
ER +; 114/180 (63%) 
VI Absent; 108/180 (60%) 
VI 1-3 vessels; 18/180 (10%) 
VI >3 vessels; 54/180 (30%) 
 
Diagnostic method: RT-PCR 
Treatment: 
h Yes; 23/180 (13%) 
h No; 157/180 (87%) 
a Yes; 66/180 (37%) 
a No; 114/180 (63%) 
s Breast conserving; 97/180 (54%) 
s mastectomy; 83/180 (46%) 
Outcome: NR 
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Study, Year Intervention General Characteristics Diagnosis (es) [include details] Treatments and Outcomes 
Fan, 2006 
(cont’) 
Good prognosis Age, n (%) 
<40yrs, 11 (10) 
40-44yrs, 44 (38) 
45-49yrs, 43 (37) 
≥50yrs, 17 (15) 
Menopausal status: NR 
Race: NR 
Exclusion criteria: see poor 
prognosis 
H I (good); 56/115 (49%) 
H II (intermediate); 45/115 (39%) 
H III (poor); 14/115 (12%) 
TS ≤20mm; 71/115 (62%) 
TS >20mm; 44/115 (38%) 
LN# 0; 60/115 (52%) 
LN# 1-3; 43/115 (37%) 
LN# ≥4; 12/115 (10%) 
ER-; 3/115 (3%) 
ER +; 112/115 (97%) 
VI Absent; 77/115 (67%) 
VI 1-3 vessels; 12/115 (10%) 
VI >3 vessels; 26/115 (23%) 
 
Diagnostic method: RT-PCR 
Treatment: 
h: Yes; 17/115 (15%) 
h: No; 88/115 (85%) 
a: Yes; 44/115 (38%) 
a: No; 71/115 (62%) 
s: Breast conserving; 64/115 (56%) 








Poor prognosis Age, n (%) 
<40yrs; 52 (29) 
40-44yrs; 41 (23) 
45-49yrs; 55 (31) 
≥50yrs; 32 (18) 
Menopausal status: NR 
Race: NR 
Exclusion criteria: 
● Previous history of cancer 
(except non-melanoma skin 
cancer) 
● Apical axillary lymph node 
involvement 
● Age at diagnosis >52 years
● Tumor >5 cm in diameter at 
pathological examination 
H I (good); 19/180 (11%) 
H II (intermediate); 56/180 (31%) 
H III (poor); 105/180 (58%) 
TS ≤20mm; 84/180 (47%) 
TS >20mm; 96/180 (53%) 
LN# 0; 91/180 (51%) 
LN#1-3; 63/180 (35%) 
LN# ≥4; 26/180 (14%) 
ER -; 66/180 (37%) 
ER +; 114/180 (63%) 
VI Absent; 108/180 (60%) 
VI 1-3 vessels; 18/180 (10%) 
VI >3 vessels; 54/180 (30%) 
Treatment: 
h: Yes; 23/180 (13%) 
h: No; 157/180 (87%) 
a: Yes; 66/180 (37%) 
a: No; 114/180 (63%) 
s: Breast conserving; 97/180 (54%) 
s: mastectomy; 83/180 (46%) 
Outcome: NR 
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Good prognosis Age, n (%)  
<40yrs; 11 (10) 
40-44yrs; 44 (38) 
45-49yrs; 43 (37) 
≥50yrs; 17 (15) 
Menopausal status: NR 
Race: NR 
Exclusion criteria: see poor 
prognosis 
H I (good); 56/115 (49%) 
H II (intermediate); 45/115 (39%) 
H III (poor); 14/115 (12%) 
TS ≤20mm; 71/115 (62%) 
TS >20mm; 44/115 (38%) 
LN# 0; 60/115 (52%) 
LN# 1-3; 43/115 (37%) 
LN# ≥4; 12/115 (10%) 
ER-; 3/115 (3%) 
ER +; 112/115 (97%) 
VI Absent; 77/115 (67%) 
VI 1-3 vessels; 12/115 (10%) 
VI >3 vessels; 26/115 (23%) 
Treatment: 
h: Yes; 17/115 (15%) 
h: No; 88/115 (85%) 
a: Yes; 44/115 (38%) 
a: No; 71/115 (62%) 
s: Breast conserving; 64/115 (56%) 
s: mastectomy; 51/115 (44%) 
Outcome: NR 
 a Poor and Good prognosis groups using the optimized sensitivity threshold from van't Veer 200221 
van't Veer, 
200221 b 
  Mean age, y (range), SD: 
44.9 (28-54),  6.9  
(for the 78 patients used to 
develop the test + 19 of the 
validation; BRCA1 patients 
non included) 
Menopausal status: NR 
Race: NR 
Exclusion criteria: 
● Tumor larger than 5cm 
(>T2) 
● metastases (M1) 
● Older than 55yrs at 
diagnosis 
● previous malignancy 
● not diagnosed between 
1983 and 1996 
H I (good); 11/97 (11.3%) 
H II (intermediate); 26/97 (26.8%) 
H III (poor); 60/97 (61.8%) 
TS ≤20mm; 57/97 (58.8%) 
TS >20mm; 40/97 (41.2%) 
LN# 0; 97/97 (100%) 
ER -; 29/97 (29.8%) (by IHC, <10% 
positive nuclei) 
ER +; 68/97 (70.2%)  (by IHC, >10% 
positive nuclei) 
PR -; 41/97 (42.3%) (by IHC, <10% 
positive nuclei) 
PR +v; 56/97 (57.7%)  (by IHC, >10% 
positive nuclei) 
VI Absent; 69/97 (71.2%) 
VI Present 28/97 (28.8%) 
LI Absent; 18/97 (18.5%) 
LI Present 79/97 (81.5%) 
Treatment:  
h: hormonal therapy (3 patients) 
a: Adjuvant Chemotherapy (3 patients) 
s: Modified radical mastectomy (35 
patients 
s: Breast conserving treatment (72 
patients) S: axillary lymph-node 
dissection (all 97 patients) 
Outcome: Metastases within 5yrs from 
surgery: 51 patient did NOT develop 
metastases ;  46 patient developed 
metastases 
 b Development (78 patients): classified in the Poor group=35 ; classified in the Good group=43 ; Validation (19 patients): classified in the Poor 
group=5 ; classified in the Good group=14 with the optimized sensitivity threshold 
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* Diagnoses: H = histology/histologic type; TS = tumor size/diameter; LN# = # of Lymph nodes at primary diagnosis; LN = lymph node status; TG = tumor grade;  ER = estrogen 
receptor status; HER = HER neu status; PR = Progesterone receptor status;  SP = S-phase fraction; Pl = ploidy; VI = vascular invasion; PTS = site of primary tumor; HR = 
hormonal status, ER or PR or both; DR = distant recurrence; LI lymphotic infiltrate 
† Treatments: H = hormonal; A = adjuvant; S = surgical; R = radiation 
‡ Treatment outcomes: OS = overall survival; RFS = relapse-free survival (first disease relapse, irrespective of site); CR = complete response; PR = partial response; RS: recurrence 
score; SD = stable disease; PD = progressive disease; PCR =  pathologic complete response; D = death 
§ Data not reported in article, referred directly to van de Vijver, 200225. 
║ Data not reported in article, referred directly to van’t Veer, 200221. 




Evidence Table 8. Analytic validity, MammaPrint® 
 
Study, year Measure Conclusions 
Ach, 2007, 57 Context: MammaPrint assay was used to evaluate the intra- and inter-laboratory 
reproducibility of the assay involving three laboratories. Variation in RNA amplification and 
labeling, hybridization and wash, and slide scanning was measured on 4 tumors, dye-flip 
design, 24 slides (8 per site). 
 




●  Replicate hybridizations Pearson’s correlation at the same site: 
For 1 tumor in 1 sub-array = 0.983 
For 2 tumor in 2 sub-arrays = 0.988 
For all the other technical replicates > 0.993 
●  Scanning reproducibility across sites: 
Cy3: Pearson correlation >0.995, slope = 0.97 
Cy5: less reproducible (data not shown) 
●  70-gene signature reproducibility: 
No differences between hybridization sites 
No differences between hybridization days (regardless of site) 
Statistically significant difference (P value <0.05) between labeling sites for two tumors 
The authors showed very low influence on 
sample-to-reference ratios based on averaged 
triplicate measurements in the two-color 
experiments; 
 
RNA labeling was the largest contributor to inter-
laboratory variation; 
 
Overall, despite this variation, measurement of 
70-gene signature in three different laboratories 





Context: The MammaPrint assay was used. Out of the 403 eligible samples the analysis was 
carried on 326 samples. 
 
Methods: Standard MammaPrint assay protocols were used, using fresh-frozen specimens 
 
Results:  
●  326 patients out of 403 successfully analyzed, for the following reasons: 
Poor RNA yield: 77/403 patients (19.1%) 




Evidence Table 8. Analytic validity, MammaPrint (continued) 
 
Study, year Measure Conclusions 
Glas, 200658 Context: MammaPrint assay development through re-analysis of patients from the van’t 
Veer21 and van de Vijver25 cohorts for which an RNA aliquot or the frozen specimen were 
available. A different reference RNA was used, as well as a different quantification method. 
 
Methods:  
●  162 total samples from fresh-frozen specimens: 
84 patients from the van de Vijver25 cohort 
All 78 patients form the van’t Veer cohort21 
A combination of the two population above: 145 (84+61) LN-negative patients 
Re-analysis on 49 patients 
●  Dye-swap hybridization over reference RNA from 105 sample from the van de Vijver series 
(balanced in terms of Good and Poor) 
●  Relative gene expression quantified as the error-weighted average over triplicate spots of 
the log10 ratio 
●  Pearson’s correlation to assess correlation with original data and reproducibility 
●  ANOVA analysis to model variability in repeated experiments using the 70 genes of the 
signature 
●  Reproducibility in time was assessed by repeated measurements of RNA aliquots: 
1 patient with cosine correlation to Good profile = 0.61, for 12 months 
1 patient with cosine correlation to Good profile = -0.44, for 12 months 
1 border-line with cosine correlation to Good profile = 0.43, for 4 months 
 
Results:  
●  Comparison to original 70-gene signature data, Pearson's Correlations and in repeated 
measurements: 
78 van't Veer21 patients, r = 0.92, p value < 0.0001 
145 (84+61) van de Vijver25 LN-negative patients: r = 0.88 p value < .0001 
49 patients analyzed twice, r = 0.995 
●  Reproducibility results from ANOVA analysis: 
No variation within individuals (p value = 0.96) 
Significant variation between individuals and genes 
●  Reproducibility in time analysis results: 
For both patients assessed over a period of 12 months measurements SD was 0.028 of 
the cosine correlation 
For the 1 border-line sample assessed over a period of 4 months measurements SD 
was 0.027 of the cosine correlation 
This latter sample was miss-classified 6 times (15%) 
The authors demonstrate for the first time that 
microarray technology can be used as a reliable 
diagnostic tool; 
 
The MammaPrint assay performed similarly to 





Evidence Table 8. Analytic validity, MammaPrint (continued) 
 
Study, year Measure Conclusions 
van't Veer21 Context: In this study the 70-gene signature was developed and no analytic validity data 




Context: In this study the 70-gene signature was developed and no analytic validity data 
about the MammaPrint assay are reported. 
 
 
RNA= ribonucleic acid; ANOVA= analysis of variance; Cy3= the green fluorescent dyes commonly used in two colors design microarray hybridization; Cy5= the red fluorescent 
dyes commonly used in two colors design microarray hybridization; LN= lymph node; SD= standard deviation;  
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Study, year Measure Conclusions 
Buyse, 
200659 
Context: This study was designed to test the validation of the MammaPrint assay through the 
TRANSBIG consortium multicenter, multinational collaborative study involving 5 distinct 
institutions. 
 
End points: OS, RFS (any recurrence as event); TTM (time to metastases as first relapse) 
 
Methods: 
●  The Kaplan-Meier product limit estimator was used in survival analyses. 
●  Hazard ratios were formulated to compare the high-risk group with the low-risk group. 
●  Hazard ratios heterogeneity across institutions was evaluated by chi-square test with four 
degrees of freedom. 
●  Gene signature hazard ratios were stratified by clinical risk and vice versa. 
●  Follow-up duration impact on hazard ratios was analyzed by censoring all observations at 
increasing time points. 
●  Sensitivity and specificity were estimated for distant metastases within 5 years and for 
death within 10 years. 
●  Time-dependent receiver operating characteristic (ROC) curves were computed by using 
the tumor expression level for the 70-genes signature and the 10-year survival probability 
for the Adjuvant! Software. 
 
Results: 
●  Kaplan-Maier analysis stratified by MammaPrint and Adjuvant (% of patients with distant 
recurrence): 
Good(R>0.4), Adjuvant!Low: 52 patients 
OS(10years): 0.88 (0.74 to 0.95) 
Good(R>0.4)Adjuvant!High: 59 patients 
OS(10years): 0.89 (0.77 to 0.95) 
Poor(R<0.4)Adjuvant!Low: 28 patients  
OS(10years): 0.69 (0.45 to 0.84) 
Poor(R<0.4)Adjuvant!High: 163 patients 
OS(10years): 0.69 (0.61 to 0.76) 
MammaPrint is a better predictor of TTM than 
Age, Size, Grade, ER, Adjuvant!, NPI, St Gallen; 
 
St Gallen is a better predictor of DFS than 
MammaPrint  
 
MammaPrint is a better predictor for OS than 
Age, Size, Grade, ER, Adjuvant!, NPI, St Gallen; 
 
The signature remained a statistically significant 
prognostic factor for TTM and OS even after 
adjustment for various risk classifications 
methods based on clinicopathologic factors; 
 
The lack of statistical significance for DFS was 
explained by  the fact that the signature was 
originally developed using TTM as the endpoint. 
 
Overall the 70-gene signature adds independent 
prognostic information to clinicopathologic risk 
assessment for node-negative untreated patients 
with early breast cancer; 
 
Clinical risk hazard ratios, adjusted for the gene 
signature were not significant, suggesting that 





Evidence Table 9. Clinical utility and validity, MammaPrint (continued) 
 
Study, year Measure Conclusions 
Buyse, 2006 
(con’t) 
●  Hazard Ratios (unadjusted): 
MammaPrint: 
TTM=2.32 (95% CI = 1.35-4.00) 
DFS=1.50 (95% CI = 1.04-2.16) 
OS=2.79 (95% CI = 1.60-4.87) 
Adjuvant: 
TTM=1.68 (95% CI = 95% CI = 0.92 to 3.07) 
DFS=1.30 (95% CI = 95% CI = 0.86 to 1.95);  
OS=1.67 (95% CI = 95% CI =0.93 to 2.98) 
●  Hazard Ratios (adjusted): 
MammaPrint adjusted by  St Gallen: 
TTM=2.15 (95% CI = 1.25 to 3.71) 
DFS=1.41 (95% CI = 0.97 to 2.06) 
OS=2.69 (95% CI = 1.53 to 4.73) 
MammaPrint adjusted by NPI: 
TTM=2.15 (95% CI =1.19 to 3.92) 
DFS=1.45 (95% CI = 0.97 to 2.16) 
OS=2.89 (95% CI = 1.58 to 5.29) 
MammaPrint adjusted by Adjuvant: 
TTM= 2.13 (95% CI = 1.19 to 3.82) 
DFS= 1.36 (95% CI = 0.91 to 2.03) 
OS= 2.63 (95% CI =1.45 to 4.79) 
Adjuvant Adjusted by MammaPrint: 
TTM=1.26 (95% CI = 0.66 to 2.40);  
DFS=1.03 (95% CI = 0.67 to 1.59) 
OS=1.08 (95% CI = 0.59 to1.99) 
●  Sensitivity for development of metastases within 5 years: 
Gene signature 0.90 (0.78 to 0.95) 
Adjuvant! software 0.87 (0.75 to 0.94) 
Nottingham Prognostic Index 0.79 (0.65 to 0.88) 
St Gallen criteria 0.96 (0.86 to 0.99) 
●  Specificity for development of metastases within 5 years: 
Gene signature 0.42 (0.36 to 0.48) 
Adjuvant! software 0.29 (0.24 to 0.35) 
Nottingham Prognostic Index 0.48 (0.42 to 0.54) 
St Gallen criteria 0.10 (0.07 to 0.14) 
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Study, year Measure Conclusions 
Buyse, 2006 
(con’t) 
●  Sensitivity for death within 10 years: 
Gene signature 0.84 (0.73 to 0.92) 
Adjuvant! software 0.82 (0.71 to 0.90) 
Nottingham Prognostic Index 0.70 (0.57 to 0.80) 
St Gallen criteria 0.95 (0.86 to 0.98) 
●  Specificity for death within 10 years: 
Gene signature 0.42 (0.36 to 0.48) 
Adjuvant! software 0.29 (0.23 to 0.35) 
Nottingham Prognostic Index 0.47 (0.41 to 0.53) 
St Gallen criteria 0.10 (0.07 to 0.14) 
●  ROC area under the curve for MammaPrint: 
TTM: 0.681 
OS: 0.659 
●  ROC area under the curve for Adjuvant: 
TTM: 0.648 
OS: 0.576 
●  Adjustments for clinical risk using different cutoff points produced only minor changes in the 
adjusted gene signature hazard ratios 
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Study, year Measure Conclusions 
Espinosa,  
200580 
Context: 70-genes signature partial validation using RT-PCR analysis: 60 out of the 70 genes 
of the signatures plus 4 additional genes. The study was conducted to reproduce the results 
obtained by microarray by an alternative method using 96 patients with full follow-up and 
frozen specimen from a single institution 
 
End points: Relapse-free survival (RFS), and overall survival (OS) measured by relapses 
dichotomization (regardless of the site of first relapse): low-risk if the patient survived 2 years 
or longer, or high risk otherwise 
 
Methods:  
●  The RT-PCR based 70-genes signature surrogate: was obtained as follows: 
Gene by gene qRT-PCR normalization, 
Gene expression categorization using the cutoff value of 0, 
Distance/similarity coefficient calculation for each patient, 
Similarity cutoff value optimization to yield the highest significance in log-rank tests for 
DFS 
●  The Kaplan-Meier product limit method was used in survival analysis and significance was 
assessed by bilateral log-rank test 
●  The Mann-Whitney test was used to compare patients’ characteristics 
●  The Fisher’s exact test was used to compare categorical variables 
●  Multivariate Cox proportional regression analysis was performed by adjusting by ER status, 
lymph node status, number of positive lymph nodes (less or more than 3) and gene profile 
 
Results: 
●  Kaplan-Meier  estimates for the Good prognosis profile: 
RFS after 70 months: 85% 
OS after 70  months: 97% 
Log-rank test P value = 0.03 
●  Kaplan-Meier  estimates for the Bad prognosis profile: 
RFS after 70 months: 62% 
OS after 70 months: 72% 
Log-rank test P value = 0.002 
●  Results of multivariate Cox proportional regression analysis: 
OS by lymph node status, HR = 1.2; 95%CI = 1.09 to 1.36 
OS by the 70-genes profile HR = 6.3; 95%CI = 1.28 to 31.07 
DFS by lymph node number, HR = 1.13; 95%CI = 1.05 to 1.25 
DFS by the 70-genes profile HR = 2.74, 95%CI = 1.13 to 6.61 
qRT-PCR reproduced the results obtained with 
microarrays for the 70-genes prognostic profile in 
women with early-stage breast cancer 
 
Both RFS and OS were significantly longer in 




Evidence Table 9. Clinical utility and validity, MammaPrint (continued) 
 
Study, year Measure Conclusions 
Fan, 200679 Context: The study is a comparison of classification agreement among 5 different gene 
expression based predictors (70-genes, Oncotype DX™, Wound-response, Intrinsic subtypes 
and two-gene ratio) using the 295 samples from the consecutive cohort originally used by van 
de Vijver 200225. 
 
Methods: 
●  Cramer V statistics 
●  Kaplan-Meier survival analysis 
●  Multivariate Cox proportional hazards analysis, adjusting for age, tumor size, tumor grade, 
ER status, number of lymph node involved 
●  All analyses were performed using all the patients, as well as the ER positive patients 
subset (N=225) 
●  NB: coefficients of clinical predictors were allowed to vary between models 
 
Results: 
●  In multivariate Cox proportional hazards analysis all tests except the two-gene ratio were 
highly significant predictors of OS and DFS: 
70 genes DFS HR = 3.4 (95%CI = 2.0-6.0), P value < 0.001 
Two-gene ratio DFS HR = 0.91 (95%CI = 0.6-1.3), P value = 0.62 
Oncotype OS HR = 4.3 (95%CI = 2.1-8.9), P value < 0.001 
70 genes OS HR = 4.71 (95%CI = 2.02-11.0), P value < 0.001 
Two-gene ratio OS HR = 1.00 (95%CI = 0.61-1.63), P value = 0.99 
Oncotype DFS HR = 6.14 (95%CI = 1.84-20.4), P value = 0.003 
●  ER status, tumor grade, tumor size, and lymph nodes were also significant predictors. 
●  Patients classification into dichotomized risks groups proved to be roughly similar, ranging 
from ~80% to ~40%: 
70-genes and RS yielded a V= 0.60 
70-genes and RS yielded an agreement of ~81% (239/295) 
Good but not perfect correlation between 
predictions, albeit surprising with different gene 
sets. Degree of prediction over and above 
“standard” clinical stratifiers is not clear – 
reclassification not done. 
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Study, year Measure Conclusions 
Glas,  200658 Context: MammaPrint assay development through reanalysis of patients from the van’t 
Veer21 and van de Vijver25 cohorts for which an RNA aliquot or the frozen specimen were 
available. A different reference RNA was used , as well as a different quantification method. 
 
Methods:  
●  162 lymph node negative, young breast cancer patients (<55 years), who did not received 
adjuvant therapy. 
●  All 78 patients form the van’t Veer 200221 cohort were available and used to reestablish the 
70-genes expression profile, using the same procedures originally used and the same 
correlation to the signature (0.4). 
●  145 sample from the van de Vijver25 cohort (61 also in van’t Veer21) were used and a higher 
correlation was used for classification purposes (0.55). 
 
Results: 
●  Comparison between MammaPrint and the original 70-genes signature using all the 78 
patients from the van’t Veer21 series for the risk of developing a metastasis as first relapse 
event within 5 years from surgery: 
MammaPrint OR = 13.95 (95%CI = 3.9-44) 
Original 70-genes signature OR = 15, 95%CI = 2.1 to 19) 
●  7 patients out of 78 were classified differently by MammaPrint with respect to the original 
70-genes signature: 
2 good prognosis patients were correctly classified by MammaPrint, but not by the 
original 70-genes signature 
1 poor prognosis patient was correctly classified by MammaPrint, but not by the original 
70-genes signature 
2 poor prognosis patient s were misclassified by MammaPrint, but not by the original 
70-genes signature 
2 good prognosis patients were misclassified by MammaPrint, but not by the original 
70-genes signature 
●  Comparison between MammaPrint and the original 70-genes signature using 145/151 LN 
negative patients from the van de Vijver25 series for the risk of developing a metastasis as 
first relapse event within 5 years from surgery: 
HR for MammaPrint = 5.6 (95%CI = 2.4-7.3, p value = 0.0001) 
●  The probability of remaining free of metastases at 5 years was not different between 
MammaPrint and the original 70-genes signature, with a p value = 0.89 in log-rank test 
●  Similar results were obtained for OS 
The authors demonstrate for the first time that 
microarray technology can be used as a reliable 
diagnostic tool 
 
The MammaPrint assay performed similarly to 
the original 70-genes signature and is, therefore, 
an excellent tool to predict outcome of disease in 
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Study, year Measure Conclusions 
van de Vijver, 
200225 
Context:70-genes signature partial validation using a gene expression array containing 
25,000 features was used to evaluate the prognostic performance of the 70-genes signature 
in a consecutive series of 295 young women (< 53 years at diagnosis), with early stage (I-II), 
ER-positive or negative, node positive or negative breast cancer, who received or not 
adjuvant therapy (hormonal therapy, chemotherapy or both). 
 
End point: distant metastases as first relapse event; patients were censored on the date of 
the last follow-up visit, death from causes other than breast cancer, the recurrence of local or 
regional disease, or the development of a second primary cancer, including contralateral 
breast cancer and Overall Survival (OS) 
In this study, 61 of the 78 patients of the van’t Veer21 cohort were included. 
 
Methods:  
●  Kaplan-Meier analysis on the time form surgery to the first metastasis event or to 
censoring. 
●  Survival curves were compared by the log-rank test. 
●  Values are expressed as means ±SE, calculated according to the method of Tsiatis. 
●  All SEs were calculated with use of the sandwich estimator. 
●  Cox proportional-hazards regression analysis was used to investigate the association 
between the correlation coefficient (C1) and metastases by adjusting for other clinical 
variables (tumor grade, vascular invasion, and number of involved axillary’s lymph-nodes: 
0 versus 1 to 3 or 0 versus > 4). 
●  The linearity of the relation between the relative hazard ratio and the diameter of the tumor, 
age, and ER level of expression was tested with use of the Wald test for nonlinear 
components of restricted cubic splines. 
●  Hazard ratio proportionality was assessed by the method of Grambsch and Therneau. 
●  Difference between the relative hazard ratio before and after five years of follow-up with 
respect to the 70-genes prognosis signature was done by the Wald test. 
The 70-genes signatures is a better predictor of 





Evidence Table 9. Clinical utility and validity, MammaPrint (continued) 
 
Study, year Measure Conclusions 
van de Vijver, 
2002 (con’t) 
Results: 
●  The 70-genes gene expression signature: 
Proved to be associated with age, tumor grade, ER status (P value<0.001), and tumor size 
(P value=0.012)  
Was not associated with lymph-nodes, vascular invasion, surgery, chemotherapy, 
hormonal  therapy 
●  OR for the various subgroups of patients in the consecutive series analyzed: 
78 node negative patients used in van’t Veer 200221  
31 Poor signature with metastases 
18 Poor signature without metastases 
3 Good signature with metastases 
26 Good signature with out metastases 
OR = 15, (95%CI = 3.3-56, p value < 0.001) 
67 node-negative patients NOT used in van’t Veer 2002: 
11 Poor signature with metastases 
23 Poor signature without metastases 
1 Good signature with metastases 
32 Good signature with out metastases 
OR = 15.3, (95%CI = 1.8-127, p value = 0.003) 
180 node-positive  and negative patients NOT used in van’t Veer 2002: 
39 Poor signature with metastases 
65 Poor signature without metastases 
3 Good signature with metastases 
73 Good signature with out metastases 
OR = 14.6, (95%CI = 4.3-50, p value < 0.0001) 
●  Probability of metastases at 5yrs for all the patients: 
115 Good signature patients: 94.7±2.1SE 
180 Poor signature patients: 60.5±3.8SE  
●  Probability of metastases at 10 yrs for all the patients 
115 Good signature patients:  85.2±4.3SE 
180 Poor signature patients: 50.6±4.5SE 
●  Probability of metastases at 5 yrs for node negative patients: 
93 Good signature patients: 4±3.2SE 
91 Poor signature patients: 56.2±5.5SE 
●  Probability of metastases at 10 yrs for node negative patients: 
60 Good signature patients: 86.8±4.8SE 
91 Poor signature patients: 44.1±6.3SE 
●  Probability of metastases at 5 yrs for node positive patients 
55 Good signature patients: 95.2±2.6SE 
89Poor signature patients: 66.3±5.2SE 
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Study, year Measure Conclusions 
van de Vijver, 
2002 (con’t) 
●  Probability of metastases at 10 yrs for node positive patients 
55 Good signature patients: 82.7±7.8SE 
89 Poor signature patients: 56.7±6.4SE 
●  OS at 5 yrs for all the patients: 
15 Good patients 97.4±1.5SE 
180 Poor patients 74.1±3.3SE 
●  OS at 10 yrs for all the patients: 
115 Good patients 94.5±2.6SE 
180 Poor patients 54.6±4.4SE  
●  OS at 5 yrs for node-negative patients: 
60 Good patients 96.7±2.3SE 
91 Poor patients 71.5±4.8SE 
●  OS at 10 yrs for node-negative patients: 
60 Good patients 96.7±2.3SE 
91 Poor patients 49.6±6.1SE 
●  OS at 5 yrs for node-positive  patients: 
55 Good patients 98.2±1.8SE 
89Poor patients 76.5±4.6SE 
●  OS at 10 yrs for node-positive patients: 
55 Good patients 92.0±4.8SE 
89 Poor patients 59.5±6.3SE 
●  HAZARD RATIO for metastases as first event over the entire follow-up period: 
All patients, HR = 5.1, (95%CI = 2.9-9.0, p value < 0.001) 
151 node negative patients, HR = 5.5, (95%CI = 2.5-12.2, p value < 0.001) 
 
144 mode positive patients, HR = 4.5, (95%CI = 2-10.2, p value < 0.001) 
●  HAZARD RATIO for OS over the entire follow-up period: 
All patients = 8.6, (95%CI = 4-19, p value < 0.001) 
● In multivariate analysis the following factors resulted to be independent predictors of risk of 
metastases as first event within 5 years: 
70-genes signature, HR = 4.6, 95%CI = 2.3-9.2, p value < 0.001 
Tumor size, HR = 1.56, 95%CI = 1.22-2.0, p value < 0.001 
Chemotherapy, HR = 0.37, 95%CI = 0.2-0.66, p value < 0.001 
The other covariates used (age, grade, node status, vascular invasion, ER status, 
surgery, and hormonal therapy) were not associated with the risk of metastasis 
 
I-60 
Evidence Table 9. Clinical utility and validity, MammaPrint (continued) 
 
Study, year Measure Conclusions 
van de Vijver, 
2002 (con’t) 
●  Reclassification and comparison with St. Gallen and NIH criteria: 
The 70-genes signature classified more node negative patients in the Good prognosis 
group than both the St. Gallen and NIH criteria (40%, 15% and 7% respectively) 
43 St. Gallen High Risk group patients were re-classified in the Good signature group 
86 St. Gallen High Risk group patients were classified in the Poor signature group 
KM analysis showed that the 70-genes signature groups defined within the St. Gallen 
High Risk group are different, with a p value < 0.001 
17 St. Gallen Low Risk group patients were classified in the Good signature group 
5 St. Gallen Low Risk group patients were classified in the Poor signature group 
KM analysis showed that the 70-genes signature groups are PROBABLY different within 
the St. Gallen Low Risk group, with a p value < 0.11 
53 NIH High Risk patients were classified in the Good signature group 
87 NIH High Risk patients were classified in the Poor signature group 
KM analysis showed that the 70-genes signature groups are different within the NIH High 
Risk group, with a p value < 0.001 
7 NIH-Low Risk group patients were classified in the Good signature group 
4 NIH-Low Risk group patients were classified in the Poor signature group 
KM analysis showed that the 70-genes signature groups are different within NIH Low 
Risk group, with a p value < 0.05; 
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Context: 70-genes gene expression signature development using a gene expression array 
containing 25,000 features was used to select genes associated with metastases free survival 
at 5 years from the surgery. 
 
End point: distant metastases as first relapse event; patients were censored on the date of 
the last follow-up visit, death from causes other than breast cancer, the recurrence of local or 




●  Kaplan-Meier analysis on the time form surgery to the first metastasis event or to 
censoring. 
●  Survival curves were compared by the log-rank test. 
●  Multivariate proportional-hazards regression analysis was used to investigate the 
association between the correlation coefficient and the time to metastases by adjusting for 
other clinical variables. 
●  In the multivariate analysis the following predictors were used: tumor grade, ER status, PR 
status, tumor size, patient age, and angioinvasion. 
●  Values were expressed as means ±SE, calculated according to the method of Tsiatis. 
●  All SEs were calculated with use of the sandwich estimator. 
 
Results: 
●  Optimized 70-genes signature performance in the training set (78 patients): 
65/78 correct predictions (patients developed or not metastases within 5 years) 
13 misclassified patients: 
5 patients with poor prognosis were classified in the 70-gene Good prognosis group 
8 patients with good prognosis were classified in the 70-gene Poor prognosis group 
●  Optimized 70-genes signature performance in the validation set (19 patients): 
17/19 correct predictions (patients developed or not metastases within 5 years) 
2 misclassified patients:  
1 patients with poor prognosis was classified in the 70-gene Good prognosis group 
1 patients with good prognosis in the 70-gene Poor prognosis group 
●  ODDS RATIO to develop metastases within 5 years for a patient in the 70-genes Poor  
prognosis group:  
OR=28, (95%CI=7-107), P value = 0.00000001 
Leave-one-out cross-validated OR =15, (95%CI=4-56), P value=0.0000041 
●  In univariate  analysis the ‘leave-one-out‘ cross-validated 70 genes signature proved to be 
a better predictor of recurrence  than grade, size(>2cm), age (<40yrs), ER negative status, 
and angioinvasion 
The 70-genes signatures is a better predictor of 




Evidence Table 9. Clinical utility and validity, MammaPrint (continued) 
 
Study, year Measure Conclusions 
van't Veer, 
2002 (con’t) 
●  In multivariate analysis the 70-genes signature showed to be an independent predictor of 
metastases within 5 years (logistic regression OR = 18, (95%CI=3.3-94, P value = 
0.00014) 
●  Comparison of the 70 genes signatures with St. Gallen and NIH criteria for risk 
stratification: 
St. Gallen: 
64/78 patients were defined as at high risk of metastases (33/34 of the patients who did 
develop metastases; 31/44 who did not develop metastases) 
NIH:  
72/78 patients were defined as at high risk of metastases (32/34 of the patients who did 
develop metastases; 40/44 who did not develop metastases) 
70-genes signature:  
43/78 patients were defined as at high risk of metastases (31/34 of the patients who did 
develop metastases; 18/44 who did not develop metastases); 
 
 
TRANSBIG= Breast International Group (BIG) network for improved treatment tailoring; OS= overall survival; RFS = relapse free survival; TTM = time to distant metastases; 
ROC= receiver operating characteristic; ER= estrogen receptor; NPI= Nottingham Prognostic Index; CI= confidence interval; RT-PCR= real time polymerase chain reaction; qRT-
PCR= quantitative real time polymerase chain reaction; HR= hazard ratio; RNA= ribonucleic acid; OR= odds ratio; SE= standard error; NIH= National Institutes of Health; Kaplan 
Meier= Kaplan Meier; PR= partial relapse. 
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period  Study Type 
Population 




















USA NR RCT 
Without 
expression 
ratio data, 50 




















Sweden 1982 - 1995 retrospective Post-
menopausal, 
264 




USA 1987-1997 retrospective Frozen, 
recurrence, 
28 






























NR Validation of 
signature 
 
NR = not reported; NA = not applicable; LN = lymph node; ER = estrogen receptor, NO = node; uk = unknown; FFPE =formalin 
fixed paraffin embedded. 
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Evidence Table 11. Study population characteristics, H/I ratio (continued) 
 
Study, 
Year Intervention General Characteristics Diagnosis (es)* Treatments and Outcomes 
Tamoxifen 
20mg/day for 5 
years 
Age, median (range): 68 (42-84) 
Menopausal status: 100 % 
Race (%): W (92) 
Exclusion criteria: NR 
H Ductal; 86% 
H Lobular; 10% 
H Other; 4% 
TS <3; 76% 
TS ≥3; 24% 
LN+ nodes 0, 63% 
LN+ nodes 1-3, 26% 
LN+ nodes 4-9, 7% 
LN+ nodes >10, 4% 
ER 10-49 fmol; 20% 
ER ≥50 fmol; 69% 
ER +; 11% 
HER2 0; 11% 
HER2 1; 36% 
HER2 2; 34% 
HER2 Unknown; <1% 
Nottingham TG 1, 26% 
Nottingham TG 2, 55% 
Nottingham TG 3, 18% 
Nottingham TG Unknown, <1% 
 
Diagnostic method: RT-PCR 
Treatment:  
s: Mastectomy; 83% 





20mg/day for 5 
years (women 
without expression 
ratio data-all treated 
with oral tamoxifen) 
Age, median (range): 64 (48-87) 
Menopausal status: 100 % 
Race (%): W (91)  
Exclusion criteria: NR 
H Not Determined 
TS <3; 90% 
TS ≥3; 10% 
LN+ nodes 0, 62% 
LN+ nodes 1-3, 15% 
LN+ nodes 4-9, 715 
LN+ nodes >10, 6% 
ER 10-49 fmol; 20% 
ER ≥50 fmol; 56% 
ER+; 24% 
HER2  Not determined 
Nottingham TG; Not determined 
 
Diagnostic method: RT-PCR 
Treatment: 
s: Mastectomy; 74% 
s: Breast Conservation; 26% 
Outcome: NR 
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Evidence Table 11. Study population characteristics, H/I ratio (continued) 
 
Study, 
Year Intervention General Characteristics Diagnosis (es)* Treatments and Outcomes 
1,683 total female 
patients diagnosed 
with breast cancer 
from 1979-1996, 
clinical information 






Menopausal status: NR 
Race: NR 
Exclusion criteria: distant spread 
at or within the first month of 
surgery 
LN-/ER- = 185 
(15%) 
Age, n (%): < 40, 166 (13) 
Menopausal status: pre, n-537 
(43%) 
Race: NR 
Exclusion criteria: missing values 
for lymph node status, ER 
protein status, and HOXB13 and 
IL17BR 
LN-/ER+ = 468 
(37%) 
Age, n (%): 40-55,: 465 (37) 
Menopausal status: post, n=715 
(57%) 
Race: NR 
Exclusion criteria: 30% epithelial 
tumor cells in their tumor 
specimens 
LN+/ER-/LN-
adjuvant = 41 (3%) 
Age, n (%): 56-70, 409 (33) 
Menopausal status: NR 
Race: NR 
Exclusion criteria: specimens of 




adjuvant = 151 
(12%) 
Age, n (%): >70, 212 (17) 
Menopausal status: NR 
Race: NR 
Exclusion criteria: NR 
Premenopausal: 
LN+ >3Nodes; 330 (27%) 
LN+ 1-3Nodes; 269 (21%) 
LN-; 653 (52%) 
TS <2cm; 392 (31%) 
TS 2-5cm; 716 (57%) 
TS >5cm/pT4; 144 (12%) 
ER High; 917 (73%) 
ER Low; 335 (27%) 
PR High; 764 (61%) 
PR Low; 417 (33%) 
 
Diagnostic method: RT-PCR 
 
note1: The cutoff point to classify primary 
breast tumors as ER and/or progesterone 
receptor (PgR) -positive was 10 fmol/mg 
cytosolic protein. 
 
note2: Follow-up, tumor staging, and 
response to therapy was defined by 
standard International Union Against 
Cancer (Geneva, Switzerland) 
classification criteria 
Treatment received by 406 patientst: 
s: breast-conserving lumpectomy, 
543 (43) 
mastectomy, 709 (57) 
h: 177 patients (44)  
a: 214 (53)  
c: 15 (3) 
Follow-up: 
72 months, all patients (2-248 
months) 
91 months, 692 patients alive (3 to 
248 months) 
46 months , 560 deaths (2 to 205 
months) 
Outcome: 
Disease recurrence occurred in 692 
(55%) of 1,252 patients. 
846 patients (68%) did not receive 
neo-adjuvant systemic therapy 
● 381 patients (45%) experienced a 
relapse, of which 285 (75%) were 
treated with hormonal therapy of 
which;193 patients (68%) received 
first-line tamoxifen monotherapy, of 
which: Therapy failure occurred in 73 
patients (38%), of which:61 patients 
(84%) had progressive disease; 12 
patients (16%) showed stable 
disease < 6 months; 
● 381 patients (45%) experienced a 
relapse, 193 patients (68%) received 
first-line tamoxifen monotherapy, of 
which: 120 (62%) of these 193  
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Study, 




LN+/ER uk/ YES 
adjuvant = 407 
(33%) 
Age: NR 
Menopausal status: NR 
Race: NR 
Exclusion criteria: NR 
 patients experienced a clinical benefit 
from first-line tamoxifen, of which: 
disease-free survival (DFS) in 
patients with primary breast cancer 
(N = 619) and progression free; 
survival (PFS) in patients with 
recurrent breast cancer treated with 







trial, comparing 2  
years (163 patients, 
62%) and 5 years 





patients: clinical trial 
comparing 
tamoxifen treatment 
versus no treatment, 
only untreated 
patients were used 
Age: NR 
Menopausal status: NR 
Race: NR 
Exclusion criteria: NR 
Postmenopausal: 
LN+; 73 (28%) 
LN-; 184 (72%) 
LN Unknown; 7 (?%) 
TS <2cm; 77 (29%) 
TS ≥2cm; 187 (71%) 
ER +; 195 (74%) 
ER -; 69 (26%) 
PR +; 142 (54%) 
PR -; 120 (46%) 
 
Premenopausal: 
LN+; 63 (28%) 
LN-; 67 (72%) 
TS <2cm; 24 (26%) 
TS ≥2cm; 69 (74%) 
ER +; 59 (63%) 
ER -; 34 (37%) 
PR +; 60 (65%) 
PR -; 33 (35%) 
Nottingham TG 4, 4 (4.9%) 
Nottingham TG 2, 38 (47%) 
Nottingham TG 3, 39 (48%) 
Nottingham TG Unknown, 12 (?%) 
 
Diagnostic method: RT-PCR 
Treatment: 
s: Modified radical mastectomy 
s: breast conserving surgery with 
axillary lymph node dissection ;  
radiotherapy (50 Gy/25 fractions) to  
lymph node-positive patients ; 
I-67 
Evidence Table 11. Study population characteristics, H/I ratio (continued) 
 
Study, 
Year Intervention General Characteristics Diagnosis (es)* Treatments and Outcomes 
Frozen, recurrence, 
n=28 
Age, mean y (range): 65.1 (48-
84) 
Menopausal status: NR 
Race: NR 
Exclusion criteria: NR 
TS mean, 2.7 
TS range, 0.9-4.7 
LN# 0, 13 
LN# 1-3, 6 
LN# >3, 6 
TG 1, 2 
TG 2, 15 












Age, mean y (range): 69.1 (54-
85) 
Menopausal status: NR 
Race: NR 
Exclusion criteria: NR 
TS mean, 2.1 
TS range, 0.8-5.5 
LN# 0, 15 
LN# 1-3, 11 
LN# >3,2 
TG 1, 1 
TG 2, 24 
TG3, 7 
ER+, 32 
PR+, 27  
 












Age, mean y (range): 65.5 (54-
93) 
Menopausal status: NR 
Race: NR 
Exclusion criteria: NR 
TS mean, 1.9 
TS range, 1.1-4 
LN# 0, 8 
LN# 1-3,1  
LN# >3, 0 
TG 1, 1 





Diagnostic method: RT-PCR 
Treatment: NR 
Outcome: 
DFS: mean months (range): 51.4 (15-
117) 
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Study, 





Age, mean y (range): 65.2 (57-
74) 
Menopausal status: NR 
Race: NR 
Exclusion criteria: NR 
TS mean, 1.7 
TS range, 0.8-4 
LN# 0, 10 
LN# 1-3, 0 
LN# >3, 0 
TG 1, 1 





Diagnostic method: RT-PCR 
Treatment: NR 
Outcome: 




All samples, n=852 Age, n (%): 
<50, 155 (18) 
>50, 695 (82) 
UK, 2 (0.2) 
Menopausal status: NR 
Race: NR 
Exclusion criteria: NR 
TS<2, 309 (36) 
TS 2-5, 460 (54) 
TS >5, 75 (9) 
TS UK, 8 (1) 
LN# =0, 613 (72) 
LN#=1-3, 134 (16) 
LN#=4+, 105 (12) 
ER+, 625 (73) 
ER-, 214 (25) 
ER UK, 13 (2) 
HER2-CISH 0-3, 589 (69) 
HER2-CISH 4-12, 133 (16) 
HER2-CISH UK, 130 (15) 
PR+, 461 (54) 
PR-, 382 (45) 
PR UK, 9 (1) 
SP<6, 215 (25) 
SP 6-10, 213 (25) 
SP>10, 287 (34) 
SP UK, 137 (16) 
PL dip, 281 (33) 
Pl An, 465 (55) 
Pl UK, 106 (12) 
Treatment: 
a: With or without adjuvant tamoxifen 
monotherapy  
s: Mastectomy or lumpectomy plus 
axillary dissection 
r: With or without postoperative 
radiation therapy 
Outcome: 
RFS: mean =70 (0-285) 
RS: 266 (31) 
D: cancer: 206 (24) 
D: other: 155 (18) 
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Study, 





Age, n (%): 
<50, 26 (9) 
>50, 260 (91) 
UK, 0 
Menopausal status: NR 
Race: NR 
Exclusion criteria: NR 
TS<2, 102 (36) 
TS 2-5, 157 (55) 
TS >5, 26 (9) 
TS UK, 1 (0.1) 
LN# =0, 138 (40) 
LN#=1-3, 79 (28) 
LN#=4+, 69 (24) 
ER+, 255 (89) 
ER-, 29 (10) 
ER UK, 2 (1) 
HER2-CISH 0-3, 204 (71) 
HER2-CISH 4-12, 42 (15) 
HER2-CISH UK, 40 (14) 
PR+, 188 (66) 
PR-, 97 (34) 
PR UK, 1 (0.1) 
SP<6, 69 (24) 
SP 6-10, 89 (31) 
SP>10, 89 (31) 
SP UK, 39 (14) 
PL dip, 95 (33) 
Pl An, 166 (58) 
Pl UK, 25 (9) 
 
Diagnostic method: RT-PCR 
Treatment: 
a: With or without adjuvant tamoxifen 
monotherapy  
s: Mastectomy or lumpectomy plus 
axillary dissection 
r: With or without postoperative 
radiation therapy 
Outcome: 
RFS: mean =68 (0-231) 
RS: 83 (29) 
D: cancer: 69 (24) 
D: other: 49 (17) 
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Study, 
Year Intervention General Characteristics Diagnosis (es)* Treatments and Outcomes 
Ma, 2006 
(con’t) 
Untreated, n=566 Age, n (%): 
<50, 129 (23) 
>50, 435 (77) 
UK, 2 (0.2) 
Menopausal status: NR 
Race: NR 
Exclusion criteria: NR 
TS<2, 207 (37) 
TS 2-5, 303 (54) 
TS >5, 49 (9) 
TS UK, 7 (1) 
LN# =0, 475 (84) 
LN#=1-3, 66 (10) 
LN#=4+, 36 (6) 
ER+, 370 (65) 
ER-, 185 (33) 
ER UK, 11 (2) 
HER2-CISH 0-3, 385 (68) 
HER2-CISH 4-12, 91 (16) 
HER2-CISH UK, 90 (16) 
PR+, 273 (48) 
PR-, 285 (50) 
PR UK, 8 (1) 
SP<6, 146 (26) 
SP 6-10, 124 (22) 
SP>10, 198 (35) 
SP UK, 98 (17) 
PL dip, 186 (33) 
Pl An, 299 (53) 
Pl UK, 81 (14) 
 
Diagnostic method: RT-PCR 
Treatment: 
a: With or without adjuvant tamoxifen 
monotherapy  
s: Mastectomy or lumpectomy plus 
axillary dissection 
r: With or without postoperative 
radiation therapy 
Outcome: 
RFS: mean =71 (0-285) 
RS: 183 (32) 
D: cancer: 137 (24) 
D: other: 106 (17) 
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Study, 
Year Intervention General Characteristics Diagnosis (es)* Treatments and Outcomes 
Reid, 2005 
69 
58 patients treated 
with Tamoxifen 
20mg/day for 5 
years 
Age, n (%): 
≥50yrs, 4 (6.9) 
>50yrs, 54 (93.1) 
Menopausal status: NR 
Race: NR 
Exclusion criteria: NR 
H Ductal; 48/58 (83.0%) 
H Lobular; 6/58 (10.2%) 
H Ductal + Lobular; 2/58 (3.4%) 
H Other; 2/58 (3.4%) 
TS ≤2cm; 22/58 (37.9%) 
TS >2cm; 36/58 (62.1%) 
LN# 0; 13/58 (22.5%) 
LN# 1-3; 31/58 (53.5%) 
LN# ≥4; 14/58 (24.0%) 
TG 1; 3/58 (5.0%) 
TG 2; 28/58 (48.3%) 
TG 3; 12/58 (20.7%) 
TG Not Assessed; 15/58 (26.0%)HER2 -; 
46/58 (77.6%) 
HER2 +; 12/58 (20.7%) 
PR -; 12/58 (20.7%) 
PR +; 46/58 (79.3%) 
 
Diagnostic method: RT-PCR 
Treatment: NR 
Outcome: NR  
 
* Diagnoses: H = histology/histologic type; TS = tumor size/diameter; LN# = # of Lymph nodes at primary diagnosis; LN = lymph node status; TG = tumor grade;  ER = estrogen 
receptor status; HER = HER neu status; PR = Progesterone receptor status;  SP = S-phase fraction; Pl = ploidy; VI = vascular invasion; PTS = site of primary tumor; HR = 
hormonal status, ER or PR or both; DR = distant recurrence 
† Treatments: H = hormonal; A = adjuvant; S = surgical; R = radiation; c = combination  
‡ Treatment outcomes: OS = overall survival; RFS = relapse-free survival (first disease relapse, irrespective of site); CR = complete response; PR = partial response; RS: recurrence 
score; SD = stable disease; PD = progressive disease; PCR =  pathologic complete response; D = death 
§ Data not reported in article, referred directly to van de Vijver, 200225. 
║ all patients were analyzed, however the following groups are of relevance: (LN-/ER+) and (LN+/ER+/NO-adjuvant); and 116 from (LN-/ER+) and 77 from (LN+/ER+/NO-
adjuvant), total of 193 (15%), who received first-line tamoxifen treatment 
NR= not reported; RT-PCR= reverse transcriptase polymerase chain reaction; DFS= disease free survival; FFPE= formalin-fixed paraffin embedded 
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Evidence Table 12. Analytic validity, H/I ratio 
 
Study, year Measure Conclusions 
Goetz, 
200662 
Context: Validation of the H/I ratio signature using patients from the randomized NCCTG 89-




●   LMC was performed prior total RNA preparation 
●   RT-PCR expression values for each gene were normalized using a standard curve 
obtained analyzing the human universal total RNA (Stratagen, La Jolla, CA) 
●   No reference genes were used 
 
Results: 
●   206 patients out of 256 successfully analyzed, for the following reasons: 
No specimen available: 29/256 patients (11%) 
Tumor content sufficient: 211/227 patients (93%) 
Failed RT-PCR: 5/211 patients (2.4%) 




Context: Validation of the H/I ratio signature by measuring expression levels normalized to a 
different set of control genes respect to MA et al 200661 using fresh frozen samples. From a 
population of 1693, 1,252 were considered eligible and were successfully evaluated 
 
Methods: 
●   RT-PCR was use to measure the expression levels of HOXB13 and IL17BR 
●   Two pairs of primers-probes were used to evaluated the IL17BR gene, aligning to the 3’ 
and the 5’ end of the genes and corresponding to the region of the transcripts respectively 
assayed by Ma et al 200464 and Reid et al 200569 
●   Three reference genes different from those used by Ma et 200661 were used 




In this study analytic validity data were not reported 
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Study, year Measure Conclusions 
Jerevall, 
200763 
Context: Validation of the H/I ratio signature. Expression levels were normalized to b-actin 
using . fresh frozen samples. Patients were collected from two distinct institutions; of 373 
tumor samples analyzed, RNA expression data were obtained from 357 tumors 
 
Methods: 
●   RT-PCR reactions in the two institutions were performed using the same sets of 
primers/probes and two distinct instruments 
●   In each reaction serial dilutions of a standard sample were used to construct a standard 
curve used to quantify gene expression prior normalization 
●   The reproducibility between the two institution was assessed by Pearson’s correlation 
 
Results: 
●   357 patients out of 373 successfully analyzed, for the following reasons: 
Insufficient RNA yield: 16/373 patients (4.3%) 
Overall success rate: 357/373 patients (95.7%%) 
●   Reproducibility between institutions, Pearson’s correlations, 10 patients: 
HOXB13:b-actin, r = 0.96, P < 0.001 
IL17BR:b-actin, r = 0.87, P = 0.002 
HOXB13:IL17BR, r = P < 0.001 
●   Median values for all the samples analyzed at the two centers: 
HOXB13:b-actin, 0.086 vs. 0.081 
IL17BR:b-actin, 1.4 vs. 1.3) 




Ma, 200464 Context: This study used the H/I ratio signature for the development and preliminary 
validation of the of the two-gene ratio signature. The training set was analyzed by microarray 
(n=60) and by RT-PCR (n=59) 
 
Methods: 




●   Correlations between array and RT-PCR: 
HOXB13, r = 0.83 
IL17BR , r = 0.93 
HOXB13/IL17BR, r = 0.83 
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Study, year Measure Conclusions 
Ma, 200661 Context: Development of the HOXB13:IL17BR two-gene index. Out of the 1,002 eligible The 
FFPE tissue microarrays were 4 years old, and obtained from specimens originally stored as 
fresh frozen tissues 
 
Methods: 
●   IHC for ER and PR was performed90,91 
●   IHC Allred92 scores of 3 to 8 were considered positive for ER or PR93 
●   Concordance between RT-PCR and IHC results by k statistics 
●   Since both ER and PR mRNA RT-PCR measurements were bimodal; the following 
midpoints were used as cutoffs: 
2.5 CT for ER 
5.9 for PR 
 
Results: 
●   The quality of these tissue microarrays FFPE specimens was comparable with those 
without the intervening snap-freeze step (data not shown) 
●   852 patients out of 1002 successfully analyzed, for the following reasons: 
Tumor content < 10%: 132/1002 patients (13.2%) 
Poor RNA yield: 18/870 patients (2%) 
Successful assays: 852/870 (98%) 
●   Agreement between IHC vs RT-PCR: 
ER, 91% concordance, k = 0.83, P value = .0001 
PR, 85% concordance, k = 0.70, P value = .0001 
According to the authors these results confirmed 
the significant correlations between mRNA and 
protein levels for ER and PR and provided 





NCCTG= North Central Cancer Treatment Group; FFPE = formalin fixed paraffin embedded; LMC= laser micro-dissection; RNA= ribonucleic acid; RT-PCR = reverse 




Evidence Table 13. Clinical utility and validity, H/I ratio 
 
Study, year Measure Conclusions 
Fan, 200679 Context: The study is a comparison of classification agreement among 5 different gene 
expression based predictors (70-genes, Oncotype DX, Wound-response, Intrinsic subtypes 
and two-gene ratio) using the 295 samples from the consecutive cohort originally used by van 
de Vijver 2002[reference]. 
 
Methods: 
●   Cramer V statistics 
●   Kaplan-Meier survival analysis 
●  Multivariate Cox proportional hazards analysis, adjusting for age, tumor size, tumor grade, 
ER status, number of lymph node involved 
●   All analyses were performed using all the patients, as well as the ER positive patients 
subset (N=225) 
●   NB: coefficients of clinical predictors were allowed to vary between models 
 
Results: 
●   In multivariate Cox proportional hazards analysis all tests except the two-gene ratio were 
highly significant predictors of OS and DFS: 
70 genes DFS HR = 3.4 (95%CI = 2.0-6.0), P value < 0.001 
Two-gene ratio DFS HR = 0.91 (95%CI = 0.6-1.3), P value = 0.62 
Oncotype OS HR = 4.3 (95%CI = 2.1-8.9), P value < 0.001 
70 genes OS HR = 4.71 (95%CI = 2.02-11.0), P value < 0.001 
Two-gene ratio OS HR = 1.00 (95%CI = 0.61-1.63), P value = 0.99 
Oncotype DFS HR = 6.14 (95%CI = 1.84-20.4), P value = 0.003 
●  ER status, tumor grade, tumor size, and lymph nodes were also significant predictors. 
●  Patients classification into dichotomized risks groups proved to be roughly similar, ranging 
from ~80% to ~40%: 
70-genes and RS yielded a V= 0.60 
70-genes and RS yielded an agreement of ~81% (239/295) 
Good but not perfect correlation between 
predictions, albeit surprising with different gene 
sets. Degree of prediction over and above 
“standard” clinical stratifiers is not clear – 




Evidence Table 13. Clinical utility and validity, H/I ratio (continued) 
 
Study, year Measure Conclusions 
Goetz, 
200662 
Context: Validation of the H/I ratio signature using patients from a randomized trial on 
tamoxifen treatment. 
 
End points:  
●  RFS (time from randomization to any event of recurrence, or contralateral breast cancer or 
death), DFS (time from randomization to any event of recurrence, or contralateral breast 
cancer, or other cancer, or death), and OS (time from randomization to death) 
●  RT-PCR expression values for each gene were normalized using a standard curve 
obtained analyzing the human universal total RNA (Stratagen, La Jolla, CA); No reference 
genes were used 
●  Specific cut-off points were obtained in the selected population analyzed: none negative 
(n=130) and node-positive (n=86) patients 
 
Methods: 
●  Cut-off points estimation for the HOXB13:IL-17BR ratio were obtained by minimizing the P 
value in log-rank tests 
●  Multiple testing corrected P values from the log-rank test were obtained by the Lausen and 
Schumacher method, modify by Altman 
●  Log-rank test and univariate Cox proportional hazard models were used to assess whether 
distributions of RFS, DFS, or OS differed with respect to the following clinical factors: age, 
extent of surgery, ER status, number of positive nodes, tumor size, Nottingham grade, 
HER2 status, prior exposure to estrogens 
●  Cross-validated HR in Cox proportional hazard models were obtained by the Faraggi-
Simon method 
●  Multivariate Cox proportional hazard models and the likelihood-ration test were applied to 
asses the contribution of the dichotomized ratio to the model 
●  In multivariate analysis tumor size, nodal status, tumor grade were included in model 
A high 2-gene expression ratio is associated with 
increased relapse and death in patients with 




Evidence Table 13. Clinical utility and validity, H/I ratio (continued) 
 




●  Nodal status, tumor size and Nottingham grade significantly associated with endpoints 
●  All patient in the study: 
RFS, Univariate Cox 1.90 (CI 95% 1.25, 2.90) 
RFS, Univariate F-S 1.62 (CI 95% 1.06, 2.48) 
RFS, Multivariate Cox 1.65 (CI 95% 1.06, 2.57) 
RFS, Multivariate F-S 1.45 (CI 95% 0.93, 2.27) 
DFS, Univariate Cox 2.01 (1.36, 2.96) 
DFS, Univariate F-S 1.69 (1.14, 2.51) 
DFS, Multivariate Cox 1.77 (1.17, 2.66) 
DFS, Multivariate F-S 1.57 (1.04, 2.38) 
OS, Univariate Cox 1.95 (1.25, 3.07) 
OS, Univariate F-S 1.55 (0.98, 2.45) 
OS, Multivariate Cox 1.66 (1.04, 2.66) 
OS, Multivariate F-S 1.29 (0.81, 2.08) 
●  Node negative patients in the study (n=130): 
RFS, Univariate Cox 2.22 (1.22, 4.05) 
RFS, Univariate F-S 1.99 (1.09, 3.63) 
RFS, Multivariate Cox 1.98 (1.07, 3.68) 
RFS, Multivariate F-S 1.73 (0.92, 3.25) 
DFS, Univariate Cox 2.41 (1.39, 4.18) 
DFS, Univariate F-S 2.12 (1.22, 3.68) 
DFS, Multivariate Cox 2.03 (1.15, 3.59) 
DFS, Multivariate F-S 1.77 (0.99, 3.16) 
OS, Univariate Cox 2.90 (1.47, 5.72) 
OS, Univariate F-S 2.35 (1.21, 4.58) 
OS, Multivariate Cox 2.40 (1.19, 4.84) 




Evidence Table 13. Clinical utility and validity, H/I ratio (continued) 
 
Study, year Measure Conclusions 
Jansen, 
200772 
Context: Validation of the H/I signature  by measuring expression levels normalized to a 
different set of control genes respect to Ma et al 2006.61 
 
Aims: to evaluate if the HOXB13-to-IL17BR expression ratio predicts response to tamoxifen, 
and/or cancer intrinsic aggressiveness 
 
End points: disease-free survival (DFS), progression free survival (PFS), post-relapse 
survival (PRS), and overall survival (OS); 
●   Subsets of patients used from the total population (n=1252) for specific end points: 
DFS ER+, node negative primary breast cancer, no adjuvant therapy (N = 468); 
PFS in ER+ primary breast cancer, whose recurrence was treated with first-line 
tamoxifen (N = 193) 
 
Methods: 
●   Two-gene ratio as dichotomized or continuous variable 
●   Non-parametric methods: 
Spearman rank correlations for ER status, PR status, age; 
Kruskal - Wallis exact test for grade, size, LN status; 
Mann-Whitney U test for menopausal status; 
●   Univariate and multivariate Cox regression analysis to compute the hazard ratio 
●   In multivariate analysis the model for OS and DFS included age, menopausal status, 
tumor size, lymph node status, grade, and log ER and log PgR mRNA levels 
●   The model for PRS and PFS included age, menopausal status, DFS, site of relapse, and 
log ER and log PgR mRNA levels 
 
Results: 
●   All 1252 patients, associations with clinical factors, HOXB13: 
Grade, P < 0.001 
ER status, P < 0.001 
PR status, P < 0.001 
●   All 1252 patients, associations with clinical factors, I17RB (both 3’ and 5’): 
Age, P < 0.001; 
Menopausal status, P < 0.005 and P < 0.026 
Tumor size P < 0.035 and P < 0.098 
LN status, P < 0.001 
Grade, P < 0.001 
ER status, P < 0.001 
PR status, P < 0.001 
High HOXB13-to-IL17BR ratio expression levels 
associate with both tumor aggressiveness and 
tamoxifen therapy failure. 
 
The ratio was significantly associated with DFS 
and PFS in the specific subsets of patients. 
 
In multivariate analysis, the ratio was associated 






Evidence Table 13. Clinical utility and validity, H/I ratio (continued) 
 
Study, year Measure Conclusions 
Jansen, 2007 
(cont’) 
●   Multivariate analysis, ER+, node negative, no adjuvant therapy (N = 468): 
Continuous ratio with 3’ I17RB, DFS HR = 1.04; 95% CI = 1.01 to 1.08; P = 0.015 
Continuous ratio with 5’ I17RB, DFS HR = 1.05; 95% CI = 1.02 to 1.08; P = 0.004 
Dichotomized ratio with 3’ I17RB, DFS HR = 1.74; 95% CI = 1.17 to 2.59; P = 0.006 
Dichotomized ratio with 5’ I17RB, DFS HR = 1.61; 95% CI = 1.08 to 2.41; P = 0.019 
●   Multivariate analysis, relapsing ER+, tamoxifen treated (N = 193): 
Continuous ratio with 3’ I17RB, PFS HR = 1.07; 95% CI = 1.04 to 1.11; P < 0.001 
Continuous ratio with 5’ I17RB, PFS HR = 1.05; 95% CI = 1.02 to 1.08; P = 0.004 
Optimal dichotomized ratio with 3’ I17RB, PFS HR = 2.97; 95% CI = 1.82 to 4.86; P < 
0.001; 
Standard dichotomized ratio with 3’ I17RB, PFS HR = 1.95; 95% CI = 1.39 to 2.73; P < 
0.001; 
Optimal dichotomized ratio with 5’ I17RB, DFS HR = 3.31; 95% CI = 2.05 to 5.34; P < 
0.001; 




Context: Validation of the H/I ratio signature. Expression levels were normalized to b-actin. 
 
Aims: to evaluate if the HOXB13-to-IL17BR expression ratio can predict the benefit of 5 
years versus 2 years of tamoxifen treatment of postmenopausal patients; 
 
End points: Recurrence-free survival (RFS), defined as the time from diagnosis to local, 
regional, or distant recurrence or death due to breast cancer; OS, defined as the time elapsed 
from diagnosis to the date of death due to breast cancer; 
 
Methods:  
●   The relationships between grouped variables were analyzed with the chi-squared test, or 
the chi-squared test for trend when required; 
●   Spearman’s rank order correlation was used when comparing HOXB13 and IL17BR 
levels; 
●   Survival curves were calculated using the Kaplan-Meier method and analyzed with the log 
rank test. 
●   Multivariate analysis of recurrence and mortality rates was performed with Cox 
proportional hazard model; 
●   A Cox model was also used to test for the interaction between the two-gene ratio and the 
benefit from prolonged duration of tamoxifen treatment; 
●   The following variables were included: HOXB13:IL17BR, treatment (5 vs. 2 years), lymph 
node status (N+ vs. N–), tumor size ( > 20 mm vs. > 20 mm), PgR status (PgR+ vs. PgR), 
and an interaction variable (HOXB13:IL17BR x treatment); 
The ratio or HOXB13 alone can predict the 
benefit of endocrine therapy, with a high ratio or a 
high expression rendering patients less likely to 
respond. 
 
Lower expression of IL17BR, but not HOXB13, 
was correlated to several factors related to poor 
prognosis, IL17BR might be an independent 





Evidence Table 13. Clinical utility and validity, H/I ratio (continued) 
 




●   The ratio is significantly correlated to: 
tumor size, P = 0.003 
ER, P < 0.001 
PR, P < 0.001 
HER2, P = 0.003 
NHG, P < 0.001 
Ploidy, P < 0.001 
S-phase, P = 0.005 
ER, HER2, S-phase and NHG correlations are mostly due to IL17BT 
PR and ploidy correlation have contribution from both genes 
●   Post-menopausal ER+ patients, low ratio was associated with a benefit from a prolonged 
tamoxifen treatment (P = 0.021; in KM analysis for RFS), mainly due to the low expression 
of HOXB13 genes (P = 0.010, in KM analysis for RFS) 
●   Postmenopausal ER+ patients (n=179), multivariate Cox proportional hazard model 
analysis: 
Recurrence Rate (5y vs 2y), low ratio: 0.39 (CI 95% = 0.17–0.91), P value = 0.030 
Test for interaction: P value = 0.035 
Recurrence Rate (5y vs 2y), HOXB13: 0.37 (CI 95% = 0.17–0.83), P value = 0.015 
Test for interaction: P value = 0.018 
●   Postmenopausal ER+, node negative, patients (n=134), multivariate Cox proportional 
hazard model analysis: 
Recurrence Rate (5y vs 2y), low ratio: 0.27 (CI 95% = 0.10–0.72), P value = 0.0087 
Test for interaction: P value = 0.014 
Recurrence Rate (5y vs 2y), HOXB13: 0.30 (CI 95% = 0.12–0.73), P value = 0.0083 




Evidence Table 13. Clinical utility and validity, H/I ratio (continued) 
 
Study, year Measure Conclusions 
Ma, 200464 Context: This study used the two-gene ratio signature for the development and preliminary 
validation of the of the two-gene ratio signature  prognostic value in patients with early stage 
breast cancer treated with tamoxifen. The training set was analyzed by microarray (n=60) and 
by RT-PCR (n=59); the validation set (n=20) was evaluated by RT-PCR (3’ probes used) 
 
End points: DFS was calculated from the date of diagnosis. 
 
Methods: 
●   Two-sample t test; 
●   Receiver Operating Characteristic (ROC) analysis; Statistical test of significance of ROC 
curves by the DeLong method 
●   Univariate and multivariate logistic regression; All predictors (tumor size, PGR, ERBB2, 2 
gene-ratio) used as continuous variables 
●   Kaplan-Meier survival analysis and log-rank test 
 
Results: 
●   Microarray data, training set, two-genes ratio, Univariate logistic regression: 
OR = 10.17 (95% CI 2.9–35.6, p Value = 0.0003) 
●   Microarray data, training set, two-genes ratio, Multivariate logistic regression: 
OR = 7.3 (95% CI 2.1–26.3, p Value = 0.002 
This outperforms the other variables 
●   Classification results in the validation set (RT-PCR data): 
16/20 correctly classified 
Correct prediction probability = 0.01 (95% CI = 56%–94%), by exact binomial test; 
9/10 disease free patients correctly classified 
7/10 relapse patients correctly classified 
●   Kaplan-Meier survival analysis, log-rank test, RT-PCR on the training set: P value = 
0.0000058 
●   Kaplan-Meier survival analysis, log-rank test, RT-PCR on the validation set: P value = 
0.002 
2-gene ratio predicts tumor recurrence in the 





Evidence Table 13. Clinical utility and validity, H/I ratio (continued) 
 
Study, year Measure Conclusions 
Ma, 200661 Context: Development of the HOXB13:IL17BR two-gene index, through validation of the 
HOXB13:IL17BR two-gene ratio signature. 
 
Aim: to evaluate if the two-gene expression index (HOXB13:IL17BR) could predict outcome 
in patients treated and untreated with tamoxifen monotherapy 
 
End points: Relapse-free survival (RFS), defined as the time from initial diagnosis to any 
recurrence. Optimal threshold for dichotomization was identified and applied in the analysis 
 
Methods:  
●  Spearman rank correlation was used to assess association between the HOXB13:IL17BR 
index and the other prognostic factors 
●  Cox proportional hazards regression and Kaplan-Meier analyses were used to examine the 
associations between gene expression indices and RFS 
●  Using untreated patients, cut-point selection was tuned to obtained the smallest log-rank P 
value using values between the 10th and 90th percentile; Cut-point selection was obtained 




●  Interaction of HOXB13:IL17BR index with other clinical factors in ER+ patients: 
Node status, r = 0.13, P value = 0.0015 
HER2, r = 0.17, P value < 0.0001 
S-phase, r = 0.15, P value = 0.0004 
ER, r = -0.23, P value < 0.0001 
PR, r = -0.26, P value < 0.0001 
●  Univariate Cox regression analysis: 
All patients (n=852), Interquartile HOXB13:IL17BR HR = 1.47 p = 9e-06 
Node positive (n = 239), Interquartile HOXB13:IL17BR HR = 1.19 p = 0.1 
Node negative (n = 613), Interquartile HOXB13:IL17BR HR = 1.64, p = 2e-05 
●  Kaplan-Meier survival analysis results, ER+, node negative patients: 
Untreated patients, Test set (n=103), P value 0.0012 
Treated patients, (n=122), P value =0.026 
●  Multivariate Cox Regression Analysis; ER+ node negative, untreated test set and 
tamoxifen treated patients (n = 225), dichotomized HOXB13:IL17BR index (high versus 
low): 
HR = 3.9 (95% CI = 1.5 to 10.3) p value = 0.007 
●  Two-gene index on a continuous scale, 5-year recurrence risk for untreated patients: 
Index of -2.0 = 15% (95% CI, 9.8% to 20.5%) 
Index of +2.0 = 36% (95% CI, 26.5% to 45.2%) 
The HOXB13:IL17BR index was only significant 
in node-negative patients. 
 
Higher HOXB13:IL17BR index was associated 
with a higher risk of relapse. 
 
Two-gene index was a significant predictor of 
clinical outcome in ER+, node-negative, patients 





Evidence Table 13. Clinical utility and validity, H/I ratio (continued) 
 
Study, year Measure Conclusions 
Reid, 200569 Context: Validation of the H/I ratio signature using an independent cohort of 58 ER+ patients 
treated with tamoxifen. Re-analysis of the original microarray data and of an independent 
data set 
 
End points: DFS 
 
Methods: 
●   RT-PCR measurement of HOXB13 and IL17BR gene expression (5’ probes used) 
●   Univariate logistic regression 
●   Area Under the receiver-operating-Characteristic curve (AUC) 
●   Two-sample t test and Mann-Whitney test 
 
Results: 
●   Univariate logistic regression: odds ratio: 
HOXB13 OR = 1.04, 95% CI = 0.92 to 1.16, P = 0.54 
IL17BR OR = 0.69, 95% CI = 0.40 to 1.20, P = 0.18 
HOXB13/IL17BR OR = 1.30, 95% CI = 0.88 to 1.93, P = 0.18 
●   Similar results by the other methods 
●   About Ma 2004 validation data: 
9/10 disease free patients were correctly classified; Correct prediction probability 0.02 
(95% CI = 52%–99%) 
7/10 relapse patients correctly classified; Correct prediction probability = 0.34 (95% CI 
= 35%–93%) 
Although the proposed predictive model is very 
appealing the use of the two-gene ratio signature 
in an independent population yielded statistically 
non-significant results. 
 
The authors failed to confirm he association of 
the ratio with response to tamoxifen on their 
cohort (which is however different in terms of 
clinical characteristics from the original Ma, 
200464 cohort). The authors also failed to classify 
patients using Discriminant Linear Analysis on 
two published data sets, including the Ma, 200464 
original series. 
 
ER = estrogen receptor; OS = overall survival; DFS= disease free survival; HR= hazard ratio; CI= confidence interval; RFS = recurrence free survival; RT-PCR= reverse 
transcriptase polymerase chain reaction; RNA= ribonucleic acid; HER-2 = human epidermal growth factor receptor 2; PFS = progression LN = lymph node; mRNA=  messenger 
ribonucleic acid; NHG= Nottingham histologic grade; ROC= receiver operating characteristic; PGR= progesterone receptor gene; AUC= area under the receiver operating 
characteristic curve 
 
